# Cecilie Therese Hagemann


Medical findings and legal outcome among postpubertal women attending the Sexual Assault Centre at St. Olavs Hospital, Trondheim, Norway

A record-based study from 1997–2010

Thesis for the degree of Philosophiae Doctor

Trondheim, October 2014

Norwegian University of Science and Technology Faculty of Medicine Department of Public Health and General Practice



# NTNU

Norwegian University of Science and Technology

Thesis for the degree of Philosophiae Doctor

Faculty of Medicine Department of Public Health and General Practice

© Cecilie Therese Hagemann

ISBN 978-82-326-0546-0 (printed ver.) ISBN 978-82-326-0547-7 (electronic ver.) ISSN 1503-8181

Doctoral theses at NTNU, 2014:317

Printed by NTNU-trykk



Illustration: Sylvia Stølan

# Medisinske funn og rettslig utfall blant kvinner som har oppsøkt overgrepsmottaket ved St. Olavs Hospital, Trondheim, i perioden 1997 – 2010

Overgrepsmottaket ved St. Olavs Hospital i Trondheim har siden 1989 tilbudt helsehjelp og rettsmedisinsk undersøkelse til ungdom og voksne utsatt for seksuelle overgrep. Utbredelse av seksuelt overførte infeksjoner og hvilke rusmidler som kan påvises har hittil ikke vært undersøkt blant de som søker helsehjelp etter voldtekt i Norge. Det er dessuten begrenset kunnskap om politiets og rettsvesenets bruk av medisinsk informasjon i den rettslige prosessen.

Formålet med studien var å beskrive forekomsten av seksuelt overførbare infeksjoner blant kvinner som oppsøkte overgrepsmottaket, og å kartlegge om noen av disse kunne ha blitt overført under overgrepet. Vi ville også beskrive funn av rusmidler for å se om noen kunne ha vært utsatt for rusmiddelassistert voldtekt. Til slutt ville vi se på det rettslige utfallet av de anmeldte voldtektssakene, og om det fantes noen sammenheng med påvisning av skader og sæd/DNA.

Vi gjennomførte 4 studier der de involverte hadde rapportert seksuelt overgrep til politiet og/eller til overgrepsmottaket i perioden 1997 – 2010. Til sammen ble data fra mer enn 400 kvinner hentet fra sykehusjournaler og/eller fra politiets registre.

Vi fant at seksuelt overførte infeksjoner ble diagnostisert hos 9 % av pasientene. Bare i svært få tilfeller kunne vi konkludere med at smitten hadde skjedd under overgrepet, fordi det er vanskelig å skille slik infeksjon fra allerede eksisterende infeksjon. Hos 22 % av pasientene med rusprøver, mistenkte de ufrivillig påført bedøvelse. Noen få av disse kvinnene testet positivt for bedøvende midler, men vi kunne her ikke utelukke frivillig inntak. Av de som ble testet innen 12 timer, fikk 85 % påvist alkohol, og vi beregnet alkoholkonsentrasjonen i blodet rundt tidspunktet da overgrepet ble begått til gjennomsnittlig 1,9 ‰.

I mer enn halvparten av de anmeldte voldtektssakene ble saken henlagt på grunn av manglende bevis. Bare i 11 % ble det tatt ut tiltale, og da forelå det oftere sporsikringsanalyse og dokumentasjon på moderat/alvorlig skade på fornærmedes kropp.

Tilgang til rask og kvalifisert helsehjelp etter seksuelle overgrep kan sikre de utsatte helsemessig tilheling og bedre den rettslige prosessen. Både helsevesenet og politiet kan dra nytte av bedre samarbeid og utveksling av kunnskap, for i siste instans å optimalisere forholdene for ofre for seksuelle overgrep.

Kandidat: Cecilie Therese Hagemann

Institutt: Institutt for samfunnsmedisin, NTNU

Veiledere: Professor Berit Schei, førsteamanuensis Arne Kristian Myhre og professor

Kari Ormstad

**Finansiering:** ExtraStiftelsen Helse og Rehabilitering via Norske Kvinners Sanitetsforening, Samarbeidsorganet mellom Helse Midt-Norge RHF og NTNU, St. Olavs Hospital, Trondheim og til slutt Kompetansesenter for sikkerhets-, fengsels- og rettspsykiatri for Helseregion Sør-Øst

# **Table of contents**

Α	cknowledgements	I
Li	st of papers	III
Α	bbreviations	IV
Sι	ummary	V
1	Introduction	1
	Personal background	2
2	Background	3
	2.1 Sexual violence, sexual assault, and rape	3
	2.1.1 Sexual violence according to the World Health Organization	3
	2.1.2 Rape according to the Norwegian penal code	4
	2.2 Prevalence of sexual violence, sexual assault, and rape	4
	2.2.1 Prevalence of sexual violence in population surveys	4
	2.2.2 Rape crime statistics	7
	2.2.3 Health care after sexual assault, the Sexual Assault Centers (SACs)	9
	2.3 Medical findings after sexual assault	. 11
	2.3.1 Sexually transmitted infections among rape victims	. 12
	2.3.2 Toxicological findings – Drug-facilitated sexual assault (DFSA)	. 23
	2.3.3 Extragenital injuries, anogenital injuries, and trace evidence	. 34
3	Aims of the study	. 40
	3.1 Purpose	. 40
	3.2 Objectives	. 40
4	Material and methods	. 41
	4.1 Study design	. 41
	4.2 Setting: The Trondheim SAC	. 41
	4.3 Study samples	. 42
	4.3.1 SAC recruited (Papers I and II)	. 42
	4.3.2 Police recruited (Paper III and expanded analyses (EA))	. 43
	4.4 Data collection and storage	. 46

4.4.1 From medical records (all studies)	46
4.4.2 From police files (Paper III and EA)	46
4.5 Definition of variables	46
4.5.1 Medical record variables (all studies)	46
4.5.2 Police variables	53
4.5.3 Quality control of the variables	54
4.5.4 The merging of the data (Paper III and the EA)	54
4.6 Data storage	55
4.7 Calculations and statistical analyses	55
4.7.1 Analyses for Paper I	56
4.7.2 Analyses for Paper II	56
4.7.3 Analyses for Paper III and the EA	57
4.8 Study approval	57
4.8.1 Study approval Paper I and II	57
4.8.2 Study approval Paper III and EA	58
4.9 Ethical considerations	58
5 Results/Overview of papers	60
5.1 Sexually transmitted infections (Paper I)	60
5.1.1 Results according to aims (Paper I)	60
5.1.2 Results from follow-up visits	61
5.1.3 Assault-transmitted STI and legal outcome	62
5.2 Toxicological findings (Paper II)	62
5.2.1 Results according to aims (Paper II)	62
5.2.2 Toxicological findings and legal outcome	67
5.3 Medico-legal findings and legal outcome (Paper III and the EA)	72
5.3.1 Results according to aims (Paper III)	72
5.3.2 Additional exploration of trace evidence analysis (Paper III)	77
5.3.3 Police use of forensic report, expert witness and toxicology (Paper III)	78
5.3.4 Results according to aims for the expanded period 1997 - 2010	79
6 Discussion	84

6.1 Methodological limitations and strengths
6.1.1 Study design and data collection
6.1.2 Random error
6.1.3 Systematic error (bias)
6.1.4 Generalizability of the findings not related to errors
6.1.5 Reliability and validity
6.2 Discussion of the results
6.2.1 Sexually transmitted infections (Paper I)
6.2.2 Toxicological findings and DFSA (Paper II)
6.2.3 Injuries and analysis of trace evidence (Paper III and expanded analyses) $111$
6.3 Clinical and forensic implications
6.3.1 Sexually transmitted infections (Paper I)
6.3.2 Toxicological findings and DFSA (Paper II)
6.3.3 Injuries and trace evidence (Paper III and the EA)
6.4 Future research
7 Conclusion
References
Paper I – III with the E-tables
Appendix 1 Registration form Paper III
Appendix 2 Case report form, hospital data
Appendix 3 Case report form, police data

Appendix 4 Information letter in Norwegian

# **Acknowledgements**

This thesis is based on work carried out at the Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology (NTNU) during the period 2009 – 2014. The work has been financed by the following sources: the Norwegian ExtraFoundation for Health and Rehabilitation through the NGO Norwegian Women's Public Health Association; the Liaison Committee between the Central Norway Regional Health Authority and the NTNU; St. Olavs Hospital, University Hospital of Trondheim; and the Centre for Research and Education in Forensic Psychiatry at the South Eastern Norway Regional Health Authority.

This work has only been possible through the support of many people and institutions, although only some could be mentioned here.

I wish to express my sincere gratitude to my three supervisors for invaluable academic guidance: To Professor Berit Schei, my main supervisor, for introducing me into the field of research and giving me the unique opportunity to be included in several networks of research on sexual violence. She initiated the study, encouraged me to start, and supported and challenged me throughout the various stages of this work. Her creativity and insight into the field of epidemiology has made this thesis come true. To Professor Kari Ormstad, always encouraging me, and contributing great forensic and medical knowledge, in addition to supplying linguistic refinement. To Associate Professor Arne K. Myhre, a dear clinical colleague and giver of constructive feedback during this Ph.D. process. In addition, I want to thank Senior Researcher and Psychologist Jim Aage Nøttestad for securing one year's worth of research funding and for comments which were always inspiring and cheerful.

I am also truly thankful to my co-authors at the St. Olavs Hospital: To the Consultant Pharmacologist Arne Helland for spending time with me categorizing and discussing, and for always promptly and enthusiastically answering my questions; to Professor Olav Spigset for sharing his great experience of research and critically reviewing my manuscripts; to the Consultant Pharmacologist Ketil Arne Espnes for contributing interesting discussions and pharmacological knowledge; and to the Associate Professor Svein Arne Nordbø for navigating me through the complicated field of microbiology.

I thank the staff and colleagues at the Department of Obstetrics and Gynecology, St. Olavs Hospital. Special thanks to the head of the department, Runa Heimstad, for giving me extra study-leave and letting me conduct this research project to completion. Thanks to Professor Eszter Vanky for invaluable comments and encouragement during the initial phase of my Ph.D. project. I dearly appreciate my colleagues at the Department for making such a supportive work environment. I am really grateful for our SAC-team, all of whom encouraged my research even in times of staff scarcity. Special thanks to Gunn Alsaker Gjershaug and Gerd Eva Fenheim for practical help and supportive and empathetic comments.

I thank the staff, colleagues, and my fellow Ph.D. students at the Department of Public Health and General Practice, NTNU. The staff provided practical and administrative support. Special thanks to Jon Magnussen, at that time the head of the department, for his supportive and encouraging attitude. In addition, I want to thank Pål Romundstad for invaluable help and methodological advice. I have appreciated colleagues and fellow Ph.D. students for a positive work environment, especially at the 4<sup>th</sup> floor. I am especially thankful to Lise Eilin Stene, my office-mate throughout most of the Ph.D. period, for her knowledgeable thoughts and feedback as a co-author, for sharing with me important aspects

of research ethics, and for supplying well-needed encouragement. Thanks to Anna Brenne Grønskag and Marie Flem Sørbø for sharing feelings during times of gloom and despair, and to Risa Lonnee-Hoffmann and Mari Hoff for thoughtful discussions. Finally, thanks to Ingunn Harstad and Jenifer Infanti for good advice in writing.

I thank the staff at the Trondheim police station (Sør-Trøndelag Police District) for practical and administrative support and willingness to let this interdisciplinary research become possible. Special thanks to the co-ordinators/police investigators Jorunn Leksås, Hanne Finanger, and Marit Johanne By for constructive and knowledgeable discussions and cooperation. Thanks for the invaluable help from the analysis-department, represented by Tom Espen Weie and Dag Magne Loe. Without their support and cooperation, I would hardly have started this project. Thanks to the police prosecutors Jarle Wikdahl and Marianne Høyer, and to the head of the Public Prosecutors in Trøndelag, Bjørn Kristian Soknes, for fruitful legal discussions, advice, and education.

Thanks to Helle Nesvold and Henriette Myhre Waitz at the Oslo Emergency ward; to Grethe Johnsen and Kjersti Alsaker in Bergen at the National Centre for Emergency Primary Health Care; to Grete Dyb at the Norwegian Centre for Violence and Traumatic Stress Studies; to Miriam Lukasse and Lena Henriksen, all of them for collegial and interesting discussions of different aspects of sexual violence.

Thanks to the students Katharina Frydendal Pedersen, Karen Løhre, and Anna Hjorth-Hansen who participated in the registration of the hospital data, and to the students Amalie Steinsbekk, Amanda Rygvold, Ingvild Johansen, and Eirik Alberto Brattheim for reading and recording the police data – the data collection period would have been extended to several years without their help.

Thanks to Berit Marianne Bjelkåsen at the Unit of Applied Clinical Research, NTNU, who kindly provided the web-based registration form and converted it to an SPSS-file, to Kellie Donovan-Condron, who contributed to important manuscript language improvements, and to Sylvia Stølan who made the illustrative drawing solely for this thesis.

Finally, heartfelt thanks to my husband Gunnar for invaluable emotional support and advice through periods of distress, and to my three children Eivind, Brage and Tora, for making life worth living. Without your distractions, I would probably have finished faster, but at a much poorer existence. Thanks also to my mother for unconditional love and patience and to my beloved sisters Ingeborg, Elin, and Greta for encouragement and unfailing faith.

# List of papers

This thesis is based on the following original papers, and referred to in the text:

## Paper I

Hagemann CT, Nordbø SA, Myhre AK, Ormstad K, Schei B. Sexually transmitted infections among women attending a Norwegian Sexual Assault Centre. Sex Transm Infect. 2014 Jun;90(4):283-9. Epub 2014/02/24

doi: 10.1136/sextrans-2013-051328

PMID: 24567522

## Paper II

Hagemann CT, Helland A, Spigset O, Espnes KA, Ormstad K, Schei B. Ethanol and drug findings in women consulting a Sexual Assault Center – Associations with clinical characteristics and suspicions of drug-facilitated sexual assault. J Forensic Leg Med. 2013 Aug;20(6):777-84. Epub 2013/06/25

doi: 10.1016/j.jflm.2013.05.005

PMID: 23910880

#### Paper III

Hagemann CT, Stene LE, Myhre AK, Ormstad K, Schei B. Impact of medico-legal findings on charge filing in cases of rape in adult women. Acta Obstet Gynecol Scand. 2011 Nov;90(11):1218-24. Epub 2011/07/29

doi: 10.1111/j.1600-0412.2011.01246.x

PMID: 21793810

#### **Abbreviations**

AGW: Anogenital warts

BAC: Blood alcohol concentration

BBV: Blood borne viruses
CI: Confidence interval
CMV: Cytomegalovirus
CRF: Case report form
CT: Chlamydia trachomatis
df: degrees of freedom

DFSA: Drug-facilitated sexual assault EA: Expanded analyses (for Paper III)

ED: Emergency department

FVU: First void urine

GUM: Genitourinary medicine

HBV: Hepatitis B virus

Markers: HBs (surface) antigen, HBc (core) antibody

**HCV**: Hepatitis C virus

Marker: HCVAb: HCV antibody

HSV: Herpes simplex virus MG: Mycoplasma genitalium

NAAT: Nucleic acid amplification test

NG: Neisseria gonorrhoeae

OR: Odds ratio

PCR: Polymerase chain reaction

SA: Sexual assault

SAC: Sexual Assault Center

STI: Sexually transmitted infection STD: Sexually transmitted disease

TV: Trichomonas vaginalis

WHO: World Health Organization

## Summary

Background: Since 1989, the Sexual Assault Center (SAC) at St. Olavs Hospital in Trondheim, Norway has offered medical assistance and forensic examination to victims of sexual assault. The purpose of the acute medical examination is to identify and treat disease and injuries important for the victim's health. Certain findings could also be pertinent to the police investigation and possibly decisive for the legal outcome. Until now, sexually transmitted infections (STIs) and toxicological findings have not been described among Norwegian adult and adolescent sexual assault victims seeking acute medical help. There have been prior studies of police-reported rapes, but there is limited knowledge of the impact that medical information has had on legal outcome. Objectives: Firstly, we wanted to describe the prevalence of sexually transmitted infections (STIs) among female adult and adolescent patients who visited the SAC, and to evaluate whether STIs diagnosed at the initial visit could have been assaulttransmitted. Secondly, we aimed to describe which drugs were found in urine and/or blood, to further evaluate whether the test results were consistent with so-called "proactive" drug-facilitated sexual assault (DFSA). Finally, we wanted to describe the legal outcome among cases of rape and attempted rape and to explore whether extragenital and anogenital injuries and biological trace evidence had any association with the filing of criminal charges.

*Methods:* The studies were conducted from two different samples of women reporting sexual assault to the police and/or to a hospital SAC (1997 – 2010). Four studies were conducted. The first two studies explored STIs and toxicological findings among 412 and 264 SAC patients, respectively, using information from the hospital records only. The third and fourth study, examining the association between medical findings and legal outcome among 101 and 324 police-reported rapes, respectively, used merged data from both hospital and police records. All studies were retrospective and descriptive, but comparisons were done for the different outcome variables. We used Pearson's  $\chi$ 2 test, Exact Unconditional test/Fisher's Exact test, Pearson's  $\chi$ 2 test of heterogeneity, or Kruskal-Wallis test as appropriate. In addition, further exploration by binary and multivariable logistic regression analysis was performed.

Results: Altogether, at least one STI was diagnosed in 8.5% of the patients attending the SAC. The proportion of women diagnosed with genital chlamydia infection was notable (6.4%), but lower than in the comparable clinical population. Differentiating STI transmitted during assault from pre-existing STI is difficult, and in only two cases was the STI suspected to be assault-transmitted. Ethanol and/or drugs were detected in 59% of the SAC patients tested, including benzodiazepine-like substances in 12% of the patients. A suspicion of proactive DFSA was expressed by 22%; however, only in five patients were the detected sedative drugs not accounted for by voluntary intake. All of these five patients had a history of drug abuse/anxiety. Therefore, no cases could be unequivocally attributed to proactive DFSA. Among those tested for ethanol within 12 hours of the assault, 85% tested positive. The median estimated blood alcohol concentration at the time of the assault was 1.9 g/L. Those testing positive for ethanol more often reported a public venue, a stranger assailant, and more than one assailant. However, those testing negative for ethanol more often had another vulnerability. Criminal charges were not filed in more than 50% of the cases because of insufficient evidence. The proportion of cases taken to court was 16% in 1997 – 2003, but reduced to 8% during 2003 – 2010. The police's decision to submit trace evidence for analysis was associated with the filing of charges, and moderate/serious bodily injury was more often documented among the cases taken to court.

Conclusion: STI prevalence among SAC patients was lower than in the comparable clinical population, and only two cases of STI were probably assault-transmitted. Alcohol was the dominating drug found in urine and/or blood samples from SAC patients, and no cases of "proactive" DFSA could be unequivocally verified. Only a small proportion of police-reported rape cases were taken to court; in such cases, a higher proportion had moderate/serious bodily injury and the trace evidence was analyzed more often. Available access to immediate and qualified health care after sexual assault should ensure that victims receive valuable recreational help and that their legal rights are protected. However, both health care and the police would benefit from better cooperation and exchange of knowledge to improve outcomes for victims of sexual assault.

#### 1 Introduction

The idea for this thesis surfaced after years of interest in the field while working as part of a sexual assault team of gynecologists, pediatricians, psychologists, and nurses. As a gynecologist working at the Sexual Assault Centre (SAC) at St. Olavs Hospital in Trondheim, Norway, I prioritized adult and adolescent women exposed to sexual assault for this thesis, although our team also treats children and men. Physicians working at the SAC need to take into account both health care and forensic perspectives when dealing with sexual assault victims, and this need for dual perspective was part of my motivation. The unique situation for the SAC patient at the intersection of medical and legal disciplines compelled me to further explore the topic.

This thesis discusses some of the medical findings documented during the clinical and forensic medical examinations of female victims of sexual assault, particularly sexually transmitted infections (STIs), drugs detected in urine and/or blood, as well as injuries and trace evidence. These topics could be of interest for the patient only, for the police investigators/prosecutors only, or for both of these groups. Some knowledge about the health consequences of sexual assault has already been established from Norwegian SAC studies. However, the Norwegian research on medical findings revealed from SACs is fragmentary and limited, at least regarding STIs and drugs. The prevalence of injuries after rape in a Norwegian context has been estimated, but the use of such information by the police, and its final consequences for legal outcomes, is not clear. The lack of research in this field stands in stark contrast to the tremendous attention given to the issue of sexual assault in the media and in political discussions.

This thesis consists of three original papers, some expanded analyses and a summarizing part. All information used in this thesis has been collected from two different record systems: medical records and police files. A substantial part of the thesis is descriptive, although comparisons have been done for different outcomes. My aim is to increase knowledge about the health care and forensic services in sexual assault cases in a Nordic context. This information could be used to improve the

quality of such health care. I want to attract attention to the legal use of data collected from SAC patients, and highlight the benefit of using medical information to investigate rape cases. While the mental or long-term health consequences after sexual assault are of great concern, these issues are beyond the scope of this thesis.

# Personal background

- Authorized as a Norwegian physician in 1996
- Worked at a hospital SAC since 1997
- Courses in legal medicine 2003 2004
- Consultant specialist in Obstetrics and Gynecology in 2004
- Senior SAC worker/supervisor since 2004
- SAC project coordinator during 2007
- Ph.D. project on sexual assault/rape from 2009
- Have personally performed a considerable percent of the SAC examinations included in this study
- Teacher at courses in legal medicine

# 2 Background

In this section, some central terms will be defined, according to the World Health Organization (WHO) and to the Norwegian penal code. To assess the scope of the problem, prevalence estimates of sexual violence will be addressed in different settings: in population surveys, according to rape crime statistics, and in health care settings. Finally, the background for each of the papers will be introduced in detail, in terms of a critical exploration of the relevant literature and the body of research in the field which informed the writing of the present papers. The most extensive review of the literature regards STI and sexual assault, as there is a lack of recent overviews on this topic.

### 2.1 Sexual violence, sexual assault, and rape

#### 2.1.1 Sexual violence according to the World Health Organization

Sexual violence is ubiquitous, affects all social classes (1), and is classified by the WHO as a major public health problem (2). According to the WHO, sexual violence is defined as "any sexual act, attempts to obtain a sexual act, or acts to traffic for sexual purposes, directed against a person's sexuality using coercion, harassment or advances made by any person regardless of their relationship to the victim, in any setting, including but not limited to home and work" (1, 3).

Sexual violence includes rape, generally defined as physically forced or otherwise coerced penetration of the vulva or anus, using the penis, other body parts, or an object. The attempt to do so is denoted as "attempted rape" (3). The term "sexual assault" usually refers to a single episode, and is often identical to rape and attempted rape. In contrast, the term "sexual abuse" is more commonly used when discussing sexual violence against children, and also when forced sexual activity is part of an abusive relationship or domestic violence. Violence, on the other hand, is the intentional use of physical force or power that either results in or has a high likelihood of resulting in physical or psychological harm (3). Health care often uses the term "sexual assault," thereby avoiding the legal term "rape," whereas the police force often uses the terms "rape" and "attempted rape." For the purpose of this thesis, the

term "sexual assault" will be used for those attending health care, and "rape"/"attempted rape" for those attending the police.

## 2.1.2 Rape according to the Norwegian penal code

Legal definitions of rape vary greatly in scope (1). The Norwegian Penal Code states the following (4, 5): "A person committing rape or attempted rape is defined as one who obtains sexual activity by means of violence or threats, or with any person who is unconscious or for any other reason incapable of resisting the act, or by means of violence or threats compels somebody to engage in sexual activity with another person, or to carry out similar acts with him- or herself."

In addition to vaginal, anal and oral intercourse, touching of genitals, a man's exposed genitals being rubbed between a woman's thighs or buttocks, or on her belly, masturbation, licking or sucking of genitals, or insertion of fingers or objects into the vagina or anus is defined as rape (6).

The punishment for rape could be more severe if the victim contracts a sexually transmitted infection as a result of the rape (section 192, 3. paragraph, letter d). The sexual exploitation of a person's helplessness due to unconsciousness, intoxication, or sleep was in the year 2000 included in the category of rape (section 192, 1. paragraph, letter b), thereby increasing the level of punishment for such a crime (5, 6). An additional paragraph can also be used for situations when the suspect has induced a condition mentioned above to achieve sexual intercourse (section 192, 2. paragraph, letter b) (5). Attempted rape is also punishable, but covered by another paragraph in the Norwegian Penal Code (section 192, cf. section 49).

# 2.2 Prevalence of sexual violence, sexual assault, and rape

# 2.2.1 Prevalence of sexual violence in population surveys

Women and girls are more likely to be the victims of sexual violence, and men are more likely to be the assailants. In most instances, the assailant is known to the victim (1). The WHO multi-country study performed in 10 mostly middle- and low-

income countries<sup>a</sup> estimates that between 6 and 59% of women reported ever being subjected to sexual violence by an intimate partner and between 0.3 and 12% by a non-partner (7). Furthermore, this study reveals that between 1 and 21% of women were subjected to sexual abuse before the age of 15 years. According to the International Violence Against Women Study, 13 to 34% of women in high income countries<sup>b</sup> reported ever having been raped during their lifetime (8, 9). Comparable numbers from the U.S. are 18% (10, 11). In addition, a recent systematic literature review found that 7% of women aged 15 years and older worldwide had ever experienced non-partner sexual violence (12). According to this study, estimated prevalence of non-partner sexual violence was 12%, 13% and 16% for women in Western Europe<sup>c</sup>, North America<sup>d</sup> and Australasia<sup>e</sup>, respectively.

In comparison with the prevalence of rape globally, women in Norway seem to experience rape at about a similar rate as other Western countries. Recently, a national large-scale study of the prevalence of sexual violence was conducted in Norway. Among 2,435 women aged 18 to 75 years, the researchers found a lifetime prevalence of rape<sup>f</sup> of 9%, and half of the women who reported rape had been raped before the age of 18 years (13). In a prior Norwegian national survey of 2,143 everpartnered women only, 10% reported being raped after the age of 15 years (14). However, the prevalence of rape in Norway is not clear, since a smaller national survey drawn from a random sample of 387 Norwegian women in 2012 found that as many as 16% had experienced unwanted sexual intercourse after the age of 16 years, and 11% at an earlier age (15). The risk of being sexually assaulted is higher among adolescents and young adults than among older women (13, 16). In all of these Norwegian studies, some men also report being subjected to sexual assault, but at much lower rates (1 – 3%) than women.

<sup>a</sup> Bangladesh, Brazil, Ethiopia, Japan, Namibia, Peru, Samoa, Serbia and Montenegro, Thailand, Tanzania

<sup>&</sup>lt;sup>b</sup> Germany, Italy, Switzerland, Denmark, Sweden, Australia

Switzerland, Spain, Isle of Man, Sweden, U.K., Denmark, Finland, Germany


<sup>&</sup>lt;sup>d</sup> U.S., Canada

<sup>&</sup>lt;sup>e</sup> New Zealand, Australia

f I.e., forceful vaginal, anal, or oral intercourse or the insertion of fingers or objects into the vagina or anus. Notably, the authors excluded in the definition of rape those sexual acts occurring when the person was intoxicated (incapacitated rape) and the touching of genitals.

Findings from the U.S. and Norway show that about 30% of raped women have been physically injured (13, 17). However, only one third of women who have been injured as a result of rape receive medical treatment (17). Injury could play a role in the decision to report. Whatsoever, it is estimated that only around 5-25% of victims attend acute health care and/or contact the police after sexual assault (6, 14, 16-24).


Figure 1 is a modified illustration after Schei *et al* (25) and depicts a theoretical model of assumed occurrence of sexual assault in various female populations in relation to the samples addressed in this thesis, that is, the proportion of women reporting to health care and to the police. In Norway, 55 - 66% of those contacting the police after rape receive medical care (26, 27), while a similar fraction (50 - 60%) of those contacting SACs report the sexual assault to the police (20, 28).



**Figure 1** Theoretical model of the proportion of women from the entire population, who participate in population surveys, who report in population surveys being subjected to sexual assault, and finally, who report to health care (red) and/or to the police (green). (Not drawn to scale. Those participating in surveys are not necessarily the same as those reporting to health care/police. Modified illustration after (26))

#### 2.2.2 Rape crime statistics

Statistics regarding rapes and attempted rapes can also be estimated by those reporting to the police. Annual national statistics can be produced using STRASAK<sup>g</sup>, the electronic Norwegian crime register. According to a recent publication from the police, 1,233 rapes and attempted rapes were reported to the Norwegian police in 2013 (29). Figure 2 illustrates that there has been a steady increase in reported rapes from the second half of the 1990s, corresponding to an increase of 12% over the last five years (30). However, there is only a minor increase in the annual number of rapes/attempted rapes where charges have been filed in Norway throughout the period 1998 – 2011. As a result there is an increasing gap between the number of reported rapes and those proceeding to prosecution.



**Figure 2** Annual proportion of police-reported rapes/attempted rapes where charges are filed, Norway 1998 – 2011. Source: Statistics Norway


When a rape is reported to the Norwegian police, opening an investigation is mandatory, that is so-called "public prosecution". However, during the initial briefing interview and investigation, the police and prosecuting authority may decide that no crime has been committed. These cases are not included when presenting the national

7

g Norwegian: Straffesaksregisteret

statistics of "investigated" rapes (31). In Norwegian rape cases, the final legal decisions to prosecute rape cases are made by a regional public prosecutor<sup>h</sup> or by the Director General of Public Prosecution<sup>i</sup>.

Among the investigated cases, various legal outcomes are possible, see Figure 3 (31, 32). The unsolved cases are those where no suspected assailant has been identified and cases with insufficient evidence. Solved cases consist of those taken to a court of law, those where the suspect was not legally responsible at the time of the crime, and those cases where charges have been withdrawn. Total national numbers of reported and investigated rapes as well as legal outcome for the period 1996 – 2011 are summarized in Table 1.



Time frame/scale

Figure 3 Illustration of course of criminal cases through the criminal justice system, from reporting to charge filing (32)

<sup>&</sup>lt;sup>h</sup> Statsadvokat

Riksadvokat

<sup>&</sup>lt;sup>j</sup> E.g., assailant < 15 years of age

Table 1. Total national numbers of reported and investigated rapes<sup>k</sup> as well as legal outcome of rape cases registered for the period 1996 – 2011 (source: Statistics Norway)

Attrition	Total number of rape cases <sup>k</sup> , N (%)
Total reported	13,718 (100)
Total investigated	11,618 (85)
Unsolved cases	8,888 (65)
No suspect identified	2,012 (15)
Insufficient evidence	6,803 (50)
Other unsolved	73 (0.5)
Solved cases	2,730 (20)
Charges filed/court proceedings	2,192 (16)
Suspect not legally responsible j	270 (2)
Charges withdrawn, other solved	263 (2)
Ticket/fine <sup>l</sup>	5 (0.04)

The legal system's treatment of rape in Norway is not unique in the region.

Despite the Nordic countries' reputation as pioneers for women's rights and gender equality, a report from Amnesty International in 2008 points out the high proportion of rape cases being dismissed by the legal system in all of the Nordic countries (33). Less than one fifth of police-reported rape cases in four Nordic countries<sup>m</sup> ends in a conviction.

The initial police investigation following rape/attempted rape could be crucial for a case to be proceeded in a court of law, and several steps to improve investigations of rape cases have been suggested (6). One of these steps is enhanced cooperation between the police and health care, while another is using better forensic equipment (e.g., photo documentation) and increasing the competence of the medical staff.

# 2.2.3 Health care after sexual assault, the Sexual Assault Centers (SACs)

Before the establishment of the first SACs worldwide, the forensic management of a complainant was typically conducted in the police station when an allegation of a sexual crime was made. These situations of medical care were inappropriate, since

<sup>&</sup>lt;sup>k</sup> Rapes (including indecent assault by means of threats/devious behavior and indecent assault to an unconscious subject) and attempted rapes

Incl. two cases of indecent assault by means of threats/devious behavior, one case of indecent assault to an unconscious subject, and two cases of attempted rapes

<sup>&</sup>lt;sup>m</sup> Denmark, Finland, Norway, and Sweden were included in this report

after the examination, the victims were obliged to seek help from several agencies in different locations. Thus, a multi-disciplinary model developed, where professionals from different fields cooperated. The first such SAC was established in the U.S. in the early 1970s, followed by those in Australia (34). In Europe, hospital-based SACs were first established in Ireland in 1985, and in the U.K. in 1986 (35). The first Nordic multidisciplinary SAC was set up in Oslo at the municipal emergency ward<sup>n</sup> in 1986 (36, 37), followed by the SAC established at the University Hospital of Trondheim in 1989 (19). After that, centers have been established in other Nordic countries (20, 34, 38-40), and further in other parts of the world (41-45).

Patients contacting SACs need acute medical care to ensure that short- and long-term health consequences are reduced to a minimum. The patient should be examined by trained physicians and nurses who provide both emergency medical treatment and psychosocial support and care. An evaluation of Norwegian SACs finds that these clinical issues are well taken care of (46). However, in addition to examination and prophylaxis for STIs and offering emergency contraception, a forensic examination should be performed in conjunction with the clinical evaluation.

The organization of forensic medicine in Norway requires that the examining physician may be requested to prepare a forensic report to assist in a police investigation. If summoned, he or she must act as an expert witness in court. It has therefore been important to systematize the documentation of injuries and the collection of biological trace evidence (47, 48). Forensic education for medical personnel is offered through regular national courses, but still, the forensic skills among physicians working at Norwegian SACs seem not to be prioritized. The quality of forensic documentation varies across the country's 23 SACs. It has been especially difficult to achieve high quality forensic service in the smaller SACs, which annually receive only a few patients (46, 49, 50).

Altogether, a total of 1,207 patients subjected to sexual assault contacted one of the Norwegian SACs during 2011 (51). The Trondheim SAC has experienced a steady increase in the annual number of patients attending health care after sexual assault

r

<sup>&</sup>lt;sup>n</sup> Legevakten

(Figure 4). We do not know whether the increased attendance rate is due to a growing awareness of the available specialized health care services or to an actual increase in prevalence of sexual assault.




Figure 4 Annual numbers of patients attending the Trondheim SAC, 1997 – 2013

## 2.3 Medical findings after sexual assault

An exploration of the acute medical findings among women subjected to sexual assault is motivated by three main objectives: 1) discovering those findings important for women's health and well-being, but with no or limited legal interest; 2) tracing those findings important both for women's health and for legal interest; and 3) disclosing medico-legal findings of no relevance to the woman's health, but pertinent to the police investigation and possibly decisive for the legal outcome.

An example of the first objective is examination and prophylaxis for STIs, which are important health-wise, but not necessarily applicable as medico-legal evidence in a rape investigation<sup>o</sup>. The possibility of detecting drugs in urine and/or blood is important to the woman herself as well as to the police officers and prosecuting

11

<sup>°</sup> Especially in coitally experienced women

authorities, particularly in cases where drug-facilitated sexual assault is suspected. In these cases, the medical staff's descriptions of the victim's state of intoxication may be highly pertinent. Furthermore, the documentation of injuries, retrieval of spermatozoa, and recovery of a suspect's DNA from swabs collected from the victim's body could be of interest mainly to the police investigation (52-54).

As important as the medical findings may be to a police investigation, the well-being of the victim is the most crucial point at every stage of the process. Cooperation with the victim and securing her consent at any stage of examination and forensic documentation is the top priority, ranking above all investigatory and legal issues. In particular, the anogenital examination has the potential to be intrusive and traumatizing for the patient if not undertaken in a sensitive and well-prepared way.

Below, I will address three different medical areas concerning the acute medical examination of sexual assault victims. Hence, the background for the papers dealt with in this thesis will be presented in the following sections.

#### 2.3.1 Sexually transmitted infections among rape victims

Many victims contact health care because of a fear of contracting STIs/BBVs after the sexual assault (55). In theory, the risk of transmission of STIs/BBVs during a sexual assault is dependent on the prevalence in the general population and especially among assailants, the assailant's use of a condom, the number of assailants, the sexual acts performed, whether ejaculation occurred, and finally, the presence of anogenital injuries or ulcerative lesions (especially for BBVs).

# 2.3.1.1 Prevalence of STIs/BBVs in SAC studies

The prevalence of STIs/BBVs among adult and adolescent female victims of sexual assault has been described in several studies. However, the most recent literature reviews are almost 15 years old (56-60), and most studies reviewed were conducted under conditions quite different from today. More sensitive diagnostic tools, such as the nucleic acid amplification test (NAAT) instead of culture, have been developed recently. The use of urine or vaginal swabs, and not only cervical swabs, has simplified collection of samples and a full genital examination is no longer

necessary for the purpose of STI detection.

Studies on STIs after sexual assault are difficult to compare. Different study designs exist, although most are retrospective without follow-up data. Differences in the victims' ages and sexes, sociodemographic factors, countries, proportions examined, and post-assault intervals vary across the studies. In the U.K., where many of the studies are conducted, the acute forensic examination is dealt with by a different health care team than the one dealing with the clinical examination and treatment for STIs<sup>p</sup>. Collecting samples for STI detection is sometimes thought to hamper the quality of trace evidence collection and is mostly devoid of legal interest (61-63). The diseases dealt with (some include PID, candidiasis and bacterial vaginosis, CMV<sup>q</sup> and pediculosis pubis) and the detection rate of the different microbes vary between the studies as different diagnostic approaches are used.

I searched for articles published after 1985 using the MeSH<sup>r</sup>-terms "Sex Offenses" and "Sexually Transmitted Diseases." In addition, I manually checked for citations in the reference lists of the retrieved articles. Studies dealing with children under 12 years of age and those regarding only male victims were excluded. Publications in Scandinavian and English languages were prioritized. The tables below give an overview of the literature published between 2003 and today (named "recent," Table 2) and from 1985 until 2003 (named "older," Table 3). Except for one, all studies in Table 3 are from the U.K. and the U.S. Only one Nordic study has been published, more than 15 years ago (64).

For this thesis, the following STIs and BBVs described in Table 2 and 3 will be explored: "any STI, s", Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and seropositivity for HIV, hepatitis B virus (HBV), and syphilis.

The term "any STI" is reported in a number of studies. Among the most recent studies, eight report prevalence of "any STI": from 5% in a U.S. study (65), varying

<sup>r</sup> Medical Subject Headings

<sup>&</sup>lt;sup>p</sup> STD (sexually transmitted disease) clinic, also called GUM (genitourinary medicine) clinics in the U.K.

<sup>&</sup>lt;sup>q</sup> Cytomegalovirus

<sup>&</sup>lt;sup>s</sup> Serologic markers for BBVs not included in this term

Table 2. Prevalence of sexually transmitted infections (STI)<sup>†</sup> and blood borne pathogens (BBP) among victims of sexual assault, as well as post-exposure prophylaxis offered. Overview of 13 studies published 2003 – 2012, chronologically

			/		
First author, ublication year,	Sample size, setting and, years included, design	STI prevalence, at initial visit (at presentation), No.	BBP prevalence at initial visit (at presentation), No.	Post-exposure prophylaxis: antibiotics,	Sex, age, time from assault, test method, follow-up
ountry		testing positive/no. tested (%)	testing positive/no. tested (%)	HBV <sup>v</sup> vaccination, and HIV PEP (offered/ received) (%)	
Meel,	n=1691 attending a SAC;		HIV: 197/1435 (14%)		All female
2011, South Africa (42)	2001 – 2005; retrospective				Aged 1 – 55 years
Jo,		1: n=104 (33%) (CMV	HIV: 0/313;		All female
2011, South Korea (41)	based service for victims of SA; 2008 – 2010; retrospective	incl.); NG: 19/303 (6%);	HBV: n=1 HBsAg <sup>v</sup> positive; syphilis: 1/316 (0.3%)		Mean age 23 years (± 8.7) Mean 69 h from SA
		CT: 90/312 (29%); > 1 STI: 9/301 (3%)			Cervical PCR-test (CT, NG and CMV)
		Positive for both CT and syphilis, n=1	ilis, n=1		
Adlington, 2011,	n=65 attending an STD clinic	Any STI: 14/63 (22%)	HIV: 0	HBV: 16/23 who came	All but one female
U.K. (66)	after SA; 2005 – 2008;			within 21 days;	Median age 23 years $(12-53)$
	retrospective			HIV-PEP: 2/4 who came <	Median 26 days from SA
				72 h after assault	
Ranney,	n=321 attending a hospital		HIV: 7/285 (2.5%);	Antibiotics: 261/311 (84%);	94% female
2011,	unit; 2007 – 2008;		HBV: 4/203 (2.0%); syphilis: HIV-PEP: 195/309 (63%)	HIV-PEP: 195/309 (63%)	Median age 14 years
Kenya (43)	retrospective		2/257 (0.8%)		97% came within 72 h after SA
Gilles,	n=356 attending a hospital	CT: 18/221 (8%)	HIV: 5/326 (1.5%);	Antibiotics: 144 (40%);	All female
2010,	emergency department; 2002		HBV: HBsAg: 6/311 (2%);	HBV: 12 (3%);	Median age 25 years (15 - 79)
Belgium (67)	<ul><li>2007; retrospective</li></ul>		HCV: 12/318 (4%); syphilis:	HIV-PEP: 62 (18%)	Within 2 days of assault in 85%
			3/270 (1%)		PCR-test used (CT)
Bechtel,	n=114 attending an emergency	Any STI: 6/114 (5%);	HIV: 0/106;	Antibiotics: 88/105 (84%);	98% female
2008,	department; 2004 – 2006;	NG: 1/110 (1%);	HCV: 0/102;	HIV-PEP: 41/60 (68%)	Mean age 14 years (all ≤19 years)
U.S. (65)	retrospective	CT: 5/110 (5%)	syphilis: 0/102		All examined ≤ 100 h after SA
					Urine/swabs, PCR-test (CT/NG)

Forbes, 2008, U.K. (68)	n=69 attending an STD clinic after SA; 2006 – 2007; retrospective	NG: 1/54 (2%); CT: 5/54 (9%); TV: 1/54 (2%)	ніV: 0/28	Antibiotics: 19/45 (42%); HBV: offered if within 6 weeks of assault (n=45); HIV-PEP: n=2 (of 10 who came within 72 h)	All female Median age 26 years (16 - 53) 20% came within 7 days of assault Follow-up attending rate 40/65 (62%)
beyesekera, 2007, U.K. (69)	19 STD clinics reported on n=521 patients, of which n=134 case-notes were reviewed; 2002; retrospective	Any STI, females: 29/111 (26%); > 1 STI: 7/111 (6%)	HIV: n=110 tested (no result given)	Antibiotics: 19%; HBV: 60%; HIV-PEP: 3%	N=120 female, n=14 male Median age 26 years (16 – 60) Examined < 1 – 2 weeks after assault in 36% Follow-up rate 93/120 (76%)
Ackerman, 2006, U.S. (70)	n=812 attending an emergency department after SA; 2001 – 2004; retrospective	NG: 47% tested; CT: 46% tested (no results given)	"Small numbers of positive tests" for HIV and hepatitis	Antibiotics: 696/812 (86%); HIV-PEP: 34/812 (4%)	All female Aged 15 – 80 years Examined "acutely" 36% attended for follow-up
Thompson, 2006, U.K. (71)	n=212 attending an STD clinic; 2002 – 2004; retrospective	Any STI: 23/209 (11%); NG: n=2 (1%); CT: n=19 (9%); genital warts: n=1; genital herpes: n=2; > 1 STI: n=1			90% female Median age 21 (IQR 11) Median 18 days after SA
Das, 2004, U.K. (72)	n=68 attending an STD clinic; 2001 – 2002, retrospective	Any STI: 11/68 (16%); CT: 4/68 (6%); TV: 6/68 (9%); > 1 STI: 1/68 (1%)	n=51 (75%) had syphilis, HBV, HCV and HIV serology tests (no results given)	Antibiotics: 5/68 (7%); HBV: 18/20 presenting within a week	Median age 22 years (12 – 50) 29% came < 1 week after SA Follow-up: 16/20 among those who came < 1 week after SA
Kawsar, 2004, U.K. (73)	n=98 sexual assault victims referred to an STD clinic; 1996 – 2000, retrospective	Any STI: 23/88 (26%) (incl. candida and BV); NG: n=2; CT: 10/88 (11%); > 1 STI: 2/88 (2%)	HIV: 0/33; HBV: 0/57; HCV: 0/57; syphilis: 0/57	Antibiotics: 13/98 (13%); HBV: 8 (8%); HIV-PEP: 0	All females All ≤ 16 years of age, but 84% were ≥ 13 years 17% examined within 7 days n=69 (70%) were followed-up within 3 months
Kerr, 2003, U.K. (74)	n=370 SAC patients who were followed-up for "sexual health counselling"; 2000 – 2001; retrospective	Any STI: 23/211 (11%); NG: n=4 (2%); CT: n=12 (6%); TV: n=6 (3%); genital warts, n=1 (0.5%)	HBV-markers: n=1 (0,5%); syphilis: n=1 (0,5%)	Antibiotics: 47 (7%); HIV-PEP: 34 (5%)	94% females Mean age 26 years (11 -66) STI-screened 6 – 10 days after SA

<sup>&</sup>lt;sup>t</sup> CT: Chlamydia trachomatis; NG: Neisseria gonorrhoeae; TV: Trichomonas vaginalis; CMV: Cytomegalovirus <sup>u</sup> Excluded HBsAb results (immunity) <sup>v</sup> HBV: Hepatitis B; HBsAg: HBs (surface) antigen; HBc (core) antibody; HCV: Hepatitis C virus

Table 3. Prevalence of sexually transmitted infections (STI)<sup>w</sup> and blood borne pathogens (BBP) among victims of sexual assault, as well as post-exposure prophylaxis offered. Overview of 16 studies published 1985 – 2003, chronologically

prophylaxis offer	prophylaxis offered. Overview of 16 studies published 1985 – 2003, chronologically	ıblıshed 1985 – 2003, chror	nologically		
First author,	Sample size, setting and,	STI prevalence <sup>x</sup> , at initial	BBP prevalence <sup>y</sup> at initial	Post-exposure	Sex, age, time from assault, test
ublication	years included, design	visit (at presentation), No.	visit (at presentation), No.	prophylaxis: antibiotics,	method, follow-up, incl. conversion
ear,		testing positive/no. tested	testing positive/no. tested	Hepatitis B vaccination,	from neg. to pos. test
country		(%)	(%)	and HIV PEP (offered/received) (%)	
Gibb,	n=53 attending a hospital STD	NG: n=0/50;		Antibiotics: 22/25 (88%)	All female
2003,	service after SA; 1997 – 1999;	CT: n=4/50 (8%);			>16 years of age
U.K. (75)	retrospective	TV: n=3/50 (6%)			All attended within 2 weeks of SA
					Culture (NG, CT, TV)
					ELISA <sup>2</sup> and wet film (CT and TV)
					Follow-up: 57% by 2 weeks, and 30%
					by 6 – 12 weeks
Riggs,	n=1076 attending a hospital	NG: 12/393 (3%)		Antibiotics: 88%	96% females
2000,	service after SA; 1992 – 1995;	CT: 24/441 (5%)			Median age 23 years $(1-85)$
U.S. (76)	prospective				Probably all acute
					Culture (NG) and ELISA <sup>2</sup> (CT)
Bottomley, 1999,	n=58 attending a hospital	Any STI: 6/41 (15%);	$HBV^{ ext{*}}$ : 1/41 (2.4%);	Antibiotics: 26 %	All female, except n=3
U.K. (77)	service after SA;	NG: 2/41 (5%);	HCV <sup>aa</sup> : 1/41 (2.4%)		Mean age 27 years $(14 - 60)$ .
	1996; retrospective	CT: 3/41 (7%);	(one patient had both)		STI screen advised at ≥ 3 days after
		TV: 1/41 (2%);			SA
		genital warts: n=0;			Follow-up: 50%
		HSV: n=0			
Holmes,	N=411 attending a SAC;	NG: n=20 (5%);	HIV: n=5 (1%);	Antibiotics: 97%	All females
1998,	1995 – 1997; retrospective	CT: n=11 (3%)	HBV: HBsAg: n=1;		Mean age 24 years (12 – 88)
U.S. (78)			syphilis: n=14 (4%)		All examined acute (≤ 72 h?)
					Follow-up: 31% at mean 8 weeks
Worm,	n=28 SAC-patients referred to	Any STI: 0/24;	HIV: 0/27;		All female, except n=3
1997,	a follow-up STD clinic; 1992 –		syphilis: 0/24		Median age 25 years (range 15 – 80)
Denmark (64)	1995; retrospective				Mean 18 days from forensic exam to
					STD clinic visit
					Follow-up: Some had HIV-test at 3-4
					months

Doingr	n=40E attacher a basis	NC: 9/22E /2%).	11/1: 2 /00 (2%).	Antihiotic: 331/300 (EE%)	المراد الا
1994, U.S. (79)	unit after SA; 1990 – 1993; retrospective	CT: 23/292 (8%)	syphilis: 2/326 (1%)	Allubionics: 22 1/333 (33.4)	Median age 21 Median 7 – 11 h from SA
Pavies, 992, J.K. (80)	n=110 attending an STD clinic; 1987 – 1989; retrospective	Any STI: 14/110 (13%); NG: 2/110 (2%); CT: 9/110 (8%); TV: 6/110 (5%); genital warts: 2/110 (2%); HSV: 3/110 (3%); > 1 STI: 14 patients had 22 infections	"No cases of HIV, hepatitis or syphilis were detected"		All female Aged 12 – 61 years Mean 12 days (1 – 134) from SA
Rambow, 1992, U.S. (81)	n=191 attending a hospital after SA; 1983; retrospective	NG: 18/177 (10%)	Syphilis: 1/177 (0.6%) (known from before)		All female ≥ 16 years of age 96% examined within 24 h of SA Culture (NG); FTAA® (syphilis) Follow-up: n=1 (of 101) converted to a pos NG test after 3 – 5 days; n=2 (of 55) seroconverted (syphilis) suggesting infection acquired at the time of assault
Glaser, 1991, U.S. (82)	n=76 attending a hospital emergency "room; 1983 – 1986; <b>prospective</b>	NG: 2/76 (3%); CT: 13/76 (17%); TV: 15/76 (20%); HSV: 0	Syphilis: 0%	Antibiotics: n=63 (83%): i.m. inj. of penicillin; oral tetracycline for 7 days (for n=7)	All postpubertal female Mean age 22 years (range 13 – 48) All within 60 h of SA Culture (CT) and serology <sup>å</sup> (CT) Followed-up: 76% after 2 weeks; 49% after 6 – 12 weeks Assault transmitted CT-infection, n=9 (16%) (positive culture and serology titer rise at follow-up)
Ross, 1991, U.K. (83)	n=43 attending an STD clinic after SA; 1987 – 1989; retrospective	Any STI: 6/43 (14%); NG: n=1 (2%); CT: n=2 (5%); TV: n=1 (2%); genital warts: n=1 (2%);	HIV: 0/25 (0%)		All female Mean age 26 years (range 16 – 63) Mean 7 weeks after SA Followed-up: 70% after 2 weeks

<sup>&</sup>quot; CT: Chlamydia trachomatis; NG: Neisseria gonorrhoeae; TV: Trichomonas vaginalis; HSV: Herpes simplex virus \* Only urogenital tests results given

Y Excluded HBsAb results (immunity)

Excluded HBsAb results (immunosorbent assay

ELISA: Enzyme-linked immunosorbent assay

HBV: Hepatitis B; HBsAg: HBs (surface) antigen; HBc (core) antibody; HCV: Hepatitis C virus

Fluorescent treponemal antibody absorption test

Chlamydial microimmunofluorescence IgM and IgG

Table 3. Prevalence of sexually transmitted infections (STI)" and blood borne pathogens (BBP) among victims of sexual assault, as well as post-exposure prophylaxis offered. Overview of 16 studies published 1985 – 2003, chronologically

pi opinylaxis or	propriylaxis oriered: Overview or to studies published 1969 – 2005, cili oriologically	Julisiieu 1303 – 2003, Cili 0	illologically		
First author,	Sample size, setting and,	STI prevalence <sup>x</sup> , at initial	BBP prevalence <sup>v</sup> at initial	Post-exposure	Sex, age, time from assault, test
ublication	years included, design	visit (at presentation), No.	visit (at presentation), No.	prophylaxis: antibiotics,	method, follow-up, incl. conversion
sar,		testing positive/no. tested	testing positive/no. tested	Hepatitis B vaccination,	from neg. to pos. test
country		(%)	(%)	and HIV PEP (offered/received) (%)	
		HSV: n=1 (2%)			
Tucker,	n=1007 attending a hospital	Any STI (syphilis. incl.):	HIV: No routine testing;	Did not offer HIV-PEP	No sex and age given
1990,	emergency department;	147/919 (16%);	syphilis: 8/804 (1%)		n=994 (99%) examined ≤ 17 h after
U.S. (84)	treated by SARS <sup>aa</sup> nurses; 1985	NG: 46/191 (5%);			SA
	– 1989; retrospective	CI: 33/465 (7%);			
Estreich,	n=124 attending an STD clinic	Any STI: n=36 (29%);	HIV: 1/44 (2.3%);		All female
1990,	after SA;	NG: n=15 (12%);	HBV: n= 1/92 (both HBsAg		Mean age 26 years (range 16 - 45)
U.K. (85)	1986 – 1989;	CT: n=6 (5%);	and HBeAg positive);		46% examined within 2 weeks of SA
	retrospective	TV: n=15 (12%);	syphilis: 0/123		Culture (CT, NG); smears <sup>bbcc</sup> (NG, TV)
		genital warts: n=6 (5%);			Follow-up: 84% at mean 31 days,
		HSV: n=2 (2%) (unlikely to			and 61% at mean 11 weeks
		have been ass. with the			n=3 women had STI on follow-up
		rape);			only and no intervening coitus: CT:
		> 1 STI: n=18 (15%)			n=1; genital warts, n=2
					n=37 of those with a neg. HBV test
					were re-tested at > 3 months
Lacey,	n=90 presenting to a SAC	Any STI: n=13 (14%);	Syphilis: 0		All female
1990,	following SA;	NG: n=2 (2%);	HIV: 0/6 (after 3 months)		Mean age 25 years (range 13 — 77)
U.K. (86)	1989; retrospective	CT: n=7 (8%);			27% within 48 h of SA
		TV: n=6 (7%);			Culture (CT, NG); smears <sup>eeff</sup> (NG, TV);
		genital warts: n=2 (2%);			serology (CT)
		> 1 STI: n=3 (3%)			Follow-up: n=43 (48%) after 2
					weeks, n=41 (45%) after 3 months
					(serology)
Sturm,	n=232 victims of sexual assault	Any STI: 5%;		Not offered	All female
1990,	attending a hospital	NG: 10/210 (5%);			Mean age 23 years (range 3 – 94)
U.S. (87)	emergency department;	CT: 13/213 (6%);			Follow-up: n=73 (32%) at 1 week:
	1987 – 1988; retrospective	> 1 511: 2/ 203 (1%)			n=1 converted to a positive CI-test

Jenny,	n=335 attended a hospital	NG: 13/203 (6%);	HIV: 1/123 (0.8%); syphilis: Antibiotics: 59 (29%)	Antibiotics: 59 (29%)	All postmenarcheal female
1990,	after recent SA, n=204 were	CT: 20/198 (10%);	2/199 (1.0%)		Mean age 25 years $(12-37 \text{ years})$
U.S. (88)	screened for STI at initial visit;	TV: 30/204 (8%);			Examined < 72 h after SA
	1985 – 1986; prospective	HSV: 4/170 (2%);			Follow-up: n=109 (53%) after two
					weeks; $n=52 (26\%)$ after $6-12$
					weeks
					Conversion to positive test: NG:
					3/109 (4%); CT: 1/109 (2%); TV
					<b>10/109 (12%)</b> None seroconverted
					(HSV, HIV, Syphilis) at follow-up
Tintinally, 1985,	n=372 attending a hospital	NG: 5%	Syphilis: 2% (VDRL)	Antibiotics: 92 %	All female
U.S. (89)	emergency department;				Mean age 25 years $(13 - 78)$
	1980; retrospective				79% examined ≤ 24h after SA

 <sup>&</sup>lt;sup>28</sup> Sexual Assault Resource Service
 <sup>29</sup> Gram-stained smears collected from the urethra, cervix and/or rectum, examined for Gram-negative intracellular diplococcic (NG)
 <sup>20</sup> Vaginal smears suspended in saline and examined microscopically (TV)

between 11 and 26% in the U.K. studies (66, 69, 71-74) and as many as 33% in the study from South Korea (41). Among the older studies, the one from Denmark did not disclose any STIs at all (64), while seven of the other older studies found a prevalence of "any STI" between 5 and 29% (77, 80, 83-87).

One of the most common STIs worldwide is due to CT. No recent Nordic SAC study has been published on the prevalence of CT, except for one from the Copenhagen SAC presented at a conference in 2008. In that study, 10% tested positive for CT (90). Among the recent publications (Table 2), the CT prevalence varies from 5% in a U.S. study (65), through 6-11% in the U.K. and Belgian studies (67, 68, 71-74), to as high as 29% in the South Korean study (41). Older SAC studies show a CT prevalence of 5-8% in the U.K. (75, 77, 80, 83, 85, 86), and as high as 10-17% prevalence in two of the U.S. studies (82, 88).

Because the NG and TV microbes were more prevalent in the U.K. and U.S. during the 1980s and 1990s than currently, most of the SAC studies presented in Tables 2 and 3 give numbers of positive tests for these STIs. Of the recent studies, those from the U.K. and the U.S. report 1-2% of patients testing positive for NG (65, 68, 71, 73, 74), while the study from South Korea reports 6% (41). Only two of these studies describe the diagnostic tools used. The one from South Korea and one of the U.S. studies both used PCR-diagnostics (41, 65). Many of the older studies report a NG prevalence of 5-12%, and even if not always stated, probably all were diagnosed by the less sensitive culture test (77, 78, 81, 84, 85, 87-89). Among the recent SAC studies, only three, all from the U.K., report TV-prevalence, between 2 and 9% (68, 72, 74), while two of the older studies report as many as 12-20% being infected with the microbe (82, 85).

Of great concern for many victims of sexual assault worldwide is the fear of contracting a BBV infection, especially HIV. Among the recent SAC studies, eight report HIV prevalence ranging from mostly 0 (41, 65, 66, 68, 73) through 1.5-2.5% in Kenya and Belgium (43, 67) to as high as 14% among South African SAC patients (42). However, in the older studies, testing for HIV was less common and reported in only seven studies with results between 0 and 3% (64, 78-80, 83, 85, 88). Prevalence of HBV

markers was low in all studies, although the definition of HBV markers was not always specified. Of the markers, hepatitis B surface antigen (HBsAg<sup>33</sup>) was most frequently reported. In the recent studies, less than one percent of all SAC patients tested positive for HBV markers in the U.K., the U.S. and even in South Korea (41, 70, 73, 74). In the Belgian and Kenyan SACs, 2% tested positive for HBV markers, respectively (43, 67), the former reporting a high proportion of non-Western patients. Four of the older studies report similar low numbers of patients with HBV markers (77, 78, 80, 85). Finally, syphilis was found in  $\leq$  1% in six of the recent SAC studies (41, 43, 65, 67, 73, 74), while almost all the older SAC studies reported on prevalence of positive test for syphilis of up to 4% (64, 78-82, 84-86, 88, 89).

# 2.3.1.2 Post-exposure prophylaxis (PEP)

Most Nordic SACs offer antibiotics and anti-viral prophylaxis following a sexual assault. For those SAC studies reporting STI/BBV prevalence, the proportions of SACs which offered such prophylaxis are shown in Tables 2 and 3. According to the recent studies, only 7-42% of the U.K. and Belgium SACs offered prophylactic antibiotics (67-69, 72-74), while 84-86% offered such treatment in the U.S. and the Kenyan SACs (43, 65, 70).

Whether anti-viral prophylaxis was offered to victims depends on when they sought health care. Hepatitis B prophylaxis was offered to only those who presented to a SAC up to 6 weeks after the sexual assault, and only to 3 – 70% of those victims (Table 2) (66-69, 72, 73). Anti-HIV PEP was offered to a proportion of those attending SACs within 72 hours of the assault, to between 0 and 68% of the victims. Again, the lowest numbers are reported in the U.K., and the highest numbers in one of the U.S. and the Kenyan studies (43, 65-70, 72-74).

Some SAC studies do not report STI prevalence, but instead describe the use of post-exposure prophylaxis. In a Danish SAC<sup>34</sup>, only 26% were offered antibiotic prophylaxis in the year 2000 (20), while this had increased to 70% in the period from

<sup>33</sup> HBsAg indicates current hepatitis B infection

<sup>&</sup>lt;sup>34</sup> At the Rigshospitalet, Copenhagen

2001 – 2005 for the same SAC (90). According to a U.S. study, 77% were offered antibiotic prophylaxis and 19% HIV prophylaxis (91). In a Brazilian SAC, 87% were offered antibiotics, 83% HBV-vaccine and a further 84% HIV-PEP (45), probably reflecting a greater fear than in Western countries of contracting BBVs after a sexual assault. In an Israeli study, all victims were offered antibiotics, and 40% were offered anti-HBV treatment, but HIV-PEP was given to only 14% (44). In Canada, even if offered and initiated, only 34% of adolescent rape victims completed the 4-weeks course of the HIV-PEP (92).

#### 2.3.1.3 Assault-transmitted STI/BBV

Some studies have tried to deduce whether STIs detected following a sexual assault could have been assault-transmitted. Such a conclusion can easily be justified for patients with no previous coital experience. Even if an STI is diagnosed at the initial visit shortly after a sexual assault, low levels of the microbe might be detected if infected semen is caught in the swab (93). This has been found to be the case for 1 – 4% of the total group of SAC patients (Table 2 and 3) (41, 73, 82, 85).

Although most studies report that victims' recent consensual coital activity makes it impossible to attribute the infection to the assault (41, 66, 71, 94), it is important to emphasize that patients with previous coital experience can catch assault-transmitted infections. We have found one study describing a case of assault-transmitted genital herpes (71). Another study reported that two patients were found to have an STI and had not been sexually active within the 3 months prior to the sexual assault (86), thereby suggesting assault-related transmission, but this could be harder to prove.

Only two of the studies in Tables 2 and 3 are prospective, both U.S. studies which collected information as far back as the mid-1980s. These studies included follow-up visits. Jenny, *et al*, defined an STI as assault-transmitted if it was detected at the follow-up visit, but not at the initial visit, and no treatment with targeted antimicrobial agents had been given in between visits (88). A total of 14 STIs were found on follow-up tests and suspected to be assault-transmitted: one patient had CT, three had NG,

and ten had TV. However, excluding new transmission of an STI from intervening consensual coital activity might still be difficult. Glaser, *et al*, used a different diagnostic tool which is no longer in use: CT culture combined with a rise in the "titre" of CT antibodies. Together with a history of no other recent sexual activity, this was interpreted as assault-transmitted CT infection, and nine patients qualified for this description in the follow-up period (82). In the same study, the researchers assumed that five other patients contracted TV infection during their assaults. Although retrospective, two other studies each described a case of CT infection detected at the follow-up only (85, 87). However, only one of these studies had information on intervening coitus (85).

Among the older studies reporting from a period in which syphilis was more common, none of the patients who were initially seronegative for syphilis had a positive test at the follow-up visit (78, 82, 88). Only four studies reported follow-up of as long as 3 months (64, 68, 78, 88), but even within this timeframe, a few patients (0 – 2%) seroconverted to HIV positive. Contracting HIV or hepatitis B after a sexual assault has also been described in case reports (95, 96).

With this thesis, I want to deepen this prior research by adding new information about the prevalence of STIs in patients attending a Norwegian SAC, and by discussing the proportion of these STIs that could be assault-transmitted. Even if our SAC is police-independent, assault-transmitted STI could be of legal interest in selected cases.

# 2.3.2 Toxicological findings – Drug-facilitated sexual assault (DFSA)

A substantial proportion of women contacting SACs or the police claim to have been involuntarily drugged and sexually assaulted, or sexually assaulted while asleep or in a state that rendered them unable to consent or resist (23, 26, 97-101). Sometimes the woman does not remember or know exactly what has happened, but may have a vague feeling of genital discomfort or may have woken up in a disheveled state and missing her underwear. Others may have told her about her participation in sexual activity, or shown her explicit images or video recordings. Some of these

patients may have been subjected to involuntary drugging<sup>35</sup> with medicinal or illicit drugs (so-called "date rape drugs") followed by sexual assault. For decades, it has been known that certain fast-acting color-, odor-, and tasteless drugs can be added to drinks, inducing a hypnotic condition, loss of memory, and impaired motor activity and judgment, and therefore facilitating lack of resistance to sexual activity. Unfortunately, most of these substances have a short biological half-life.

# 2.3.2.1 Definition of DFSA

A comprehensive definition of drug-facilitated sexual assault (DFSA) was given during Operation Matisse in the U.K., when the Association of Chief Police Officers cooperated with the Forensic Science Service and the Sexual Assault Referral Centers (SARCs) in 2006. This work divided the phenomenon into two categories, denoted "proactive" and "opportunistic" DFSA (102). The former is defined as deliberate surreptitious drugging, i.e., covert administration of drug(s) to an unsuspecting victim, as described above. The latter category includes taking advantage of someone already inebriated or intoxicated by voluntary ingestion of drugs or alcohol. A situation including both of these conditions is also possible, with the victim being intoxicated because of both voluntary and involuntary ingestion of drugs (103). In all of these cases, valid consent to sexual activity is precluded. In this thesis, I use the terms "proactive" and "opportunistic" DFSA as described above.

# 2.3.2.2 Prevalence of DFSA

Studies describing the proportion of assaulted victims who suspect proactive DFSA are usually either surveys of the entire female population or information collected from the police or SACs. These studies often include information on self-reported intake. An example is a population-based survey among more than 5,000 female college students in the U.S., reporting that 15% of those exposed to sexual assault during the past year suspected proactive DFSA (104). An additional 57% reported voluntary intake of alcohol and drugs before the assault (opportunistic DFSA).

<sup>&</sup>lt;sup>35</sup> Also called "chemical submission" or spiking

Western SAC studies report that between 12 and 26% of patients suspect proactive DFSA (23, 97-99), and the prevalence seems to be increasing (19, 97, 100). Furthermore, the proportion of victims attending SACs or the police after sexual assault and reporting intake of alcohol before the assault is 47 - 77% (26, 97, 98, 105-109) and, for illicit drugs, 9 - 20% (26, 98, 107). However, only three of these studies included results of toxicological analyses.

# 2.3.2.3 Prevalence of alcohol/drug findings in DFSA laboratory studies

Toxicological test results of urine/blood samples collected from rape victims are often published from forensic laboratories, but sometimes also originate from SAC or police records. Most sexual assaults included in these studies are police-reported.

A comprehensive review of the literature regarding the toxicological findings of drugs and alcohol in DFSA cases (110) includes 11 studies from Western countries (the U.S., France and the U.K.) published between 1996 and 2005 (111-121). After 2005, we have found nine similar studies, again all Western, but from a broader group of countries (105, 106, 122-128), presenting toxicological laboratory test results among sexual assault victims. We chose not to present studies including other crimes, such as robbery or murder (129). The results of studies published after 2005 are presented in Table 4, modified after Beynon, *et al* (110).

The toxicological studies differ in many directions. Firstly, the indication for testing varies. Many of the studies published before 2005 were initiated from toxicological laboratories, and included only victims suspecting proactive DFSA (111, 114, 117, 118, 121). However, in some of the early U.S. studies, sexual assault victims were screened "when drug use was suspected to be involved" and "at the examiner's discretion" (113, 115, 116, 119). Again, in the three Nordic studies, a rather unselected proportion of SAC/police-reported sexual assault victims were tested (106, 124, 127).

Secondly, test material varies across the studies. In most of the 20 studies in Table 4, urine was screened for a selection of drugs (105, 111-113, 115-128), with or without the addition of collected blood samples. One of the studies included blood tests only (106), which diminishes the time window for the detection of substances

Table 4. Toxicological findings among victims of sexual assault and specifically in cases of drug-facilitated sexua

First author, publication year, country	Sample size, setting, years included, design	Method, time from assault	Number and/or percentage of the sample where ea		
		-	Illicit	Sedatives	
Birkler, 2012, Denmark (106)	n=167sexual assault victims recruited from a SAC (i.e, 63% of all the SAC victims); 2007 –2009; prospective	Blood only. Median time from sexual assault7 h (mean 13)	Illicit drugs in 7%	Benzodiazepines 10%; opioids 1%	
Jones, 2012, Sweden (127)	n=1460 female police reported sexual assault victims; from a national forensic toxicology laboratory; 2008 – 2010; retrospective	Urine and/or blood. No info on time from SA	Cannabis 6%; amphetamines 4%	Benzodiazepines > 6%: diazepam 6%; alprazolam 2%; zopiclone 2%. Opioids 1%. Anti-depressants 2%	
Bosman, 2011, The Netherlands (126)	N=135 DFSA cases (94% women), data from police files and a national Forensic Institute; 2004 – 2006; retrospective	Urine and/or blood 42%; urine only 37%; blood only 21%. Time from SA: < 12 h 40%; 12 – 24 h 21%; > 24 h 22%; unknown 17%	Cocaine 14%; MDMA 10%, cannabis 10%, amphetamines 4%	Benzodiazepines 10% (incl. flunitrazepam 1%); zolpidem 1%; codeine 1%; methadone 1%; GHB 2%; ketamine 1%	
Du Mont, 2010, Canada (125)	n=178 sexual assault victims ≥ 16 years (i.e., 20% of those attending the SACs); 2005 – 2007; prospective	Urine tests only. 80% came < 24 h; all ≤ 72 h of the SA	Cannabis 34%; cocaine 21%; amphetamines 7%; MDMA 7%	Benzodiazepines > 6%: lorazepam 6%; flunitrazepam 0%. Anti-depressants 7%. GHB 1%. ketamine 1%	
Hall, 2008, Northern Ireland (123)	n=294 police reported DFSA cases (i.e., 28% of all police reported rapes); toxicological tests at a	Urine and/or blood. No info on time from SA	Cannabis 8%; central stimulants 3%	Analgesics 13% (of these opioids 10%); benzodiazepines 11%; anti-depressants 4%	

 $^{36}$  BAC (blood alcohol concentration) in g/L (‰), mean and range [ ] or SD (standard deviation) given

national Forensic Service;

1999 – 2005; retrospective

assault (DFSA). Overview of nine studies published after 2005 (modified after (110))

drug was detected			Voluntary intake vs. findings, strength and limitations	
	Alcohol, BAC <sup>36</sup> at assault	Other	-	
	Alcohol 35%	At least one drug in 50%: alcohol only in 29%; alcohol + other drug(s) in 7%; other drug(s) only in	In 20% (4 out of 20) sedative drugs were detected, which were not reported (taken voluntarily) by the victim	
		14% (Non-sedative drugs in 6%)	Strengths: Active inclusion into study. Control group of non-DFSAs. Information on intake and suspicion of DFSA.	
			Limitations: Only those who agreed to participate in the study. Small sample size. Only blood tests included. Includes non-sedative prescription drugs in the analyses	
	Alcohol 54%. Mean BAC at time of sampling 1.2	At least one drug in 68%: alcohol only 41%; alcohol + other drug(s) 13%; other drug(s) only 14%	Strength: Large sample size  Limitations: No information on voluntary intake. Retrospective	
	Alcohol 38%.  Mean BAC at time of sampling 1.2 ± 0.07; mean BAC at time of assault 2.0 ± 0.07	At least one drug in 73%: alcohol only in 19%; alcohol and drug(s) in 19%; drug(s) only in 35% (Non-sedative drugs in > 20%)	Strengths: Includes details of alcohol/drug combinations case-wise  Limitations: No information on voluntary intake. Retrospective. Small sample size. Includes non-sedative prescription drugs in the analyses	
	Alcohol 31%	At least one drug in 76%: alcohol only in 13%; alcohol and drug(s) in 18%; other drug(s) only 45%	In 49% drugs were detected, which were not reported voluntarily ingested by the victim  Strengths: Well defined definition of DFSA, study group, and flow chart. Information on voluntary intake, and time from assault. Prospective inclusion.	
	Alcohol 56%.  Mean BAC at time of assault 2.0 [1.0 – 4.1] estimated among those sampled within 12 h	At least one drug in 69%: alcohol only in 34%; alcohol + other drug(s) in 18%; other drug(s) only 13%	Limitations: Urine only. Small sample size. Limitations: No information about self- reported intake. Retrospective. Includes non-sedative prescription drugs in the analyses	

First author, publication year, country	Sample size, setting, years included, design	Method, time from assault	Number and/or percentage of the sample where ea		
			Illicit	Sedatives	
Jones, 2008, Sweden (124)	n=1806 police reported alleged female SA, examined at a national forensic toxicology laboratory, 2003 – 2007; retrospective	Urine and/or blood 79%; urine only 9%; blood only 12%. No info on time from SA	Cannabis 6%; amphetamines 5%; ecstasy < 1%; heroin metabolites < 1%; cocaine < 1%	Benzodiazepines 8%: diazepam 5%; flunitrazepam 1%; zopiclone 2%; codeine 2%; GHB < 1%; other pharmaceuticals 12%	
Juhascik, 2007, U.S. (122)	N=144 sexual assault patients (i.e, 17% of those attending the SACs), cases of "DFSA" defined as "those with a positive toxicological test <72 h"; patients from SAC records; 2002 – 2004; prospective	Urine. Time from sexual assault mostly < 72 h (2 – 456 h]	Cannabis 33%; cocaine 18%; amphetamines 7%	Opioids 7%; benzodiazepines 3% (incl. flunitrazepam in > 1%)	
Hurley, 2006, Australia (105)	n=76 DFSA cases (i.e., 18% of police reported adult SA); data from files of an Institute of Forensic Medicine; 2002 – 2003; retrospective	Urine and blood if < 24 h after SA, urine only if > 24 h. Median time from sexual assault 20 h (2 – 106 h)	Among those not reporting intake, n=15: cannabis n=4; amphetamines n=4  Among those reporting intake, n=20: ≥ 1 "recreational drug" found in all but 3 cases	Among those not reporting intake, n=15: diazepam, n=4; opioids n=4; antidepressants n=5; antipsychotics n=1  Among those reporting intake, n=26: "prescription medications" found in all but one case	
Read, 2005, U.S. (128)	n=464 sexual assault victims (i.e. 45% of police- reported rapes); data from female patients' records; 1997 – 1999; retrospective	Urine and blood. No info of time from SA	Cocaine 28%; cannabis 12%; "other <sup>37</sup> " 6%	Opiates 15%	

<sup>&</sup>lt;sup>37</sup> "Other": phencyclidine, barbiturates, amphetamines, benzodiazepines

assault (DFSA). Overview of nine studies published after 2005 (modified after (110))

drug was detected		Voluntary intake vs. findings, and limitations	
	Alcohol, BAC <sup>36</sup> at assault	Other	-
	Alcohol 55%  Mean BAC at time of sampling 1.2 [0.1 – 3.7]; mean estimated BAC at time of assault 2.0 [1.7 – 2.5]	At least one drug in 69%: alcohol only in 43%; alcohol + other drug(s) in 12%; other drug(s) only in 15%	Strength: Large sample size  Limitations: No info regarding proactive  DFSA suspicion, no information regarding voluntary intake; only assumed interval from sexual assault to ≈ 5 h; retrospective
	Alcohol 10%	At least one drug in 43%  Positive for more than one drug 30%	Several cases (no exact proportion given) had drugs detected, which were not reported voluntarily ingested by the victim
			Strengths: Relates findings to self- reported intake, prospective study inclusion.
			Limitations: Small sample size
	Alcohol 37%.  Mean BAC at time of sampling 1.1; mean estimated BAC at time of		In 20% drugs were detected, which were not reported voluntarily ingested by the victim
	assault 2.6 [2.2 – 3.3]		Strengths: gives results according to reported intake
			Limitations: Retrospective chart review. Small sample size. Restricted to unexpected findings
	Alcohol 23%	At least one drug in 53%: alcohol only in 12%; alcohol + other drug(s) in 11%; other drug(s) only 30%	Strengths: contains patient and assault characteristics  Limitations: no information about self-reported intake or DFSA suspicion.

and decreases the number of positive tests compared to urinary testing (130). On the other hand, adding a blood test yields an opportunity to relate the drug concentration to the clinical status, as done in two of the early studies (111, 118) and in six of those published after 2005 (105, 123, 124, 126-128).

Biological specimens for toxicological analyses should be collected as soon as possible after a suspected assault, since detection times for the different drugs vary considerably and for some are very short (131), see Table 5. Thus, a toxicological test may turn out to be a false negative after an interval of > 12 hours in certain cases, for example, after alcohol or gamma-hydroxybutyric acid (GHB) ingestion. In almost all previous U.S. studies (112, 113, 115, 116, 119, 121), and in one French study (117), 90 – 100% of the samples were collected within 72 hours. In more recent studies, most or all of the patients attended the SAC within 72 hours – see the U.S. and the Canadian studies, respectively (122, 125) – and 61% attended within 24 hours in the Dutch study (126). The post-assault interval was given as a median (7 and 20 hours) in two other studies (105, 106). However, in four studies, the post-assault interval was not mentioned (123, 124, 127, 128).

Table 5. Time limits for detection of drug in urine (modified from (131) and (103))

Drug	Time detectable <sup>38</sup>
Alcohol	7 – 12 hours
GHB <sup>39</sup>	7 – 12 hours
Diazepam	14 – 21 days <sup>40</sup>
Other benzodiazepines (flunitrazepam, oxazepam, clonazepam, nitrazepam,	3 – 7 days
alprazolam)	
Z-hypnotics (zopiclone, zolpidem <sup>41</sup> )	12 - 24 hours
Cannabis (THC)	3 – 40 days <sup>42</sup>
Opiates/opioids (morphine, codeine, oxycodone, methadone, heroin)	2 – 5 days
Amphetamines (and methamphetamines)	2 – 9 days
Ecstasy (MDMA <sup>43</sup> , MDA <sup>44</sup> )	2 – 3 days
Cocaine	2 – 5 days

 $<sup>^{\</sup>rm 38}$  There is considerable individual variation in the persistence of these substances in urine

<sup>&</sup>lt;sup>39</sup> Gamma-hydroxybutyric acid

Detected as the metabolites desmethyldiazepam and oxazepam

<sup>&</sup>lt;sup>41</sup> Following therapeutic doses: for zolpidem: 12 hours, and for zopiclone: 24 hours

<sup>42</sup> After regular use of cannabis, THC is sometimes detected at low concentrations several months after last intake

<sup>&</sup>lt;sup>43</sup> MDMA=3,4-methylenedioxymethamphetamine

<sup>44</sup> MDA=3,4-methylenedioxyamphetamine

Several different drugs were detected across the studies, as shown in Table 4. In older studies reporting the proportion of positive tests for at least one drug, including ethanol, the range varied from 59 to 69% of victims in the U.S. and the U.K. studies (113, 115, 116, 118-121), to as high as 77 – 83%, mostly for benzodiazepines in the selected French series (111, 117). Among the more recent studies, 43 – 53% of the victims tested positive in two U.S. studies and one Danish study (106, 122, 128), the lower numbers probably reflecting the more unselected material in one of the U.S. studies (128), and a relatively low proportion of positive ethanol tests in the two others (106, 122). This again might be caused by a long interval between the assault and the test, and by blood only being used for the analyses. In the remaining recent studies reporting total numbers of positive tests, 68 – 76% of victims of sexual assault tested positive for at least one drug (123-127).

Regarding drugs other than ethanol, prevalence vary according to country, and hence the proportion of illicit drugs in the community, and the number and type of drugs screened for. The proportion of positive tests for drugs other than ethanol in the Nordic toxicological studies ranged from 21 to 27% of victims (106, 124, 127), while 31% were drug positive in a series from Northern Ireland (123). The Dutch laboratory study found that a total of 54% of victims tested positive for at least one drug other than ethanol, although a considerable proportion of the detected drugs were non-sedative medicinal drugs assumed not relevant in DFSA cases (126). In the most recent U.S. and Canadian studies, up to 63% of victims tested positive for drugs other than ethanol; illicit drugs not typically considered "date rape drugs" (e.g., cannabis and cocaine) were detected in about one third of the cases (122, 125, 128). Similar high proportions of illicit drugs were found also in some of the older U.S., French, and U.K. studies (113-116, 118-121), probably reflecting the fact that recreational drug use was and is more common there compared to in the Nordic countries (132-134).

Benzodiazepines and related agents (zopiclone, zolpidem) are assumed to be more relevant in proactive DFSA. In two of the older French studies, positive tests for benzodiazepines dominated, since detecting such drugs was the main purpose of their toxicological analyses (111, 117). However, in most of the other studies,

benzodiazepines were found only in a minority of cases (3 - 13%), and most of those were not what we usually characterize as the classical date rape drugs (Table 4) (105, 106, 113-116, 118, 119, 121-128).

Several studies have screened for "typical" date rape drugs, that is, flunitrazepam and GHB. Flunitrazepam was only detected in 0-1% of the cases in the 15 studies reporting it (105, 106, 112, 113, 115, 116, 118, 119, 121-127), while GHB was found in 0-4% of the subjects, with the highest proportions in the older U.S. studies (105, 113, 115, 116, 118, 119, 121, 123-127). In another British study of 120 police-reported rapes, flunitrazepam was detected in no cases, but GHB was found in two (102). The newer, rapidly metabolized sedative drugs, such as the z-hypnotics – zolpidem and zopiclone – were present in only 0-2% of the subjects in studies published after 2004 (118, 122, 124, 126, 127).

## 2.3.2.4 Suspicion of proactive DFSA compared to voluntary intake

Of the 20 toxicological studies, only five (105, 106, 118, 122, 125) contain information about victim-reported voluntary intake of alcohol and/or drugs before the assault, and exclude such intake from their interpretations. In the only large-scale case series of police-investigated rapes, the U.K. authors concluded that only 2% of victims had been subjected to proactive DFSA with sedating or disinhibiting drugs, mostly benzodiazepines (not flunitrazepam), but also zopiclone, antihistamines, antidepressants, GHB and ecstasy (118). In an Australian retrospective study, 20% of the positive drug findings were unexpected (benzodiazepines, excluding flunitrazepam; opioids; antidepressants; cannabis; and amphetamines) (105). However, voluntary use of prescription medication and recreational drugs was missing in these studies in as many as 46 and 63% of the subjects, respectively. The U.S. prospective study presented some of the cases classified as DFSA, but even if impairment caused by the drugs detected in these victims was obvious, only one of the patients actually seemed to be surreptitiously drugged by oxazepam and an antihistamine. The authors claimed that self-reported intake of drugs was unreliable (122). In the prospective Canadian study, in as many as 49% of those suspecting proactive DFSA, unexpected findings

were not attributable to self-reported voluntary ingestion (125). Once again, however, the most frequent unexpected findings were not the typical date rape drugs, but illicit drugs like cannabinoids, cocaine, and amphetamines, whereas benzodiazepines, ketamine and GHB were seldom seen. Finally, the recent Danish prospective study reports that among 20 patients suspecting proactive DFSA, four had a positive blood test for one or more sedative drug (benzodiazepines, but not flunitrazepam, a barbiturate, and oxycodone) not reported to be taken voluntarily, and might thus have been drugged prior to the assault (106). Further substantiation of the suspected drugging in a court of law was not described in any of these studies, and these cases may be difficult to prosecute even when a drug test actually turns out positive.

#### 2.3.2.5 Blood ethanol concentration in DFSA cases

Positive tests for ethanol have been described in almost all the above-mentioned studies (105, 106, 113-116, 118, 119, 121-128), and for the U.K. study, even reported in detail in a separate publication (135). Between 10 and 56% of those tested were positive for ethanol. A discrepancy between the proportion of victims reporting voluntary intake of alcohol and the proportion testing positive is common, mostly because of a long post-assault interval (105, 106, 125). Mean blood alcohol concentrations (BAC) at the time of sampling are usually high, between 1.1 and 1.2 g/L (105, 124, 126, 127). Even more important is the back-calculated mean BAC at the time of the assault, which was estimated to be between 2.0 and 2.6 g/L in four studies (105, 123, 124, 126), and in the U.K. study, 74% of those testing positive for ethanol within 12 hours of the assault had an estimated BAC of > 1.5 g/L at the time of the assault (135). The authors of the latter study claimed that such a degree of inebriation in itself would render the victim unable to give valid consent to sex, a statement that could be used as legal evidence of opportunistic DFSA. Similar high ethanol levels were also described in the smaller British crime study (102).

# 2.3.2.6 Associations between ethanol/drug findings and certain characteristics

A few studies have investigated which characteristics are associated with positive

tests for alcohol and/or drugs among victims of sexual assault.

The Swedish authors demonstrated that mean BAC at time of sampling differed between age groups, specifically, an increased BAC was seen with increased age (124, 127). Different kinds of drug findings have also been described for the different age groups. Those testing positive for ethanol, the antidepressant fluoxetine, and/or cannabis were younger (mean 23 - 25 years) than those testing positive for codeine, zopiclone, and/or amphetamine (mean 34 - 39 years) (127). In a U.S. study, the likelihood of testing positive for alcohol and/or drugs increased with age (128). The drug most often found among those 13 - 16 years old was cannabis (16%), while half of the subjects aged 31 - 50 years tested positive for cocaine.

During the period from 2003 to 2010, the annual number of toxicological analyses in rape cases increased in Sweden (127), but the proportion of victims testing positive for ethanol and/or drugs and the mean BAC remained stable. This is in contrast to results from Northern Ireland, where the proportion of victims testing positive for alcohol and/or drugs rose during the period from 1999 to 2005 (123).

In a U.S. study, a positive test for ethanol was most common among those assaulted at a friend's home, while those testing positive for other drug(s) were usually assaulted while walking; 58% of the drug-positive victims were assaulted by a stranger (128). In addition, those testing positive for drugs more often had extragenital injuries.

# 2.3.3 Extragenital injuries, anogenital injuries, and trace evidence

In Western countries, most injuries in women exposed to sexual assault are fortunately minor and of limited relevance to the woman's health. However, even minor injuries can be crucial in some cases for a police investigation and decisive to a legal outcome. Collecting such medico-legal evidence is sometimes problematic. The search has the potential to be harmful since it requires the assaulted woman to endure an "unnecessary" gynecological examination.

Also, even if medico-legal evidence is used to some degree by the police and prosecuting authorities in cases of rape, the weight of this contribution to the evidence in the progression of rape cases through the legal system is unclear (136). A global

literature review of the impact of medico-legal evidence in sexual assault cases was conducted in 2007 (52) and included 12 papers to map associations between particular types of medico-legal findings (e.g., injuries or sperm) and legal outcomes (e.g., charge filing or conviction) in adolescent and adult sexual assault cases (19, 81, 89, 137-145). Nine of these studies were from North America and another three from the Nordic countries, albeit the latter three dating back from more than 20 years. After the publication of the review in 2007, four papers with a similar scope have been published: three European and one South-African (99, 136, 146, 147). All 16 studies were retrospective and many with limited sample sizes. Below is a modified table (Table 6) with an overview of three of the studies published after 2007, in accordance with Table 4.1 in the global review (52). The fourth study will be presented in the Discussion section.

#### 2.3.3.1 Legal outcome in rape cases

Although these 16 studies looked at different legal outcomes, three levels of legal prosecution can be identified in most of them and the studies document considerable attrition of cases through these three levels. In summary, a suspect was arrested in 34 - 45% of the police-reported rape cases (136, 138, 142), a charge was filed (trial commenced) in 11 - 55% of the cases (19, 81, 89, 136, 137, 139-141, 143-145, 147) and a conviction was reached in 3 - 29% of the cases (19, 81, 89, 99, 136, 137, 140, 145, 147).

# 2.3.3.2 Medico-legal findings and trace evidence analysis

The medico-legal variables studied in these 16 papers differed to some degree, but extragenital injuries were found in 23-90% of the rape cases (19, 81, 89, 136-144, 146); anogenital injuries in 6-67% of the cases (19, 81, 89, 136, 138-146); forensic samples collected by medical staff in 54-91% of the cases (99, 136, 143, 146); forensic kits sent to lab (by the police) in 57-69% of the cases (136, 146); analysis of trace evidence by the forensic lab (sperm/semen (acid phosphatase)/DNA) was performed in only 1% of cases in South Africa (136), through to 51-57% of cases

Table 6. Medico-legal evidence and legal outcome. Overview of three studies published after 2007, a continuation

First author, publication year, country	Sample size, setting, years included, design	Medico-legal findings <sup>45</sup>			
•		Extragenital injury	Anogenital injury	Biological samples	
Jewkes, 2009, South Africa (136)	n=951 sexual assault victims ≥ 18 years, drawn from a sample of police-reported rapes in 70 randomly selected province police stations; data from police dockets and medical examination forms; 2003; retrospective	No injury in 39%; both extragenital and genital injury 16%; extragenital (or anal) injuries in 23% (Incl. incised wounds, lacerations, grazes, bruises, and areas of tenderness)	"Genital injury with a skin tear/break" 22%  (Defined as an incised wound, scratch, abrasion, or laceration, if bleeding was seen, or if scarring believed to be from the injuries caused by the rape)	Forensic kit completed 91%; forensic kit sent to lab 69%; report from forensic lab on DNA 1% (n=10): no info on sperm, DNA did not match in 5 cases	
Ingemann- Hansen, 2008, Denmark (146)	n=307 female and male rape victims reported to a police department; SAC and police record data; 1999 – 2004; retrospective	Among females, extragenital injury 77%; ≥ 4 lesions 31%	Genital injuries 19%	Trace evidence sent to lab 57%; sperm seen in forensic lab 35%; positive DNA match in 15% (Sperm seen in SAC's microscope 45%)	
Saint-Martin, 2007, France (99)	n=230 female and male (5%) victims ≥ 15 years of age; 66% examined within 72 h; hospital SAC; data from medicolegal reports and courtroom proceedings; 1996 – 2002; retrospective	Acute injury 45%; 85% of these bruises, most frequently to the "extremities" (here, head and hands)	Genital lesions 11%: tears in the post. forchette 6%; recent hymenal tears 10%; recent anal/rectal lesion 13% Erythema and tenderness excluded	Of those who came within 72 h, 82% had vaginal, anal and/or oral samples collected  No lab report on sperm/DNA available	

 <sup>&</sup>lt;sup>45</sup> Emotional presentation not reported in any of these studies
 <sup>46</sup> Adjusted odds ratio
 <sup>47</sup> Judgment for failure to prosecute the case or to introduce sufficient evidence

Legal outcome	Relationship of medico-legal evidence to legal outcome	Limitations and strength
Suspect arrested or asked to appear in court 45%; charged in court 38%; trial commenced 11%; found	Injuries not associated with arrest or commencing trial. Conviction more likely if injuries, whether extragenital	Limitations: Retrospective review, the quality of medical documentation not optimal.
guilty of sex offence 3%; sentenced to imprisonment in 3%	alone (OR <sup>46</sup> 6.3, 95% CI 1.1 – 34), genital alone (OR <sup>46</sup> 7.0, 95% CI 1.4 – 34), or both extragenital and genital injury (OR <sup>46</sup> 12.3, 95% CI 2.9 – 53). No association between DNA and legal outcome (although DNA was more often present when trial was commenced, 5% vs 2%, p=0.06). DNA match led to acquittal in one case	Strengths: From a developing country, recent data, containing info on DNA matching, large sample size, possible to study association on different levels of legal outcome, broad geographic area, multivariable analyses. Study of associations presented separately for children (< 18 y) and adults.
Charges filed 55%; conviction set 19% (fines, conditioned sentences, social supervisory control, imprisonment); no suspect identified 25%;	Extragenital and genital injuries not associated with conviction among the cases charged (p=0.5 and 0.3, resp.); borderline association	Limitations: Retrospective, single jurisdiction, small sample size when study of association with conviction among those cases charged.
charges not filed 10%; false reports 11%; dropped before prosecution 32%	with conviction when ≥ 4 lesions (p=0.07). Detection of sperm and victim-suspect DNA match not associated with conviction (p=0.4 and 0.3 resp.)	Strength: Recent data, incl. info on DNA matching, multivariable model
Convictions 26%: (professional judges 13%; popular jury 13%; juvenile court, 1%); insufficient evidence 60%; order of non- suit <sup>47</sup> 12%; still before the courts 3%	Presence of extragenital injury (OR 1.1, 95% CI 0.6 – 2.0) and anogenital injury (OR 0.8, 95% CI 0.5 – 1.4) not associated with conviction	Limitations: Retrospective, single jurisdiction, small sample size for those ≥ 15 years of age. Mixture of analyses for association with legal outcome of both those less than and those older than 15 years of age. Do not report actual numbers (frequencies) in the analyses, bivariable statistics.
		Strengths: Detailed, descriptive information. Data from children < 15 years of age and for those ≥ 15 years of age mostly presented separately

in Canada and Scandinavia (143, 146, 148), and to up to 95% of the cases in two older studies (81, 138); spermatozoa were detected in 7 - 59% of the cases (19, 81, 89, 137-143, 145, 146); and finally, a DNA match with a suspect was achieved in less than one per cent in the South African cases (136) versus in 15 - 18% of cases in Scandinavia (146, 148).

#### 2.3.3.3 Associations between medico-legal findings and legal outcome

Some of these studies have found a significant association between any documented extragenital injuries and charge filing (143) or conviction (81, 142); in other studies, only moderate to severe injuries (including injuries to the head, neck, or face region) were associated with charge filing (139, 140) or conviction (138, 143). However, many of the studies disclosed no association at all between the documented injuries and charge filing (89, 137, 141, 144) or conviction (19, 99, 146). The South African study found an impact of medical information at different levels in the legal process: no association was found between the documentation of injuries and arrest of assailant or charge filing, however, a conviction was more likely if somatic injuries were documented (136).

Two older studies have found an association between the presence of anogenital injuries and more than one site of anogenital injury, respectively, and charge filing (139, 144), while in a more recent study, anogenital injury was associated with conviction (136). However, genital injury alone was not associated with charge filing (140, 143, 145) or conviction (19, 99, 143, 146) in most other studies.

Regarding the biological samples, the collection of sperm or semen was not associated with arrest of a suspect or charges filed in a Canadian study (141). However, documentation in police files of receiving forensic samples collected by medical staff was significantly associated with charge filing in another Canadian study (143). In general, the detection of sperm/semen was not associated with charge filing (89, 138, 140) or conviction (19, 81, 142, 143, 146). None of the 12 studies in the review explored the relationship between the DNA findings and legal outcomes (52). However, a DNA match was not associated with a conviction in two of the recent

studies (136, 146).

By going through the existing international literature on the field of medical findings and sexual assault, some important aspects need to be explored in a Nordic context. Until now, the degree to which STIs are a concern in health care after assault and the use of drugs in cases of DFSA has not been explored among Norwegian adult and adolescent sexual assault victims. In addition, prior studies of police-reported rapes have been performed in Norway, but there is limited knowledge of the police's use of medical information and of the impact that medical information has on legal outcome. As a health care worker dealing with victims of sexual assault, being aware of steps important for rape investigation is crucial. The intersection of these two fundamentally different services could benefit from each other, in order to better understand how to provide optimal care to, and respect the rights of, victims of sexual assault. This thesis contributes to such transfer of evidence and to filling knowledge gaps in a Norwegian context.

# 3 Aims of the study

## 3.1 Purpose

The overall purpose of the study is to increase knowledge about both the health care and the forensic services in sexual assault cases, in order to improve the quality of health care and attract attention to the legal use and benefit of medical information.

# 3.2 Objectives

## Sexually transmitted infections (Paper I)

- What is the prevalence of STIs and BBVs among female adult and adolescent patients who visited the SAC?
- Could any of the STIs diagnosed at the initial visit have been assaulttransmitted?
- Are there any associations between hospital data (background/assault characteristics, clinical findings) and the detection of STIs and BBVs?

# Toxicological findings (Paper II)

- Which drugs are found in urine and/or blood among female adult and adolescent patients who visited the SAC?
- Are the test results consistent with self-reported voluntary intake or with proactive DFSA?
- Are there any associations between hospital data (background/assault characteristics, clinical findings) and the results of drug analyses?

# Medico-legal findings and legal outcome (Paper III and the EA)

- What is the legal outcome among cases of rape and attempted rape?
- Are there any associations between medical findings (extragenital/anogenital injuries, and biological trace evidence) and charge filing?

# 4 Material and methods

#### 4.1 Study design

This thesis is based on studies from two different samples of women reporting sexual assault to police and/or to a hospital SAC. All of the studies are retrospective and descriptive, but comparisons have been done for different outcome variables. The information derives from records from the regional police district as well as from the hospital (Figure 1). Both serve the county of Sør-Trøndelag, situated in central Norway with 295,000 inhabitants, including more than 170,000 living in the major city, Trondheim (149).

## 4.2 Setting: The Trondheim SAC

The SAC is situated at the Department of Obstetrics and Gynecology/Department of Pediatrics at St. Olavs Hospital, Trondheim University Hospital, Norway, and offers 24/7 low-threshold health care to those presenting after recent<sup>48</sup> sexual assault. The SAC provides acute psychosocial and medical care by trained nurses and resident/specialist physicians in gynecology or pediatrics. All patients are offered follow- up psychosocial support.

Furthermore, all patients are offered a forensic examination by the same team in conjunction with the medical assessment. If they consent, injuries are documented and biological trace evidence is collected from women's anogenital area and from other relevant areas of the body. The SAC stores the trace evidence for up to three months, after which it is discarded if not requested by the police. The police decide whether to request an analysis by the National Institute of Public Health<sup>49</sup> in Oslo.

Before 2003, the toxicological service was only offered on police request for those suspecting proactive DFSA, and most of the police-ordered analyses at that time were performed at the National Institute of Forensic Toxicology. <sup>50</sup> Between 2003 and

 $<sup>^{48}</sup>$  If > 72 hours since assault, a consultation could be offered during office hours

<sup>&</sup>lt;sup>49</sup> Institute of Forensic Medicine (FMI) existed until 2011, thenceforth organized under National Institute of Public Health

<sup>&</sup>lt;sup>50</sup> National Institute of Forensic Toxicology existed until 2003, thenceforth organized under National Institute of Public Health

2006, the Department of Clinical Pharmacology, St. Olavs Hospital, offered such testing for patients suspecting proactive DFSA, regardless of police-report. Since 2007, the laboratory has offered analyses of urine/blood samples from all victims attending the SAC within the first few days after an assault.


# 4.3 Study samples

# 4.3.1 SAC recruited (Papers I and II)

These study samples originate from the SAC records only. In Papers I and II, we included female patients ≥ 12 years of age who were examined at the SAC between July 1, 2003 and December 31, 2010. Figure 5 depicts the exclusion and inclusion of patients from the studies.

During the study period, we performed a total of 730 individual consultations on patients  $\geq$  12 years. Males (n=20), and those not medically examined (n=43) were first excluded from the studies. All patients eligible for inclusion (n = 623 patients, involved in a total of n = 667 visits) received a letter of information, with instructions on how to actively withdraw their records from the studies (see section 4.8.1). Those who did not want their medical records to be used were excluded (n=9).

Later, we discovered that some patients had not been sexually assaulted according to criteria stated in a Canadian study (98) (n = 21), and additionally that some had not undergone medical examination (n=25). These patients were also excluded. A total of 573 patients involved in 612 individual consultations were therefore finally eligible for the studies. Further exclusion criteria are described in the Methods section of Papers I and II.




**Figure 5** Flow chart for Paper I and II, cases based on patients attending the Trondheim Sexual Assault Centre during the period July 2003 through 2010

# 4.3.2 Police recruited (Paper III and expanded analyses (EA))

These samples consist of police-reported sexual assault cases. We identified all police-reported cases of rape and attempted rape of women ≥16 years of age, in Sør-Trøndelag, Norway.

For Paper III, cases reported between January 1, 1997 and June 20, 2003 were included. Cases were selected according to specific codes in the current Norwegian

Penal Code (4). In addition to rape (section 192) and attempted rape (section 192, cf. section 49), the codes "indecent assault on an unconscious subject," "indecent assault by means of threats/devious behavior," and "indecent conduct/exploitation facilitated by superior position" were included (27). For Paper III, a total of 222 cases were identified. Exclusion criteria were victim being < 16 years of age (age of sexual consent), male and unidentified victims (Figure 6). For the remaining 185 women, medical information from the SAC was available in 101 cases (55%).



**Figure 6** Flow chart for Paper III, cases based on police-reported rapes and attempted rape between 1997 and June 2003, in Sør-Trøndelag police district

Since the sample size for Paper III was small, additional data were collected from the period July 2003 through 2010. The Norwegian Penal Code has been revised after the data was collected for Paper III. For the analyses for the expanded period, in addition to rape (section 192, 1st – 3rd paragraph) and attempted rape, we therefore

included the so-called negligent<sup>51</sup> rape (section 192, 4th paragraph). However, the code "indecent assault by means of threats/devious behavior" had almost disappeared, and "indecent assault on an unconscious subject" had been included in the category of rape (into section 192, 1. paragraph, letter b) after the year 2000.

For the period July 2003 through 2010, altogether 475 cases of rape and attempted rape were identified. Hence, a total of 697 cases of rape and attempted rape were included in the expanded data set (Figure 7). Again we excluded victims being < 16 years of age, male and unidentified victims, as well as duplicate cases. Those not medically examined (n=6), those refused having their data used in the




Figure 7 Flow chart of included and excluded cases of rape and attempted rape for the period 1997 – 2010, Sør-Trøndelag Police District. Regarding "drop-outs" etc. see text for details

<sup>&</sup>lt;sup>51</sup> Norwegian: "Uaktsom voldtekt"

study (n=3), and those not sexually assaulted (n=1) were also excluded (see section 4.3.1). In the remaining 569 cases, medical information from the SAC was available in 324 cases.

# 4.4 Data collection and storage

#### 4.4.1 From medical records (all studies)

Clinical, forensic, and laboratory information was extracted from the patients' records. For the period 1997 – 2003, the data was fed manually into a paper-based registration form (see Appendix 1). The registration scheme was then revised before the collection of new data from 2003 – 2010. For the second period, medical record information was registered through a web-based data collection system (case report form, CRF) developed and administered by the Unit of Applied Clinical Research at the Norwegian University of Science and Technology (see Appendix 2). Through this system, all information was encrypted and de-identified.

#### 4.4.2 From police files (Paper III and EA)

For Paper III, information was manually collected from the police files, by a paper-based registration form (see Appendix 1). However, for the EA, we used a similar web-based data collection system (web-CRF, police, see Appendix 3) as for the hospital data (see section 4.4.1).

# 4.5 Definition of variables

## 4.5.1 Medical record variables (all studies)

Variables used in the different studies are shown in Table 7. The variables are grouped into the following categories: Patients' (victims') characteristics, assault and assailant characteristics, variables describing the clinical documentation, the laboratory findings, and finally, the police/legal variables (Paper III and the EA only). Some of the variables were differently defined in the first (Paper III) and the second (Paper I and II and EA) data collection periods (see section 6.1.1). Definitions of some of the variables follow below.

Table 7. Variables used in the different studies

Variables	Paper I	Paper II	Paper III	EA
Patients' (victims') characteristics				
Age	Х	х	Х	Х
Country of origin	Х	Х		
Living situation		Х		
Residency		Х		
Education		Х		
Occupation	Х	Х		
Vulnerability factors	Х	Х	Х	Χ
Sexual/gynecological/hormonal history	X			
Assault and assailant characteristics				
Intake of alcohol	Х	Х	Х	Х
Intake of medicinal/recreational drugs		Х		
Patients suspecting proactive DFSA	Х	х		
Verified proactive DFSA findings		Х		
Victim – assailant relationship	Х	Х	Х	Χ
Venue	Х	Х	Х	Х
Time of day of assault		Х		
Physical violence	Х	Х	Х	Χ
Type of sexual assault	Х	Х	Х	Χ
Police-reporting	X	Х		
Assault-transmitted STI	Х			
Mental state of the assailant			Х	
Clinical documentation				
Interval from assault to examination	Х	х	Х	Х
General status at SAC presentation	Х	Х	Х	Х
Extragenital Injuries		Х	Х	Χ
Anogenital injuries	Х	Х	Х	Χ
Treatment	X			
Laboratory findings				
Detection of spermatozoa	Х		Х	Х
Microbiology	Х			
Toxicology		х		
Police variables				
Reported incident			Х	Х
Legal outcome			Х	Х
Information about police investigation			Х	

EA: Expanded analyses; DFSA: DFSA: Drug-facilitated sexual assault; STI: Sexually transmitted infection; SAC: Sexual Assault Center

## 4.5.1.1 Patients' (victims') characteristics

Vulnerability factors

In Paper I, we defined the concept of vulnerability factors to include three features: mental health problems<sup>52</sup>; drug abuse<sup>52</sup>; and/or prior history of sexual assault. The definition of "mental health problems" included a diagnosis of affective/psychotic illness, use of antidepressant/antipsychotic medication, and a history of use of mental health services, deliberate self-harm/attempted suicide and eating disorder as defined in a previous study (150).

For Paper II, mental or physical disability was added to the "vulnerability factor" definition. For Paper III, the definition of vulnerability factors included the same four features as in Paper II, but "mental health problems" was restricted to psychiatric inpatient hospital admission or other psychiatric treatment (27).

Sexual, gynecological and hormonal history

Use of contraceptives was grouped into combined hormonal contraceptives, progestagen injections/implants, intrauterine device, and tubal ligation. In addition, a history of hysterectomy and menopausal status was recorded.

# 4.5.1.2 Assault and assailant characteristics

Intake of alcohol

Self-reported alcohol intake in relation to the assault was classified as no intake, < 5 units of alcohol, and  $\ge 5$  units of alcohol. We used a definition of one alcohol unit corresponding to 12 g ethanol, which equals approximately a 33 cl can of beer, a 12 cl glass of table wine, or a 4 cl drink of spirits (151).

Intake of medicinal/recreational drugs

Self-reported voluntary intake of medicinal or recreational (non-prescribed) drugs was recorded from the initial SAC visit, the follow-up visits, or from recent relevant hospital records.

-

<sup>&</sup>lt;sup>52</sup> Prior or current

Patients suspecting proactive DFSA

A patient was classified as suspecting proactive DFSA when she herself raised a suspicion of being involuntarily drugged and assaulted, in combination with at least one of 16 associated symptoms, e.g. total or partial amnesia, "blackout," hangover, or symptoms inconsistent with the amount of alcohol or drugs voluntarily ingested (98).

Verified proactive DFSA

Among those suspecting proactive DFSA, those with a discrepancy between positive test for a sedative drug and self-reported intake were as a rule regarded as victims of proactive DFSA. However, in patients with a history of drug abuse and/or anxiety disorder, recent voluntary intake of such drugs could not be excluded and the case could not be defined as verified proactive DFSA.

Relationship between victim and assailant

The relationship between victim and assailant was defined as known, including previous or current partner/husband/boyfriend, family member, acquaintance (assailant known > 24 h), casual acquaintance (assailant known < 24 h), or stranger.

Venue

The location of the assault was defined as private (the victim's, the assailant's, or other person's residence) or public (any public indoor or outdoor location or a vehicle).

Physical violence

In Paper I and III, violence were graded as none/verbal threats, light/moderate, or severe. Severe physical violence was defined as presence of weapon and/or attempted strangulation. In addition, for Paper I, gagging, or punching/kicking towards head and for Paper III, fracture or internal injuries were included in this category.

Light/moderate violence was in Paper I defined as holding, tearing off of clothes, slapping, kicking, tying up, biting, sucking, stinging with needle, while for Paper III, only holding, punching, or kicking was included in this category. The use of physical violence was only dichotomized (yes/no) in Paper II.

# Type of sexual assault

For Paper I, regarding STIs, penetration (whether vaginal, anal, oral) was defined as penile only. For Paper II, penetration included both by foreign object (vaginal, anal) and penis (vaginal, anal, oral). For Paper III, penetration of the different orifices was recorded separately. If more than one orifice was penetrated, this was ranked -- anal, vaginal, oral.

For all papers, when a finger was used to penetrate, as well as when other sexual acts like forced masturbation, attempted penetration, or touching up/fondling were reported, the assault was recorded as non-penetrative.

#### Reporting to the police

In Paper I and II, the event was recorded as police-reported if the patient said so or if the police requested a medico-legal report for investigational use.

#### Assault-transmitted STI

The STI was considered assault-transmitted when the patient testing positive had no prior coital experience, and, for herpes simplex virus (HSV), a positive swab NAAT was followed by HSV seroconversion in the follow-up period.

# 4.5.1.3 Clinical documentation

# Extragenital Injuries

For Paper II, extragenital injuries were only dichotomized (yes/no). For Paper III, details of the observed extragenital injuries such as location, type, and number of injuries were described. For Paper III and the EA, extragenital injuries were categorized into minor (erythema, swelling, bruises, abrasions, lacerations, suction marks), moderate (bruising of head/neck expected to result in significant headache, lacerations requiring suture/dressing (143), bite/injection marks), and serious (evidence of attempted strangulation, head injury with concussion, and stab/incision wounds).

## Anogenital injuries

For all papers and the EA, observed anogenital injuries included tears, abrasions,

and bruises (ecchymoses/petechiae). Redness and/or swelling were not regarded as injury (152-154). Anogenital injuries were initially diagnosed by gross visualization, but from 2008, photocolposcopy was mostly used. For Paper I, we recorded whether a full speculum examination or only inspection of the anogenital area was performed.

For Paper I and II, anogenital injuries were only dichotomized (yes/no). For Paper III and the EA, location, type and number were recorded.

#### **Treatment**

We recorded whether any prophylactic treatment was given at the initial visit according to Norwegian guidelines: e.g., a one-dose regimen of oral azithromycin, hepatitis B vaccination, and/or HIV PEP.

# 4.5.1.4 Laboratory findings

Detection of spermatozoa

For Paper I and the EA, the presence of spermatozoa at hospital microscopy<sup>53</sup> was given. For Paper III, the presence of spermatozoa found at the FMI (Institute of Forensic medicine, Oslo, Norway) was used.

# Microbiology

Several different sample materials were submitted. Swabs taken from the urogenital (urethra, vagina, cervix and those labelled "urogenital secretion"), anorectal, and/or pharyngeal area were used for microbiological examination for NG, CT, and MG. 54 From 2005, a first void urine (FVU) sample was alternatively offered for examination for CT and MG. 54 If clinically indicated, specimens for additional microbiological agents, e.g. TV or HSV, were collected. Anogenital warts were clinically diagnosed.

The Department of Medical Microbiology, St. Olavs Hospital examined all swabs and urine samples. CT, MG, and HSV were diagnosed by NAAT. All positive tests were reproducible by re-testing. Standard culture techniques were used for the detection of

<sup>&</sup>lt;sup>53</sup> Before 2007, performed at the Fertility Clinic, Department of Obstetrics and Gynecology. Later the Department of Cytology, St. Olavs Hospital took over this service From 2008

#### NG and TV.

A blood sample from all consenting patients was screened for serological markers of BBVs: HIV (HIVAg/Ab Combo test), hepatitis B (HBsAg, hepatitis B core antibody (HBcAb), and occasionally hepatitis B surface antibody (HBsAb)), hepatitis C (hepatitis C antibody (HCVAb)), syphilis (*Treponema pallidum* antibody), and occasionally HSV antibody. If not previously verified, positive screening tests were confirmed by alternative tests. For details of analytical methods for the detection of the different microbiological agents, see description in Paper I's Method section.

# Toxicology

Patients were offered a toxicological screening according to the existing guidelines at that time, see section 4.2. The date and hour for toxicological sampling was recorded; if not specifically stated, the sampling was assumed to have taken place one hour after the arrival at the SAC. To estimate the time interval between the assault and the toxicological sampling, we used the mid-point of the time period for the assault (135).

Urine and/or blood samples were analyzed at the Department of Clinical Pharmacology, St. Olavs Hospital. If available, urine samples were screened for a predefined selection of substances likely to be used in DFSAs (155), and included ethanol and the drug classes benzodiazepines/benzodiazepine-like drugs, cannabinoids, opioids, central stimulants and some others, such as GHB and ketamine (see Supplementary Table 1, Paper II, for details). If the urinary screening test was positive, the corresponding substances were also quantified in serum. In cases with only serum available, specific analyses were prioritized according to the clinical characteristics. For details, see description in Paper II's Methods section 2.4.

Among those tested within 12 hours of the assault, the BAC was estimated from the measured serum ethanol concentration using a serum-to-blood ratio of 1.14. If a serum sample was missing, but the ethanol concentration in urine was known, a mean elimination phase urine-to-blood ratio of 1.345 was used to estimate the BAC (156). To estimate the BAC at the time of assault, concentrations were back-calculated assuming

no ethanol intake after the assault and a metabolic rate of  $0.15~\mathrm{g/L}$  ethanol per hour (124).

## 4.5.2 Police variables

In case of discrepancy between police and medical record information (e.g., regarding number of assailants), since Paper III and the EA were studies of police-reported assaults, information retrieved from the police files was chosen.

Reported incident

The reported incident was dichotomized into attempted rape versus rape. The latter category comprised the following crime denominations: "indecent assault on an unconscious subject," "indecent assault by means of threats/devious behavior," and "indecent conduct/exploitation facilitated by superior position." For the EA only, negligent<sup>55</sup> rape was also included in the rape category, see section 4.3.2.

## Legal outcome

Legal outcome was classified according to the Norwegian Administration of Justice Act and regrouped into four categories: charges filed (prosecution of the case into a court of law); no suspect identified; charges not filed (dismissal); and "other reason." The latter category comprised cases in which the police concluded that no crime had been committed (unfounded); cases dropped because of withdrawal; cases treated without criminal proceedings; cases dropped because the suspect was deceased; cases let at rest (according to section 250); cases sent for investigation abroad; and those with missing legal outcome (see Figure 10 and 12, section 5.3). The category "charges not filed" comprised three categories: time-barred (too long an interval from incident to formal report), insufficient evidence, or suspect not legally responsible.

Information about police investigation

Investigational issues were classified according to whether forensic medical examination had been carried out (including whether trace evidence had been

53

<sup>55</sup> Norwegian: "Uaktsom voldtekt"

collected from the victim), whether analysis of the trace evidence had been conducted and if so, the results of the trace evidence analysis, the results of toxicological analyses, whether a medical forensic report had been requested by the police, and finally whether a physician from the SAC had been summoned as an expert witness in court.

# Mental state of the assailant

The assailant was classified as "mentally disordered or impaired" if he was psychotic during the event, mentally retarded, or considered at risk of repeating the offense.

#### 4.5.3 Quality control of the variables

For the purposes of Paper I and II, three students and I reviewed all patient records from this time period. To ensure accuracy, one of the students and I crosschecked with the records. Any discrepancies were addressed and consensus was reached in collaboration with the supervisors.

For Paper II, for correct classification of the variable "suspecting proactive DFSA," one of the co-authoring pharmacologists and I reviewed all assault descriptions case-by-case. If necessary, the case was discussed with all authors gathered. Still, a few cases qualified for the "uncertain" category.

For Paper III, all the collected medical information, including injury descriptions and sketches, and laboratory reports from the FMI, were reviewed and re-coded.

The final control of the data from the EA has not yet been completed, and the laboratory findings (trace evidence and DNA) were unfortunately not ready at the time of the analyses for this thesis. We therefore present those results as preliminary. However, medical record data used for the EA are the same as for Paper I and II.

# 4.5.4 The merging of the data (Paper III and the EA)

The data were merged by the following procedure. The collected police data were merged with the collected medical record data based on a key code (the personal identification code). Victims reporting more than one incident of rape were specifically

explored to avoid duplication of the cases, and the merged dataset was checked for mismatching date of assault in the police-file as compared to the SAC-file. The merged file was then de-identified. This procedure was conducted first for the 1997 - 2003 dataset (for Paper III), and later, for the 2003 - 2010 dataset. Finally, to achieve the dataset suitable for the EA, we merged the oldest (1997 - 2003) data file with the newest (2003 - 2010).

#### 4.6 Data storage

The identifiable list (including the key identifier) of patients receiving the letter of information about the study (for Paper I and II) is stored in a separate research file area provided from the Data Protection Official<sup>56</sup> at the St. Olavs Hospital.

The first paper-based registration forms were fed manually into an SPSS<sup>57</sup> data file. After completing the collection of the newer data, the Unit of Applied Clinical Research at the Norwegian University of Science and Technology converted the webbased data into SPSS<sup>57</sup> files. The original files are stored in the same research file area as mentioned above.

#### 4.7 Calculations and statistical analyses

For all analyses, descriptive characteristics were reported as frequencies and proportions for the categorical variables, and as mean, median, and ranges for the continuous variables.

For the comparisons, Pearson's χ2 test, Exact Unconditional test (or Fisher's Exact test), Pearson's χ2 test of heterogeneity, or Kruskal-Wallis test were used as appropriate. In addition, associations between the independent categorical variables and the outcome variables were explored by binary logistic regression analysis, calculating crude odds ratios (ORs) with corresponding 95% confidence intervals (CIs). We used multivariable logistic regression analysis without stepwise selection (157, 158). We entered patient's age (all papers), substance abuse (Paper I), interval from

<sup>&</sup>lt;sup>57</sup> IBM Statistical Package for the Social Sciences (SPSS Inc. Chicago, IL, U.S.)

assault to sampling for toxicological test (Paper II), and interval from assault to clinical examination (Paper III and the EA) into the different models, as indicated below.

Missing data were calculated, but mostly excluded when statistical tests were performed. Statistical significance was assumed when p < 0.05. Data analysis was performed with  $SPSS^{57}$  for Windows, version 16.0 (Paper III), and version 19.0 (Paper I, II and the EA).

#### 4.7.1 Analyses for Paper I

We analyzed whether the independent variables were associated with a diagnosed STI/BBV. Patients testing negative for several microbes or serologic markers, but one test with uncertain/missing test result, were regarded as negative for the group outcome variable.

Associations between independent categorical variables and diagnosed STI/BBV were explored by logistic regression analysis. To adjust for patient age, we used age as a 5-categorical variable for the STI comparisons due to the skewed distribution of STI by age, and as a 2-categorical variable for the BBV comparisons. For the latter, we also adjusted for substance abuse.

# 4.7.2 Analyses for Paper II

We explored in detail those patients suspecting proactive DFSA, i.e., information on self-reported intake of alcohol/drugs was compared to the toxicological findings.

Among those tested for ethanol within 12 hours of the assault, we compared cases with a positive test for ethanol with cases with negative test (Table 4, Paper II). Multivariable logistic regression was applied to adjust for patients' age (3-categorical) and interval from assault to toxicological sampling (2-categorical). After estimating the BAC at the time of assault, we categorized the patients into tertiles according to BAC levels, and comparisons between the different "tertile-groups" were done for several of the independent variables. In addition, we compared those with a positive test for at least one drug other than ethanol with those with negative drug test (see section 5.2.1).

### 4.7.3 Analyses for Paper III and the EA

For Paper III, we compared cases charged in a court of law with the cases not charged, mainly because of insufficient evidence. For the statistical comparisons, those cases with no potential for a charge were therefore excluded, i.e., those cases with no suspect identified and those classified as "other reason" (see section 4.5.2 and Figure 10 and 12, section 5.3).

For Paper III, comparisons were done both for the total group of police-reported cases (Table 1, Paper III) and among those with SAC medical record information only (Table 2, Paper III). For the EA, only the corresponding latter sample was analyzed. We used multivariable logistic regression to adjust for age (3-categorical) and interval from assault to medical examination (as 2-categorical); see Table 13 and 16 in section 5.3.

In addition, for Paper III, to rule out whether some of the assault characteristics could have influenced the physical findings, we restricted the analysis of body injuries to only those patients subjected to physical violence (n=65), and the analysis of anogenital injury to only those patients subjected to anal and/or vaginal penetrative assault (n=71) (stratified analyses) (Table 14 in section 5.3.1).

Finally, for Paper III, we explored whether trace evidence analysis was associated with some characteristics (e.g., victim's age, the relationship to the assailant, self-reported penetration, and time interval from assault to collection).

#### 4.8 Study approval

All studies were approved by the Regional Committee for Medical and Health Research Ethics (REK-Midt).

### 4.8.1 Study approval Paper I and II

All eligible patients (n=623) received a letter with general information (see Appendix 4 for the information letter in Norwegian), thereby giving the individual patients an opportunity to withdraw their records from the study. After receiving this letter, a total of 15 patients contacted the researchers. Nine patients withdrew their record information, two wanted only the main researcher (and not medical students)

to collect their record data, and four patients called to get more information about the study, but did not withdraw.

## 4.8.2 Study approval Paper III and EA

For Paper III and the EA, as the selection of cases was based on police-reported rapes, additional permission was obtained from the Norwegian Director General of Public Prosecutions<sup>58</sup> (through the Advisory Board on Secrecy and Research<sup>59</sup>).

The Norwegian Directorate of Health<sup>60</sup> was informed about the study, and the Norwegian Data Protection Authority<sup>61</sup> provided a license so that the study could be performed with an exception from the principle of informed consent. In addition, the study was approved by the Data Protection Officer<sup>62</sup> at the Norwegian Social Science Data Services.<sup>63</sup>

Because of the small sample size in Paper III, we wanted to expand the study.

Permission to collect additional data was again approved by the REK-Midt, and in addition, by the Norwegian Director General of Public Prosecutions. According to the Data Protection Officer, these permissions were sufficient.

#### 4.9 Ethical considerations

Information about sexual assaults and rapes reported to health care and/or police in Norway fills important gaps of knowledge in this field. This field is subjected to disproportionately large media attention, and many people express strong emotionally-laden opinions in newspapers and on the web. However, expert statements have often been difficult to communicate because of the lack of evidence-based medicine regarding sexual assaults. Knowledge has been difficult to achieve because of the sensitive nature of this kind of research.

Using already collected information from the clinical and police settings reduces the psychological strain for the patients. However, in future studies, one might

<sup>&</sup>lt;sup>58</sup> Riksadvokaten

<sup>&</sup>lt;sup>59</sup> Rådet for taushetsplikt og forskning

<sup>&</sup>lt;sup>60</sup> Helsedirektoratet

<sup>61</sup> Datatilsynet

Personvernombudet for forskning

<sup>&</sup>lt;sup>63</sup> Norsk samfunnsvitenskapelig datatjeneste AS, NSD

consider asking for patients' consent to participate in research, preferably in the follow-up phase after the sexual assault rather than during the period of acute crisis, see section 6.4.

The negative ethical issues in the project are mainly related to handling and storing sensitive data about the patients/victims, and in the case of police-data, of a third party (that is, the suspects). In addition, some of the results in the study could eventually be experienced as offensive, or at least not positive, for the group of women who have experienced sexual assaults.

In retrospect, we contacted the identified patients by mail to inform about the study. This could be experienced as a painful and humiliating reminder of an assault which might have happened many years ago. Whatsoever, the study participants' safety is a primary concern in any research. Since the letter of information was constructed in a very general way, a reprisal for reporting a sexual assault (e.g., by a violent partner) should be reduced to a minimum.

It may be perceived as unethical to investigate only female patients subjected to sexual assault, but too few men have contacted the SAC or reported rape to the police, resulting in an insufficient sample size for any of the statistical analyses for male patients. However, for gaining gender equality in research, future studies of sexual assaults should include male patients as well.

# 5 Results/Overview of papers

## 5.1 Sexually transmitted infections (Paper I)

### 5.1.1 Results according to aims (Paper I)

# What is the prevalence of STIs and BBVs among the SAC patients<sup>64</sup>?

The prevalence of STIs was twice that of BBV-markers. CT was detected in a total of 25 patients (6.4%), while two tested positive for MG (1.9%). <sup>65</sup> At the examination of swabs collected from two patients with clinically suspicious HSV genital lesions, one tested positive for HSV. Additionally, eight patients (1.9%) had visible anogenital warts. Altogether, at least one STI was diagnosed in 35 patients (8.5%). Only one patient was diagnosed with more than one STI, who tested positive for CT and demonstrated genital warts.

Seven patients had serological markers compatible with prior HBV infection, while nine were HCVAb positive. A total of 14 patients (3.7%) tested positive for at least one BBV-marker. <sup>66</sup> Two patients tested positive for both HBcAb and HCVAb, and one for both HCVAb and MG.

### Could any of the STIs diagnosed at the initial visit have been assault-transmitted?

One patient tested positive for CT and claimed to have no previous coital experience; we therefore concluded that she probably had acquired an assault-transmitted infection. The patient with HSV infection demonstrated a suspected HSV primary-like ulcer around 53 hours after the assault. In this case, at initial visit, genital swabs were HSV NAAT positive. The patient had an HSV serology test collected at the initial visit, which was negative, and by follow-up after around six weeks, both HSV IgM and IgG were positive. We therefore concluded that this infection most probably was assault-transmitted.

# Are there any associations between relevant hospital data and the STI findings?

Comparisons between those with and without an STI are shown in Table 2 and in

 $<sup>^{\</sup>rm 64}$  All test results are from the initial visit

<sup>65</sup> n=393 tested for CT and n=106 tested for MG

 $<sup>^{\</sup>rm 66}$  Additionally, 20 patients tested positive for HBsAb at the initial visit

the E-table, Paper I. Substance abuse and stating a non-Western assailant was associated with STI, after adjustment for patient age.

Patients' age was significantly associated with both STIs and BBVs. Patients aged 16-19 years had significantly higher STI prevalence than any other age group. Stratifying patients by age groups in accordance with the CDC (159), we found a CT prevalence as shown in the Table 8. For BBV markers, those  $\geq 25$  years of age had significantly more positive tests than younger patients. After adjustment,  $^{67}$  substance abuse and being unemployed was associated with BBV positive findings at the initial SAC visit (Table 3, Paper I).

Table 8. Chlamydia trachomatis: Positive test at the initial SAC visit by age groups

Patient age, years	Positive/tested (%)	
< 15	1/20 (5)	
15 - 19	15/139 (11)	
20-24	6/129 (5)	
25-29	2/36 (6)	
30-39	1/37 (3)	
> 40	0/30 (0)	
Total	25/391 (6)	

# 5.1.2 Results from follow-up visits

After the initial visit, 195 patients (47%) attended at least one follow-up consultation and 81 patients underwent a second clinical examination by a physician at the SAC. Thirty-three patients were re-tested for an STI within 6 weeks of the initial visit. All tests were negative, except one CT test "converted" from a negative at initial visit.

After at least 3 months, re-screening for serologic markers of HIV/syphilis was conducted in 114 patients, while 57 had a re-screening for hepatitis B/C markers after at least 6 months. No new cases were positive for HIV or HBcAb during follow-up, while one turned out positive for syphilis (not tested at the initial visit) and three for HCVAb (one seroconverted, while two were not tested at the initial visit). Each of these

 $<sup>^{67}</sup>$  Substance abuse adjusted for age, and being unemployed adjusted for age and substance abuse

three had additional risk factors for HCV infection. In addition, 19 patients were only tested for HBsAb on follow-up: 26 were positive, 22 of whom after recent vaccination.

## 5.1.3 Assault-transmitted STI and legal outcome

Neither of the two women who probably had acquired an assault-transmitted infection reported their assaults to the police. Hence, no legal consequences ensued for the assailants in these cases.

# 5.2 Toxicological findings (Paper II)




Figure 8 Drug and ethanol findings (Paper II)

# 5.2.1 Results according to aims (Paper II)

## Which drugs are found in urine/blood among the patients who visited the SAC?

Among the 264 patients included, ethanol and/or drugs were detected in 155 (59%). The different drug groups detected are shown in Figure 8. None of the patients

tested positive for GHB or ketamine. Overview of the drug combinations and detailed information of drugs other than ethanol (including concentrations in serum) are shown in Table 2 and 3, Paper II.

Among 120 patients tested for ethanol within 12 hours of the assault, 85% tested positive. The median estimated BAC at the time of the examination was  $1.20 \, \text{g/L}$ .

### Could the findings be consistent with voluntary intake or with proactive DFSA?

Among those 57 patients who suspected proactive DFSA, 13 tested positive for at least one drug other than ethanol. The number of positive cases for each drug among the patients suspecting proactive DFSA is shown in Table 3, Paper II, right column. Details of each case are given in Table 9 above, modified according to Birkler *et al* (106). Some of the benzodiazepines detected have long half-lives (clonazepam, diazepam). It is therefore difficult to interpret these findings when the interval from assault to test is long. High concentrations might be caused by recent intake, and not from the period before the assault. Some cases require further comments:

Case # 1: The patient was intoxicated (high levels of ethanol) upon arrival at the hospital. She reported taking some pills which she believed were analgesics, but might instead have been drugged with clonazepam?

Case # 2: We found very high serum levels of benzodiazepines (clonazepam, diazepam) only four hours after the assault, and even though stating voluntary intake, someone may have surreptitiously drugged her or made her take more than the usual dosage.

Case # 8: Although no unexpected findings, there was a high level of zopiclone, which might be caused by intake of the drug <u>after</u> the assault or by surreptitious drugging with her regular hypnotic?

However, in summary, only in five patients a positive test for sedative drugs (clonazepam (n=1) and diazepam/oxazepam (n=4)) was not accounted for by self-reported voluntary intake. All these patients reported a history of either drug abuse or anxiety. Thus, no cases could be unequivocally attributed to proactive DFSA.

Table 9. Drug findings among the 13 cases suspecting surreptitious drugging who had positive toxicological findings (of drugs of

Case #	Time from assault to sampling	Blood alcohol concentration, g/L	Self-reported alcohol intake (units)	Drugs detected, serum concentration ng/ml (nmol/l) <sup>68</sup>
1	12	1.8	> 5	Clonazepam 25 (79)→
2	5	0	< 5	Clonazepam 152 (481) $\uparrow \uparrow$ ; diazepam 1650 (5890) $\uparrow \uparrow$ ; (oxazepam 70 $\downarrow$ ); methamphetamine 270 (1809) $\uparrow$ ; (amphetamine 42 (311) $\rightarrow$ )
3	81	0	<5	Diazepam $40 \downarrow$ ; (oxazepam $6 \downarrow \downarrow$ ); nitrazepam $60 \downarrow$ ; Morphine $50 (175) \rightarrow$ ; oxycodone (positive in urine only) $\downarrow$ ; cannabis $0.8 \downarrow$ ; amphetamine/ methamphetamine (urine only tested)
4	76	0	< 5	Diazepam 2300 (8078) $\uparrow \uparrow$ ; (oxazepam 41 $\downarrow \downarrow$ ); amphetamine (40 (300)/methamphetamine 242 (1622) $\uparrow$
5	10	0.3 (estimated from urine)	> 5	Flunitrazepam 6 (20)→
6	54	0	> 5	Oxazepam 11 (38)↓↓
7	3 (urine)	1.5 (estimated from urine)	< 5	Oxazepam 117 ↓
8	13	0.6 (estimated from urine)	>5	Zopiclone 100 (257)↑
9	13	0	< 5 (one beer, then black-out)	Cannabis 0.5 ↓; amphetamine 287 (2123)↑
10	37	2.3 (estimated from urine)	> 5 (been drinking for many days)	Amphetamine (urine only tested)
11	20	0	> 5	Amphetamine and methamphetamine (urine only tested)
12	165	0	0	Methamphetamine (urine only positive)
13	39	0	> 5 (claimed to have been forced to drink)	Methylphenidate (urine only tested)

\_

 $<sup>\</sup>frac{1}{68}$  Arrows indicate whether the measured serum concentration is within the therapeutic range ( $\rightarrow$ ), or higher ( $\uparrow$ ) or lower ( $\downarrow$ ) than the therape

# other than alcohol), modified according to Birkler et al (106)

Self-reported intake of drugs	Unexpected findings (no self-reported intake)	Comments
Was given some unknown white pills (thought it was an analgesic)	Yes, clonazepam	Surreptitious drugging with clonazepam?
Clonazepam; fluoxetine	Yes, diazepam (and amphetamines)	Surreptitious drugging with clonazepam/diazepam? (Suspected being drugged with morphine sulphate)
Oxazepam; nitrazepam; amphetamine and ecstasy	Yes, diazepam (cannabis and analgesics)	Presented late. Most likely intake after the assault (esp. analgesics)
No information on intake, but reported anxiety/depression	Yes, diazepam/oxazepam (amphetamines)	Most likely intake after the assault
Flunitrazepam, i.e. several h before arrival	No	Surreptitious drugging with flunitrazepam? Bus-concentration no higher than expected for regular use over time?)
No information on intake, except for venlafaxine, but reported anxiety/depression	Yes, oxazepam	Presented late. Concentration may have been considerably higher at the time of assault, provided no intake after the assault.
Oxazepam	No	Drug positive as expected, she was found outdoors perished and "under the influence o alcohol/drugs"
Zopiclone	No	Higher concentration than expected from therapeutic use. Intake after assault or surreptitious drugging?
No information on intake. Plastic bag with white powder collected from her vagina at pelvic examination	(Cannabis/amphetamine only)	Presented too late for detection?
Reported alcohol/drug abuse, but no exact information on intake, except alcohol	(Amphetamine only)	
Prior record of amphetamine intake	No	
Voluntarily injected amphetamine, but higher dose than intended?	No	Claimed to have become "paralyzed" after the drug was injected
Methylphenidate	No	Arrived too late for detection of alcohol

eutic range


### Is there any association between relevant hospital data and the drug findings?

Alcohol positive vs. negative

We compared patients testing positive for ethanol with those testing negative (among those tested within 12 hours of the assault), see Table 4, Paper II. Those testing positive for ethanol more often reported a high intake of alcohol (≥ 5 units), reported a public place of assault, stranger assailant, more than one assailant, and assault occurring between midnight and 7 a.m. However, those testing negative for ethanol more often had at least one vulnerability factor. Adjusting for patients' age and interval from assault to toxicological sampling did not alter any of the relations.

Lower vs. higher estimated BAC at time of assault

Median BAC at time of the assault was 1.87 g/L, and the distribution of the BAC is shown in Figure 9. When separating the cases into tertiles according to estimated BAC at time of assault (Table 11), there was a significant association between high estimated BAC at the time of assault and high self-reported intake of alcohol, suspicion of proactive DFSA, the assailant being a stranger, and a clinical impression of inebriation on examination.



Estimated BAC (g/L) at time of assault

**Figure 9** Distribution of estimated blood alcohol concentration (BAC) at the time of the assault among 102 ethanol positive patients tested within 12 hours of the assault

Drug positive vs. negative

For this thesis, I explored some of the associations between case characteristics and drug findings (Table 12 below). Patients' background characteristics like older age, mental health problems/drug abuse, no intake of alcohol, and unemployment were significantly associated with a positive test for at least one drug other than ethanol. The assault occurring being between 7 a.m. and midnight and serious extragenital injuries were also associated with a positive drug test.

# 5.2.2 Toxicological findings and legal outcome

For the expanded analyses (1997 – 2010) described in section 5.3.4, we explored whether sampling for a toxicological test was performed, and if so, whether a positive toxicological finding was associated with charge filing. No association with legal outcome was found for either of these two variables (see Table 10 below, which is an extract of Table 16).

Among those 13 cases suspecting surreptitious drugging and who had positive toxicological findings referred in Table 9, only five were identified in the police files as reported rapes. None of these five cases ended in court: three were not charged because of insufficient evidence, while no suspect was identified in the other two cases.

Table 10. Toxicological tests among 324 women who reported rape to the police by charge filing <sup>69</sup>, in Sør-Trøndelag, Norway, 1997 through 2010

		<b>Charges filed</b>	, N=213	
Variable	Total, N=324	Yes, n=38	No, n=175	<i>p</i> -value
	n (%)	n (%)	n (%)	
Toxicological test collected, n=324				
No	198 (61)	24 (63)	103 (59)	
Yes	126 (39)	14 (37)	72 (41)	$0.62^{70}$
Toxicological test result, n=126				
Negative	37 (29)	3 (21)	25 (35)	
Positive	89 (71)	11 (79)	47 (65)	0.38 <sup>71</sup>

<sup>&</sup>lt;sup>69</sup> Missing excluded from the analyses

<sup>71</sup> Exact unconditional test

Chi-square, df=1

Table 11. Blood alcohol concentration (BAC) (estimated) at mean time of assault by background and assault characteristics and clinical findings among 120 female victims attending the Trondheim SAC 2003 – 2010 and tested for alcohol within 12 hours of the assault

		5		
Variable	< 1.43,	1.43 - 2.014,	> 2.014,	p (test method <sup>72</sup> ), degrees of freedom
	n=40,	n=40,	n=40,	
	(%) u	n (%)	u (%)	
Age groups (n=120)				
12-17 years	9 (23)	5 (13)	5 (13)	
18-24 years	20 (50)	24 (60)	27 (68)	
≥ 25 years	11 (28)	11 (28)	8 (20)	0.51 <sup>73</sup>
Vulnerability factors (n=120)				
Yes	9 (23)	13 (33)	15 (38)	
ON	31 (78)	27 (68)	25 (63)	0.34
Alcohol consumption (n=118)				
Intake of < 5 units	20 (51)	6 (15)	9 (23)	
Intake of ≥ 5 units	19 (49)	34 (85)	30 (77)	0.001
Suspected being drugged (n=115)				
Yes	3 (8)	9 (24)	12 (32)	
No	37 (93)	28 (76)	26 (68)	0.027
Occupation (n=118)				
Employed/student	26 (67)	32 (80)	30 (77)	
Unemployed	13 (33)	8 (20)	9 (23)	0.36
Type of sexual assault (n=116)				
Penetration	28 (72)	20 (51)	21 (55)	
No penetration/other acts	4 (10)	3 (8)	2 (5)	
No recollection	7 (18)	16 (41)	15 (40)	0.12 <sup>74</sup>

		0.71			0.28			0.002			0.16			0.49			0.35			0.0001			0.55			0.31
	17 (71)	7 (29)		19 (56)	15 (44)		20 (61)	13 (39)		8 (23)	27 (77)		18 (67)	9 (33)		9 (23)	31 (78)		30 (77)	9 (23)		23 (62)	14 (38)		11 (32)	23 (68)
	20 (74)	7 (26)		21 (57)	16 (43)		24 (67)	12 (33)		8 (22)	28 (78)		24 (80)	6 (20)		9 (23)	31 (78)		28 (74)	10 (26)		26 (68)	12 (32)		8 (22)	29 (78)
	28 (80)	7 (20)		28 (72)	11 (28)		35 (95)	2 (5)		3 (8)	35 (92)		26 (77)	8 (24)		14 (35)	26 (65)		12 (31)	27 (69)		22 (56)	17 (44)		14 (38)	23 (62)
Physical violence (n=86)	Light/moderate/severe	None/verbal	Location of assault (n=110)	Private	Public	Victim/assailant relationship (n=106)	Known	Stranger	More than one assailant (n=109)	Yes	No	Assailant origin (n=91)	Norwegian/western	Non-western	Time of the day of assault (n=120)	7 a.m. – midnight	Midnight – 7 a.m.	Clinically intoxicated (n=116)	Yes	No	Extragenital injury (n=114)	Yes	No	Anogenital injury (n=108)	Yes	No

<sup>72</sup> Chi-square, df=2 unless otherwise stated
73 Chi- square, df=4
74 Kruskall Wallis test for ordinal data, df=2

Table 12. Drug findings by background and assault characteristics and clinical findings among 264 female patients attending the Sexual Assault Center between July 1, 2003 and December 31, 2010

Variable	Drug <sup>75</sup> positive, $n = 50$ , $n$ (%)	Drug Error! Bookmark not defined. <b>negative</b> , $n = 214$ , $n$ (%)	d
Background characteristics			
Patient age, $n = 264$			
12 – 17 years	6 (12)	51 (24)	
18 – 24 years	19 (38)	118 (55)	
≥ 25 years	25 (50)	45 (21)	$< 0.001^{76}$
Vulnerability factors, $n = 264$			
No vulnerability factor	6 (12)	89 (42)	
Physical or cognitive disability	8 (16)	17 (8)	
Mental health problems/substance abuse	35 (70)	73 (34)	
Previous sexual assault(s)	1 (2)	35 (16)	$< 0.001^{77}$
Alcohol consumption, $n = 257$			
No intake	13 (28)	22 (11)	
Intake of < 5 units	10 (21)	40 (19)	
Intake of ≥ 5 units	24 (51)	148 (71)	$0.005^{76}$
Suspected proactive drug-facilitated sexual assault, $n = 252$			
No	35 (73)	160 (78)	
Yes	13 (27)	44 (22)	0.4178
Occupation, $n = 255$			
Student	13 (28)	115 (55)	
Employed	10 (22)	55 (26)	
Unemployed	23 (50)	39 (19)	< 0.001 <sup>76</sup>
Assault reported to the police, $n = 241$			
No	9 (21)	78 (39)	
Yes	33 (79)	121 (61)	$0.029^{78}$
Assault characteristics			
Type of sexual assault, $n = 259$			
No penetration/other acts	6 (13)	14 (7)	
Penetration	27 (56)	115 (55)	
No recollection	15 (31)	82 (39)	$0.31^{76}$

0.13 <sup>78</sup>	9	0.55′°		$0.19^{78}$		82	0.053′°			1	$0.061^{76}$		ì	0.14		Ç.	0.005				$0.19^{78}$			1	$0.029^{79}$			0.5878		î	0.18'8
46 (32) 96 (68)	128 (65)	69 (35)	153 (81)	36 (19)		169 (87)	26 (13)		60 (38)	64 (41)	33 (21)		124 (74)	43 (26)		49 (23)	161 (77)			135 (65)	72 (35)		68 (33)	135 (65)	4 (2)		149 (75)	51 (26)		108 (51)	106 (50)
6 (19) 26 (81)	32 (70)	14 (30)	41 (89)	5 (11)		33 (75)	11 (25)		10 (29)	11 (31)	14 (40)		25 (63)	15 (38)		20 (44)	26 (57)			27 (55)	22 (45)		10 (21)	34 (71)	4 (8)		31 (71)	13 (30)		20 (40)	30 (60)
Physical violence, $n = 174$ No/verbal Yes	Location of assault, <i>n</i> = 243 Private	Public	Victini/assanant relationsinp, $n = 255$ Known	Stranger	More than one assailant, $n = 239$	No	Yes	Assailant age group, n=192	≤ 24 years	25 – 34 years	≥ 35 years	Assailant origin, $n = 207$	Western	Non-western	Time of day of assault, $n = 256$	7 a.m. – midnight	Midnight - 7 a.m.	Clinical findings	Clinically intoxicated, $n = 256$	No	Yes	Extragenital injury, $n = 255$	None	Minor/moderate	Serious	Anogenital injury, $n = 244$	No	Yes	Time from assault to sampling, $n = 264$	< 12 h	≥ 12 h


<sup>&</sup>lt;sup>75</sup> Drug(s) other than ethanol, but could in addition be positive for ethanol <sup>76</sup> Chi-square test, df = 2 <sup>77</sup> Chi-square test, df = 3 <sup>78</sup> Chi-square test, df = 1

# 5.3 Medico-legal findings and legal outcome (Paper III and the EA)

# 5.3.1 Results according to aims (Paper III)

# What is the legal outcome among cases of rape and attempted rape?

For the 185 cases included in Paper III, the reported assault was classified as attempted rape in 28 cases (15%), and the rest were rape notifications. Legally binding decisions had been reached in all but one of the 185 cases. The legal outcome is illustrated in Figure 10. A total of 30 cases were charged in a court of law. Of these,




**Figure 10** Legal outcome among all police-reported cases of rape and attempted rape, Sør-Trøndelag police district 1997 through June 2003 (Figure 1, Paper III)

22 convictions were reached,<sup>79</sup> while eight cases ended in an acquittal. In three of these cases, the suspects were initially convicted in the city/district court, but acquitted upon a second trial in the Court of Appeal.

# Is there any association between medical findings and charge filing?

Only those who had been medically examined at the SAC were included in these analyses. Figure 11 shows the legal outcomes for the 101 cases medically examined.



**Figure 11** For those rape victims who had been medically examined at the SAC, comparisons were done between those cases with a potential for charge to be filed. Those 54 where a charge was not filed included 53 cases with insufficient evidence and one case were the assailant was not legally responsible

Table 13 below describes details of the medico-legal findings by legal outcome. Extragenital injuries were more often present when charges were filed vs. not filed, especially moderate/ serious injuries. However, this association fell below the level of

<sup>&</sup>lt;sup>79</sup> Among the 22 cases ending with a convicting sentence, one assailant was convicted in each of 15 cases. As many as four assailants were convicted in one case. In contrast, one and the same assailant was convicted in four and two cases, respectively. All the 18 assailants went to prison for a period of 45 days to four years. In addition, assailants were convicted with up to 9 years of additional preventive supervision. Compensation for criminal injuries was granted to 24 victims

Table 13. Medico-legal findings among 101 women who reported rape and attempted rape to the police and had I

	Total	Charges filed	, N=72	
Variable	N=101 n (%)	Yes, n=18 n (%)	No, n=54, n (%)	<i>p</i> -value
	(/0/	(/5/	(70)	
Victim's age, n=101				
16 - 17 years	23 (23)	5 (28)	13 (24)	
18 - 24 years	45 (45)	7 (39)	23 (43)	
≥ 25 years	33 (33)	6 (33)	18 (33)	0.94 <sup>83</sup>
Interval assault to medical examination, n=99		, ,		
≤ 24 h	70 (71)	12 (71)	40 (76)	
> 24 h	29 (29)	5 (29)	13 (25)	0.7284
Emotional state at examination, n=79	,	, ,	` ,	
Calm, rational	16 (20)	4 (27)	9 (21)	
Distressed (e.g. crying, shaking )	63 (80)	11 (73)	33 (79)	0.71 <sup>84</sup>
Extragenital injuries, n=90	00 (00)	(///	33 (73)	0.72
None	41 (46)	5 (29)	24 (51)	
Minor	39 (43)	8 (47)	18 (38)	
Moderate /serious	10 (11)	4 (24)	5 (11)	0.23 <sup>83</sup>
≥ 4 extragenital injuries, n=90	10 (11)	7 (24)	3 (11)	0.23
No	67 (82)	13 (81)	36 (84)	
Yes	15 (18)	3 (19)	7 (16)	0.8484
Anogenital injuries, n=92	13 (10)	3 (13)	, (10)	0.01
No	78 (85)	13 (87)	40 (82)	
Yes	14 (15)	2 (13)	9 (18)	0.71 <sup>84</sup>
More than one anogenital injury, n=91	14 (13)	2 (13)	3 (10)	0.71
No	83 (91)	13 (87)	43 (90)	
Yes	8 (9)	2 (13)	5 (10)	0.9184
Any injury, n=95	8 (3)	2 (13)	3 (10)	0.51
No	41 (43)	6 (33)	23 (47)	
Yes	54 (57)	12 (67)	26 (53)	0.32 <sup>85</sup>
Spermatozoa found at SAC, n=66	34 (37)	12 (07)	20 (33)	0.32
No	50 (76)	7 (70)	28 (78)	
Yes	16 (24)	3 (30)	8 (22)	0.73 <sup>84</sup>
Trace evidence sent for analysis FMI, n=89	10 (24)	3 (30)	0 (22)	0.75
No	59 (66)	3 (20)	34 (71)	
Yes	, ,	12 (80)	34 (71) 14 (29)	< 0.001 <sup>85</sup>
	30 (34)	12 (00)	14 (29)	\ \ 0.001
Spermatozoa detected at FMI, n=30 No	12 /45\	E /42\	G (AG)	
	13 (45)	5 (42)	6 (46)	0.8285
Yes	16 (55)	7 (58)	7 (54)	0.82

Those with missing information were excluded from the analyses

1 Adjusted for age (3-categorical)

2 Adjusted for time interval (2-categorical)

3 Kruskal Wallis test, df=2

4 Exact Unconditional test

5 Chi-square, df=1

undergone medical examination, and by charge filing<sup>80</sup>, in Sør-Trøndelag, Norway, 1997 through June 2003

Crude OR	OR adjusted for age <sup>81</sup>	OR adjusted for interval assault to med. exam. <sup>82</sup>	OR adjusted for age and interval assault – exam.
		_	
Reference		Reference	
0.8 (0.2 – 3.0)		0.8 (0.2 – 3.2)	
0.9 (0.2 – 3.5)		0.7(0.2-3.0)	
0.8 (0.2 – 2.6)	0.8 (0.2 – 2.6)		
Reference	Reference		
Reference	Reference	Reference	Reference
0.8 (0.2 – 2.9)	0.6 (0.1 – 2.6)	1.1 (0.2 – 5.1)	0.9 (0.2 – 4.4)
Reference	Reference	Reference	Reference
2.1 (0.6 - 7.6)	2.3 (0.6 - 8.7)	2.2 (0.6 - 8.0)	2.4 (0.6 - 9.2)
3.8 (0.8 - 20)	4.7 (0.9 - 26)	3.7 (0.7 - 19)	4.5 (0.8 -25)
Reference	Reference	Reference	Reference
1.2 (0.3 – 5.3)	1.4 (0.3 – 6.8)	1.0 (0.2 – 4.8)	1.2 (0.2 – 6.1)
1.5 (0.3 – 7.7)	1.5 (0.3 – 8.4)	1.3 (0.2 – 7.0)	1.4 (0.2 – 7.6)
Reference	Reference	Reference	Reference
Reference	Reference	Reference	Reference
1.3 (0.2 – 7.6)	1.3 (0.2 – 7.7)	1.8 (0.3 – 11)	1.7 (0.3 – 11)
Reference	Reference	Reference	Reference
1.8 (0.6 – 5.5)	2.0 (0.6 – 6.4)	2.1 (0.6 – 6.8)	2.4 (0.7 – 8.4)
Reference	Reference	Reference	Reference
1.5 (0.3 – 7.2)	1.9 (0.4 – 10)	1.6 (0.3 – 8.2)	2.0 (0.3 – 12)
Reference	Reference	Reference	Reference
9.7 (2.4 – 40)	11 (2.5 – 45)	13 (2.4 – 66)	14 (2.4 – 78)
Reference	Reference	Reference	Reference
1.2 (0.2 – 5.8)	1.6 (0.3 – 8.9)	1.7 (0.3 – 9.8)	4.2 (0.4 – 46)

significance, even after adjusting for victims' age and interval from assault to medical examination. There were no differences in charge filing when the victim had more than three extragenital injuries. Anogenital injuries were documented in 14 victims and ranged from none to ten (median two); five were single site, four victims had two or three injuries, while four had four or more injuries documented. There were no differences in the frequency of anogenital injuries among those cases where charges were filed vs. not filed, and no differences between those with more than one anogenital injury vs. fewer. Adjusting for age and time interval from assault to medical examination did not change this pattern. The documentation of any injury (extragenital and/or anogenital) or both extragenital and anogenital injury had no association to charges being filed.

In the result section of Paper III, we stated that we restricted the analysis of anogenital injuries vs. charges filed to only those (n=71) reporting anal/vaginal penetration. The numbers are given in Table 14, and show that there were still no association between anogenital injuries and charge filing (p=0.70<sup>86</sup>). When restricting the analyses of extragenital injuries vs. charges filed to only those reporting physical violence (n=65), a higher proportion of those with injuries was charged in court, however, not significantly higher (p=0.20<sup>86</sup>).

Table 14. Extragenital and anogenital injury according to history in police-reported rapes, and by charge filing<sup>87</sup>, in Sør-Trøndelag, Norway, 1997 through June 2003

Characteristics/variable	Examined SAC N=101	•	es filed =72
	n (%)	Yes, n=18 n (%)	No, n=54 n (%)
Extragenital injuries among w	omen exposed to violence,	, n=65	
Yes	37 (57)	10/13 (77)	16/32 (50)
No	23 (35)	3/13 (23)	13/32 (41)
Missing	5 (8)	0	3/32 (9)
Anogenital injuries among wo	men exposed to penetration	on, n=71	
Yes	10 (14)	1/10 (10)	7/44 (16)
No	58 (82)	9/10 (90)	34/44 (77)
Missing	3 (4)	0	3/44 (7)

<sup>&</sup>lt;sup>86</sup> Exact unconditional test

<sup>&</sup>lt;sup>87</sup> Excluded cases with unknown assailant, n=22 and unfounded cases, n=7

During examination at the SAC, swabs were collected from 90 victims. Only in 30 cases, the police submitted these swabs for analysis. Police decision to submit trace evidence for analysis was associated with charge filing. Adjusting for victim's age and interval from assault to examination even enhanced this association (Table 13). Spermatozoa were identified in a total of 16 swabs collected from the victims' anogenital and/or umbilical area. Spermatozoa were equally present among the charged and uncharged cases (Table 13). In the five cases showing a DNA-match between swabs collected from the victim and the suspect, a charge was filed in four cases, while in one case evidence was considered insufficient<sup>88</sup> (Table 2, Paper III).

### 5.3.2 Additional exploration of trace evidence analysis (Paper III)

We wanted to explore whether trace evidence analysis was associated with certain victim and assault characteristics. These analyses are illustrated in Table 15.

There was no pattern towards more analyses being performed when the assailant had

Table 15. Trace evidence analysis by certain characteristics of 72 women police-reporting rapes with charge filing potential<sup>89</sup>, Sør-Trøndelag, Norway, 1997 through June 2003

Variable	Charges filed, total,	Trace evi	dence analyze	d, n=63
	N=72	Yes, n=26	No, n=37	<i>p</i> -value
		n (%)	n (%)	
Victim's age, n=101				
16 - 17 years	18 (25)	5 (19)	11 (30)	
18 - 24 years	30 (42)	14 (54)	14 (38)	
≥ 25 years	24 (33)	7 (27)	12 (32)	$0.43^{90}$
Victim – assailant relationship, n=97				
Partner/acquaintance	48 (69)	18 (69)	21 (60)	
Casual acquaintance /stranger	22 (31)	8 (31)	14 (40)	$0.46^{91}$
Self-reported penetration <sup>92</sup> , n=82				
Yes	56 (95)	19 (86)	30 (100)	
No	3 (5)	3 (14)	0	$0.07^{93}$
Interval assault to medical examination,	n=99			
≤ 24 h	52 (74)	23 (92)	26 (72)	
> 24 h	18 (26)	2 (8)	10 (28)	0.10 <sup>93</sup>

<sup>&</sup>lt;sup>88</sup> Among the 4 cases where swabs from the victim showed unidentified male DNA, only one were not charged because of unidentified suspect, while in the 3 other cases evidence was considered insufficient

<sup>89</sup> Excluded cases with unknown assailant and unfounded cases

<sup>90</sup> Chi-square, *df*=2

<sup>&</sup>lt;sup>91</sup> Chi-square, *df*=1

<sup>&</sup>lt;sup>92</sup> Anal, vaginal or oral penetration

<sup>93</sup> Fisher's exact test

a more distant relationship to the victim. Similarly, we found no significant differences in women's age, in self-reported penetration, or in the interval from assault to medical examination vs. trace evidence analysis, although the latter two were borderline significant.

## 5.3.3 Police use of forensic report, expert witness and toxicology (Paper III)

In 84 of the cases in which SAC medical examination had been performed, the police requested a medical forensic report; in each of the 18 cases forwarded to court, such a report was included in the police files. On the other hand, a medical report from the SAC had also been sent to the police in 46 of the 54 cases where charges were not filed. An expert witness from SAC testified in court during the proceedings in only five cases.

In 11 cases, victims had urine and/or blood sampled for toxicological tests. Nine tests from the victims were positive: four tests were positive for ethanol and five tests were positive for other drugs like benzodiazepines, opioids, cannabis, and central stimulants. No association was found whether toxicological analysis was performed or not, or whether test results were positive or negative, and charge filing among those tested (p=0.68 and 0.50, respectively).

### 5.3.4 Results according to aims for the expanded period 1997 - 2010

# What is the legal outcome among cases of rape and attempted rape?

The legal outcome of the cases for the total period of 1997 – 2010 is shown in Figure 12. The proportion of cases ending in court (charges filed) was halved: i.e., from 16% in the period 1997 – June 2003, to as low as 8% in the period July 2003 – 2010. Those cases classified as no crime was correspondingly doubled: i.e., from 6% in the first period to 12% in the second.

After the exclusion of cases with no potential for a charge to be filed, a total of 380 cases were left, of which 213 had medical information from the SAC (see Figure 13 below).




Figure 12 Legal outcome among all police-reported cases of rape and attempted rape, Sør-Trøndelag police district. The subscript 1 is for the period 1997 - 2003, subscript 2 from 2003 - 2010, while subscript named "total" is for 1997 - 2010. The group of legal outcomes named miscellaneous (only from period 2) included: those cases treated outside criminal proceedings (n=4), those cases dropped because the suspect was deceased (n=4), those cases let at rest (according to section 250) (n=1), and finally those cases sent for investigation abroad (n=1)

Table 16. Medico-legal findings among 324 women who reported rape and attempted rape to the police and had

	Total	Total Charges filed, N=213		
Variable	N=324	Yes, n=38	No, n=175	<i>p</i> -value
	n (%)	n (%)	n (%)	
Victim's age				
16 - 17 years	71 (22)	7 (18)	45 (26)	
18 - 24 years	154 (48)	16 (42)	79 (45)	
≥ 25 years	99 (31)	15 (40)	51 (29)	0.40 <sup>97</sup>
Interval assault to medical examination, n=321				
≤ 24 h	232 (72)	29 (78)	121 (70)	
> 24 h	89 (28)	8 (22)	53 (31)	0.28 <sup>98</sup>
Emotional state at examination, n=297				
Calm, rational	61 (21)	6 (18)	38 (24)	
Distressed (e.g. crying, shaking )	236 (80)	28 (82)	123 (76)	0.45 <sup>98</sup>
Extragenital injuries, n=298				
None	115 (39)	12 (32)	65 (41)	
Minor	156 (52)	18 (49)	81 (51)	
Moderate /serious	27 (9)	7 (19)	13 (8)	0.14 <sup>99</sup>
≥ 4 extragenital injuries, n=289				
No	200 (69)	24 (67)	110 (71)	
Yes	89 (31)	12 (33)	45 (29)	0.61 <sup>98</sup>
Anogenital injuries, n=296				
No	225 (76)	27 (82)	128 (77)	
Yes	71 (24)	6 (18)	38 (23)	0.55 <sup>98</sup>
More than one anogenital injury, n=294				
No	251 (85)	28 (85)	140 (85)	
Yes	43 (15)	5 (15)	24 (15)	0.95 <sup>100</sup>
Any injury, n=310				
No	107 (35)	12 (32)	63 (38)	
Yes	203 (66)	26 (68)	105 (63)	0.49 <sup>98</sup>
Spermatozoa found at SAC, n=229				
No	165 (72)	16 (62)	92 (73)	
Yes	64 (28)	10 (39)	34 (27)	0.24 <sup>98</sup>
Toxicological test collected, n=324				
No	198 (61)	24 (63)	103 (59)	
Yes	126 (39)	14 (37)	72 (41)	0.62 <sup>98</sup>
Toxicological test result, n=126	, ,		, ,	
Negative	37 (29)	3 (21)	25 (35)	
Positive	89 (71)	11 (79)	47 (65)	0.38 <sup>100</sup>


<sup>94</sup> Those with missing information were excluded from the analyses
95 Adjusted for age (3-categorical)
96 Adjusted for time interval (2-categorical)
97 Chi-square, *df*=2
98 Chi-square, *df*=1
99 Kruskal Wallis test, *df*=2
100 Exact unconditional test

undergone medical examination, and by charge filing 94, in Sør-Trøndelag, Norway, 1997 through 2010

Crude OR	OR adjusted for age <sup>95</sup>	OR adjusted for interval assault to med. exam. 96	OR adjusted for age and interval assault to med. exam.
Reference		Reference	
1.3 (0.5 – 3.4)		1.2 (0.4 – 3.2)	
1.9 (0.7 – 5.1)		1.6 (0.6 – 4.5)	
1.6 (0.7 – 3.7)	1.5 (0.6 – 3.6)		
Reference	Reference		
Reference	Reference	Reference	Reference
1.4 (0.6 – 3.7)	1.4 (0.5 – 3.7)	1.6 (0.6 – 4.5)	1.6 (0.6 – 4.5)
Reference	Reference	Reference	Reference
1.2 (0.5 – 2.7)	1.2 (0.5 – 2.7)	1.2(0.5 - 2.7)	1.2(0.5 - 2.7)
2.9 (1.0 – 8.8)	2.8 (0.9 – 8.5)	2.9 (1.0 – 8.9)	2.8 (0.9 – 8.6)
Reference	Reference	Reference	Reference
1.2 (0.6 – 2.7)	1.2 (0.6 – 2.7)	1.2 (0.6 – 2.7)	1.2 (0.6 – 2.7)
1.3 (0.5 – 3.5)	1.4 (0.6 – 3.8)	1.3 (0.5 – 3.5)	1.4 (0.5 – 3.8)
Reference	Reference	Reference	Reference
Reference	Reference	Reference	Reference
1.0 (0.4 – 3.0)	1.0 (0.3 – 2.8)	1.0 (0.3 – 2.9)	1.0 (0.3 – 2.8)
Reference	Reference	Reference	Reference
1.3 (0.6 – 2.8)	1.3 (0.6 – 2.7)	1.3 (0.6 – 2.9)	1.3 (0.6 – 2.9)
Reference	Reference	Reference	Reference
1.7 (0.7 – 4.1)	1.7 (0.7 – 4.1)	1.6 (0.7 – 4.0)	1.6 (0.7 – 3.9)
1.2 (0.6 – 2.5)	1.2 (0.6 – 2.4)	1.3 (0.6 – 2.8)	1.3 (0.6 – 2.8)
Reference	Reference	Reference	Reference
Reference	Reference	Reference	Reference
2.0 (0.5 – 7.6)	1.3 (0.3 – 5.6)	1.0(0.2-4.1)	1.1(0.2-4.8)

### Is there any association between medical findings and charge filing?

Figure 13 shows the legal outcomes for the 324 cases medically examined.



**Figure 13** Legal outcome among the police-reported rape cases where medical examination at the SAC had been performed. Comparisons were done between those cases with a potential for charge to be filed. For explanation of the subscripts 1, 2 and total see Figure 12. Other reason included cases dropped because of withdrawal (n=1), cases treated outside criminal proceedings (n=2), cases dropped because the suspect was deceased (n=2), and cases let at rest (n=1)

The same variables presented in Table 13 were analyzed for the total period 1997 – 2010, and the results are presented below in Table 16. For this total period, there was no significant association with charge filing for any of the medico-legal variables analyzed. However, moderate/serious body injury was more often documented among the cases taken to court, although only borderline significant after adjustment.

### **Key findings**

- Altogether, at least one sexually transmitted infection (STI) was diagnosed in 8.5% of the patients attending the Sexual Assault Center (SAC)
- The proportion of women diagnosed with genital chlamydial infection was notable (6.4%), but lower than in the comparable clinical population
- Differentiating STI transmitted during assault from pre-existing STI is difficult, and in only two cases the STI was suspected to be assaulttransmitted
- STI prevalence was highest among 16 19 year-old patients, while those
  positive for blood-borne virus (BBV) were older; claiming a non-Western
  assailant was associated with STI; substance abuse was associated with both
  STI and BBV
- Ethanol and/or drugs were detected in 59% of the SAC patients tested: At least one drug other than ethanol was detected in 19%: Benzodiazepine-like substances in 12%; cannabis in 5%, opioids 4%; and central stimulants in 5%
- 22% of the patients suspected proactive drug-facilitated sexual assault: however, the detected sedative drugs were not accounted for by voluntary intake in only five patients. All five had a history of drug abuse/anxiety. Therefore, no cases could unequivocally be attributed to proactive DFSA
- Among those tested for ethanol within 12 hours of the assault, 85% tested positive. The median estimated blood alcohol concentration (BAC) at the time of the assault was 1.9 g/L
- Those testing positive for ethanol more often reported a public venue, stranger assailant, and more than one assailant. However, those testing negative for ethanol more often had another vulnerability factor
- There was a significant association between increasing estimated BAC at the time of assault and suspicion of proactive DFSA and stranger assailant
- The proportion of cases taken to court was 16% in 1997 − 2003, but reduced to 8% during 2003 − 2010. Cases were not filed in 55 − 56% because of insufficient evidence, in 20% no suspect was identified, while in 6 − 12% the case was classified as no crime
- The police's decision to submit trace evidence for analysis was associated with charge filing (1997 2003)
- Moderate/serious body injury was more often documented among the cases taken to court, though this was of only borderline significance after adjustment

### 6 Discussion

### 6.1 Methodological limitations and strengths

In addition to the limitations and strengths already discussed in the three papers, some more general methodological issues will be considered in the following section. The limitations and strengths of the study design will be explored, as well as the different types of research errors. These research errors are separated into random and systematic errors (or bias), the latter categorized into selection bias, information bias, and confounding (160). Some comments regarding missing information and considerations of the differences between clinical and statistical causal pathways will be addressed. Finally, the phenomenon of generalizability, reliability, and validity will be discussed.

#### 6.1.1 Study design and data collection

Our studies are all retrospective (cross-sectional) and descriptive, thereby not allowing us to conclude on causal relationships. However, for Paper III and the EA, even if we retrospectively collected and then merged information from medical and police records, this study could be regarded as having some qualities otherwise belonging to a prospective cohort design. The medical findings were mostly documented shortly after the sexual assault. On the other hand, the legal decisions were often set up many months ahead. We collected the information about legal outcome almost two years after the assault was first reported to the police, thereby optimizing information on final legal outcomes.

The retrospective design did not allow us to collect more information than already present in the records. Information was gathered in a clinical setting, not in a research-designed context using standardized CRFs. Due to haste or to other urgent on call-duties, some questions might not have been asked, e.g. whether attempted strangulation was reported, resulting in the underreporting of such assault details. In addition, there is a possibility that SAC staff or police officers may not always exactly copy into the records the information as it was given, but rather may have recorded an abbreviated or "edited" version. Finally, information could be erroneously collected

into the database by the researchers (see section 4.5.3). Information collected from different sources, i.e., both from nurses' and physician's records, might have increased the possibility of complete collection of variables such as voluntary intake of medicinal drugs, although this could result in some differential misclassification (see 6.1.3.2). Furthermore, the close access to medical records allowed us to study relations and details not always accessible for research.

The definition of the variables shifted throughout the data collection period, thereby making comparisons between the older and the newer data challenging. We did this because updated standards for classification was recommended by others, for example, for injuries and mental health problems (143, 150, 161). As a result, more detailed information was collected in the second data collection period.

### 6.1.2 Random error

Random error describes the variability in the data that we cannot readily explain (160). The larger the study, the more this kind of error is reduced. It affects the precision of the point estimate (in this thesis OR) represented by the width of the CI: wide CIs represent less precision. In our studies, many of the outcome groups were small, resulting in wide CIs and imprecise effect estimates. However, since police and medical record data altogether has been collected from a total of 14 years, the relatively large sample size increases our studies' credibility.

To evaluate to what degree our results were influenced by type II statistical error, an example could be drawn from Paper III. We increased the sample size by two thirds in the EA. Through this, we wanted to evaluate whether such enlargement could result in the association between, for example, body injury and charge filing becoming significant. In Paper III, the unadjusted p-value was 0.23 when comparing extragenital injuries by charge filing (Table 13 in section 5.3). For the total period, the same comparison resulted in a lower unadjusted p-value of 0.14 (Table 16 in section 5.3), hence, only a minor degree of type II statistical error was illustrated.

## 6.1.3 Systematic error (bias)

#### 6.1.3.1 Selection bias

This bias is introduced to a study by erroneous selection of participants. Several levels of selection bias exist in the studies presented in this thesis. For all papers, we assume a skewed selection of study participants, since those attending SACs or those filing a police report are not representative of all raped women. As stated in section 2.2.1, probably only a proportion of victims contact SACs and/or police after a sexual assault (6, 14, 17-23). Those women experiencing a fear of injury or death, assaulted by a stranger, and concerned about contracting STIs might be over-represented in the present studies (22, 162, 163). In addition, those attending SACs more often than the general population could be familiar to seeking health care for other reasons (164). Similarly, those attending the police after rape are more often registered in the criminal records (26). In contrast to those contacting centers for battered women, non-Western subjects seem to be underrepresented among Norwegian SAC patients (165, 166).

It is reasonable to believe that most of the female patients brought to our hospital after sexual assault are identified. Even if the patients are admitted to other hospital departments due to diagnoses other than sexual assault (e.g. serious intoxication, head injury, or attempted suicide), our SAC will be contacted for forensic examination and follow-up. However, not all patients disclose information of recent sexual assault when contacting health care. In addition, reported incidents of sexual assault not classified by the police as rape codes (described in section 4.3.2) would not be included in our studies.

Since the papers in this thesis aimed to study medical findings, those not subjected to medical examination were excluded. For Papers I and II, those not medically examined (n=68, 10%) are assumed to have longer interval from assault, be less injured, and only claiming psychosocial support. This will limit our possibility to study, for example, differences in assault and assailant characteristics regarding these patients. In addition, those not wanting their records used in the study were excluded

from Papers I and II. However, this fraction was rather small (n=9, 1%) and probably had no noteworthy impact on our results.

Among those 612 eligible consultations (depicted in Figure 5, section 4.3.1), we compared those included vs. those not included in the papers regarding certain characteristics (Table 17 below). Those who attended the SAC more than one or two weeks after the assault were excluded from Paper I and II, respectively.

For both papers the individuals excluded were younger, and more often were students, thus an obvious selection of cases. This could have misled us to underestimate STI prevalence among the SAC patients because younger age is associated with STI (159, 167). There also seemed to be a selection of coitally experienced women included, which could have increased the prevalence of STI found in Paper I.

Those described in Paper II more often suspected proactive DFSA, more often had been drinking alcohol, and more often had no recollection of the assault compared to those patients excluded (Table 17). Hence, there is a possibility of us overestimating the occurrence of these phenomena among the sexually assaulted women attending the SAC. However, the proportion of women with a history of drug abuse, which could influence both STI and suspicion of proactive DFSA prevalence, were only borderline significantly more often included in the papers. Furthermore, those with no anogenital examination were not included in the study for Paper I (n=28, 5%). Those refusing such inspection could represent those less injured, as described above, indicating a falsely high prevalence of anogenital injury among those included in the study. However, the prevalence of anogenital injury in Paper I was lower than that found by others.

For Paper II, only those tested for alcohol/drugs participated. In 2008, we changed the guidelines for collection of toxicological tests, lowering the threshold for testing and offering tests to far more patients. Because of this change, only 30% of those attending the SAC during 2003 - 2007 were included, in contrast to as many as 70% of those attending during the 2008 - 2010 time period (p < 0.001, chi-square, df=1). Accordingly, twice as many of the participants in Paper II suspected proactive

		Paper I	
	Included in Paper I,	Excluded from Paper I,	
Variable	n = 412, n (%)	n = 161, n (%)	p <sup>102</sup>
Background characteristics			·
Patient age, n = 573			
12 – 17 years	114 (28)	83 (52)	
18 – 24 years	188 (46)	41 (26)	
≥ 25 years	110 (27)	37 (23)	< 0.001
Occupation, n = 552			
Student	217 (55)	113 (73)	
Employed	99 (25)	22 (14)	
Unemployed	81 (20)	20 (13)	< 0.001
Country of origin, n = 568	- ( - /	- ( - /	
Norwegian/Western	389 (95)	140 (88)	
Non-Western	20 (5)	19 (12)	0.003
Substance abuse, n = 569	== (5)	-5 ()	0.000
No	366 (90)	152 (94)	
Yes	42 (10)	9 (6)	0.077
Prior coital experience, n = 525	72 (10)	3 (0)	0.077
No	31 (8)	55 (40)	
Yes	357 (92)	82 (60)	< 0.001
Assault characteristics	337 (32)	82 (00)	V 0.001
Alcohol consumption, n = 524			
No intake	75 (19)	67 (54)	
Intake of < 5 units	86 (22)	19 (15)	
Intake of < 5 units	239 (60)	38 (31)	< 0.001
Suspected proactive drug-facilitated s	* *	36 (31)	< 0.001
No	340 (85)	131 (87)	
Yes	, ,	, ,	0.69
Type of sexual assault, n = 554	58 (15)	20 (13)	0.09
No penetration/other acts	38 (9)	27 (18)	
	, ,	` '	
Penetration	244 (61)	98 (65)	0.001
No recollection	121 (30)	26 (17)	0.001
Assault reported to the police, n = 530		67 (44)	
No	121 (32)	67 (44)	0.007
Yes	258 (68)	84 (56)	0.007
Clinical findings			
Extragenital injury, n = 516	442 (27)	02 (7.1)	
None	143 (35)	83 (74)	
Minor/moderate	251 (62)	28 (25)	
Serious	10 (3)	1 (1)	< 0.001
Anogenital injury, n = 522			
No	303 (76)	112 (91)	
Yes	96 (24)	11 (9)	< 0.001
Interval from assault to medical exam	•		
< 72 h	381 (93)	19 (12)	
72 h – 1 week	31 (8)	4 (3)	
> 1 week	0	133 (85)	< 0.001

For Paper I, cases which were not primary visit (n=39) were excluded from the comparisons this chi-square test, df = 1 or df = 2

Paper II			
Included in Paper II,	Excluded from Paper I,		
n = 264, n (%)	n = 348, n (%)	p <sup>102</sup>	
n = 612	4.45 (42)		
57 (22)	145 (42)		
137 (52)	106 (31)	4 0 00	
70 (27) n = 588	97 (28)	< 0.00	
128 (50)	210 (63)		
65 (26)	62 (19)		
62 (24)	61 (18)	0.00	
n = 607	01 (10)	0.00	
252 (96)	315 (91)		
10 (4)	30 (9)	0.01	
n = 608	30 (3)	0.01	
226 (87)	317 (91)		
35 (13)	30 (9)	0.06	
n = 564			
14 (5)	75 (24)		
243 (95)	232 (76)	< 0.0	
	- ( -/		
n = 559			
35 (14)	119 (39)		
50 (20)	61 (20)		
172 (67)	122 (40)	< 0.0	
n = 588			
195 (77)	311 (93)		
57 (23)	25 (7)	< 0.0	
n = 591			
20 (8)	48 (15)		
142 (55)	231 (70)		
97 (38)	53 (16)	< 0.0	
n = 566			
87 (36)	111 (34)		
154 (64)	214 (66)	0.63	
n = 552			
78 (31)	157 (53)		
169 (66)	137 (33)		
8 (3)	10 (3)	< 0.00	
n = 555	10 (3)	\ 0.00	
180 (74)	261 (84)		
64 (26)	50 (16)	0.00	
n = 607	30 (10)	0.00	
238 (90)	196 (57)		
20 (8)	16 (5)		
6 (2)	131 (38)	< 0.00	

DFSA in the first time period vs. the latter (34% vs. 16%, p=0.007, df=2, KW-test<sup>103</sup>). This heterogeneity of the study participants included in Paper II makes our results more difficult to interpret.

For Paper III, for the purpose of studying the impact of medical findings on legal outcome, only those having undergone examination at the SAC were included. A prior study drawn from the same study sample has addressed characteristics of those medically examined as compared to those not, among the police-reported cases of rape and attempted rape (27). Victims not examined at the SAC more often had more than one week delay from assault to police-report and more often reported the assault to a rural police office. Only very few victims of attempted rape had a medical examination, and parallel to this, more often reported vaginal penetration. This possibly gave us an overestimated proportion of raped women with anogenital injuries in the Paper III case series. However, the use of physical violence did not differ between those examined vs. those not examined, indicating representative frequency of extragenital injuries included in Paper III.

All of these factors contribute to the assumption that those participating in the three studies are selected and not representative of all assault victims attending the SAC or reporting to the police. The prevalence of the different variables may be affected by this selection bias. However, the study of associations could still give a realistic picture.

#### 6.1.3.2 Information bias/misclassification

This phenomenon denotes erroneous classification or categorization of collected information, that is, addresses the accuracy of the collected data (160). In a small dataset, misclassification of only one case may distort the results. Several levels of misclassification exist in the present studies.

For all of the papers, patients' self-reported information given to health care and/or police may not be completely truthful, for example, the information might be incomplete, false, or exaggerated. Patients may overreport the use of violence, penile

 $<sup>^{\</sup>rm 103}$  Those with missing information were included in the analysis

penetration, and non-Western, stranger, and more than one assailant to satisfy to the "rape myths criteria" (168) or to obtain sympathy/attention. If over-reporting of stranger rapes were more common among those testing positive than among those testing negative for ethanol, this misclassification may result in an overestimation of the association of stranger rape and positive ethanol test (exposure differential misclassification). Likewise, if those testing positive for BBVs disclosed a history of substance abuse more often than those testing negative, this misclassification may have distorted our results towards a higher OR. In addition, if cases without extragenital injuries were "erroneously" classified by the police as "charges not filed because of insufficient evidence" ("disease" or outcome differential misclassification) more often than those with injuries, this will falsely strengthen the relation between injuries and charge filing (Paper III and the EA).

On the other hand, if the documentation of anogenital injuries were equally wrongly diagnosed both among those cases ending in court and among those dismissed, this phenomenon of misclassification will bias our results towards "null effect" ("exposure" non-differential misclassification). Similar dilution of a potential effect exists if we for some reason under-detected the findings of GHB equally often among those with and without a history of drug abuse ("disease" or outcome non-differential misclassification).

Sexual history could be difficult for some patients to recall or be frank with. For example, patients' false claim to virginity is a misclassification that probably would lead to a higher prevalence of STI among those categorized as virgins, and a lower OR of the association between STI and coital experience (Paper I). However, only one of those classified as coitally inexperienced had a positive finding of CT, thereby rendering this misclassification probably only exceptional.

For Paper II, fear of being blamed for illegal drug use or embarrassment about amnesia regarding the event, may have caused some SAC patients to report that a drug could have been covertly administered to her. Thus, cases of opportunistic DFSA could be wrongly classified as proactive DFSA, and result in an overestimation of the prevalence. In our SAC, however, urine and/or blood were tested for the purpose of

detecting surreptitious drugging only, and the results could not elicit any legal sanctions against the victim. In addition, like in Australia (105), a lower, rather than a higher, prevalence of proactive DFSA was found when the victims themselves addressed the issue, rather than SAC staff or police investigators. It therefore seems that the prevalence of 22% among the group of patients included in Paper II is not an overestimation.

For Paper II, an example of recall bias is the underreporting of drug intake, especially of drugs with long half-lives (cannabis and some benzodiazepines), which might explain some of the unexpected findings of drugs in urine/blood. However, two patients actually admitted self-reported intake of hypnotics (flunitrazepam and zopiclone), but might still have been surreptitiously drugged since we found higher serum levels of the drugs than expected many hours after intake (Table 9, section 5.2.1). Because positive tests for ethanol was in accordance with patients' history of drinking both in Paper II and in a previous study, self-reported history of alcohol use is rather reliable among our SAC patients (169).

By excluding those attending too late for an alcohol/drug test, we may have missed diagnosing some cases of true DFSA. Sophisticated hair-analysis for, e.g., single intake of benzodiazepines (one month in advance), was not available during our study period.

The role of a clinician is to be the patient's solicitor or helper. This deep-rooted aim could hamper objectivity in evaluating the medical findings. There is a risk of overemphasizing the medical findings, for example, a physical injury that is hardly visible, but is reported as painful by the patient. When reading the medical records, we were aware of this limitation and only defined as injuries if documented by sketch or by photo in the records.

### 6.1.3.4 Regarding missing information

For some of the independent variables studied in the three papers, the number of cases with missing information is substantial. However, when we included those with missing data into the analyses, the results remain unchanged. Still, some effects

may have been over- or underestimated. I have chosen to explore this phenomenon with examples from Paper I, but similar considerations could also be drawn from the two other papers.

Regarding the outcome of whether a patient had an STI or not, missing data may have an impact on our results for some of the variables: for example, for genital examination with a speculum, prior coital experience, and origin of the assailant (Table 18). For genital examination with a speculum, only one patient among those with missing information (3%) was diagnosed with an STI. It is reasonable to believe that

Table 18. Sexually transmitted infections (STIs)<sup>104</sup> and blood borne viruses (BBVs)<sup>105</sup> disclosed at initial visit: Selected variables by presence of STI/BBV (%, prevalence shown) (Paper I)

STI present N=25		
	STI present, N=35	
Variable	n/total tested (%)	
Genital examination with speculum		
Genital speculum inspection	31/366 (8)	
Genital inspection only	3/12 (25)	
Missing information	1/34 (3)	
Prior coital experience		
No	1/31 (3)	
Yes	32/356 (9)	
Missing information	2/25 (8)	
Assailant origin		
Norwegian/Western	16/245 (7)	
Non-Western	12/81 (15)	
Missing	7/86 (8)	
	Marker(s) of BBVs present <sup>105</sup> , N=14	
	n/total tested (%)	
Prior coital experience		
No	0/27 (0)	
Yes	14/334 (4)	
Missing information	0/20 (0)	
Time since last consensual coitus, n=354 <sup>106</sup>		
≤ 2 weeks	5/139 (4)	
> 2 weeks	2/135 (1)	
Missing information	7/80 (9)	

<sup>&</sup>lt;sup>104</sup> Positive test at initial visit for at least one of the microbes *Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, Trichomonas vaginalis,* and/or HSV, and/or clinically diagnosed anogenital warts <sup>105</sup> Positive test at initial visit for at least one of the serological markers: HIV, hepatitis B and/or C (see text for details)

Those reporting no prior coital experience were excluded

when it is not documented in the medical record whether a speculum was used or not, that the speculum actually was used, since this is standard procedure. This means that the difference between the groups could be larger, that is, results could be underestimated. For prior coital experience, among those 25 with missing information, two patients (8% out of 25) had an STI. It is, however, reasonable to believe that those with no information about this variable had prior coital experience. STI was marginally less common among those with missing information than among those who reported prior coital experience. Hence, we do a minor overestimation of the results. For the origin of the assailant, the missing category is considerable (n=86 or 21%), but equally distributed between the two outcomes. Among those with missing information on assailant origin, we found an STI prevalence in-between the prevalence rates of the other two categories. Still, the difference between those reporting Western vs. non-Western assailant is large. Hence, including those with missing information into the model does not influence our final results regarding this variable.

For the outcome of whether a patient tested positive for a BBV marker or not, the amount of missing data for some of the variables may influence our results: prior coital experience, and time since last consensual intercourse (Table 18 above). As for prior coital experience, none was positive for any BBV marker among those with missing information. It is, again, reasonable to believe that those with no information about this variable have had prior coital experience, hence, a minor overestimation of the difference between the two groups. As for time since last consensual intercourse, for calculating the influence of missing information for this variable, all of those with no prior coital experience were excluded (n=27). Still, information is missing in as many as 23%. We found the highest prevalence of BBVs among those with missing information. We therefore regard those with missing information as having particular characteristics. The high prevalence of BBV markers in the group with missing information could partly be through the effect of substance abuse (see Table 3, Paper I). However, including the missing category in the analyses did not change the difference between the two groups (last consensual intercourse being ≤ or > 2 weeks).

# 6.1.3.3 Confounding, mediation and stratification

The concept of confounding expresses that the observed association between the independent variable and the outcome actually represents an association between another variable and the outcome, a confusion of effects, or that the effect of the independent variable is admixed with the effect of another variable (160). Mediation refers to the mechanism of a causal relationship: the independent variable influences an intermediary factor which in turn influences the outcome. In multivariable models, it is possible to adjust for some potentially confounding factors, for example by using logistic regression, which we used in this thesis.

In Paper I, this can be illustrated by the fact that being a student was associated with a higher prevalence of STI in the unadjusted analysis. However, after adjustment for age, this association disappeared, that is, the "effect" of being a student on STI prevalence actually was through the effect of age. Hence, age is a confounder in this example. In contrast, the effect of substance abuse on STI prevalence actually increased (and became significant) after adjustment for age. Age is here a special type of confounder called suppresser (170) (Table 2, Paper I).

In the same Paper, substance abuse could also be regarded as a confounder. The effect of unemployment on the findings of BBV markers (Table 3, Paper I) diminished when we adjusted for substance abuse. Obviously, the effect of unemployment on BBV positivity was partly through the effect of substance abuse, that is, substance abuse is a confounder. However, substance abuse could also be an intermediary factor, that is, substance abuse is in the causal pathway between unemployment and BBV positivity. Since in Norway, both hepatitis B and C are more prevalent among subjects injecting drugs, the latter possibility may be more likely.

Confounding could be regarded as a sophisticated method of stratification. In Paper III we adjusted for the time interval from assault to medical examination, hence, regarded this as a confounder for the association between the detection of injuries and charge filing. No change in the association between injuries and legal outcome remained after adjustment for post-assault interval. Certainly, time interval from assault influences the possibility to detect injuries. Even though, whether the best

strategy for the analyses here is adjustment as in logistic regression instead of other kinds of stratification, has not been evaluated.

In Paper II, another strategy was to restrict (stratify) the analyses (of alcohol positive vs. negative) to only those arriving within 12 hours of the assault. This was because ethanol would not have been detectable anyway for those attending later. In Paper III, we also restricted the analyses between injury and legal outcome to those reporting physical violence (for body injury) and anogenital penetration (for anogenital injuries) – assuming a causal relationship between action and injury. However, unknown factors on the causal pathway between injury and legal outcome may be present.

We found a convincing association between the analysis of trace evidence and charge filing. However, Paper III does not give an answer whether the decision to analyze the swabs collected from the women's bodies comes before or after the decision to file charges. It remains unknown whether the investigators chose to analyze the swabs only in cases with a potential for prosecution. Moreover, our study contains no information regarding whether some women refused to have her already-collected SAC swabs sent for analysis by the police.

When studying association with legal outcome in Paper III, variables related to the circumstances of the sexual assault (for example, age and number of suspects, victim – suspect relationship, police interview, and the suspect being previously convicted etc.) might have influenced the legal outcome and could be regarded as confounders. In a South African study, the authors used whether a first witness statement was taken by the police or not as a confounder, since this was regarded as an indicator of the quality of the police investigation (136). This dichotomous variable was included in their logistic regression model searching for the association between medical findings and charges filed. However, for the present study, we did not include any similar variables as a proxy for quality of police investigation. Due to the small sample size in Paper III, additional confounding was difficult to adjust for, but probably there are several, and many are unknown factors.

### 6.1.3.4 Clinical vs. statistical causal pathways

As a continuation of the concepts of confounding, we need to address some differences in the two ways of thinking about the causal pathways. On the one side is the clinical/forensic approach, and on the other side is the statistical/epidemiological approach. The clinical way of thinking takes signs and symptoms into account for a disease (for example, anal penetration associated with a case of rectal NG). Likewise, the forensic physician evaluates whether external mechanisms could have caused an injury (for example, anal penetration associated with anal injury), and often a causal relationship could be established. However, this causal relationship cannot be established when analyzing retrospectively collected data material from records. The epidemiological/statistical approach is to test quantitative data and look into mathematical relationships. This technique evaluates whether there is a statistical association or a probability that the variable under study could be associated with (but not causing) the outcome.

Some examples of the differences between forensic and statistical thinking about causal relationships could be used to illustrate. For example, most anogenital injuries found in cases of sexual assault are superficial and transient. We did not find any statistical association between this finding and legal outcome. However, occasionally anogenital injury documentation could be crucial for a case to proceed in court. Unfortunately, our study was not able to identify whether such evidence alone was used in single cases. Likewise, in some individual cases, DNA may be of invaluable evidence for the case, but when the system is viewed as a whole, no obvious association was found.

## 6.1.4 Generalizability of the findings not related to errors

As stated in section 6.1.3.1, many victims of sexual assault do not seek medical care, and our results are therefore not necessarily applicable to victims of sexual assault in general. Moreover, generalization of our findings to other countries should be done with caution. Both the populations subjected to sexual assault and those seeking help may differ considerably between countries, and the medical indications

for performing the different examinations and laboratory testing may vary. Differences in the organization and financing of health care may reduce the validity of our findings in countries with lower income and lower access to expensive technology. However, similar findings of STI-prevalence, toxicology results, and injuries as those presented here have been found in other studies from Western countries, increasing the probability of our findings being representative for these populations.

Different thresholds for police reporting, women's rights and gender equality issues, as well as different legal systems and attitudes among investigators/prosecutors, could diminish generalizability of the findings in Paper III and the EA outside the Nordic countries. Similar studies should therefore be performed in countries with a minor degree of gender equality as well.

## 6.1.5 Reliability and validity

#### 6.1.5.1 Microbiology and toxicology test

Regarding positive STI/BBV laboratory tests, all tests were repeated with the same or an alternative test method according to recommendations (cf. details in section 4.5.1.4 and in the Method section in Paper I). In case of urine samples testing positive on drug screening, the corresponding blood samples were analyzed to confirm the results (cf. section 4.5.1.4 and Method section 2.4 in Paper II).

# 6.1.5.2 Anogenital injuries

Regarding the clinical findings, for example, evaluating anogenital injuries may be difficult and is partly dependent on the examiner's experience. One study has shown that the more experienced physicians were less apt to classify findings as genital injuries (171). This could result in over- or underestimating the prevalence of injuries in our studies. Peer-reviewing all injuries present would improve the interpretation, and since 2008, the Trondheim SAC staff have systematically performed such quality control. Hence, at least one physician, in addition to the examiner on duty, has examined the colposcopic photos.

### 6.1.5.3 Sensitivity and specificity of swabs and urine samples (Paper I)

Different sensitivity exists for both CT- and MG-detection by FVU versus swabs collected from the urogenital area. According to three studies from our hospital's laboratory, FVU seems to be as sensitive as vaginal swabs for the detection of CT, while FVU seems to be somewhat more sensitive than swabs for MG detection (172-175). The specificity is generally high for all sampled materials (172).

In Paper I, altogether 383 patients had microbiological swabs collected from the urogenital area<sup>107</sup>, while 81 had FVU<sup>108</sup> tested. Regarding urogenital CT, all positive tests were from urogenital swabs, except for two tests performed in FVU only. For urogenital MG, only one tested positive, and positive in FVU only (negative in urogenital swab). Since vaginal swabs should be as sensitive as FVU for the detection of CT, we do not expect the differences in detection rate between the different samples to influence our results to a large degree. However, since only a quarter of the samples were tested for MG, and more than half of these were not examined in FVU, MG is probably underdiagnosed in our series.

Regarding Paper I, urogenital swabbing was the method of choice for the whole period of time (2003 – 2010). However, since we became more aware of the possibility of detection of CT from different locations (FVU, anorectal area and pharyngeal area) during that period, an increasing load of tests collected from locations other than the cervix were submitted beyond the period. In addition, for increasingly more patients, we collected samples from more than one location. However, except for two cases, all positive tests were collected from the urogenital area (incl. FVU); one sample testing positive for CT came from the pharynx and one for MG from the anus. Others have found that the sensitivity increases considerable when combining test materials (176).

### 6.1.5.4 NG culture compared to PCR (Paper I)

The gold standard for NG diagnosis has been culture. NG is a fastidious bacterium, needing optimal sampling, transport medium, transport time, and

<sup>107</sup> n=377 tested for CT/MG (TV/HSV) and additionally n=6 for NG only

transport conditions to allow for high sensitivity culture. As for other STIs (for example, CT and MG), NAAT has been developed for NG detection as well. During 2013, the St. Olavs Department of Microbiology has started to test for NG by using NAAT instead of culture. One Norwegian study, on the sensitivity and specificity of NG-testing when using culture vs. NAAT, has found that the sensitivity of culture was only 71% vs. 100% for NAAT (177). Especially for pharyngeal and rectal samples, the sensitivity was significantly lower for culture than for NAAT. However, the negative predictive value for NG culture was 95% (and the specificity and positive predictive value was 100%).

In Paper I, we had 300 cervical samples cultured for NG, while only 53 and 61 samples were collected from the anorectal and pharyngeal area, respectively. Since the microbial laboratory is situated at the same hospital, transport of samples was easy and rapid. It is reasonable to assume a low number of false negatives, although limiting our NG detection to culture might have resulted in this infection being underdiagnosed.

### 6.2 Discussion of the results

This thesis has critically explored some findings obtained during the acute medical examination of female victims of sexual assault in Norway. Until now, STIs and toxicological findings among Norwegian sexual assault victims seeking help have not been described. Issues regarding assault-transmitted STIs and considerations of proactive DFSA prompted us to explore the cases further, which has only been done in a few earlier studies. When studying police-reported rapes, our findings are in accordance with those made by the Oslo SAC, that the police's use of medical information is limited. Beyond that, it has added some new aspects of the impact of medical information in rape investigation in Norway, for example, the impact of extragenital findings on charge filing. Each of the three different topics dealt with in this thesis will be discussed in the following sections.

### 6.2.1 Sexually transmitted infections (Paper I)

This study has added to our knowledge of STIs in victims of sexual assault in a

Nordic setting. We have described the relatively low prevalence of STI/BBVs in a Norwegian SAC, corresponding to the knowledge that such infections might be less frequent than in many other countries. Norwegian assault victims were rarely found to be infected during the assault. Our findings will be compared to what have been described by others in sections 6.2.1.1 - 6.2.1.4.

### 6.2.1.1 Prevalence of STI/BBVs

The results from Paper I are presented in Table 21 in a similar way as for the comparable studies discussed in section 2.3.1 (Tables 2 and 3). We have described the STI/BBV prevalence among those presenting to a hospital SAC within one week of the assault. Only four recent studies describe the STI findings from the acute examination (41, 65, 67, 74). Except for in the U.S. study regarding adolescent sexual assault victims (65), we found the lowest prevalence of "any STI." Our CT prevalence of 6% was comparable to the only U.K. study reporting STI-prevalence "shortly" after the assault and to the U.S. adolescent SAC study (65, 74), a little lower than in the Belgian study (67), but much lower than the prevalence of 29% that was found among the South Korean SAC patients (41). None of the other studies from Table 2 has reported MG prevalence, so this is the first study to add knowledge about this newly diagnosable sexually transmitted agent.

We did not find any case positive for NG or TV, reflecting the low prevalence in the Norwegian general population. In two recent western SAC studies, only 1 – 2% of patients had NG (65, 74), while as many as 6% of those attending the South Korean SAC tested positive (41). Even if the latter study used PCR for testing (see section 6.1.5.4), Norwegian surveillance data, which includes some NG PCR tests, show low prevalence of the microbe as well. This emphasizes the higher risk of infection in other parts of the world. Correspondingly, more than one STI was found in 3% in the South Korean study, while we only found this in one single patient (0.2%). An audit among 19 U.K. STD-clinics reported that as many as 6% of victims of sexual assault had more than one STI (69). However, the authors did not include details of the microbes found, and only one third of the patients were tested within two weeks of the assault. A U.K.

First author, publication	irst author, Sample size, setting and, ublication years included, design	ng and, STI prevalence, at initial sign visit (at presentation),	BBP prevalence <sup>109</sup> at initial visit (at	Post-exposure Sex, age, time from prophylaxis: antibiotics, method, follow-up	Sex, age, time from assault, test method, follow-up
year, country		No. testing positive/no. tested (%)	presentation), No. testing positive/no. tested (%)	hepatitis B vaccination, and HIV PEP (offered/received) (%)	
Hagemann,	N=412 attending a SAC;	Any STI: n=35 (8%);	HIV: 0/374	Antibiotics: 374/412	All female
2014, Norway	<b>2014, Norway</b> 2003 – 2010;	NG: 0/304;	HBsAg: 0/362	(91%);	Median age 21 years $(12-61)$
(Paper I)	retrospective	CT: 25/393 (6%);	HBcAb: 7/344 (2%)	$HBV^{110}$ : 80/412 (19%);	Median 12 h from sexual assault (1 –
		MG: 2/106 (2%);	HCVAb 9/330 (3%)	HIV-PEP: 11/381 (3%)	165 h)
		TV: 0/58;	syphilis: 0/213		Urine/swabs PCR-test (CT, MG, HSV)
		anogenital warts: 8/412			Swabs culture (NG, TV)
		(2%);	n=2 tested positive for		Anogenital warts clinically diagnosed
		HSV: n=1 (of the 2	both HBcAb and HCVAb		Follow-up rate 195/412 (47%)
		tested);			
		> 1 STI: n=1			
		Positive for both MG and HCV, n=1	HCV, n=1	Ī	

 $<sup>^{109}</sup>$  Excluded HBsAb results (immunity)  $^{110}$  Offered to 41% of the patients attending during 2008 – 2010, reflecting a change in the guidelines

study from the 80s reported a frequency of more than one STI of as high as 15%, again due to the higher prevalence of both NG and TV at that time in contrast to nowadays (85).

We found no positive tests for HIV, which is in accordance with many of the other recent studies presented in Table 2 (41, 65, 66, 68, 73), but contrasting the findings from South Africa, where as many as 14% of the SAC patients tested positive for HIV at the initial visit (42). None of our patients currently had hepatitis B infection (all negative for HBsAg). However, 2% had gone through this viral infection during their lifetime, testing positive for HBcAb. When excluding among the HBV markers those testing positive for HBsAb only (indicating immunity after vaccination), the proportions testing positive for HBV markers in other SAC studies are similarly low (41, 43, 67, 73, 74). Hepatitis C is mostly transferred through contaminated syringes or blood, whereas sexual transmission is less frequent (178). A total of 3% of our SAC patients tested positive for HCV markers. Only 3 other SAC studies report prevalence of this infection. All tested negative in the two studies of adolescent patients (65, 73), while 4% tested positive in the Belgian study (67). The latter consisted of older patients with more mixed ethnic background. Syphilis was not found in any of our patients tested at the initial SAC visit, which is in accordance with other recent SAC studies (41, 43, 65, 67, 73, 74).

## 6.2.1.2 Post-exposure prophylaxis

We offered antibiotic prophylaxis to more than 90% of our patients attending within a week of the assault. This is the highest level we have found among all SAC studies, except for in Israel where all victims were offered antibiotics (44). Hepatitis B immunization was increasingly offered to our SAC patients throughout the study period, see Table 21 for details. In four U.K. studies, HBV vaccination was offered to more than half of those patients attending shortly after the assault (66, 68, 69, 72). We only offered HIV-PEP to 3% of our victims attending within 72 hours of the assault, whereas corresponding numbers from the U.S., Kenya and Brazil were 63 – 84% (43, 45, 65). The South African HIV-prevalence authors claimed offering HIV-PEP to a

proportion of the SAC patients tested, but did not include numbers (42).

#### 6.2.1.3 Assault-transmitted STI/BBV

Altogether, we could conclude that two patients in our study contracted the infection during the assault. One of those with no prior coital experience tested positive for CT, while another patient got an HSV infection.

Only some older prospective and retrospective studies have estimated the risk of different infections following sexual assault (see section 2.3.1.3). However, no recent studies have tried to give similar estimates for assault-transmitted STIs among non-virgins, since excluding pre-existing infections are almost impossible. Still, patients with previous coital experience could become infected during the assault.

As stated, the Trondheim SAC offer as a routine one-dose azithromycin prophylactic treatment at the initial post-assault visit. Among those re-tested for an STI within 6 weeks, one patient who initially tested negative, subsequently tested positive for CT at the follow-up. Similarly, in a U.S. study, even if all patients diagnosed with an STI at the follow-up consultation had received prophylactic antibiotics at the initial visit, NG and CT were each detected in three cases (78). Some of the victims may not be able to ingest the medications offered, might have been re-infected through consensual sex, or might have been infected with resistant bacteria.


Re-screening for serologic markers in our study revealed no new cases positive for HIV or HBcAb, while three tested positive for HCVAb during the follow-up. Each of these three patients had additional risk factors for HCV infection. Re-screening for serologic markers of HIV and/or syphilis must be performed after at least 3 months, while for hepatitis B and/or C diagnostics, at least 6 months should have passed for a reliable negative test. Only one recent SAC study reports follow-up testing for BBVs of as long as 3 months (68). None of the patients had seroconverted to HIV positive. However, with such a long incubation period, intervening BBV transmission is possible and further complicates our possibility to interpret assault-transmission of BBVs.

### 6.2.1.4 Characteristics associated with the detection of STIs/BBVs

Both STI and BBV-detection was associated with patient age, although in different patterns. We found a strong association between increasing patient age and positive test for at least one BBV marker. Similarly, no patients < 20 years of age were found to test positive for BBVs in an older U.S. SAC study (79).

In contrast, STI prevalence was highest among the 16-19 year-old patients. When looking into CT prevalence only, a similar pattern was found (Table 8 in section 5.1.1): highest among the 15-19 year olds (11%), followed by those aged 20-24 years (5%). In the study from the South Korean SAC, the highest proportion of CT-positive tests was among the 15-19 year olds, followed by those aged 10-14 years (41). The proportion of women diagnosed with genital chlamydial infection after the age of 15-19 years has been shown to decrease with age in several different settings and studies (159, 167, 179, 180).

As shown in Figure 14 below, the Trondheim SAC CT-prevalence was lower than



**Figure 14** Proportion with positive tests for CT in % of those tested in 3 different clinical settings: Data from the Trondheim SAC, other clinical data from St. Olavs Hospital (180), and data from national Norwegian surveillance (167)

in comparable clinical populations. According to Norwegian national surveillance data among the women tested, the highest proportions testing positive for CT were found in the 15-19 years-old-group (13%), followed by those aged 20-24 years (10%) (167, 181). According to a clinically based study from the catchment area of our SAC, the prevalence of CT in 2006 was as high as 16% among the youngest women (15-19 years) and 12% among those aged 20-24 years (180). Similarly, in other studies, prevalence of STI among SAC patients has been compared to the prevalence among other gynecological or STD-clinic patients, and found to be lower (80, 87) or "no greater" (71). This is in contrast to the sexual assault victims' assumed higher risk of STIs.

We could also compare the CT prevalence reported in Paper I with that of the general Norwegian population. A prevalence of around 2% has been reported among female volunteers younger than 25 years of age (182-184), except for in a recent survey among adolescents in the north of Norway, where as many as 7% of the girls tested positive for CT (185). Unfortunately, only a few studies have been conducted regarding BBV-markers in the general Norwegian population. The prevalence of HBV-markers has only been presented as a conference proceeding (186). In the Oslo Health Study, more than 5,000 women aged 30 – 75 years were tested for HBV markers: 5% tested positive for HBcAb, while only 0.3% were positive for HBsAg, both values a little higher than found in our SAC study. However, for HCV markers, two Norwegian antenatal surveys reported a prevalence of HCVAb of only 0.2 – 0.7% (187, 188), which is considerably lower than HCV prevalence among our SAC patients. The latter is in contrast to what was found in South Africa, where the prevalence of HIV positive test among SAC patients was less than half that found in an antenatal HIV surveillance survey (42). Different age distribution might be one reason for the disagreement.

We found associations between positive tests for STI or BBV and a history of alcohol or drug abuse. This contrasts to what was found in a U.S. study, where patients with a history of drug abuse (and/or mental illness) did not have a higher rate of infection than others (88). Drug abuse might induce risky sexual behaviour, thereby giving higher chance of STI infection. In addition, according to both Norwegian and

Australian authorities, transmission of hepatitis B and C among people not originating from high-endemic areas occurred predominantly through injecting drugs (189, 190).

The only assault and assailant characteristic associated with a higher prevalence of STI was non-Western origin of the assailant. The recent South Korean SAC study neither found any association between ejaculation during the assault and STI positivity (41). Some have described that anal penetration was associated with a case of rectal NG (85). We did not find any SAC studies reporting on the association of anal penetration/anogenital injury and BBV infections. This might be difficult to prove, although anogenital injury may facilitate the transmission of these viral infections (191, 192). In a U.K. case report, vaginal penetration by more than one assailant probably caused transmission of hepatitis B to the victim during the assault (96). To conclude, population-based global data have found associations between sexual intimate partner violence and risk factors for HIV infection (193, 194).

Regarding the clinical variables and STI, those not undergoing speculum-assisted examination at our SAC, had a 4-fold higher prevalence of STI. This is in contrast to a U.K. SAC study which found a higher prevalence of STIs in patients completing a speculum examination (73). On the other hand, studies from non-SAC settings have found higher sensitivity of MG and CT when other test materials than cervical swabs are used in the diagnosis, like FVU and vaginal self-test (172, 173, 176, 195, 196). Finally, the finding of sperm at our SAC had no association with STI positivity, contrasting to what was found in a U.S. study, where the majority of those with new STI diagnosed at follow-up had sperm detected at the initial SAC visit (88).

## 6.2.2 Toxicological findings and DFSA (Paper II)

This study has added to our knowledge of the use and findings of alcohol and drugs in Norwegian victims of sexual assault, as well as to map out the prevalence of suspicion of proactive DFSA. We have found that alcohol was the dominant drug in urine/blood samples from the SAC patients, and that no cases of DFSA could be verified unequivocally. Our findings will be compared to what have been described by others in sections 6.2.2.1 - 6.2.2.3.

### 6.2.2.1 Ethanol and drugs findings among our SAC patients

The results from Paper II are presented in Table 22 below in a similar way as for the comparable studies discussed in section 2.3.2 (Table 4). The proportion of our patients testing positive for at least one drug, including ethanol, is in accordance with findings from the other studies cited in section 2.3.2.3. However, the proportion testing positive for ethanol is rather high and the proportion testing positive for other drugs is correspondingly low, which also is in accordance with the findings from the other Nordic surveys of sexual assault victims (106, 124, 127). The differences are mostly due to the higher proportion of cases testing positive for illicit drugs (cannabis, cocaine, etc.) in the North American, U.K., and French studies (113-116, 118-122, 125, 128).

We did not screen for other drugs, like antidepressants, antipsychotics, sedating antihistamines, or non-sedative therapeutic drugs. We could therefore not exclude drugging with such substances. This makes comparisons with those studies reporting such testing difficult, for example, the Australian and the Dutch (105, 126).

Only half of the victims came within 12 hours of the assault. Hence, for those attending later, we could not detect drugs with lower urine detection time than 12 hours, for example, GHB and ethanol. We restricted the analyses to only those tested within 12 hours, and found that the distribution of ethanol levels, both at time of sampling and estimated at time of assault, was similar to what has been reported in studies from Europe and Australia (102, 105, 123, 124, 126, 127, 135).

# 6.2.2.2 Suspicion of proactive DFSA; findings compared to voluntary intake

We explored in detail those 57 patients who suspected proactive DFSA. In five of these patients, we unexpectedly found a sedative drug, which means the drug was not reported as having been ingested voluntarily. One patient tested positive for clonazepam and another four for diazepam/oxazepam. Since these five patients all had a history of anxiety/drug abuse, we did not find it justified to verify proactive DFSA. This is in accordance with the five prior studies mentioned in section 2.3.2.4. Although several cases reported a suspicion of proactive DFSA and a proper investigation had been performed, a conclusion of proven proactive DFSA could only be made in a small

Table 22. Summarized toxicological findings among victims of sexual assault and specifically in cases of drug-facilitated sexual assault (DFSA) (Paper II) (cf Table 4)

(Paper II) (cf Table 4)	f Table 4)						
First author, publication year, country	Sample size, setting, years included, design	Method, time from assault	Number and/or <sub>I</sub>	percentage of the sa	Number and/or percentage of the sample where each drug was detected	ug was detected	Voluntary intake vs. findings, strength and limitations
			Illicit	Sedatives	Alcohol, BAC <sup>111</sup> at assault	Other	
Hagemann,	n=264 attending	Urine and	Cannabis 5%;	Opioids 4%;	Alcohol 45%	At least one drug	Strengths: contains patient
2014,	a hospital SAC;	blood. Median	blood. Median central stimulants	benzodiazepines	Mean BAC at time	in 59%: alcohol	and assault characteristics.
Norway	2003 - 2010;	time from	2%	12%:	of sampling 1.2	only in 40%;	Gives results according to
(Paper II)	retrospective	sexual assault		oxazepam 7%;	[0.2 – 2.8]; mean	alcohol + other	reported intake. Unselected
		13 h (1 h – 16		clonazepam 3%,	estimated BAC at	drug(s) in 5%;	material
		days)		diazepam 3%;	time of assault 1.9 other drug(s) only	other drug(s) only	
				flunitrazepam 1%; [0.4 – 4.0]	[0.4 - 4.0]	14%	Limitations: Retrospective
				nitrazepam 1%;			chart review. Small sample
				zopiclone 2%			size

111 BAC (blood alcohol concentration) in g/L (‰), mean and range [ ] or SD (standard deviation) given

### 6.2.2.3 Ethanol and drug positivity and certain characteristics

We did not find any association between age and alcohol positivity or between age and estimated BAC at time of assault. This is in contrast to what was found in the large Swedish case series (124, 127). However, older age was associated in our study with a positive test for at least one drug other than ethanol, which has also been described by others (128). Our study did not have sufficient power for a detailed analysis of each of the specific drugs by age.

Those testing positive for ethanol in Paper II more often reported a public place of assault and a stranger assailant. In addition, high estimated BAC at the time of assault was associated with the assailant being a stranger. In contrast, a positive drug test had no association with the relationship to the assailant, but was associated with serious extragenital injuries. Contrasting our findings, as referred in section 2.3.2.6, in a U.S. SAC study, private place of assault was associated with a positive test for alcohol, whereas those testing positive for drugs more often were raped by a stranger (128). In Norway, alcohol is the recreational drug of choice used by a high proportion of the population, whereas other illicit or medicinal drugs are restricted to certain subgroups. In the U.S., however, even in some years back (1997 – 1999), illicit drug use seemed to be more common, at least among those attending this particular U.S. SAC. Different rates of attendance and a selection of those subjected to stranger rapes, could, however, partly explain the differences.

This is the first study to demonstrate an association between high estimated BAC at the time of assault and a suspicion of proactive DFSA, even though others have stated that in many cases the amount of voluntarily ingested alcohol probably is underestimated (135), particularly when taking into account the victim's age and drinking experience (124). Still, there is also a possibility that drinks actually could have been spiked with alcohol by others (124).

We found that patient background characteristics, like mental health problems/drug abuse and unemployment, were associated with a positive test for at

least one drug other than ethanol. However, this has not been described in any previous SAC studies. Even if those drugs tested for are not the first drugs of choice in the treatment of mental health problems, use of anxiolytics/hypnotics is quite common among women with mental health problems (197).

#### 6.2.3 Injuries and analysis of trace evidence (Paper III and expanded analyses)

These studies have added to our knowledge of police-reported rapes and attempted rapes in Norway. We have pointed out that only a small and a steadily decreasing proportion of police-reported rape cases were taken to court. More than half of the cases were dismissed because of insufficient evidence. Among the cases taken to court, a higher proportion had moderate/serious body injury and more DNA analyses were performed. Our findings will be compared to what have been described by others in sections 6.2.3.1 and 6.2.3.2.

### 6.2.3.1 Legal outcome among the cases of rape and attempted rape

We found a considerable attrition of the rape cases through the Norwegian legal system. As shown in Figure 12, section 5.3.4, a charge was filed in 16% of cases during the period 1997 – June 2003, but the rate was as low as 8% for the period July 2003 – 2010, ending with a charge filing rate of 11% for the total period in the EA. The latter proportion is the lowest of all the other studies commented in section 2.3.3.

### 6.2.3.2 Injury and trace evidence – association with legal outcome

The results from Paper III and the EA are presented in Table 23 below in a similar way as for the comparable studies discussed in section 2.3.3 (Table 6). The prevalence of extragenital injuries (of 49 and 56%, respectively) in our studies is similar to that found in many of the studies cited in section 2.3.3.2 (19, 81, 89, 136-144, 146, 147). The documentation of moderate/severe injury had a greater impact on charge-filing than no or minor injury. However, the association was only borderline significant. Significant association between moderate/severe injury and charge filing has been shown in two North American studies (139, 140), but refuted in others (89, 137, 141, 144). Actually, in South Africa, researchers found a high number of cases where an

Table 23. Summarized medico-legal evidence's relationship to legal outcome. Results from Paper III and the

First author, publication year, country	Sample size, setting, years included, design	Medico-legal findings <sup>11</sup>	2	
		Extragenital injury	Anogenital injury	Biological samples
Hagemann, 2011, Norway (Paper III)	n=101 female victims ≥ 16 years of age; 87% examined within 72 h; hospital SAC; data from medical and police records; 1997 – 2003; retrospective	Any extragenital injury 49%: minor 39%; moderate 5%; serious 5%; ≥ 4 lesions 15%	Any anogenital injury 14%; > 1 injury 8% (range 1 – 10 number of injuries); vestibule 5%; post. forchette 3%; perianal 3%; perineum 2%; tear/laceration 11%; abrasions 3%  Erythema and tenderness excluded, gross visualization	Vaginal, anal and/or oral samples (swabs) collected 88%; trace evidence analyzed 30%; sperm detected in forensic lab and/or SAC 16%; DNA typing 18%; male DNA found 9%; DNA matching suspect 5%
McLean, 2011, UK (147)	n=500 sexual assault victims ≥ 18 years; claiming penile-vaginal rape by one assailant; attending a SAC within 48 h of the SA; data from forensic client notes incl. legal progress info; 1997 – 2001; retrospective	Extragenital injury 72%	At least one genital injury 23%; 36% of these had > 1 injury. Location: 61% in post. forchette; 33% labia; 10% vagina; 9% urethra; 8% hymen. Type: 10% laceration; 10% abrasion; 7% bruise	NA
Hagemann, 2014, Norway (The EA <sup>113</sup> )	n=324 female victims ≥ 16 years of age; 87% examined within 72 h; hospital SAC; data from medical and police records; 1997 – 2010; retrospective	Any extragenital injury 56%: minor 48%; moderate 6%; serious 2%; ≥ 4 lesions 27%	Any anogenital injury 22%; > 1 injury 13%  Erythema and tenderness excluded, gross visualization and colposcopy used 114	Sperm detected at the SAC: 20%

Emotional presentation reported in Paper III but not presented in the table. Emotional presentation not reported in McLean *et al* sexpanded analyses, included in this thesis only 114 In the period 1997 – 2003, only gross visualization was used; during 2003 – 2007 and after 2008, colposcopy was used in 22% and 75

Legal outcome	Relationship of medico-legal evidence to legal outcome	Limitations and strength
Charges filed 18%; conviction set 12% (prison and preventive supervision); no suspect identified 20%; charges not filed 56%; no crime 6%; withdrawal 1%	Presence of minor (OR 2.2, 95% CI $0.6-8.0$ ) and moderate/serious extragenital injuries (OR 3.7, 95% CI $0.7-19$ ), absence of anogenital injuries (OR 1.4, 95% CI $0.2-7.6$ ) and presence of more than one anogenital injuries (OR 1.8, 95% CI $0.3-11$ ) not associated with charge filing. Trace evidence analysis associated with charge filing (OR 13, 95% CI $2.4-66$ ), but the findings of spermatozoa (OR 1.7, 95% CI $0.3-9.8$ ) was not. Detection of victimsuspect DNA match ended in a charge in four of five cases	Limitations: Retrospective, single jurisdiction, small sample size  Strengths: Detailed, descriptive information, incl. info on DNA matching, multivariable model
Trial commenced 15%; conviction 6%; acquittal 5%; lack of evidence 10%; allegations withdrawn before trial 25%; 33% with missing legal outcome	No significant differences in the proportions with genital injuries between those with different legal outcomes (p=0.59), although genital injuries were more common in cases which resulted in a conviction (34%) vs. other outcomes (21%) (p=0.08). There were more genital injuries in cases pursued (i.e., charge filed) (32%) vs. cases dropped (21%) (p=0.2)	Limitations: Retrospective review, only two thirds of the cases had known legal outcome, single jurisdiction, only focused on genital injuries, bivariable statistics  Strengths: Detailed, descriptive information of genital injuries, studies association of genital injury on different levels of legal outcome
Charges filed 11%; no suspect identified 20%; charges not filed 56%; no crime 10%; withdrawal 1%	Presence of moderate/serious extragenital injuries (OR 2.8, 95% CI $0.9-8.6$ ) was borderline significant associated with charge filing. The presence of minor extragenital injury (OR 1.2, 95% CI $0.5-2.7$ ), absence of anogenital injuries (OR 1.4, 95% CI $0.5-3.8$ ) presence of more than one anogenital injuries (OR 1.0, 95% CI $0.3-2.8$ ), and the findings of spermatozoa at the SAC (OR 1.6, 95% CI $0.7-3.9$ ) was not associated with charge filing.	Limitations: Retrospective, single jurisdiction, rather small sample size  Strengths: Detailed, descriptive information, using a multivariable model

arrest was made even if no injuries were documented on the victim (136).

Anogenital injury was found in only 14 and 24% of the victims in Paper III and the EA, respectively, which is in the lower range of results reported in other similar studies (19, 81, 89, 136, 138-147). In the first study period 1997 – 2003 (Paper III), injuries were diagnosed by gross visualization only. After 2007, however, we used colposcopy in a proportion 115 of the cases. Most of the other studies mentioned in section 2.3.3.2 documented anogenital injuries by gross visualization. In contrast, many U.S. SACs include additional diagnostic equipment like toluidine blue staining and colposcopy (198-202) in diagnosing anogenital injuries among adult and adolescent women. These SACs often report high proportions of the patients with anogenital injuries. Another reason for disparity is that classification of the findings as injuries differ between studies. Our recorded scarcity of such injuries could be due to us including as anogenital injuries only tears, abrasions, and bruises (ecchymoses/petechiae), and excluding redness and/or swelling due to their unspecific and subjective nature. This is in contrast to the TEARS classification (tears, ecchymoses, abrasions, redness and swelling) introduced by U.S. authors (203). Those recommending this as a guideline acronym for diagnosing anogenital injury report higher rates of anogenital injuries (139, 161, 201). However, low prevalence of anogenital injuries could also be due to less penetration and less violence used by assailants in Norwegian rape cases, although this assumption seems less likely.

Anogenital injury was neither associated with charge filing in Paper III, nor in the EA, which has been confirmed by others (140, 143, 145). However, anogenital injury alone was significantly associated with charge filing in a U.S. study using gross visualization and including only bruises, abrasions, and lacerations (144), whereas more than one site of anogenital injury was associated with charge filing in another U.S. study using colposcopy and toluidine blue staining for diagnosis, and including redness and swelling as an injury (139). The more specific "genital injury with a skin tear" (included abrasion, bleeding or scarring), a definition probably used to indicate a

 $<sup>^{115}</sup>$  In the period 2003 – 2007: 22%, after 2008: 78%. When colposcopy were used, 37% had anogenital injuries documented

more serious genital injury diagnosed by gross visualization, was associated with conviction in the more recent South African study (136).

We found that almost 90% of the victims had trace evidence swabs collected from their skin or mucosal surfaces. However, only in 30% of cases was the collected trace evidence sent for analysis by the police. This is lower than reported in two of the recent studies referred in Table 6 (136, 146) and also lower than in another Norwegian study with record data from the late 90s (148). The Norwegian National Forensic Laboratory found spermatozoa in 16% of the cases, which is in the lower range of frequencies reported by others (19, 81, 89, 137-143, 146). DNA was matching a suspect in only 5% of the cases included in Paper III, which is lower than what has been found in other Nordic studies (146, 148).

The only medico-legal finding significantly associated with charge filing in Paper III was the analysis of the collected trace evidence. We explored these cases in detail (Table 15 in section 5.3.2). Surprisingly, we did not find that more analyses were performed when the assailant had a more distant relationship to the victim. However, we found that self-reported penetration and an interval from assault to medical examination being  $\leq$  24 hours were borderline significant with trace evidence analysis. In a study from the Oslo SAC, similar findings were reported. Here, fewer analyses of the victims' samples were performed if the reported crime was coded as a rape (vs. attempted rape) (148). The same pattern was found if the venue was within the assailant's area. We did not find any association between the documentation of spermatozoa and charge filing, as confirmed by others (89, 138, 140).

In the five cases showing a DNA-match between swabs collected from the woman and the suspect, a charge was filed in four cases, while in one case evidence of rape was considered insufficient (Paper III). Among the four cases where unidentified male DNA was found on swabs from the woman, in three cases evidence was considered insufficient, while one case was dismissed because of unidentified suspect. In the South African study, the DNA report more often led to an acquittal when the profile did not match that of the suspect (136). In addition, a match did not secure conviction, since in one case the suspect was acquitted even if the DNA profile

matched. In Denmark, a DNA match was found in a higher proportion of the cases ending in conviction vs. those ending in acquittal (26% vs. 18%); however, the association was still not significant (146). Finally, in an Australian forensic laboratory, no trace evidence was analyzed if the suspect had admitted sexual intercourse with the victim. If analyzed, DNA evidence was associated with conviction in the prosecuted rape cases (204).

### 6.3. Clinical and forensic implications

### 6.3.1 Sexually transmitted infections (Paper I)

This study documented that CT prevalence among sexual assault victims was lower than in the comparable clinical population. Differentiating STI transmitted during assault from pre-existing STI is difficult, but the clinician could reassure patients about the rather low risk of testing positive for an STI after sexual assault in Norway.

Patients' age (lower for STI and higher for BBV) and a history of substance abuse could indicate higher risk for a positive test, thereby indicating a need for closer follow-up.

Of the assault characteristics, only assailant of non-Western origin was associated with diagnosed STI. Other assault characteristics (for example, more than one assailant, and anal penetration) should guide the clinician's decision about when to initiate prophylactic anti-viral treatment, like HBV immunization and HIV-PEP. However, our study did not include follow-up of a sufficient number of patients during a sufficient time interval after the assault, to evaluate this guideline regarding sexual assault victims.

Those not undergoing speculum-assisted examination had a higher prevalence of STI. This should be borne in mind when testing adolescents or other women not accepting an invasive gynecological examination. A speculum examination is, however, useful in differentiating between hemorrhage from the cervical orifice or from a vaginal injury as well as for proper trace evidence collection by means of cervical swabs (sperm/DNA).

Because of routine antibiotic treatment, a follow-up test probably could not catch an assault-transmitted CT-infection in case of a negative test at the initial visit.

Hence, follow-up in our routine clinical practice will probably not disclose any extra information regarding CT detection. However, if untreated patients are offered only a second visit for testing two weeks later at an STD clinic, for example, the psychological burden of waiting for symptoms of a potential infection must also be taken into account. According to other studies, follow-up rates after sexual assault are low (67, 68, 70, 74, 75, 78). Even prospectively designed studies planned to investigate whether patients are infected after sexual assault have a follow up rate of only 53 – 75% (82, 88).

The issue of offering antibiotic prophylaxis to all SAC patients is discussed in a U.K. paper with similar prevalence of STI as in our study (75). They found that a one-dose regimen of azithromycin was acceptable to the patients. Other authors have reported that almost all of the rape survivors they saw preferred prophylactic treatment to returning to the clinic for additional testing (94). On the other hand, if a multiple-dose antibiotic regimen is to be applied, we may reconsider our routines of prophylactic treatment after sexual assault. The disadvantages of using bacterial prophylaxis are the possibility of unnecessary treatment and the reinforcing belief that there was a high risk of infection, which in itself may raise levels of anxiety (205).

The two STI positive patients in our study who probably contracted assault-transmitted infections nevertheless did not report their assaults to the police. According to the Norwegian penal code (section 2.1.2), transferring a sexually transmitted infection to somebody during a rape increases the legal punishment. For this purpose, one needs evidence that the victim tested negative and the assailant positive before the assault. Even if both are testing positive, she might have transferred it to him during the assault. In selected cases, sophisticated techniques could be used to prove similar genetic subtypes of the microbe (for example, of CT and NG), but evidence is less valid than that of a DNA analysis. However, in the very young victim, matching subtypes could be used as indication of assault-related transmission, and has been tried in a court of law in Norway. 116

WHO and U.K. guidelines do not encourage testing for STI at the initial SAC visit

. . .

<sup>&</sup>lt;sup>116</sup> Personal communication, Arne K. Myhre and Svein A. Norbø

(61, 63). However, the Canadian Public Health Agency recommend such baseline diagnostic STI testing (206). In my opinion, sexual assault examination is an important opportunity to diagnose any STI, for the identification of the distribution of STIs, and for reason of partner notification. Testing should in addition include NG culture, to evaluate NG antibiotic resistance. Since many SACs offer immediate prophylactic antibiotics against CT/NG, important information may be lost if no tests are performed before initiating treatment.

Some authors claim that STI testing should be omitted during the initial SAC visit, for fear of interfering with the legally important trace evidence collection (66).

Norwegian SAC guidelines underline the importance of swabbing for trace evidence before the collection of microbial swabs, thus eliminating such interference and the need for two separate gynecological examinations. This is in accordance with the Norwegian model of being a clinician and a forensic examiner in the same pair of shoes. On the other hand, most forensic kits do not contain tests for STIs or BBVs, since these kits are equipped for legal purposes rather than for health care issues. A separate STI-test kit should be available to any forensic examiner dealing with victims of sexual assault. Since both clinical and legal aspects usually come together, it is advisable that all specimens collected from the victim for health care reasons should be retained in case of additional or repeated testing being required (206). Finally, the same principle of securing the chain-of-evidence should be applied to STI-testing as to the trace evidence collection and storage (205).

# 6.3.2 Toxicological findings and DFSA (Paper II)

Before our study, only self-reported data on alcohol and drug intake from police and SAC records were available in Norway, and little was known about the drugs used in DFSA cases.

We found that a quarter of the women suspecting proactive DFSA tested positive for a drug other than ethanol, although no cases of proactive DFSA could be unequivocally verified. However, the evaluation of the findings needs to be interpreted with caution, since patients with a history of drug abuse and/or anxiety disorder could

theoretically have been surreptitiously drugged by their usual medication. An urgent police-investigation in these cases could possibly have better results than those revealed by health care settings alone.

Finding so meager evidence of proactive DFSA in a Norwegian SAC could partly be explained by patients' late attendance, since only half of the patients were tested within a time frame of 12 hours after the assault. One message to the public is therefore to have samples for the toxicological test collected as soon as possible after a suspected DFSA. On the other hand, since as many as 128 patients actually had a drug test within 12 hours of the assault, we may in the future reassure concerned patients that such involuntary drugging probably happens only seldom in Norway.

Of more concern is the very high ethanol levels that could be estimated at the time of assault, and indicates a high degree of inebriation in unaccustomed young women. A mean BAC at time of the assault of almost 2 g/L renders most young women unable to give valid consent to sex. As described in section 2.1.2, this will qualify for being a victim of the legal definition of rape, and in my opinion, the BAC findings from blood tests should be used more as legal evidence of opportunistic DFSA.

Any causal relationship of high ethanol intake, high BAC levels, and rape could not, however, be established from our data. However, a report from the Norwegian Centre for Violence and Traumatic Stress Studies (NKVTS) points out that being under the influence of alcohol/drugs is one of the main risk factors for rape, after female gender and young age (16). In addition, U.S. cross-sectional publications point out that young women's heavy drinking increases vulnerability for sexual assault (207, 208), and that risk of sexual victimization increases with the level of estimated BAC (209). In addition, a recent school survey of almost 4,000 Norwegian teenage girls found that 70% of the girls had been intoxicated during the past year, of which 7% had experienced (incapacitated) sexual assault (210). The author found that both high frequency of intoxication and experiencing severe drunkenness were associated with being a victim of sexual assault among these young women. This knowledge should be used in preventive and informational campaigns targeting adolescents and young adults at schools or universities. However, I need to add that the victims are in no

sense responsible for the rape; the responsibility remains solely with the assailant. The distinction between vulnerability and possible risk factors on the one side and a responsibility and blame on the other side is essential, and must be unquestionable.

The National Bureau of Crime Investigation<sup>117</sup> collects annual information on reported rape cases (30). According to their report, a high proportion of the victims were influenced by alcohol and drugs during the rape. In November 2013, the Bureau initiated a preventive "gentleman" campaign.<sup>118</sup> This campaign is directed towards young men and calls on them to take care of their peers (especially females) rendered vulnerable because of the influence of alcohol/drugs. The main aim is to prevent sexual assaults occurring in a party context.

Only a few of the cases of suspecting proactive DFSA were police-reported, and none of them were taken to court. Awareness among the police and legal authorities is important, although evidence of both surreptitious drugging and rape seems to be hard to find. Except for a few cases of video-recorded documentation of sexual activity involving unconscious or non-responsive victims, prosecutors will have a hard time proving such crimes. This is in contrast to the clear Norwegian legal rules (section 2.1.2). Documentation of legal consequences in cases of proactive DFSA are rather scarce in non-English-speaking European countries, while in the U.K., U.S., Canada, and New Zealand, several cases has been prosecuted (211).

#### 6.3.3 Injuries and trace evidence (Paper III and the EA)

We studied only those police-reported cases of rape where the victim had undergone a medical examination. Various aspects of medical evidence had different impact on charge filing of the case. Anogenital injury had no association with charge filing. However, more victims had documented moderate and/or severe extragenital injury among the charged cases vs. those cases dismissed because of insufficient evidence. This underlines the importance of proper injury documentation in the acute phase after rape.

We found that the analysis of trace evidence was associated with charge filing.

118 Kjernekar

<sup>117</sup> Kripos

Trace evidence is used to assess physical contact between the victim and the assailant (or the venue). When the scenario is such that sexual activity seems plausible (that is, in cases of partner/acquaintance relationship), and situations where the assailant admits to sexual contact with the woman, the decision not to request analysis of biological samples may be reasonable. In such cases, the results might not supply the police or court with additional evidence. Given that the police may apply such logic, we would expect that trace evidence would be more often analyzed in the case of stranger/casual acquaintance relationship. This was not the case in our study. Still, reporting penetrative assault and attending medical examination within 24 hours of the assault had a borderline significant association with trace evidence analysis.

The presence of sperm did not influence the legal prosecution of the rape cases in our study, and others have stated that this has poor sensitivity in securing a conviction (146). Sperm findings alone do not give information about the host. If there is doubt whether sexual contact has taken place, a DNA analysis is necessary.

However, matching DNA between the victim and the suspect predicted a charge in four of the five cases in Paper III. This points out the importance of DNA-analysis in selected cases. However, even if DNA could be used as evidence of (sexual) contact between the suspect and the victim, no definitive answer as to consent or guilt may be given. DNA is of no value if the basis of the defense is consent. Nonetheless, we believe that DNA analysis is affordable in Western countries, and most reported rape cases are not intimate partner rapes. Therefore, DNA has at least the potential to contribute and in my opinion should be analyzed more frequently.

However, the finding of sperm and mismatching DNA to a suspect's could be used by the defense as an argument that no intercourse has taken place. In cases of such mismatch, this could be due to recent consensual intercourse unconnected to the rape. Nevertheless, an important role for the forensic doctor, therefore, is to inform the police and/or court that in some cases of sexual assaults, trace evidence is absent, for example, in cases of condom use, no ejaculation, azoospermic ejaculate, or if a foreign object was used to penetrate. As a consequence, absence of the suspects' DNA on the victim's body does not exclude him as a suspect.

Since the presented use of collected samples in Paper III dates more than ten years back, we expect that the police have increased their use of such evidence. In 2008, a legal reform made possible an expansion of the DNA registry for criminal investigation and procedure (212, 213). This will allow for more extensive testing and long-time registration of profiles. In addition, a recent national centralized funding model should secure that analysis of the collected trace evidence should be performed as appropriate in serious crime cases. However, this has yet to be evaluated.

Investigation of rape cases is often complicated. Since medico-legal evidence has limited impact on legal outcome, non-medical factors might even be more important, for example, the initial victim's statement, suspect's statement, other witnesses' statements, inspection of the venue, photographic documentation, torn or soiled garments, etc. Medical information alone does not secure charge filing, but may be a part of the evidentiary chain of factors strengthening the case. However, our criminal justice system only pleads cases when there is no reasonable doubt. Hence, a dismissal of the case due to insufficient evidence is not equal to ignorance or distrust in the victim, only that the evidence is not strong enough for a conviction. This is important to communicate to the victims in dismissed cases of rape.

## 6.4 Future research

Through the work of this thesis, many aspects of the area of sexual assault, involving medical examination and health consequences, remain unknown. Some suggestions for future research will be addressed in this section.

Since the main outcome of sexual assault medical examinations are the health and well-being of the victim, a qualitative research project should be initiated which would deal with the patients' experience of the SAC visit, especially regarding the anogenital examination. The emotional impact of the anogenital examination was evaluated in an earlier research project of non-abused preschool children conducted by members of our SAC team (214). In addition, as a part of the evaluation of Norwegian SACs, a questionnaire was handed out to adult and adolescent victims at the follow-up visit, but recruiting patients post-assault was a challenge (215). Even if

several aspects of the SAC consultation, like care-taking, psychosocial support, and follow-up were evaluated for some few patients, future studies should target especially the victims' experience of the physical examination. Through this, SAC staff could get useful information about how to adjust their service to take better care of the victims.

Since many SACs offer follow-up visits, especially regarding psychosocial care, a future study should evaluate the possibility of achieving active informed consent from the patients to participate in SAC record studies. Even if staff-demanding and follow-up could be subjected to considerable rates of dropping-out of participation in the studies, evaluation of certain health outcomes, like pregnancy, STI/BBV, and mental health consequences should be performed after certain intervals of the assault. Such a study is presently ongoing at the Stockholm SAC, and interesting preliminary results have been presented at a conference (216). In such a prospectively designed study, the effects of early interventions of psychosocial care could be evaluated. In addition, predictors for persistent high degree of PTSD<sup>119</sup>-symptoms could be established, which in turn could able us to select patients who are in the need of more targeted specialist health care.

Whether anogenital injuries are more common after rape than after consensual coital activity still remains uncertain. A recent Danish study of student volunteers have shown that injuries are rather common and long-standing after consensual sex (154). Certainly, more such studies are needed, and in a context of gynecological or general practice, since those performing sexual assault examinations in Norway are not forensic specialists. Preferable, however, would be to initiate a Nordic multi-center study of injuries after consensual sex, and including into this study an evaluation of the use of colposcopy in adult and adolescent anogenital examination.

There is a need for systematic registration of patients who have attended Norwegian SACs. I would suggest that a future health registry of all sexual assault victims attending Norwegian SACs be established. Essential baseline data of the patients, of the assault, and of the medical findings should be collected. SAC registry

<sup>&</sup>lt;sup>119</sup> Post-traumatic Stress Disorder

data could then be linked to other health registries, for example, the Medical Birth Registry, the Cause of Death Registry, the Norwegian Prescription Database, or the Norwegian Labor and Welfare Service's registries. Through this, we could get knowledge about the impact of sexual assault on future health consequences. An example of such linkage has been performed in Iceland, where SAC visit information was linked to the national Icelandic birth registry (217217), and similar studies are ongoing in the Copenhagen SAC in Denmark. The establishment of such a registry has been tried elsewhere in Norway<sup>120</sup>, but refused by the regional and national ethical committees. Ethical issues, therefore, could limit our possibilities to further study health consequences of sexual assault in a prospective design. The inclusion of research participation in Norway could be regarded as guided by the ethical committees' issues rather than scientists'.

Our quantitative study lacks essential case information of the flow of medical information in the individual police investigation of the cases. A qualitative research project interviewing the individual police investigators and prosecutors, and describing their way of thinking about the use of medical information, could rule out when medical information actually was invaluable for a case to be proceeded. Such research could detect examples of how trivial medical findings was crucial for rape cases to be proceeded in court, since regular feed-backing from police to health care and wise versa is often hampered by the professional secrecy.

Another study could scrutinize in-depth all of the individual Norwegian SAC forensic medical reports, evaluating whether the reports are correctly written, whether the interpretations stand to reason, or if the conclusions relate medical findings to the history in a proper way. Educating and giving feedback to Norwegian physicians regarding writing forensic reports must be a prioritized issue for securing future quality of medical information in police-investigated rape cases.

Finally, it is essential to secure that validated direct and behaviorally specific questions about experienced victimization (and perpetration) of sexual assault are included in future population-based health surveys. Questions regarding whether the

 $<sup>^{120}</sup>$  By the National Centre for Emergency Primary Health Care

subject was injured during the assault and whether the event was reported to health care and/or police should be added. Both genders are to be asked and the information gained combined with other health outcome measures. An example of a longitudinal study which should implement such questions in their self-reporting surveys is the future HUNT<sup>121</sup>-4 study.

### 7 Conclusion

This thesis demonstrates that STI prevalence among more than 400 SAC attenders was lower than in the comparable clinical population, and that only two cases were probably assault-transmitted. Furthermore, alcohol was the dominant drug found in urine/blood samples from SAC patients, and no cases of DFSA could be unequivocally verified. Finally, more than half of the police-reported rape cases were dismissed because of insufficient evidence, and only a tenth of the cases were taken to court. In such cases, a higher proportion had moderate/serious body injury and more DNA analyses were performed. However, medical findings altogether seemed to have little impact on charge filing.

Quick and available access to qualified health care after sexual assault should ensure valuable help for victims and protect their legal rights. However, both health care and the police would benefit from better cooperation and exchange of knowledge in order to ultimately improve the outcomes for victims of sexual assault.

121 The Nord-Trøndelag Health Study

## References

- 1. Dartnall E, Jewkes R. Sexual violence against women: the scope of the problem. Best practice & research Clinical obstetrics & gynaecology. 2013;27(1):3-13.
- 2. Krug EG, Mercy JA, Dahlberg LL, Zwi AB. The world report on violence and health. Lancet. 2002;360(9339):1083-8.
- 3. Krug EG, Dahlberg LL, Mercy JA, Zwi AB, Lozano R. World report on violence and health. Geneva: World Health Organization, 2002.
- 4. The Norwegian General civil penal code. Unofficial English translation Oslo: Norwegian Ministry of Justice, Legislation Department; 2006 [cited 2014 June 1]. Chapter 19, page 76-82]. Available from: <a href="http://www.ub.uio.no/ujur/ulovdata/lov-19020522-010-eng.pdf">http://www.ub.uio.no/ujur/ulovdata/lov-19020522-010-eng.pdf</a>.
- 5. Lovdata Online Oslo: Lovdata; 2010 [cited 2014 June 1]. Available from: <a href="http://www.lovdata.no/all/tl-19020522-010-023.html">http://www.lovdata.no/all/tl-19020522-010-023.html</a>.
- 6. Fra ord til handling. Bekjempelse av voldtekt krever handling. Oslo: Justis- og politidepartementet; 2008.
- 7. Garcia-Moreno C, Henrica A, Watts C. WHO multi-country study on women's health and domestic violence against women. Initial results on prevalence, health outcomes and womens responses. 2005.
- 8. UN Women: Violence against women prevalence data: surveys by country New York2011 [cited 2014 June 1]. Available from: <a href="http://www.endvawnow.org/uploads/browser/files/vaw\_prevalence\_matrix\_15april\_2011.pdf">http://www.endvawnow.org/uploads/browser/files/vaw\_prevalence\_matrix\_15april\_2011.pdf</a>.
- 9. Mouzos J, Makkai T. Women's experiences of male violence: findings from the Australian component of the International Violence Against Women Survey (IVAWS) Canberra: Australian Institute of Criminology; 2004 [cited 2014 June 1]. Available from: http://www.aic.gov.au/publications/current%20series/rpp/41-60/rpp56.html.
- 10. Black MC, Basile KC, Breiding MJ, Smith SG, Walters ML, Merrick MT, et al. The National Intimate Partner and Sexual Violence Survey (NISVS): 2010 summary report. Atlanta, Georgia: CDC, 2011 Nov 2011. Report No.
- 11. Kilpatrick DG, Resnick HS, Ruggiero KJ, Conoscenti LM, McCauley J. Drugfacilitated, Incapacitated, and Forcible Rape: A National Study. Charleston, South Carolina, USA: National crime victims research & treatment center, Medical University of South Carolina; 2007 February 1. 72 p.
- 12. Abrahams N, Devries K, Watts C, Pallitto C, Petzold M, Shamu S, et al. Worldwide prevalence of non-partner sexual violence: a systematic review. Lancet. 2014.
- 13. Thoresen S, Hjemdal OKr. Vold og voldtekt i Norge. En nasjonal forekomststudie av vold i et livsløpsperspektiv. Oslo: Nasjonalt kunnskapssenter om vold og traumatisk stress, 2014 Feb 25. Report No.: 1/2014.
- 14. Haaland Tr, Clausen SE, Schei B. Vold i parforhold ulike perspektiver. Resultater fra den første landsdekkende undersøkelsen i Norge [Couple Violence different perspectives. Results from the first national survey in Norway] Oslo: 2005 NIBR-rapport 2005:03
- 15. Steine IM, Milde AM, Bjorvatn B, Grønli J, Nordhus IH, Mrdalj J, et al. Forekomsten av seksuelle overgrep i et representativt befolkningsutvalg i Norge [The

- prevalence of sexual abuse in a Norwegian representative population sample]. Tidsskrift for Norsk Psykologforening. 2012;49(10):950 7.
- 16. Kruse AE, Strandmoen JF, Skjørten K. Menn som har begått voldtekt en kunnskapsstatus. Oslo: Nasjonalt kunnskapssenter om vold og traumatisk stress, 2013.
- 17. Tjaden P, Thoennes N. Full report on the prevalence, incidence and consequences of violence against women. Washington, DC: 2000.
- 18. Schei B, Muus KM, Bendixen M. Forekomst av seksuelle overgrep blant studenter i Trondheim [Occurrence of sexual abuse among students in Trondheim]. Tidsskr Nor Laegeforen. 1994;114(21):2491-4.
- 19. Schei B, Muus KM, Moen MH. Medisinske og rettslige aspekter av voldtekt. Henvendelser til voldtektsteamet ved Regionsykehuset i Trondheim i perioden 1989-92. Tidsskr Nor Laegeforen. 1995;115(1):30-3.
- 20. Schei B, Sidenius K, Lundvall L, Ottesen GL. Adult victims of sexual assault: acute medical response and police reporting among women consulting a center for victims of sexual assault. Acta Obstet Gynecol Scand. 2003;82(8):750-5.
- 21. Rohde MC, Charles AV, Banner J, Brink O. Rape and attempted rape in Aarhus County, Denmark. Forensic Sci Med Pathol. 2006;2:33-8.
- 22. Feldhaus KM, Houry D, Kaminsky R. Lifetime sexual assault prevalence rates and reporting practices in an emergency department population. Ann Emerg Med. 2000;36(1):23-7.
- 23. Nesvold H, Friis S, Ormstad K. Sexual assault centers: attendance rates, and differences between early and late presenting cases. Acta Obstet Gynecol Scand. 2008;87(7):707-15.
- 24. NTU 2011. Om utsatthet, trygghet och förtroende. Stockholm: Brottsförebyggande rådet (Brå), 2012.
- 25. Schei B, Stene LE, Ormstad K. Tilheling og rettferdighet helsehjelp og rettspleie ved voldtekt Oslo: ExtraStiftelsen Helse og Rehabilitering; 2008.
- 26. Sætre M, Grytdal V. Voldtekt i den globale byen Endringer i anmeldte voldtekter og seksualkultur i Oslo. Oslo: Strategisk stab, Oslo Politidistrikt, 2011.
- 27. Stene LE, Ormstad K, Schei B. Implementation of medical examination and forensic analyses in the investigation of sexual assaults against adult women: a retrospective study of police files and medical journals. Forensic Sci Int. 2010;199(1-3):79-84.
- 28. Nesvold H, Ormstad K, Friis S. Sexual assault centres and police reporting an important arena for medical/legal interaction J Forensic Sci. 2011;56(5):1163-9.
- 29. Anmeldt kriminalitet og straffesaksbehandling 2013. Kommenterte STRASAK-tall. Politidirektoratet, editor. Oslo: Politiet; 2014 6. februar. 25 p.
- 30. Voldtektssituasjonen 2012. Oslo: Politiet, Kripos, voldtektsgruppa; 2013.
- 31. Stene RJ. Seksualforbrytelser skjebner i rettssystemet. Samfunnsspeilet. 2001;15(3):2-12.
- 32. Stene RJ. Politiet er mest avgjørende i rettssystemet. Samfunnsspeilet. 2002;16(3):2-18.
- 33. Case Closed. Rape and Human Rights in the Nordic Countries Amnesty International 2008.
- 34. Bramsen RH, Elklit A, Nielsen LH. A Danish model for treating victims of rape and sexual assault: The multidisciplinary public approach. Journal of Aggression, Maltreatment & Trauma. 2009;18(8):886-905.

- 35. Eogan M, McHugh A, Holohan M. The role of the sexual assault centre. Best practice & research Clinical obstetrics & gynaecology. 2013;27(1):47-58.
- 36. Dahl S. Acute response to rape a PTSD variant Acta psychiatrica Scandinavica / Supplementum. 1989;80(Suppl. 355):56 62.
- 37. Bang L. Who consults for rape? Sociodemographic characteristics of rape victims attending a medical rape trauma service at the Emergency Hospital in Oslo. Scand J Prim Health Care. 1993;11(1):8-14.
- 38. Heimer G, Posse B, Stenberg A, Ulmsten U. A national center for sexually abused women in Sweden. Int J Gynaecol Obstet. 1996;53(1):35-9.
- 39. Ingemann-Hansen O. The western Danish center of prevention, treatment and research of sexual assault. Scandinavian Journal of forensic science. 2006;12:25-9.
- 40. Agnarsdottir G, Skuladottir S. A new rape trauma service at the emergency department of the Reykjavik city hospital. Arctic Med Res. 1994;53(Suppl. 2):531-3.
- 41. Jo S, Shin J, Song KJ, Kim JJ, Hwang KR, Bhally H. Prevalence and correlated factors of sexually transmitted diseases chlamydia, neisseria, cytomegalovirus in female rape victims. The journal of sexual medicine. 2011;8(8):2317-26.
- 42. Meel B, Kwizera E. Prevalence of HIV in the Mthatha area of South Africa, as estimated from the testing of rape victims. Med Sci Law. 2011;51(2):106-8.
- 43. Ranney ML, Rennert-May E, Spitzer R, Chitai MA, Mamlin SE, Mabeya H. A novel ED-based sexual assault centre in western Kenya: description of patients and analysis of treatment patterns. Emergency medicine journal: EMJ. 2011;28(11):927-31.
- 44. Golan A, Dishi-Galitzky M, Barda J, Lurie S. The care of sexual assault victims: The first regional center in Israel 10 years experience. Israel Medical Association Journal. 2012;14(11):658-61.
- 45. Facuri CdO, Fernandes AM, Oliveira KD, Andrade Tdos S, Azevedo RC. [Sexual violence: a descriptive study of rape victims and care in a university referral center in Sao Paulo State, Brazil]. Cad Saude Publica. 2013;29(5):889-98.
- 46. Eide AK, Fedreheim GE, Gjertsen H, Gustavsen A. "Det beste må ikke bli det godes fiende!" En evaluering av overgrepsmottakene. Nordlandsforskning 2012 NF-Rapport nr. 11/2012.
- 47. Rettsmedisinsk sakkyndighet i straffesaker. Oslo: Justis- og politidepartementet 2001.
- 48. Overgrepsmottak: Veileder for helsetjenesten. Oslo, Norway: Sosial- og helsedirektoratet; 2007.
- 49. Claussen MW. Jeg har sett rapporter som er noe håndskrevet rabbel. Aftenposten. 2012 Jan 20.
- 50. Den rettsmedisinske kommisjon. Årsrapport 2012. Oslo: Statens sivilrettsforvaltning, 2013.
- 51. Johnsen G, Hunskår S, Alsaker K, Nesvold H, M ZS. Beredskapssituasjonen ved norske overgrepsmottak 2011. Bergen: Nasjonalt kompetansesenter for legevaktmedisin, Uni Helse, Uni Research, 2012.
- 52. Du Mont J, White D. The uses and impacts of medico-legal evidence in sexual assault cases: A global review. Geneva: World Health Organization, 2007.
- 53. Dalton M, editor. Forensic gynaecology. London: RCOG Press; 2004.
- 54. Stark M. Clinical forensic medicine a physician's guide. New Jersey: Humana Press; 2005. 438 p.

- 55. Resnick H, Monnier J, Seals B, Holmes M, Nayak M, Walsh J, et al. Raperelated HIV risk concerns among recent rape victims. Journal of interpersonal violence. 2002;17(7):746-59.
- 56. Schwarcz SK, Whittington WL. Sexual assault and sexually transmitted diseases: detection and management in adults and children. Rev Infect Dis. 1990;12 Suppl 6:S682-90.
- 57. Beck-Sague CM, Solomon F. Sexually transmitted diseases in abused children and adolescent and adult victims of rape: review of selected literature. Clin Infect Dis. 1999;28 Suppl 1:S74-83.
- 58. Glaser JB, Hammerschlag MR, McCormack WM. Epidemiology of sexually transmitted diseases in rape victims. Rev Infect Dis. 1989;11(2):246-54.
- 59. Lamba H, Murphy SM. Sexual assault and sexually transmitted infections: an updated review. Int J STD AIDS. 2000;11(8):487-91.
- 60. Reynolds MW, Peipert JF, Collins B. Epidemiologic issues of sexually transmitted diseases in sexual assault victims. Obstet Gynecol Surv. 2000;55(1):51-7.
- 61. Jina R, Jewkes R, Munjanja SP, Mariscal JDO, Dartnall E, Gebrehiwot Y. Report of the FIGO Working Group on Sexual Violence/HIV: Guidelines for the management of female survivors of sexual assault. Int J Gynecol Obstet. 2010;109(2):85-92.
- 62. Welch J. Post-examination issues. In: Dalton M, editor. Forensic gynaecology. London: RCOG Press; 2004. p. 153.
- 63. Management of STIs and related conditions in children and young people: British Association for Sexual Health and HIV (BASHH); 2010 [cited 2014 June 1]. Available from: <a href="http://www.bashh.org/guidelines">http://www.bashh.org/guidelines</a>.
- 64. Worm AM, Johansen MS, Nielsen NH. Seksuelle overgreb bedømt ud fra retslægelige undersøgelser [Sexual abuse assessed by forensic examinations]. Ugeskr Laeger. 1997;160(1):41-4.
- 65. Bechtel K, Ryan E, Gallagher D. Impact of sexual assault nurse examiners on the evaluation of sexual assault in a pediatric emergency department. Pediatr Emerg Care. 2008;24(7):442-7.
- 66. Adlington R, Browne R. Management of patients seen post-sexual assault at a north London inner city genitourinary medicine clinic 2005-2008. Int J STD AIDS. 2011;22(5):286-7.
- 67. Gilles C, Van Loo C, Rozenberg S. Audit on the management of complainants of sexual assault at an emergency department. Eur J Obstet Gynecol Reprod Biol. 2010;151(2):185-9.
- 68. Forbes KM, Day M, Vaze U, Sampson K, Forster G. Management of survivors of sexual assault within genitourinary medicine. Int J STD AIDS. 2008;19(7):482-3.
- 69. Obeyesekera S, Jones K, Forster GE, Welch J, Brook MG, Daniels D, et al. Management of rape/sexual assault cases within genitourinary medicine clinics: results from a study in North Thames. Int J STD AIDS. 2007;18(1):61-2.
- 70. Ackerman DR, Sugar NF, Fine DN, Eckert LO. Sexual assault victims: factors associated with follow-up care. Am J Obstet Gynecol. 2006;194(6):1653-9.
- 71. Thompson C. Review of 212 individuals attending a city centre genitourinary medicine clinic following acute sexual assault. J Clin Forensic Med. 2006;13(4):186-8.
- 72. Das S, Huengsberg M. An audit on the management of female victims of sexual assault attending a genitourinary medicine clinic. Int J STD AIDS. 2004;15(7):484-5.

- 73. Kawsar M, Anfield A, Walters E, McCabe S, Forster GE. Prevalence of sexually transmitted infections and mental health needs of female child and adolescent survivors of rape and sexual assault attending a specialist clinic. Sex Transm Infect. 2004;80(2):138-41.
- 74. Kerr E, Cottee C, Chowdhury R, Jawad R, Welch J. The Haven: a pilot referral centre in London for cases of serious sexual assault. BJOG. 2003;110(3):267-71.
- 75. Gibb AM, McManus T, Forster GE. Should we offer antibiotic prophylaxis post sexual assault? Int J STD AIDS. 2003;14(2):99-102.
- 76. Riggs N, Houry D, Long G, Markovchick V, Feldhaus KM. Analysis of 1,076 cases of sexual assault. Ann Emerg Med. 2000;35(4):358-62.
- 77. Bottomley CPEH, Sadler T, Welch J. Integrated clinical service for sexual assault victims in a genitourinary setting. Sex Transm Infect. 1999;75(2):116-9.
- 78. Holmes MM, Resnick HS, Frampton D. Follow-up of sexual assault victims. Am J Obstet Gynecol. 1998;179(2):336-42.
- 79. Peipert JF, Domagalski LR. Epidemiology of adolescent sexual assault. Obstet Gynecol. 1994;84(5):867-71.
- 80. Davies AG, Clay JC. Prevalence of sexually-transmitted disease infection in women alleging rape. Sex Transm Dis. 1992;19(5):298-300.
- 81. Rambow B, Adkinson C, Frost TH, Peterson GF. Female sexual assault medical and legal implications. Ann Emerg Med. 1992;21(6):727-31.
- 82. Glaser JB, Schachter J, Benes S, Cummings M, Frances CA, McCormack WM. Sexually transmitted diseases in postpubertal female rape victims. J Infect Dis. 1991;164(4):726-30.
- 83. Ross JD, Scott GR, Busuttil A. Rape and sexually transmitted diseases: patterns of referral and incidence in a department of genitourinary medicine. J R Soc Med. 1991:84(11):657-9.
- 84. Tucker S, Claire E, Ledray LE, Werner JS, Claire E. Sexual assault evidence collection. Wis Med J. 1990;89(7):407-11.
- 85. Estreich S, Forster GE, Robinson A. Sexually transmitted diseases in rape victims. Genitourin Med. 1990;66(6):433-8.
- 86. Lacey HB. Sexually transmitted diseases and rape: the experience of a sexual assault centre. Int J STD AIDS. 1990;1(6):405-9.
- 87. Sturm JT, Carr ME, Luxenberg MG, Swoyer JK, Cicero JJ. The prevalence of Neisseria gonorrhoeae and Chlamydia trachomatis in victims of sexual assault. Ann Emerg Med. 1990;19(5):587-90.
- 88. Jenny C, Hooton TM, Bowers A, Copass MK, Krieger JN, Hillier SL, et al. Sexually transmitted diseases in victims of rape. N Engl J Med. 1990;322(11):713-6.
- 89. Tintinalli JE, Hoelzer M. Clinical findings and legal resolution in sexual assault. Ann Emerg Med. 1985;14(5):447-53.
- 90. Jørgensen PH, Hilden M, Worm AM. Chlamydia: Prevalence and treatment among sexual assault victims. The first international conference on survivors of rape; Aarhus, Denmark2008.
- 91. Merchant RC, Phillips BZ, Delong AK, Mayer KH, Becker BM. Disparities in the provision of sexually transmitted disease and pregnancy testing and prophylaxis for sexually assaulted women in Rhode Island emergency departments. J Womens Health (Larchmt). 2008;17(4):619-29.

- 92. Du Mont J, Myhr TL, Husson H, Macdonald S, Rachlis A, Loutfy MR. HIV postexposure prophylaxis use among Ontario female adolescent sexual assault victims: a prospective analysis. Sex Transm Dis. 2008;35(12):973-8.
- 93. Holmes M. Sexually transmitted infections in female rape victims. Aids Patient Care STDS. 1999;13(12):703-8.
- 94. Ledray LE. Sexual assault nurse clinician: an emerging area of nursing expertise. AWHONNS Clin Issues Perinat Womens Health Nurs. 1993;4(2):180-90.
- 95. Claydon E, Murphy S, Osborne EM, Kitchen V, Smith JR, Harris JR. Rape and HIV. Int J STD AIDS. 1991;2(3):200-1.
- 96. Crowe C, Forster GE, Dinsmore WW, Maw RD. A case of acute hepatitis B occurring four months after multiple rape. Int J STD AIDS. 1996;7(2):133-4.
- 97. Haugen K, Slungard A, Schei B. Seksuelle overgrep mot kvinner skademønster og relasjon mellom offer og overgriper [Sexual assault against women Injury pattern and victim-perpetrator relationship]. Tidsskr Nor Laegeforen. 2005;125(24):3424-7.
- 98. Du Mont J, Macdonald S, Rotbard N, Asllani E, Bainbridge D, Cohen MM. Factors associated with suspected drug-facilitated sexual assault. Can Med Assoc J. 2009;180(5):513-9.
- 99. Saint-Martin P, Bouyssy M, O'Byrne P. Analysis of 756 cases of sexual assault in Tours (France): medico-legal findings and judicial outcomes. Med Sci Law. 2007;47(4):315-24.
- 100. McGregor MJ, Lipowska M, Shah S, Du Mont J, De Siato C. An exploratory analysis of suspected drug-facilitated sexual assault seen in a hospital emergency department. Women Health. 2003;37(3):71-80.
- 101. Voldtektssituasjonen. Beskrivelser av de 50 siste påtaleavgjorte voldtektssaker i Sør-Trøndelag politidistrikt. Trondheim: Sør-Trøndelag politidistrikt; 2014 Januar 14 p.
  102. Gee D, Owen P, McLean I, Brentnall K, Thundercloud C. Operation MATISSE: investigating drug facilitated sexual assault. London: The Association of Chief Police
- 103. McBrierty D, Wilkinson A, Tormey W. A review of drug-facilitated sexual assault evidence: an Irish perspective. J Forensic Leg Med. 2013;20(4):189-97.

Officers (ACPO), 2006.

- 104. Krebs CP, Lindquist CH, Warner TD, Fisher BS, Martin SL. College women's experiences with physically forced, alcohol- or other drug-enabled, and drug-facilitated sexual assault before and since entering college. J Am Coll Health. 2009;57(6):639-47.
- 105. Hurley M, Parker H, Wells DL. The epidemiology of drug facilitated sexual assault. J Clin Forensic Med. 2006;13(4):181-5.
- 106. Birkler RI, Telving R, Ingemann-Hansen O, Charles AV, Johannsen M, Andreasen MF. Screening analysis for medicinal drugs and drugs of abuse in whole blood using ultra-performance liquid chromatography time-of-flight mass spectrometry (UPLC-TOF-MS) toxicological findings in cases of alleged sexual assault. Forensic Sci Int. 2012;222(1-3):154-61.
- 107. Gisladottir A, Gudmundsdottir B, Gudmundsdottir R, Jonsdottir E, Gudjonsdottir GR, Kristjansson M, et al. Increased attendance rates and altered characteristics of sexual violence. Acta Obstet Gynecol Scand. 2012;91(1):134-42.
- 108. Moller AS, Backstrom T, Sondergaard HP, Helstrom L. Patterns of injury and reported violence depending on relationship to assailant in female Swedish sexual assault victims. J Interpers Violence. 2012;27(16):3131-48.

- 109. Hilden M, Schei B, Sidenius K. Genitoanal injury in adult female victims of sexual assault. Forensic SciInt. 2005;154(2-3):200-5.
- 110. Beynon CM, McVeigh C, McVeigh J, Leavey C, Bellis MA. The involvement of drugs and alcohol in drug-facilitated sexual assault: a systematic review of the evidence. Trauma Violence Abuse. 2008;9(3):178-88.
- 111. Boussairi A, Dupeyron JP, Hernandez B, Delaitre D, Beugnet L, Espinoza P, et al. Urine benzodiazepines screening of involuntarily drugged and robbed or raped patients. J Toxicol Clin Toxicol. 1996;34(6):721-4.
- 112. Armstrong R. When drugs are used for rape. J Emerg Nurs. 1997;23(4):378-81.
- 113. ElSohly MA, Salamone SJ. Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol. 1999;23(3):141-6.
- 114. Grossin C, Sibille I, Lorin de la Grandmaison G, Banasr A, Brion F, Durigon M. Analysis of 418 cases of sexual assault. Forensic Sci Int. 2003;131(2-3):125-30.
- 115. Hindmarch I, Brinkmann R. Trends in the use of alcohol and other drugs in cases of sexual assault. Human Psychopharmacology-Clinical and Experimental. 1999;14(4):225-31.
- 116. Hindmarch I, ElSohly M, Gambles J, Salamone S. Forensic urinalysis of drug use in cases of alleged sexual assault. J Clin Forensic Med. 2001;8(4):197-205.
- 117. Marc B, Baudry F, Vaquero P, Zerrouki L, Hassnaoui S, Douceron H. Sexual assault under benzodiazepine submission in a Paris suburb. Arch Gynecol Obstet. 2000;263(4):193-7.
- 118. Scott-Ham M, Burton FC. Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med. 2005;12(4):175-86.
- 119. Slaughter L. Involvement of drugs in sexual assault. J Reprod Med. 2000;45(5):425-30.
- 120. Juhascik M, Le NL, Tomlinson K, Moore C, Gaensslen RE, Negrusz A. Development of an analytical approach to the specimens collected from victims of sexual assault. J Anal Toxicol. 2004;28(6):400-6.
- 121. Mullins ME. Laboratory confirmation of flunitrazepam in alleged cases of date rape. Acad Emerg Med. 1999;6(9):966-8.
- 122. Juhascik MP, Negrusz A, Faugno D, Ledray L, Greene P, Lindner A, et al. An estimate of the proportion of drug-facilitation of sexual assault in four U.S. localities. J Forensic Sci. 2007;52(6):1396-400.
- 123. Hall J, Goodall EA, Moore T. Alleged drug facilitated sexual assault (DFSA) in Northern Ireland from 1999 to 2005. A study of blood alcohol levels. J Forensic Leg Med. 2008;15(8):497-504.
- 124. Jones AW, Kugelberg FC, Holmgren A, Ahlner J. Occurrence of ethanol and other drugs in blood and urine specimens from female victims of alleged sexual assault. Forensic Sci Int. 2008;181(1-3):40-6.
- 125. Du Mont J, Macdonald S, Rotbard N, Bainbridge D, Asllani E, Smith N, et al. Drug-facilitated sexual assault in Ontario, Canada: Toxicological and DNA findings. J Forensic Leg Med. 2010;17(6):333-8.
- 126. Bosman IJ, Verschraagen M, Lusthof KJ. Toxicological Findings in Cases of Sexual Assault in the Netherlands. J Forensic Sci. 2011;56(6):1562-8.

- 127. Jones AW, Holmgren A, Ahlner J. Toxicological analysis of blood and urine samples from female victims of alleged sexual assault. Clinical toxicology (Philadelphia, Pa). 2012;50(7):555-61.
- 128. Read KM, Kufera JA, Jackson MC, Dischinger PC. Population-based study of police-reported sexual assault in Baltimore, Maryland. The American Journal of Emergency Medicine. 2005;23(3):273-8.
- 129. Djezzar S, Questel F, Burin E, Dally S. Chemical submission: Results of 4-year French inquiry. Int J Legal Med. 2009;123(3):213-9.
- 130. Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26(2):200-5.
- 131. Castberg I, Sandvik P. Prøvetaking ved rusmiddeltesting i urin. [Substance abuse detection in urine]. Tidsskr Nor Laegeforen. 2005;125(3):293-4.
- 132. Narkotikasituasjonen i Europa 2010. Oslo: Norwegian Institute for Alcohol and Drug Research; 2010.
- 133. Hibell B. Rusmiddelbruk blant skoleelever i 35 europeiske land [The 2007 European School Survey Project on Alcohol and Other Drugs (ESPAD) report]. Stockholm: European School Survey Project on Alcohol and Other Drugs (ESPAD), 2009.
- 134. Vedøy TF, Skretting A. Ungdom og rusmidler. Resultater fra spørreskjemaundersøkelser 1968-2008. Oslo: Norwegian Institute for Alcohol and Drug Research, 2009.
- 135. Scott-Ham M, Burton FC. A study of blood and urine alcohol concentrations in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med. 2006;13(3):107-11.
- 136. Jewkes R, Christofides N, Vetten L, Jina R, Sigsworth R, Loots L. Medico-legal findings, legal case progression, and outcomes in South African rape cases: retrospective review. PLoS Med. 2009;6(10).
- 137. Helweg-Larsen K. The value of the medico-legal examination in sexual offences. Forensic Sci Int. 1985;27(3):145-55.
- 138. Penttila A, Karhumen PJ. Medicolegal findings among rape victims. Med Law. 1990;9(1):725-37.
- 139. Lindsay SP. An epidemiologic study of the influence of victim age and relationship to the suspect on the results of evidentiary examinations and law enforcement outcomes in cases of reported sexual assault. San Diego: University of California, San Diego; 1998.
- 140. McGregor MJ, Le G, Marion SA, Wiebe E. Examination for sexual assault: Is the documentation of physical injury associated with the laying of charges? A retrospective cohort study. Can Med Assoc J. 1999;160(11):1565-9.
- 141. Du Mont J, Parnis D. Sexual assault and legal resolution: querying the medical collection of forensic evidence. Med Law. 2000;19(4):779-92.
- 142. Gray-Eurom K, Seaberg DC, Wears RL. The prosecution of sexual assault cases: Correlation with forensic evidence. Ann Emerg Med. 2002;39(1):39-46.
- 143. McGregor MJ, Du Mont J, Myhr TL. Sexual assault forensic medical examination: Is evidence related to successful prosecution? Ann Emerg Med. 2002:39(6):639-47.
- 144. Wiley J, Sugar N, Fine D, Eckert LO. Legal outcomes of sexual assault. Am J Obstet Gynecol. 2003;188(6):1638-41.

- 145. Cahill LL. Adolescent sexual assault: timing of physical exam, exam findings, prior sexual history, and legal outcome Spokane, WA: Gonzaga University, US 2004.
- 146. Ingemann-Hansen O, Brink O, Sabroe S, Sorensen V, Charles AV. Legal aspects of sexual violence does forensic evidence make a difference? Forensic Sci Int. 2008;180(2-3):98-104.
- 147. McLean I, Roberts SA, White C, Paul S. Female genital injuries resulting from consensual and non-consensual vaginal intercourse. Forensic SciInt. 2011;204(1-3):27-33.
- 148. Nesvold H, Ormstad K, Friis S. To be used or not to be used, that is the question: legal use of forensic and clinical information collected in a self-referral sexual assault centre. J Forensic Sci. 2011;56(5):1156-62.
- 149. Sør-Trøndelag County Authority, The official web page of the Sør-Trøndelag County Authority Trondheim2011 [cited 2014 June 1]. Available from: <a href="http://www.stfk.no/Om\_fylkeskommunen/Kort\_om\_fylkeskommunen/">http://www.stfk.no/Om\_fylkeskommunen/Kort\_om\_fylkeskommunen/</a>.
- 150. Creighton CD, Jones AC. Psychological profiles of adult sexual assault victims. J Forensic Leg Med. 2012;19(1):35-9.
- 151. Fakta om alkohol: Nasjonalt folkehelseinstitutt 2012 [cited 2014 June 1]. Available from: <a href="http://www.fhi.no/artikler?id=42834">http://www.fhi.no/artikler?id=42834</a>.
- 152. Hagemann CT, Stene LE, Myhre AK, Ormstad K, Schei B. Impact of medicolegal findings on charge filing in cases of rape in adult women. Acta Obstet Gynecol Scand. 2011;90(11):1218-24.
- 153. White C, McLean I. Adolescent complainants of sexual assault; injury patterns in virgin and non-virgin groups. J Clin Forensic Med. 2006;13(4):172-80.
- 154. Astrup BS, Ravn P, Lauritsen J, Thomsen JL. Nature, frequency and duration of genital lesions after consensual sexual intercourse Implications for legal proceedings. Forensic Sci Int. 2012;219(1-3):50-6.
- 155. Recommended Minimum Performance Limits for Common DFSA Drugs and Metabolites in Urine Samples, 2012: Society of Forensic Toxicologists (SOFT) Drug-Facilitated Sexual Assault Committee; [cited 2014 June 1]. Available from: <a href="http://soft-tox.org/sites/default/files/SOFT">http://soft-tox.org/sites/default/files/SOFT</a> DFSA Rec Det Limits 3-2012.pdf.
- 156. Jones AW. Reference limits for urine/blood ratios of ethanol in two successive voids from drinking drivers. J Anal Toxicol. 2002;26(6):333-9.
- 157. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med. 2003;138(8):644-50.
- 158. Nathanson BH, Higgins TL. An introduction to statistical methods used in binary outcome modeling. Semin Cardiothorac Vasc Anesth. 2008;12(3):153-66.
- 159. Sexually transmitted diseases surveillance 2011. 2012 [cited 2014 June 1]. Available from: <a href="http://www.cdc.gov/std/stats11/default.htm">http://www.cdc.gov/std/stats11/default.htm</a>.
- 160. Rothman KJ. Epidemiology: an introduction. Oxford: Oxford University Press; 2002. 223 p.
- 161. Sommers MS, Schafer J, Zink T, Hutson L, Hillard P. Injury Patterns in Women Resulting from Sexual Assault Trauma, Violence, & Abuse. 2001;2(3):240-58.
- 162. Resnick HS, Holmes MM, Kilpatrick DG, Clum G, Acierno R, Best CL, et al. Predictors of post-rape medical care in a national sample of women. Am J Prev Med. 2000;19(4):214-9.

- 163. Paul LA, Zinzow HM, McCauley JL, Kilpatrick DG, Resnick HS. Does encouragement by others increase rape reporting? Findings from a national sample of women. Psychol Women Q. 2014;38(2):222-32.
- 164. Pedersen KF. Barn og ungdom som oppsøker overgrepsmottaket ved St. Olavs Hospital [Adolescents attending a Sexual Assault Centre]. Oslo: Universitetet i Oslo; 2013 May.
- 165. Østby L. Hva hindrer utsatte for seksuelle overgrep i å søke hjelp? Innspill til utformingen av en nettportal for overgrepsutsatte. Oslo: Diakonhjemmet høgskole; 2012. 86 p.
- 166. Nersund R, Govasmark H. Rapportering fra krisesentertilbudene 2012. Oslo: Krisesentersekretariatet, 2013.
- 167. Norwegian Surveillance System for Communicable Diseases (MSIS) Oslo: Folkehelseinstituttet; 2011 [cited 2014 June 1]. Available from: http://www.msis.no/.
- 168. Deming ME, Covan EK, Swan SC, Billings DL. Exploring rape myths, gendered norms, group processing, and the social context of rape among college women: a qualitative analysis. Violence Against Women. 2013;19(4):465-85.
- 169. Hegstad S, Helland A, Hagemann C, Michelsen L, Spigset O. EtG/EtS in Urine from Sexual Assault Victims Determined by UPLC-MS-MS. J Anal Toxicol. 2013;37(4):227-32.
- 170. Katz MH. Chapter 1.3 What are suppressers and how does multivariable analysis help me to deal with them? Multivariable Analysis: A Practical Guide for Clinicians and Public Health Researchers. Third ed. New York, USA: Cambridge University Press; 2011. p. 8 10.
- 171. Eckert LO, Sugar N, Fine D. Factors impacting injury documentation after sexual assault: role of examiner experience and gender. Am J Obstet Gynecol. 2004;190(6):1739-43; discussion 44-6.
- 172. Bakken IJ, Bratt H, Skjeldestad FE, Nordbø SA. Påvisning av Chlamydia trachomatis i urin-, vulva- og cervixprøver [Detection of chlamydia trachomatis in urine, vulval and cervical swabs]. Tidsskr Nor Laegeforen. 2005;125(12):1629-30.
- 173. Törneke U, Fardal H. Høy forekomst av Mycoplasma genitalium hos kvinner under 25 år. Prevalensundersøkelse av M. genitalium i pasientprøver som testes for C. trachomatis. Trondheim: NTNU; 2012. 42 p.
- 174. Fardal H, Tørneke U, Pukstad BS, Nordbø SA. Høy forekomst av Mycoplasma genitalium hos unge kvinner som testes for Chlamydia trachomatis. Årskonferansen for medisinsk mikrobiologi og infeksjonsimmunologi ved Folkehelseinstituttet 5 6 desember 2013; Oslo: Folkehelseinstituttet 2013.
- 175. Fardal H, Törneke U, Pukstad BS, Nordbø SA. Høy forekomst av Mycoplasma genitalium hos unge kvinner som testes for Chlamydia trachomatis. Årskonferansen for medisinsk mikrobiologi og infeksjonsimmunologi ved Folkehelseinstituttet 5 6 desember 2013; 6. desember; Oslo, Norway: Folkehelseinstituttet 2013.
- 176. Jensen JS, Bjornelius E, Dohn B, Lidbrink P. Comparison of first void urine and urogenital swab specimens for detection of Mycoplasma genitalium and Chlamydia trachomatis by polymerase chain reaction in patients attending a sexually transmitted disease clinic. Sex Transm Dis. 2004;31(8):499-507.
- 177. Hjelmevoll SO, Olsen ME, Sollid JU, Haaheim H, Melby KK, Moi H, et al. Clinical validation of a real-time polymerase chain reaction detection of Neisseria

- gonorrheae por Apseudogene versus culture techniques. Sex Transm Dis. 2008;35(5):517-20.
- 178. Moi H, Maltau JM. Seksuelt overførbare infeksjoner og genitale hudsykdommer. Oslo: Gyldendal akademisk; 2008. 251 p.
- 179. Bakken IJ, Skjeldestad FE, Nordbø SA. Chlamydia trachomatis blant abortsøkende kvinner i Trondheim 1985-2000 [Chlamydia trachomatis infection in women seeking termination of pregnancy 1985-2000]. Tidsskr Nor Laegeforen. 2004;124(12):1638-40.
- 180. Bakken IJ, Nordbø SA. Chlamydiainfeksjon i Sør-Trøndelag prøvetaking og prevalens [Chlamydia trachomatis infection in central Norway: testing patterns and prevalence]. Tidsskr Nor Laegeforen. 2007;127(24):3202-5.
- 181. Blystad H, Kløvstad H, Kostova V, Nilsen Ø, Sandbu S, Stene-Johansen K, et al. Årsrapport 2011 for sykdomsprogrammet: Blod- og seksuelt overførbare infeksjoner. 2012.
- 182. Jensen AJ, Kleveland CR, Moghaddam A, Haaheim H, Hjelmevoll SO, Skogen V. Chlamydia trachomatis, Mycoplasma genitalium and Ureaplasma urealyticum among students in northern Norway. J Eur Acad Dermatol Venereol. 2012.
- 183. Skjeldestad FE, Marsico MA, Sings HL, Nordbo SA, Storvold G. Incidence and risk factors for genital Chlamydia trachomatis infection: a 4-year prospective cohort study. Sex Transm Dis. 2009;36(5):273-9.
- 184. Høviskeland A, Lødøen G, Røer R, Jenum PA. Genital chlamydiainfeksjon blant elever i videregående skole [Genital Chlamydia among pupils in high school]. Tidsskr Nor Laegeforen. 2007;127(16):2077-9.
- 185. Gravningen K, Furberg AS, Simonsen GS, Wilsgaard T. Early sexual behaviour and Chlamydia trachomatis infection a population based cross-sectional study on gender differences among adolescents in Norway. BMC Infect Dis. 2012;12:319.
- 186. Dalgård O, editor Prevalence of hepatitis B markes in the Oslo Health Study. Scandinavian Society for Antimicrobial Therapy/Nordic Society of Clinical Microbiology and Infectious Diseases.
- 187. Eskild A, Samdal HH, Skaug K, Jeansson S, Stray-Pedersen B, Jenum PA. Hepatitt C-virus blant gravide kvinner i Norge forekomst av antistoffer og svangerskapsutfall [Hepatitis C virus among pregnant women in Norway: occurrence of antibodies and pregnancy outcome]. Tidsskr Nor Laegeforen. 2000;120(9):1006-8.
- 188. Nordbø SA, Johansen OJ, Brubakk AM, Bakke K. Vertikal overføring av hepatitt C-virus i Sør-Trøndelag [Vertical transmission of hepatitis C virus in Sor-Trondelag]. Tidsskr Nor Laegeforen. 2002;122(20):1977-80.
- 189. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2012. Darlinghurst NSW, Australia: The Kirkby Institute for infection and immunity in society; 2012.
- 190. Smittevernboka: Hepatitt B Oslo: Folkehelseinstituttet; 2010 [updated 19.03.2014; cited 2014 June 1]. Available from: http://www.fhi.no/artikler/?id=82749.
- 191. Baggaley RF, Dimitrov D, Owen BN, Pickles M, Butler AR, Masse B, et al. Heterosexual anal intercourse: a neglected risk factor for HIV? Am J Reprod Immunol. 2013;69 Suppl 1:95-105.
- 192. Klot JF, Auerbach JD, Veronese F, Brown G, Pei A, Wira CR, et al. Greentree white paper: sexual violence, genitoanal injury, and HIV: priorities for research, policy, and practice. AIDS Res Hum Retroviruses. 2012;28(11):1379-88.

- 193. Campbell JC, Lucea MB, Stockman JK, Draughon JE. Forced Sex and HIV Risk in Violent Relationships. Am J Reprod Immunol. 2012.
- 194. Stockman JK, Lucea MB, Campbell JC. Forced sexual initiation, sexual intimate partner violence and HIV risk in women: a global review of the literature. AIDS and behavior. 2013;17(3):832-47.
- 195. Wroblewski JK, Manhart LE, Dickey KA, Hudspeth MK, Totten PA. Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium. J Clin Microbiol. 2006;44(9):3306-12.
- 196. Lillis RA, Nsuami MJ, Myers L, Martin DH. Utility of urine, vaginal, cervical, and rectal specimens for detection of Mycoplasma genitalium in women. J Clin Microbiol. 2011;49(5):1990-2.
- 197. Hausken AM, Skurtveit S, Rosvold EO, Bramness JG, Furu K. Psychotropic drug use among persons with mental distress symptoms: a population-based study in Norway. Scand J Public Health. 2007;35(4):356-64.
- 198. Anderson S, McClain N, Riviello RJ. Genital findings of women after consensual and nonconsensual intercourse. Journal of forensic nursing. 2006;2(2):59-65.
- 199. Jones JS, Rossman L, Hartman M, Alexander CC. Anogenital injuries in adolescents after consensual sexual intercourse. Acad Emerg Med. 2003;10(12):1378-83.
- 200. Sachs CJ, Chu LD. Predictors of genitorectal injury in female victims of suspected sexual assault. Acad Emerg Med. 2002;9(2):146-51.
- 201. Slaughter L, Brown CRV, Crowley S, Peck R. Patterns of genital injury in female sexual assault victims. American Journal of Obstetrics and Gynecology. 1997;176(3):609-16.
- 202. Sommers MS, Zink T, Baker RB, Fargo JD, Porter J, Weybright D, et al. The effects of age and ethnicity on physical injury from rape. J Obstet Gynecol Neonatal Nurs. 2006;35(2):199-207.
- 203. Slaughter L, Brown CRV. Colposcopy to establish physical findings in rape victims. American Journal of Obstetrics and Gynecology. 1992;166(1):83-6.
- 204. Briody M. The effects of DNA evidence on sexual offence cases in court Current issues in criminal justice. 2002 2003(14):159 81.
- 205. Cybulska B, Forster GE, Welch SJ, Lacey HB, Rogstad K, Lazaro N. UK National Guidelines on the Management of Adult and Adolescent Complainants of Sexual Assault 2011: British Association for Sexual Health and HIV; 2011 [cited 2014 June 1]. Available from: <a href="http://www.bashh.org/documents/4450.pdf">http://www.bashh.org/documents/4450.pdf</a>.
- 206. Sexual Assault in Postpubertal Adolescents and Adults: Public Health Agency of Canada; 2013 [updated 2013, Feb 01; cited 2014 June 1]. Available from: <a href="http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-6-6-eng.php">http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-6-6-eng.php</a>.
- 207. Testa M, Livingston JA. Alcohol consumption and women's vulnerability to sexual victimization: can reducing women's drinking prevent rape? Subst Use Misuse. 2009;44(9-10):1349-76.
- 208. Krebs CP, Lindquist CH, Warner TD, Fisher BS, Martin SL. The differential risk factors of physically forced and alcohol- or other drug-enabled sexual assault among university women. Violence Vict. 2009;24(3):302-21.

- 209. Neal DJ, Fromme K. Event-level covariation of alcohol intoxication and behavioral risks during the first year of college. J Consult Clin Psychol. 2007;75(2):294-306.
- 210. Pape H. Sexual assault while too intoxicated to resist: a general population study of Norwegian teenage girls. BMC public health. 2014;14(1):406.
- 211. Dorandeu AH, Pages CA, Sordino MC, Pepin G, Baccino E, Kintz P. A case in south-eastern France: a review of drug facilitated sexual assault in European and English-speaking countries. J Clin Forensic Med. 2006;13(5):253-61.
- 212. Om lov om behandling av opplysninger i politiet og påtalemyndigheten (politiregisterloven). Tilråding fra Justis- og politidepartementet av 21. august 2009. Sect. 3.7.3 (2009).
- 213. Lov om endringer i straffeprosessloven (utvidelse av DNA-registeret) 2008 [cited 2014 June 1]. Available from: https://www.lovdata.no/ltavd1/filer/nl-20080118-003.html.
- 214. Gulla K, Fenheim GE, Myhre AK, Lydersen S. Non-abused preschool children's perception of an anogenital examination. Child Abuse Negl. 2007;31(8):885-94.
- 215. Eide AK. "Å være eller ikke være". Brukerundersøkelse i tilknytning til evaluering av overgrepsmottakene i Norge. Bodø: Nordlandsforskning; 2013 10. juli 54 p.
- 216. Moller AS, editor Psychiatric morbidity should be considered in crisis management after rape. The 3rd International Conference on Survivors of Rape; 2012 November 8.-10.; Galway, Ireland.
- 217. Gisladottir A, Harlow BL, Gudmundsdottir B, Bjarnadottir RI, Jonsdottir E, Aspelund T, et al. Risk factors and health during pregnancy among women previously exposed to sexual violence. Acta Obstet Gynecol Scand. 2014.

# Paper I

## Is not included due to copyright

# Paper II



Contents lists available at SciVerse ScienceDirect

#### Journal of Forensic and Legal Medicine

journal homepage: www.elsevier.com/locate/jflm



#### Original communication

#### Ethanol and drug findings in women consulting a Sexual Assault Center – Associations with clinical characteristics and suspicions of drug-facilitated sexual assault



Cecilie T. Hagemann, MD Consultant Gynecologist a,b,\*, Arne Helland, MD Consultant Pharmacologist c Olav Spigset, MD, PhD Consultant Pharmacologist, Professor c,d, Ketil A. Espnes, MD Consultant Pharmacologist c, Kari Ormstad, MD, PhD Professor of Forensic Medicine, Consultant Clinical Forensic Pathologist <sup>e</sup>, Berit Schei, MD, PhD Professor of Women's Health, Consultant Gynecologist a,b

#### ARTICLE INFO

Article history: Received 18 October 2012 Received in revised form 17 April 2013 Accepted 31 May 2013 Available online 25 June 2013

Keywords: Drug-facilitated sexual assault Date rape drugs Toxicological findings Alcohol Forensic service Sexual assault center

#### ABSTRACT

The purpose of the study was to describe toxicological findings among women seeking health care after sexual assault, and to assess the relationship with so-called proactive DFSA (drug facilitated sexual assault). We also explored associations between ethanol in blood/urine and background data, assault characteristics, and clinical findings.

We conducted a retrospective, descriptive study of female patients  $\geq$ 12 years of age consulting the Sexual Assault Center at St. Olavs University Hospital, Trondheim, Norway. They were examined between July 1, 2003 and December 31, 2010, and urine and/or blood were analyzed for ethanol and selected medicinal/recreational drugs.

Among the 264 patients included, ethanol and/or drugs were detected in 155 (59%). Of the 50 patients (19%) testing positive for drugs other than ethanol, benzodiazepines/benzodiazepine-like drugs were found in 31, central stimulants in 14, cannabinoids in 13 and opioids in nine. None tested positive for gamma-hydroxybutyrate (GHB). In total, 57 patients (22%) suspected proactive DFSA, but only five had findings of sedative drugs that were not accounted for by self-reported voluntary intake. No cases could unequivocally be attributed to proactive DFSA.

Among the 120 patients tested for ethanol within 12 h after the assault, 102 were positive. The median estimated blood alcohol concentration (BAC) at the time of assault was 1.87 g/L. Patients testing positive for ethanol more often reported a public place of assault and a stranger assailant. Higher estimated BAC at the time of assault was associated with higher frequency of suspecting proactive DFSA.

 $Ethanol\ was\ the\ most\ prevalent\ toxicological\ finding\ in\ urine/blood\ from\ victims\ of\ sexual\ assault,\ and$ high ethanol concentrations were often detected. Among the patients suspecting proactive DFSA, very few had sedative drug findings not explained by voluntary intake. It seems like opportunistic DFSA, rather than proactive DFSA dominate among the sexually assaulted attending our SAC.

© 2013 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.

<sup>&</sup>lt;sup>a</sup> Department of Public Health and General Practice, Norwegian University of Science and Technology, P.O. Box 8905, N-7491 Trondheim, Norway

Department of Obstetrics and Gynecology, St. Olavs Hospital, Trondheim University Hospital, P.O. Box 3250, Sluppen, N-7006 Trondheim, Norway Department of Clinical Pharmacology, St. Olavs Hospital, Trondheim University Hospital, P.O. Box 3250, Sluppen, N-7006 Trondheim, Norway

d Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, P.O. Box 8905, N-7491 Trondheim,

e Division of Forensic Medicine and Drug Abuse Research, Norwegian Institute of Public Health, P.O. Box 4404, Nydalen, N-0403 Oslo, Norway

Corresponding author. Postal address: Department of Public Health and General Practice, Norwegian University of Science and Technology, P.O. Box 8905, N-7491 Trondheim, Norway. Tel.: +47 73 59 75 37 (Work), +47 958 29 490 (Mobile); fax: +47 73 59 75 77. E-mail addresses: cecilie.hagemann@ntnu.no, cehag@online.no (C.T. Hagemann).

#### 1. Introduction

During the last twenty years both the police and medical personnel have become more aware of drug-facilitated sexual assault (DFSA). The phenomenon can be divided into two categories <sup>1</sup>: i) Proactive DFSA or deliberate surreptitious drugging, i.e. covert administration of drugs to an unsuspecting victim, and ii) opportunistic DFSA, i.e. taking advantage of someone already inebriated by voluntary ingestion of sufficient amounts of drugs or alcohol to become intoxicated. In both cases, the potential victim has impaired consciousness and reduced ability to resist unwanted sexual advances.

Studies of DFSA typically emanate either from hospital records, police files or forensic toxicological laboratories. Recent studies based upon the first two categories report a high rate of selfreported voluntary ingestion of alcohol and/or drugs prior to the sexual assault<sup>2-6</sup> and that approximately one in five suspects proactive DFSA.<sup>2,6</sup> In contrast, studies from forensic toxicology laboratories report results on the basis of findings in urine/blood from cases of alleged DFSA.7-14 These studies often have vaguely defined criteria for collecting samples, but presumably, the victim, the medical examiner and/or the police suspect some type of DFSA. Typical findings are high blood ethanol levels, while drugs commonly thought to be utilized in "date rapes" (e.g. flunitrazepam, gamma-hydroxybutyrate (GHB), ketamine) are rarely found. Laboratory studies often lack information about background variables and thus cannot differentiate cases of surreptitious drugging from cases of voluntary drug intake. However, a large British study combining laboratory data with information from police investigations found that less than two percent of the sedative drug findings could be attributed to proactive DFSA, whereas the vast majority of positive tests could be explained by voluntary intake.8

For more than two decades the Sexual Assault Center (SAC) at St. Olavs Hospital in Trondheim, Norway has offered medical assistance and forensic examination to sexual assaulted victims, irrespective of police reporting. After 2007 the SAC has collected urine and/or blood for drug analysis at the Department of Clinical Pharmacology at the same hospital from most consenting patients arriving within 3–4 days after the alleged assault.

Our aim was to describe the toxicological findings in an unselected population of patients seeking health care after a sexual assault, and to investigate whether the findings could be accounted for by voluntary intake or by surreptitious drugging. We also wanted to study associations between findings of ethanol/drugs in blood/urine and background data, assault characteristics and clinical findings.

#### 2. Material and methods

#### 2.1. Study design and settings

We conducted a retrospective, descriptive study of female patients  $\geq\!12$  years of age who were examined at the SAC at St. Olavs Hospital, Norway, between July 1, 2003 and December 31, 2010. Our precinct is the county of Sør-Trøndelag, situated in central Norway, comprising about 280 000 inhabitants. The area includes the city of Trondheim, with about 160 000 inhabitants. The SAC's service is described in detail elsewhere.  $^{15}$ 

#### 2.2. Participants

A total of 730 patients  $\geq$ 12 years presented to the SAC during the study period. First, those of male sex (n=20) or with no (suspected) sexual assault according to criteria stated in a Canadian

study<sup>2</sup> (n = 21), and those in whom no medical examination was performed (n = 68), were excluded (Fig. 1).

The study was approved by the Regional Committee for Research Ethics. According to instructions from the committee, all patients eligible for inclusion received a letter with information about the study. Those who declined to participate on the basis of this letter (n=9) were also excluded (Fig. 1). Finally, patients from whom no urine or blood had been obtained for toxicological analyses (n=348) were excluded. Thus, in total, 264 patients were included in the study.

#### 2.3. Data collection and variables

Information, including forensic reports and laboratory results, was extracted from the patients' records and registered through a web-based data collection system developed and administered by the Unit of Applied Clinical Research at the Norwegian University of Science and Technology.

Sociodemographic patient characteristics registered included age, country of origin (categorized as Western if in Western Europe, North America or Oceania; otherwise as non-Western), living situation (alone or with family/partner/other), residency (in the city of Trondheim or not), education, occupational status, and psychosocial history. The latter includes vulnerability factors as defined in a previous study, <sup>16</sup> except for the concept of mental health problems that included both a diagnosis of affective/psychotic illness, use of antidepressant/antipsychotic medication and history of use of mental health services, deliberate self-harm/attempted suicide and eating disorder. <sup>17</sup>

Self-reported voluntary intake of medicinal/recreational (non-prescribed) drugs was recorded from data provided at first SAC visit, at follow-up visits, or from recent relevant hospital records. Self-reported alcohol ingestion in relation to the assault was classified as no intake, intake of <5 units of alcohol, and intake of <5 units of alcohol unit corresponding to 12 g ethanol, which equals approximately one standard-sized glass of alcoholic beverage. <sup>18</sup>

A patient was classified as suspecting proactive DFSA when she herself addressed a suspicion of being involuntarily drugged and assaulted, in combination with at least one of 16 associated symptoms/signs (e.g. total or partial amnesia; "blackout", hangover or symptoms inconsistent with the amount of alcohol or drugs voluntarily ingested).<sup>2</sup>

Assailant characteristics like assumed age, country of origin and number of assailants were recorded. Factors such as location of assault and relationship between patient and assailant were defined as in a previous paper.<sup>15</sup> Time of the day of the assault was dichotomized to 7 a.m. to midnight or midnight to 7 a.m.

Physical violence was graded as "severe" (presence of weapon, attempted strangulation, gagging, punching or kicking toward head), "light/moderate" (holding, tearing off clothes, slapping, kicking, tying up, biting, sucking, stinging with needle), or "none/verbal threats". The assault was classified as penetrative when the patient reported vaginal and/or anal penetration by foreign object, as well as when the patient reported vaginal and/or anal and/or oral penetration by penis. When the patient reported vaginal and/or anal penetration by finger, as well as other sexual acts than already mentioned, we recorded the assault as non-penetrative. The sexual act was classified as "no recollection" if the incident had occurred while the patient was asleep, heavily inebriated or unconscious.

Objective documentation upon the SAC visit included emotional status, perceived degree of inebriation, and observed extragenital and anogenital injuries. Extragenital injuries were classified as serious, moderate or minor according to a previous study.<sup>15</sup> Anogenital injuries included tears, abrasions and bruises (ecchymoses/




Fig. 1. Flow diagram showing the inclusion of subjects in the study and the toxicological findings of the 264 female patients finally included in the study.

petechiae); redness and/or swelling was not regarded as an injury.  $^{15,19,20}$ 

The event was recorded as police-reported if the patient said so or if the police requested a medico-legal report for investigational

The time point for toxicological sampling was recorded; if not specifically stated, the sampling was assumed to have taken place one hour after arrival at the SAC. To estimate the time interval between the assault and the toxicological sampling, we used the mid-point of the time period for the assault.<sup>7</sup>

The blood alcohol concentration (BAC) was estimated from the measured serum ethanol concentration using a serum-to-blood ratio of 1.14. If the serum sample was missing, but the ethanol concentration in urine was known, a mean elimination phase urine-to-blood ratio of 1.345 was used to estimate BAC.<sup>21</sup> To estimate the BAC at the time of assault, concentrations were back-calculated assuming no ethanol intake after the assault and a metabolic rate of 0.15 g/L ethanol per hour.<sup>14</sup>

#### 2.4. Toxicological examination and analysis

Urine and/or blood specimens were analyzed at the Department of Clinical Pharmacology, St. Olavs Hospital. If available, urine samples were screened for a predefined selection of substances likely to be used in DFSAs,<sup>22</sup> and included ethanol and the drug classes benzodiazepines/benzodiazepine-like drugs, cannabinoids, opioids, central stimulants and some others, including GHB and ketamine (see Supplementary Table 1 for details about the analytes determined by the different methods and their limits of detection). If the urinary screening test was positive for one or more of these substances, the corresponding substances were also quantified in serum. If the screening was negative, the serum sample was discarded. In cases with only serum available, a general drug screening was not possible due to the relatively low serum volumes obtained. In these cases, specific analyses in

serum were prioritized according to the characteristics of the individual case.

The analytical methods employed were liquid chromatography/ mass spectrometry (LC/MS), gas chromatography/mass spectrometry (GC/MS) and immunoassay. For the LC/MS analysis, the samples were extracted under alkaline conditions and neutral/acidic conditions with liquid—liquid extraction. The concentrated extracts were then analyzed on Agilent 1100 MSD single quadrupole instruments (Agilent, Palo Alto, CA), applying both electrospray and chemical ionization. Analytes were separated on a Zorbax C18 column (30  $\times$  4.6 mm, 3  $\mu$ m particle size; Agilent, Palo Alto, CA) using formic acid/ammonium acetate buffer and methanol as the mobile phase. Deuterated internal standards were used. The interday coefficients of variation were generally less than 10%.

Urine was screened for GHB and ethanol by GC/MS on an Agilent 7359 single quadrupole mass spectrometer (Agilent, Palo Alto, CA), and for Lysergic acid diethylamide (LSD) and barbiturates by an immunoassay method on a Cobas Integra 400 analyzer (Roche AG, Basel, Switzerland). From 2009, ethanol analyses were performed by this immunoassay method as well.

#### 2.5. Statistical analysis

Variables were analyzed by descriptive statistics, and the associations between the outcome variable and the independent categorical variables were analyzed. Data analysis was performed with the statistical program package SPSS version 19.0. For continuous variables we used Student's t-test. For categorical variables Pearson's  $\chi^2$  test, exact unconditional test or Pearson's  $\chi^2$  test of heterogeneity were used as appropriate. Kruskal—Wallis non-parametric test were used for some ordinal data with small sample size. Statistical significance was assumed when p < 0.05. In some analyses, multivariable logistic regression was applied to adjust for patients' age and time interval from assault to toxicological sampling.

#### 3. Results

#### 3.1. Study population

Of the 264 eligible patients, toxicological analyses were performed in both blood and urine in 206 cases, in urine only in 41 cases and in blood only in 17 cases. Altogether, 184 of the patients (70%) were included during the period 2008-2010.

Background characteristics of the 264 patients are shown in Table 1. Median age of the patients was 21 years (mean 24 years, range 12-61 years). A suspicion of proactive DFSA was stated by 57 patients (22%) and a voluntary intake of alcohol by 222 (84%). Voluntary intake of medications/drugs other than alcohol was reported by 76 patients (29%) (range 1-6 drugs), and only 22 (8%) reported no intake of either alcohol or drugs. Altogether 117 patients (44%) had a history of mental health problems and 35 (13%) reported alcohol/drug abuse.

#### 3.2. Characteristics of the assault and clinical findings

Assault and assailant characteristics are shown in Supplementary Table 2. A penetrative assault was reported by 142 patients (55%),

Background characteristics of 264 female patients attending the Sexual Assault Center between July 1, 2003 and December 31, 2010 who were tested for alcohol/ drugs in urine and/or blood.

Characteristics	Number (%
Patient age, $n = 264$	
12-17 years	57 (22)
18-24 years	137 (52)
≥25 years	70 (27)
Country of origin, $n = 262$	
Norwegian/Western	252 (96)
Non-western	10 (4)
Living situation, $n = 259$	
Alone	124 (48)
With family/partner/other	135 (52)
Residency, $n = 263$	
City of Trondheim	166 (63)
Outside Trondheim	97 (37)
Education, $n = 184$	
≤ 13 years	124 (67)
>13 years	60 (33)
Occupation, $n = 255$	
Student	128 (50)
Employed	65 (25)
Unemployed	62 (24)
Vulnerability factors, $n = 264^a$	
No vulnerability factor	95 (36)
Physical or cognitive disability	25 (9)
History of alcohol/drug abuse	35 (13)
History of mental health problems	117 (44)
Previous sexual assault(s)	105 (40)
Alcohol consumption, $n = 257$	
No intake	35 (14)
Intake of <5 units	50 (19)
Intake of ≥5 units	172 (67)
Voluntary intake of other medications/drugs, $n = 264^a$	
Benzodiazepines and/or benzodiazepine-like drugs	23 (9)
Cannabinoids	9(3)
Opioids	5(2)
Central stimulants	14 (5)
Other medications	51 (19)
No intake/missing <sup>b</sup>	188 (71)
Suspected proactive drug-facilitated sexual assault, $n = 263$	
No	195 (74)
Yes	57 (22)
Uncertain information	11 (4)

More than one category were reported by a number of patients.

while 97 (37%) had no recollection of the sexual acts. In total, 154 cases (64%) were reported to the police.

The median time interval from assault to urine/blood sample collection was 12.5 h (mean 29.6 h, range one hour to 16 days). In total, 128 (48%) arrived at the SAC within 12 h and 238 (90%) within 72 h.

#### 3.3. Findings of ethanol and drugs in urine and blood

Fig. 1 and Table 2 show findings of ethanol and drugs in urine and/or blood specimens.

A total of 50 patients (19%) tested positive for at least one drug other than ethanol in urine and/or blood; one substance was detected in 31, while two or more substances were detected in 19 patients. For drugs other than ethanol, the time from assault to sampling did not influence the rate of positive tests.

Table 3 gives an overview of the drugs other than ethanol found in serum and/or urine and the range of concentrations in the serum samples. None tested positive for GHB or Ketamine. The 154 policereported cases did not differ from the total material of cases with regard to the distribution of positive tests.

#### 3.4. Patients suspecting proactive DFSA

Among the 57 patients suspecting proactive DFSA, 22 tested negative, 22 were positive for ethanol only, while 13 were positive for at least one drug other than ethanol (eight positive for drug only. five positive for both ethanol and drug). The frequency of positive findings was similar for the group of patients not suspecting proactive DFSA. The number of positive cases for each drug group among the 13 drug positive patients suspecting proactive DFSA is shown in Table 3, right column. Among these, seven patients had drug findings that could not be explained by self-reported voluntary intake; five were positive for benzodiazepines (one for clonazepam, four for diazepam and/or oxazepam), one was positive for opioids (morphine and oxycodone), two were positive for cannabis, and four were positive for amphetamines (some tested positive for more than one drug). In addition, two patients had unexpectedly high concentrations of the drugs they had voluntarily ingested; one case with flunitrazepam and one case with zopiclone.

Among the 57 patients suspecting proactive DFSA, only three did not report intake of alcohol/drug(s), while 36 reported intake of alcohol only, 17 reported intake of alcohol and drug(s) and one reported intake of drug(s) only. The proportions were similar to those in the group not suspecting proactive DFSA ( $X^2 = 6.8$ , df = 3, p = 0.080).

Table 2 Overview of drugs found in blood and/or urine from 264 female patients attending the Sexual Assault Center between July 1, 2003 and December 31, 2010.

Substance or substance combinations	Number (%)
Ethanol only	105 (40)
Benzodiazepines only	13 (4.9)
Other central depressants only <sup>a</sup>	7 (2.7)
Ethanol + benzodiazepines	9 (3.4)
Ethanol + other central depressants <sup>b</sup>	4 (1.5)
Benzodiazepines + opioids	3 (1.1)
Central stimulants, with or without other drugs <sup>c</sup>	14 (5.3)
Negative toxicological test	109 (41)
Total	264 (100)

<sup>&</sup>lt;sup>a</sup> Cannabis (n = 6), opioids (n = 1).

<sup>&</sup>lt;sup>b</sup> Uncertain number of cases with missing information vs. no intake of medications/drugs other than alcohol,

Calinatis (n=0), opinios (n=1), because (n=1), cannabis + opioid (n=1).

Central stimulants (CS) only (n=5), CS + benzodiazepines (n=3), CS + cannabis (n=2), CS + benzodiazepines/opioids/cannabis (n=2), CS + benzodiazepines/ opioids (n = 1), CS + ethanol (n = 1).

Table 3

Overview of drugs other than ethanol found in serum and/or urine, range of concentrations determined in serum, self-reported voluntary intake and the number of cases suspecting proactive drug-facilitated sexual assault (DFSA). The results are based upon 50 positive tests from a total of 264 female patients attending the Sexual Assault Center between July 1, 2003 and December 31, 2010.

Substance	Urine and/or serum positive, <i>n</i>	Range of serum concentrations (ng/mL)	Self-reported intake, n among positive	Suspecting proactive DFSA $^{a}$ , $n$ among positive
Benzodiazepines and/or	31/256 (12%)		21/31	8/31
benzodiazepine-like drugs				
Alprazolam	1/253 (0.4%)	15	1/1	0/1
Clonazepam	8/253 (3.2%)	9-152	7/8	2/8
Diazepam/desmethyldiazepam	8/254 (3.1%)	40-2300	2/8	3/8
Flunitrazepam	2/255 (0.8%)	6 <sup>b</sup>	1/2	1/2
Nitrazepam	2/254 (0.8%)	60°	1/2	1/2
Oxazepam	18/254 (7.1%)	6-2276	10/18	5/18
Zolpidem	1/187 (0.5%)	93	1/1	0/1
Zopiclone	5/227 (2.2%)	9-100	3/5	1/5
Meprobamate	1/220 (0.5%)	327	0/1	0/1
Cannabinoids	13/239 (5.4%)		4/13	2/13
Cannabis (THC)	13/239 (5.4%)	0.50-6.10	4/13	2/13
Opioids	9/251 (3.6%)		4/9	1/9
Codeine	6/250 (2.4%)	3-494	4/6	0/6
Methadone	1/231 (0.4%)		1/1	0/1
Morphine <sup>d</sup>	5/250 (2.0%)	0.05-50 <sup>e</sup>	4/5	1/5
Oxycodone	2/216 (0.9%)	16 <sup>f</sup>	0/2	1/2
Central stimulants	14/244 (5.7%)		7/14	8/14
Amphetamine	9/244 (3.7%)	40-353	3/9	6/9
Methamphetamine	7/244 (2.9%)	8-270	4/7	5/7
Methylphenidate	4/185 (2.2%)		3/4	1/4
Total	50/264 (19%)		33/50	13/50

- <sup>a</sup> Includes some cases admitting voluntary intake, see text for details.
- <sup>b</sup> Both positive cases had the same concentration in serum.
- <sup>c</sup> Only one of the two serum samples was analyzed for nitrazepam.
- <sup>d</sup> Including the metabolites morphine 3-glucuronide and morphine 6-glucuronide.
- e Range of serum concentration for morphine only.
- f Only one of the two tested positive in serum.

#### 3.5. Ethanol positive cases

In a subsample of 120 patients tested for ethanol within 12 h after the assault, 102 (85%) were positive. Among these, median time from assault to toxicological sampling was 4.4 h (mean 5.1 h, range 1.0-11.8 h).

Some of the clinical characteristics of those testing positive and negative for ethanol, respectively, are presented in Table 4. Patients testing positive for ethanol more often reported a public place of assault, a stranger assailant and more than one assailant. Patients who tested negative for ethanol more often reported vulnerability factors.

We found no differences between the two groups regarding patient age, other background characteristics, suspicion of proactive DFSA or reporting the event to the police. Adjusting for patients' age and interval from assault to toxicological sampling did not alter any of the relations stated above.

Estimated median BAC at the time of sampling was 1.20 g/L (mean 1.19 g/L, range 0.20–2.80 g/L). Back-calculation based upon the 102 ethanol positive samples resulted in a median estimated BAC at the time of assault of 1.87 g/L (mean 1.92 g/L, range 0.44–3.95 g/L).

There was a positive relationship between estimated BAC at the time of assault and patient age (t = 3.14, p = 0.002), but not with assailant age (t = 1.24, p = 0.22).

The population of patients tested for ethanol within 12 h after the assault was divided in tertiles on the basis of estimated BAC at the time of assault. There were significant associations between increasing BAC levels and reported intake of five or more alcohol units ( $X^2 = 13.7$ , df = 2, p = 0.001), suspicion of proactive DFSA ( $X^2 = 7.2$ , df = 2, p = 0.027), the assailant being a stranger ( $X^2 = 12.3$ , df = 2, p = 0.002), and a clinical impression of inebriation on examination ( $X^2 = 21.6$ , df = 2, p < 0.001).

#### 4. Discussion

The principal findings in the present study are that among the 264 patients included, 155 (59%) tested positive for ethanol and/or drugs; 105 (40%) for ethanol only and 50 (19%) for one or more drugs other than ethanol. In total, 57 patients (22%) suspected proactive DFSA, but only five had findings of sedative drugs that could not be explained by self-reported voluntary intake. No case could unequivocally be attributed to proactive DFSA. Finally, patients testing positive for ethanol more often reported a public place of assault and a stranger assailant, and the higher estimated BAC at the time of the assault, the higher the frequency of suspecting proactive DFSA.

The finding that 59% tested positive for ethanol and/or drugs is in accordance with the results from police-initiated studies in the USA, the UK, Sweden and the Netherlands, with percentages varying between 61 and 73.8.11,13.23 A SAC-based study from Canada found a prevalence of positive tests of 76%.24 Although the numbers are relatively homogenous between studies, inclusion criteria for the collection of samples varied widely, from including all sexual crimes irrespective of any claims of DFSA, 23 via including only those who "believed that drugs were involved". 11,12 to including cases with a suspicion of proactive DFSA only. 8.9,13,24 In the present study, there were minimal differences in the prevalence of alcohol/drugs between police-reporting patients and the total group of patients attending the SAC.

In our study, 19% of the patients tested positive for one or more drugs other than ethanol, similar to findings in other Scandinavian studies, <sup>23,25,26</sup> but lower than in studies conducted in other parts of the Western world. <sup>8,13,24</sup> This probably reflects the relatively low prevalence of recreational drug use in Scandinavia as compared to other Western countries. <sup>27–29</sup> Discrepancies between studies may in part be due to differing selection of analyzed substances. <sup>8,11,13,14,24</sup>

**Table 4**Background and assault characteristics and clinical findings by ethanol results among 120 female patients attending the Sexual Assault Center between July 1, 2003 and December 31, 2010 who were tested for ethanol in urine and/or serum within 12 h after the assault.

Variable	Ethanol positive,	Ethanol negative,	р
	n = 102, n (%)	n = 18, n (%)	
Background characteristics			
Patient age, $n = 120$			
12-17 years	15 (15)	4 (22)	
18-24 years	64 (63)	7 (39)	
≥25 years	23 (23)	7 (39)	$0.16^{a}$
Vulnerability factors, $n = 120$	)		
Yes	66 (65)	17 (94)	
No	36 (35)	1 (6)	$0.012^{b}$
Alcohol consumption, $n = 11$	8		
No intake	0	10 (59)	
Intake of <5 units	21 (21)	4 (24)	
Intake of $\geq 5$ units	80 (79)	3 (18)	0.0001a
Suspected proactive drug-fac	ilitated sexual assau	ılt, n = 115	
Yes	22 (23)	2 (11)	
No	75 (77)	16 (89)	0.29 <sup>c</sup>
Occupation, $n = 118$			
Employed/student	77 (76)	11 (65)	
Unemployed	24 (24)	6 (35)	0.38 <sup>c</sup>
Assault reported to the police			
Yes	65 (68)	10 (63)	
No	30 (32)	6 (38)	$0.64^{\rm b}$
Assault characteristics			
Type of sexual assault, $n = 11$	16		
Penetration	56 (57)	13 (77)	
No penetration/other acts	8 (8)	1 (6)	
No recollection	35 (35)	3 (18)	0.75 <sup>c,d</sup>
Physical violence, $n = 86$			
Yes	52 (73)	13 (87)	
No/verbal	19 (27)	2 (13)	0.32 <sup>c</sup>
Location of assault, $n = 110$	,	,	
Private	53 (57)	15 (88)	
Public	40 (43)	2 (12)	$0.015^{b}$
Victim/assailant relationship,		` '	
Known	63 (70)	16 (100)	
Stranger	27 (30)	0	0.011 <sup>c</sup>
More than one assailant, $n =$		•	0.011
Yes	19 (20)	0	
No	74 (80)	16 (100)	0.048 <sup>c</sup>
Assailant origin, $n = 91$	()	()	
Western	55 (72)	13 (87)	
Non-western	21 (28)	2 (13)	0.27 <sup>c</sup>
Time of day of assault, $n = 12$		- ()	
7 a.m. – midnight	20 (20)	12 (67)	
Midnight – 7 a.m.	82 (80)	6 (33)	0.0002c
Clinical findings	02 (00)	0 (33)	0.0002
Clinically intoxicated, $n = 110$	6		
Yes	68 (69)	2 (12)	
No No	31 (31)	15 (88)	0.0001 <sup>b</sup>
Extragenital injury, $n = 114$	51 (51)	.5 (66)	0.0001
Yes	62 (65)	9 (50)	
No	34 (35)	9 (50)	0.24 <sup>b</sup>
Anogenital injury, $n = 108$	3. (33)	5 (50)	J.L-1
Yes	28 (31)	5 (29)	
No	63 (69)	12 (71)	0.95 <sup>c</sup>
110	05 (05)	12 (/1)	0.33

- <sup>a</sup> Kruskal Wallis test, df = 2.
- b Chi-square test, df = 1.
- <sup>c</sup> Exact unconditional test.
- $^{
  m d}$  Given *p*-value for penetration vs. no penetration/other acts by alcohol, n=78.

In addition, some studies include blood tests only, thereby narrowing the time window for the detection of substances and decreasing the number of positive tests compared to urinary testing. We analyzed both urine and blood (serum) when available, and included a considerable number of medicinal and recreational drugs, i.a. those known or suspected being used in DFSA. We did not include antidepressants, antipsychotics, sedating antihistamines or other, non-sedative, therapeutic drugs. However, as

these drugs are less likely to be involved in DFSA and would rather be expected to be used therapeutically in these populations, we argue that it is more appropriate to exclude such drugs than to include them.

We found central stimulants in 6% of the patients, whereas cannabinoids were detected in 5%. Central stimulants are probably of low relevance in cases of proactive DFSA as they do not have sedative effects, and a positive test for cannabinoids in urine does not necessarily indicate a recent intake, as the detection window can be several weeks.

Benzodiazepines and related agents (zopiclone, zolpidem) are probably more relevant in proactive DFSA, and their sedative and amnesic effects may be augmented by ethanol. We found that benzodiazepines and related agents formed the most prevalent drug group with a frequency of 12%; a proportion that is equivalent to what have been found by others, <sup>8,12,13,23,25</sup> but far less than the 82% reported among more selected cases of alleged chemical submission (of which 50% were proactive DFSAs) from France. <sup>30</sup> In two thirds of our cases positive for benzodiazepines and related agents, patients reported voluntary intake of the drug.

We found opioids in 4%, mainly the weak opioid codeine and its metabolite morphine. Although codeine is sedating, it is widely used as a painkiller in Norway, indicating that this drug could have been ingested as an analgesic also after the assault.

In many cases, there was a relatively long time interval from the assault until the sample was obtained. In these cases, we may have been unable to detect intake of short-acting drugs, such as GHB. In other DFSA case series from the last ten years, less than 2% of the tests have been positive for GHB, <sup>813,14,24</sup> but also in these studies the time intervals from assault to sampling varied considerably. Thus, the true prevalence of GHB intake in cases of sexual assault is basically unknown.

As many as 22% of the patients suspected proactive DFSA; a relatively large increase from 7% in the early nineties and 17% some ten years ago at our SAC.<sup>31,32</sup> Such an increase was also seen in Canada during the nineties, up to 23% in 1999.<sup>33</sup> This pattern most likely reflects a growing awareness of the phenomenon, e.g. promoted by coverage in media. Other studies from Western SACs report rates of suspected proactive DFSA ranging from 3% in France<sup>34</sup> via 12% in Denmark<sup>25</sup> to 21% in a recent study from Canada.<sup>2</sup> In an Australian study, 18% of the cases were defined as suspected proactive DFSA by the authors, but only 5% of the victims themselves addressed this suspicion.<sup>6</sup> Inhomogeneous inclusion criteria make a direct comparison difficult. We chose to use the relatively strict definition of (self-reported) proactive DFSA as recommended in the recent Canadian study.<sup>2</sup>

In two patients suspecting proactive DFSA, one reporting voluntary intake of flunitrazepam, and the other reporting voluntary intake of zopiclone, the blood drug concentrations were unexpectedly high. Both had combined intakes of alcohol and drugs, and reported periods of memory loss. In theory, a woman may be subjected to proactive DFSA with a substance also used voluntarily, although this seems rather unlikely. As we could not exclude voluntary drug intake after the assault, we conclude that the suspicion of proactive DFSA could not be substantiated in these two cases.

Among those suspecting proactive DFSA, sedative drugs (clonazepam, diazepam and/or oxazepam) not reported being taken voluntarily were detected in five. These patients either gave a history of alcohol/drug abuse or anxiety disorder, making recent voluntary intake of one or more of these drugs likely. We thus have concluded that none of the cases could unequivocally be attributed to proactive DFSA.

The frequency of verified proactive DFSA is low also in other studies. In a large British case series<sup>8</sup> the authors concluded that

only 2% of more than 1000 cases could be attributed to proactive DFSA. A recent Danish study found that among 20 patients suspecting proactive DFSA, four had a positive blood test for one or more sedative drugs not reported to be taken voluntarily.<sup>25</sup> Relatively high proportions of unexpected drugs were found in studies from Australia and Canada; 49% and 20%, respectively.<sup>6,24</sup> However, the ascertainment of the self-reporting of voluntary intake in these studies is unclear, and it has been claimed that self-reported intake of drugs is unreliable.<sup>35</sup> In the present study, we have tried to refine the methodology by asking the patients a second time after a positive toxicological finding whether they nevertheless might have ingested the drug voluntarily, although they did not mention that intake at the first visit.

We found a high rate (86%) of self-reported intake of alcohol, whereas slightly less than half of all patients tested positive for ethanol. This finding is comparable to the results from other studies. 6,7,9,11,13,14,24,25 The discrepancy between self-reported alcohol intake and analytical findings could be explained by the short detection time of ethanol in biological samples. When we restricted the sample to patients arriving within 12 h of the assault, 85% of the patients tested positive, which is in good accordance with the rate of self-reported intake. Urine markers of alcohol intake with longer detection times, such as ethyl glucuronide and ethyl sulfate, have been shown to be more suitable than ethanol to confirm alcohol intake when the time span from assault to sampling exceeds 12 h, 36 and should be further explored among female sexual assault victims

We estimated a median BAC at the time of assault to 1.87 g/L. Such back-calculations are inaccurate, both because the metabolic rate of ethanol is subjected to substantial inter-individual variability and because the time of the assault may be inaccurately reported and does not always coincide with cessation of alcohol intake. He even when taking these limitations into account, we consider that back-calculation gives a reasonable impression of the actual BAC levels that could occur in conjunction with sexual assaults. The result is in accordance with findings from other studies, 6,7,9,13,14 and is consistent with the fact that 77% of the women who ingested alcohol in the current study admitted to drinking more than five units. It is also well established that females have a lower body water content than males and hence will achieve a higher blood ethanol concentration after equal intake.

A high estimated BAC at the time of assault was associated with more frequent suspicions of proactive DFSA. In a study from Canada, a higher proportion reported alcohol intake among those suspecting proactive DFSA.<sup>2</sup> Although it is possible that drinks could have been spiked with alcohol by others, self-reported intake of alcohol is in many cases considerable, indicating that the women may have underestimated the effect of voluntary alcohol consumption, and rather tend to suspect proactive DFSA.

A striking finding was that ethanol positive patients more often reported being assaulted by a stranger. The police in the capital Oslo has shown that more than half of those reporting stranger rapes were under the influence of alcohol.<sup>3</sup> In a SAC-based study from Sweden, alcohol intake was also more common in cases where the assailant was a stranger or an acquaintance, in contrast to an intimate partner.<sup>37</sup> It is reasonable to believe that women with reduced consciousness and impaired ability to identify potentially risky situations due to excessive alcohol intake may more easily be selected as victims at public places by would-be stranger assailants.

In addition to the strengths and weaknesses already discussed, some more general issues should be addressed. One of the strengths is the close access to clinical variables and medical records, making it possible to study associations and relationships in detail. The design enabled us directly to compare self-reported intake of alcohol and drugs with toxicological findings and to

characterize differences between ethanol positive and negative cases for an array of variables.

As the present study represents an unselected female population attending a SAC, it would reflect the "true" prevalence of alcohol/drug findings among this group of patients, at least in the catchment area studied. However, many victims of sexual assault do not seek medical care, and our results are therefore not necessarily applicable to victims of sexual assault in general. Moreover, generalization of our findings to other countries should be done with caution. Both the populations subjected to sexual assault and those seeking help may differ considerably between countries, and the indications for performing a toxicological test may vary.

Data on voluntary drug intake may be incomplete, especially for drugs with long detection times which may have been ingested several days before the assault. Although we presented the toxicological test result to the patients at a follow-up visit, they may still hesitate to admit use of illicit or non-prescribed drugs, e.g. in case of a police investigation. Due to a fear of being blamed for illegal drug use, the patient might have found it safer to report that the drug was covertly administered to her. In our SAC, however, the results of urine and/or blood tests collected for the purpose of detection of surreptitious drugging cannot be used to initiate any legal sanctions against her. Still, there is always a possibility that information about the assault given solely by the victim (or her companions) may be incomplete, false or exaggerated. <sup>16</sup>

Our study is also limited by a relatively small sample size, especially concerning cases of suspected proactive DFSA. Comparisons between ethanol positive and ethanol negative cases may have been subjected to type 2 statistical errors, and comparisons between drug positive and drug negative cases were not possible due to the lack of power. Even so, most other studies containing information on voluntary drug consumption have included even fewer subjects. 1.6,24,25,35

#### 5. Conclusion

Ethanol, often in high concentrations, as well as sedative drugs or drugs of abuse were frequently detected in samples collected from victims of sexual assault. As very few of the patients suspecting proactive DFSA had findings of sedative drugs not explained by voluntary intake, it seems that opportunistic DFSA rather than proactive DFSA dominate in our material.

We believe that victims of sexual assault should have easy and fast access to emergency health care with a trained staff, and should be encouraged to seek immediate help. Toxicological screening should be routinely offered to achieve a comprehensive assessment in each individual case. Based on the current study, it should be communicated that the perceived danger of surreptitious drugging with so-called "date rape drugs" such as GHB and flunitrazepam is most likely overrated, whereas the dangers of voluntary excessive intake of alcohol (and drugs) should be emphasized more.

As population data indicate that sexual assailants are influenced by alcohol/drugs even more often than the victims, <sup>38</sup> we suggest that future research should explore alcohol and drug findings among the assailants in a police setting.

Conflict of interest

None of the authors have any conflict of interest by publishing this article.

Funding

Cecilie Therese Hagemann received funding from the Norwegian Extra Foundation for Health and Rehabilitation through The Norwegian Women's Public Health Association, as well as from the Liaison Committee between the Central Norway Regional Health Authority (Helse Midt-Norge) and the Norwegian University of Science and Technology. The work of the other authors was carried out solely with institutional funding.

The role of the funding sources

The funding sources have no involvement in the study design, data collection, data analysis and interpretation, in writing of manuscript or the decision to submit, except for approving the initial and revised study protocols.

Ethical approval None declared.

#### Appendix A. Supplementary data

Supplementary data related to this article can be found at http:// dx.doi.org/10.1016/j.jflm.2013.05.005.

#### References

- 1. Gee D, Owen P, McLean I, Brentnall K, Thundercloud C. Operation MATISSE: investigating drug facilitated sexual assault, London: The Association of Chief Police Officers (ACPO); 2006.
- 2. Du Mont J, Macdonald S, Rotbard N, Asllani E, Bainbridge D, Cohen MM. Factors associated with suspected drug-facilitated sexual assault. *Can Med A*: 2009;**180**:513—9.
- 3. Sætre M, Grytdal V. Voldtekt i den globale byen Endringer i anmeldte voldtekter
- og Seksualkultur i Oslo. Oslo: Strategisk stab, Oslo Politidistrikt; 2011.
  Gisladottir A, Gudmundsdottir B, Gudmundsdottir R, Jonsdottir E, Gudjonsdottir GR, Kristjansson M, et al. Increased attendance rates and altered characteristics of sexual violence. *Acta Obstet Gynecol Scand* 2012;**91**:134–42.

  5. Nesvold H, Worm AM, Vala U, Agnarsdottir G. Different Nordic facilities for
- victims of sexual assault: a comparative study. *Acta Obstetricia Et Gynecologica Scandinavica* 2005;**84**:177–83.

  6. Hurley M, Parker H, Wells DL. The epidemiology of drug facilitated sexual as-
- Hurley M, Parker H, Wells DL. The epidemiology of drug facilitated sexual assault. J Clin Forensic Med 2006;13:181–5.

  Scott-Ham M, Burton FC. A study of blood and urine alcohol concentrations in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 2006;13:107–11.

  Scott-Ham M, Burton FC. Toxicological findings in cases of alleged drug-
- facilitated sexual assault in the United Kingdom over a 3-year period. *J Clin Forensic Med* 2005;**12**:175–86.

  9. Hall J, Goodall EA, Moore T. Alleged drug facilitated sexual assault (DFSA) in
- Northern Ireland from 1999 to 2005. A study of blood alcohol levels. J Forensic Leg Med 2008;15:497–504.
- 10. ElSohly MA, Salamone SJ. Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol 1999;23:141–6.
  11. Hindmarch I, ElSohly M, Gambles J, Salamone S. Forensic urinalysis of drug use in cases of alleged sexual assault. J Clin Forensic Med 2001;8:197–205.
  12. Slaughter L. Involvement of drugs in sexual assault. J Reprod Med 2000;45:
- 425-30.
- 425–30.

  3. Bosman JJ, Verschraagen M, Lusthof KJ. Toxicological findings in cases of sexual assault in the Netherlands. *J Forensic Sci* 2011;**56**:1562–8.

  4. Jones AW, Kugelberg FC, Holmgren A, Ahlner J. Occurrence of ethanol and other drugs in blood and urine specimens from female victims of alleged sexual assault. *Forensic Sci Int* 2008;**181**:40–6.
- Hagemann CT, Stene LE, Myhre AK, Ormstad K, Schei B. Impact of medico-legal findings on charge filing in cases of rape in adult women. *Acta Obstet Gynecol*
- Scand 2011;90:1218—24.
  Stene LE, Ormstad K, Schei B. Implementation of medical examination and forensic analyses in the investigation of sexual assaults against adult women:

- a retrospective study of police files and medical journals. Forensic Sci Int 2010:199:79-84.
- 17. Creighton CD, Jones AC. Psychological profiles of adult sexual assault victims. I Forensic Leg Med 2012;19:35-9.
- Fakta om alkohol. Nasjonalt folkehelseinstitutt. Available: http://www.fhi.no/artikler?id=42834; 2008 [accessed 16.10.12].
   White C, McLean I. Adolescent complainants of sexual assault; injury patterns
- in virgin and non-virgin groups. *J Clin Forensic Med* 2006;**13**:172–80.

  20. Astrup BS, Ravn P, Lauritsen J, Thomsen JL. Nature, frequency and duration of genital lesions after consensual sexual intercourse - implications for legal proceedings. Forensic Sci Int 2012;219:50–6.

  21. Jones AW. Reference limits for urine/blood ratios of ethanol in two successive
- voids from drinking drivers. J Anal Toxicol 2002;26:333–9.

  Recommended minimum performance limits for common DFSA drugs and metabolites in urine samples. Available: http://www.soft-tox.org/images/stories/ PDF/SOFT\_DFSA\_Rec\_Det\_Limits\_3-2012.pdf; 2012 [accessed 16.10.12].

  23. Jones AW, Holmgren A, Ahlner J. Toxicological analysis of blood and urine
- samples from female victims of alleged sexual assault, Clin Toxicology (Philadelphia, Pa) 2012;50:555-61.

  24. Du Mont J, Macdonald S, Rotbard N, Bainbridge D, Asllani E, Smith N, et al.
- Drug-facilitated sexual assault in Ontario, Canada: toxicological and DNA findings. J Forensic Leg Med 2010;17:333—8.

  Birkler RI, Telving R, Ingemann-Hansen O, Charles AV, Johannsen M,
- Andreasen MF. Screening analysis for medicinal drugs and drugs of abuse in whole blood using ultra-performance liquid chromatography time-of-flight mass spectrometry (UPLC-TOF-MS) — toxicological findings in cases of alleged sexual assault. Forensic Sci Int 2012;222:154–61.
- Bogstrand ST, Normann PT, Rossow I, Larsen M, Morland J, Ekeberg O. Prevalence of alcohol and other substances of abuse among injured patients in a Norwegian emergency department. *Drug Alcohol Depend* 2011;**117**:
- Narkotikasituasjonen i Europa 2010. Oslo: Norwegian Institute for Alcohol and Drug Research. Available: http://www.sirus.no/filestore/Import\_vedlegg/ rsrapport\_10\_fulltekst2.pdf; 2010 [accessed 16.10.12]. Hibell B. The 2007 European school survey project on alcohol and other drugs (ESPAD) report, Sammendrag: Rusmiddelbruk blant skoleelever i 35 europeiske
- land. Stockholm: ESPAD; 2009. Vedøy TF, Skretting A. Ungdom og rusmidler. Resultater fra spørreskjemaundersøkelser 1968–2008. Oslo: Norwegian Institute for Alcohol and Drug Research; 2009.
- 30. Diezzar S. Ouestel F. Burin E. Dally S. Chemical submission: results of 4-year French inquiry. Int J Leg Med 2009;123:213–9.

  Schei B, Muus KM, Moen MH. Medisinske og rettslige aspekter av voldtekt.
- Henvendelser til voldtektsteamet ved Regionsykehuset i Trondheim i perioden 1989–92. *Tidsskr Nor Laegeforen* 1995;**115**:30–3. 32. Haugen K, Slungard A, Schei B. Seksuelle overgrep mot kvinner skademøn-
- ster og relasjon mellom offer og overgriper. Tidsskr Nor Laegeforen 2005;**125**:
- 33. McGregor MJ, Lipowska M, Shah S, Du Mont J, De Siato C. An exploratory analysis of suspected drug-facilitated sexual assault seen in a hospital emergency department. Womens Health 2003;37:71–80.
- Saint-Martin P. Bouvssy M. O'Byrne P. Analysis of 756 cases of sexual assault in medico-legal findings and judicial outcomes. Med Sci Law 2007;**47**:315-24.
- Juhascik MP, Negrusz A, Faugno D, Ledray L, Greene P, Lindner A, et al. An estimate of the proportion of drug-facilitation of sexual assault in four U.S. localities. *J Forensic Sci* 2007;**52**:1396–400.
- Hoiseth G, Bernard JP, Stephanson N, Normann PT, Christophersen AS, Morland J, et al. Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5-HIAA in a controlled drinking experiment. Alcohol Alcohol 2008;43:
- 37. Moller AS, Backstrom T, Sondergaard HP, Helstrom L. Patterns of injury and reported violence depending on relationship to assailant in female Swedish sexual assault victims. J Interpers Violence 2012;**27**:3131–48.
- 38. Busch NB, Bell H, DiNitto DM, Neff JA. A health survey of Texans: a focus on sexual assault. Institute on Domestic Violence & Sexual Assault, The University of Texas at Austin; 2003.

Supplementary Table 1
List of substances tested in urine with limits of detection. If metabolites were analyzed, these are given in parentheses. Unless otherwise stated, the substances were analyzed by liquid chromatography/mass

Substance	Limit of detection
Alcohols	
Ethanol <sup>a</sup>	0.1/0.3 g/L <sup>a</sup>
Benzodiazepines and benzodiazepine-like drugs	
Alprazolam (α-OH-alprazolam)	100 ng/mL
Clonazepam (7-amino-clonazepam)	100 ng/mL
Diazepam (desmethyldiazepam)	100 ng/mL
Flunitrazepam (7-amino-flunitrazepam)	100 ng/mL
Nitrazepam (7-amino-nitrazepam)	100 ng/mL
Oxazepam	100 ng/mL
Zolpidem	100 ng/mL
Zopiclone	100 ng/mL
Carisoprodol	100 ng/mL
Meprobamate	100 ng/mL
Cannabinoids	
Cannabis ( $\Delta^9$ -tetrahydrocannabinol-carboxylic acid)	30 ng/mL
	30 lig/IIIL
Opioids	
Buprenorphine	5 ng/mL
Codeine	100 ng/mL
Dextropropoxyphene	100 ng/mL
Ethylmorphine	100 ng/mL
Fentanyl	10 ng/mL
Methadone	100 ng/mL
Morphine	300 ng/mL
Oxycodone Pethidine	100 ng/mL
Tramadol	100 ng/mL 100 ng/mL
Trainador	100 lig/IIIL
Central stimulants	
Amphetamine	100 ng/mL
Cocaine (benzoylecgonine)	100 ng/mL
Methamphetamine	100 ng/mL
3,4-methylenedioxyamphetamine (MDA)	100 ng/mL
3,4-methylenedioxymethamphetamine (MDMA; ecstasy)	100 ng/mL
Methylphenidate	100 ng/mL
Other	
Barbiturates <sup>b</sup>	1000 ng/mL <sup>c</sup>
Gamma-hydroxybutyric acid (GHB) <sup>d</sup>	10 μg/mL
Ketamine	100 ng/mL
Lysergic acid diethylamide (LSD) <sup>b</sup>	0.5 ng/mL <sup>b</sup>
Phencyclidine (PCP)	10 ng/mL

<sup>&</sup>lt;sup>a</sup> Ethanol was determined by gas chromatography/mass (GC/MS) spectrometry until 2009 (limit of detection 0.3 g/L), and by an immunological method from 2009 onwards (limit of detection 0.1 g/L)

<sup>b</sup> LSD and barbiturates were determined by an immunological method

<sup>c</sup> The limit of detection for barbiturates are based on secobarbital, with differing and somewhat higher limits of detection for other barbiturates depending on their degree of cross-reactivity

<sup>d</sup> GHB was determined by GC/MS

Supplementary Table 2
Assault/assailant characteristics and clinical findings among 264 female patients attending the Sexual Assault Center between July 1, 2003 and December 31, 2010 who were tested for alcohol/drugs in urine and/or blood.

December 31, 2010 who were tested for alcohol/drugs in urine and/or blood Characteristics	Number (%)
	× /
Type of sexual assault, $^{a} n = 259$	
Penile-vaginal penetration	134 (51)
Penile-anal penetration	20 (8)
Fellatio (penile-oral penetration)	32 (12)
Object inserted in vagina and/or anus	5 (2)
Non-penetrative/other sexual acts	20 (8)
No recollection	97 (37)
Physical violence, $n = 174$	
None/verbal	52 (30)
Light/moderate	110 (63)
Severe	12 (7)
Location of assault, $n = 243$	
Private	160 (66)
Public	83 (34)
	30 (C 1)
Victim/assailant relationship, $n = 235$	11.63
Partner	11 (5)
Family	5 (2)
Acquaintance	94 (40)
Casual acquaintance	84 (36)
Stranger	41 (17)
More than one assailant, $n = 239$	
Yes	37 (15)
No	202 (85)
Assailant age, years (median, mean, range), $n = 192$	26, 29, 15 – 67
Assailant origin, $n = 207$	
Norwegian/Western	149 (72)
Non-Western	58 (28)
Time of the day of assault, $n = 256$	
Between 7 a.m. and midnight	69 (27)
Between midnight and 7 a.m.	187 (73)
between initialight and / a.m.	107 (73)
Anogenital injury, $n = 241$	
Yes	59 (24)
No	182 (76)
Extragenital injury, $n = 255$	
Serious	8 (3)
Minor/moderate	169 (66)
No	78 (31)
Emotional status, $n = 253$	
Emotively affected	187 (74)
Emotively affected  Emotively controlled	66 (26)
•	00 (20)
Clinically intoxicated, $^{b}$ $n = 124$	
Yes	73 (59)
No	51 (41)

 $<sup>^{\</sup>rm a}$  More than one type of sexual assault were reported by several patients  $^{\rm b}$  Among those 128 who attended within 12 h

Paper III

#### MAIN RESEARCH ARTICLE

## Impact of medico-legal findings on charge filing in cases of rape in adult women

CECILIE T. HAGEMANN<sup>1,2</sup>, LISE E. STENE<sup>1</sup>, ARNE K. MYHRE<sup>3</sup>, KARI ORMSTAD<sup>2,4</sup> & BERIT SCHEI<sup>1,2,3</sup>

<sup>1</sup>Department of Public Health and General Practice, Norwegian University of Science and Technology, <sup>2</sup>Department of Obstetrics and Gynecology, and <sup>3</sup>Resource Centre on Violence, Traumatic Stress and Suicide Prevention, St Olav's Hospital, Trondheim University Hospital, Trondheim, and <sup>4</sup>Institute of Forensic Medicine, Oslo University, Oslo, Norway

#### Key words

Anogenital injury, clinical forensic medicine, legal outcome, medico-legal evidence, rape, sexual assault, trace evidence

#### Correspondence

Cecilie Hagemann, Department of Public Health and General Practice, Norwegian University of Science and Technology (NTNU), NO-7489 Trondheim, Norway. E-mail: cecilie.hagemann@ntnu.no

#### Conflicts of interest

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Received: 1 June 2010 Accepted: 21 July 2011

DOI: 10.1111/j.1600-0412.2011.01246.x

#### Abstract

Objective. To assess the impact of the medical documentation and biological trace evidence in rape cases on the legal process. Design. Retrospective descriptive study. Setting and sample. Police-reported cases of rape of women ≥16 years old in the Norwegian county of Sør-Trøndelag from January 1997 to June 2003. Methods. Police data were merged with data from the Sexual Assault Center at St Olav's Hospital. Charged and non-charged cases were compared. Main Outcome Measures. Medico-legal findings and legal outcome. Results. A total of 185 police-reported cases were identified. Of the 101 cases examined at Sexual Assault Center, charges were filed in 18 cases. Extragenital injuries were documented in 49 women; five were life threatening. Anogenital injuries were documented in 14 women; eight had multiple anogenital injuries. Documentation of injuries was not associated with charge filing. In only 33% of the cases were swabs collected from women's genitals used as trace evidence by the police. When used, this increased the likelihood for charge filing. A DNA profile matching the suspect was identified in four of the 18 charged cases and in only one among the 54 non-charged cases. Conclusions. Half of the women had one or more documented injury. Only one-third of the trace evidence kits collected from the women's anogenital area were analyzed. The analysis of swabs was associated with charge filing, regardless of test results. Increased use of such medical evidence, especially in cases of stranger rape, may ensure women's rights and increase available information to the legal system.

#### Introduction

Increasing numbers of women report rape to the police. From 1997 to 2009 the numbers of police-reported rapes increased from 396 to 998 in Norway (1). However, there is an international as well as a national concern that conviction rates are low (2–6). There has been considerable political attention to increase the quality of healthcare services (7). Specialized units for victims of rape have been established. In Sør-Trøndelag, a sexual assault center (SAC) was established in 1989 at St Olav's Hospital. The service is accessible for 24 hours, seven days a week, and offers emergency medical care provided by a gynecologist/pediatrician (for minors) and trained nurses. All injuries are systematically documented. Biological trace evidence is routinely collected by multiple swabs taken from women's genitals as well as from other areas of the body on which the assailant might

have left traces such as semen, saliva, blood or epithelial cells. However, the gynecologist/pediatrician may not request the specimens to be analyzed, for instance, for the presence of sperm and DNA typing. The swabs are kept by the police, who then decide whether to request analysis by the Institute of Forensic Medicine in Oslo.

Little is known about the impact of injury documentation and results of trace evidence tests on the legal process (6,8). The aim of the study was to assess the impact on the legal process of the medical documentation and analysis of biological trace evidence in police-reported cases of rape.

#### **Material and methods**

All police-reported cases of rape and attempted rape of women (≥16 years of age) in Sør-Trøndelag, Norway between 1 January 1997 and 20 June 2003 were identified. Details of

the procedure are described elsewhere (9). Cases were selected based on codes according to the current Norwegian Penal Code (10). A person committing rape or attempted rape is defined as one who obtains sexual activity by means of violence or threats, or with any person who is unconscious or for any other reason incapable of resisting the act, or by means of violence or threats compels somebody to engage in sexual activity with another person, or to carry out similar acts with him- or herself. In addition to vaginal, anal and oral intercourse, touching of genitals, a man's exposed genitals being rubbed between a woman's thighs or buttocks or on her belly, masturbation, licking or sucking of genitals, or insertion of fingers or objects into the vagina or anus is defined as rape. Attempted rape is also punishable, but covered by another paragraph in the Norwegian Penal Code.

The following information was collected from police records: characteristics of the assault and assailant; analysis of trace evidence; and legal outcome. Legal outcome was classified according to the Norwegian Administration of Justice Act into the following four groups: charges filed; no suspect identified; charges not filed; and accusation unfounded. The last group includes cases in which the police concluded that no crime had been committed and cases in which the complaint was retracted.

If more than one assailant was reported, information regarding the most active of the assailants was recorded. The assailant was classified as mentally disordered or impaired if he was psychotic during the event, mentally retarded or considered at risk of repeating the offence. The relationship between woman and assailant was defined as partner (current or previous partner/husband/boyfriend), family member, acquaintance (assailant known >24 hours), casual acquaintance (assailant known <24 hours) or stranger (not previously known). Venues defined as private included the woman's, assailant's or other person's residence. Public venues included any public indoor or outdoor location or a vehicle. Physical violence was graded as severe (presence of weapon/attempted strangulation/fracture or internal injuries), light/moderate (holding/punch/kick) or none/verbal threats. If more than one category of violence was described, the answers were stated according to the above-mentioned order.

Penetrative assault included anal, vaginal or oral penetration. If more than one type of penetration was described, answers were ranked according to the above-mentioned order. Forced masturbation, attempted penetration, touching up/fondling and other sexual acts were classified as non-penetrative assaults. The sexual act was classified as unknown if the event had taken place while the woman was asleep, inebriated or unconscious.

Women's personal characteristics and objective findings were collected from the medical records and included age, education and occupational status, as well as psychosocial history. Reported alcohol consumption in relation to the assault was classified as no intake, intake of less than five units of alcohol and intake of five or more units of alcohol/heavily intoxicated; the last category included clinically intoxicated, with periods of amnesia and suspicion of being involuntarily drugged. Objective documentation upon SAC visit included emotional status and observed extragenital and anogenital injuries. Location, type and number of injuries were recorded. Extragenital injuries were classified as serious when evidence of attempted strangulation, head injury with concussion and stab/incision wounds were present, moderate when bruising of the head and neck could be expected to result in significant headache, lacerations requiring suture/dressing (11), bite marks and/or injection marks were present, and minor when erythema, swelling, bruises, abrasions, lacerations and/or suction marks were present. Cases with more than one type of injury were classified according to the most serious one. Anogenital injuries included tears, abrasions and bruises (ecchymoses/petechiae). Reported 'redness and/or swelling' was excluded. In the study period, gross visualization was the technique used for documentation of anogenital injuries.

The study was approved by the Regional Committee for Medical and Health Research Ethics. As the data set included police files, permission was also obtained from the Norwegian Director General of Public Prosecutions and the Advisory Board on Secrecy and Research. The merging of data was also approved by the Norwegian Data Inspectorate.

#### Statistical analysis

Variables were analyzed by descriptive statistics, and the relation between the outcome variable (charges filed) and the independent categorical variables was analyzed. Cases where no suspect was identified and cases classified by the police as accusation unfounded/complaint retracted were excluded. Data analysis was performed with SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). We used for categorical variables Pearson's  $\chi^2$  test, Fisher's exact test or Pearson's  $\chi^2$  test of heterogeneity. Significance was assumed if p < 0.05. Missing data were calculated, but excluded when statistical tests were performed. In some analyses, multivariable logistic regression was applied to adjust for time interval from assault to medical examination.

#### Results

A total number of 222 cases were identified in the police files. Male victims (n=8), minors  $(\le 16$  years of age, n=28) and unidentified victims (n=1) were excluded. For the remaining 185 women, information regarding 101 who had been medically examined at the SAC was also available from the healthcare system.

Table 1 shows women's age, assault- and assailant-related characteristics among all police-reported cases. Figure 1

**Table 1.** Assault- and assailant-related characteristics among all police-reported cases of rape and attempted rape, and by charge filing<sup>a</sup>, in Sør-Trøndelag, Norway, between January 1997 and June 2003.

Characteristics	Total reported N=185		Charges filed N=134	
	n (%)	Yes	No	
		n=30	n=104	
		n (%)	n (%)	
Woman's age				
16-17 years	48 (26)	7 (23)	24 (24)	
18–24 years	80 (43)	12 (40)	45 (43)	
25-34 years	32 (17)	5 (17)	18 (17)	
≥35 years	25 (14)	6 (20)	16 (15)	
Assault characteristics				
Woman-assailant relations	•			
Partner	22 (12)	2 (7)	17 (16)	
Family	2(1)	1 (3)	1(1)	
Acquaintance	82 (44)	18 (60)	56 (54)	
Casual acquaintance	32 (17)	3 (10)	18 (17)	
Stranger	41 (22)	6 (20)	9 (9)	
Missing	6 (3)	0	3 (3)	
Venue				
Private	118 (64)	19 (63)	78 (75)	
Public	64 (35)	11 (37)	24 (23)	
Missing	3 (2)	0	2(2)	
Physical violence				
None/verbal	43 (23)	7 (23)	29 (28)	
Light/moderate	109 (59)	19 (63)	55 (53)	
Severe	14 (8)	1 (3)	10 (10)	
Missing	19 (10)	3 (10)	10 (10)	
Type of sexual assault				
Vaginal penetration	103 (56)	13 (43)	67 (64)	
Anal penetration	8 (4)	0	6 (6)	
Oral penetration	3 (2)	2 (7)	1(1)	
Other sexual acts	46 (25)	11 (37)	18 (17)	
Missing	25 (14)	4 (13)	12 (12)	
Assailant characteristics				
Age groups				
≤24 years	47 (25)	13 (43)	28 (27)	
25–34 years	47 (25)	6 (20)	36 (35)	
≥35 years	51 (28)	11 (37)	38 (37)	
Missing	40 (22)	0	2(2)	
More than one assailant				
Yes	18 (10)	1 (3)	8 (8)	
No	164 (89)	29 (97)	96 (92)	
Missing	3 (2)	0	0	
Assumed origin				
Norwegian	127 (69)	28 (93)	82 (79)	
Non-Norwegian	33 (18)	2 (7)	21 (20)	
Missing	25 (14)	0	1(1)	
Mentally disordered/impai				
Yes	10 (5)	9 (30)	1(1)	
No	126 (68)	21 (70)	97 (93)	
Missing	49 (27)	0	6 (6)	
Assault-related alcohol cor	-			
Yes	90 (49)	24 (80)	58 (56)	
No	9 (5)	2 (7)	6 (6)	
Missing	86 (47)	4 (13)	40 (39)	

 $<sup>^{\</sup>rm a}$  Excluded cases with unknown assailant (  $n\!=\!37$  ), unfounded/withdrawn cases (  $n\!=\!13$  ) and missing outcome (  $n\!=\!1$  ).

outlines the legal outcome. Cases classified as 'charges not filed' include those where evidence was considered insufficient (n=101), one case classified as time barred and two cases in which the suspect was considered not legally responsible at the time of the crime. In a total of 30 cases charges were filed; 22 suspects were convicted. All reported assailants were male. Interrogation of the assailant was conducted in 136 cases. The majority of assailants confirmed sexual contact (n=81), and four admitted assault. The assailant being mentally disordered or impaired was associated with charge filing (p=0.0001). One single assailant was reported in 164 cases, two in 13 cases, and three or more in an additional five cases. Physical violence was described by 123 women; 14 of them reported severe violence, of whom nine reported attempted strangulation and five described the presence of a weapon. Reporting attempted penetration or other types of sexual acts was significantly associated with charge filing ( $\chi^2=5.7$ , p=0.017). However, neither having sustained physical violence nor the reporting of severe violence was associated with charge filing. Other characteristics in Table 1 were not significantly associated with charge filing in the total set of police cases.

Table 2 shows personal characteristics, documentation of injuries and results from trace evidence analysis among the 101 women medically examined at the SAC. Comparison of cases examined at the SAC in which charges were filed and not filed excluded 29 cases; 22 cases in which the assailant was unknown and seven cases assumed unfounded.

The number of extragenital injuries varied between none and 20 (median three); 15 had four or more injuries, while five women had 10 or more injuries. Most injuries were minor to moderate, but five women had sustained more serious injuries; four had signs of attempted strangulation, and one had been slashed by a knife. Injuries in the head/neck region were documented in 16 women, and at the trunk or extremities in 27. Among the latter, injuries on the ulnar side of a forearm were documented in two women, suggestive of self defense, while seven women were bruised on the inside of an upper thigh, probably from forced separation.

The documentation of any extragenital injury was not associated with charges being filed, even after adjusting for time interval from assault to medical examination.

Anogenital injuries ranged from none to 10 (median two); five were single site, four had two or three, while four had four or more anogenital injuries documented. Five injuries were located in the vestibulum, three in the posterior fourchette, three in the perianal area, two in the perineum, and one in each of the following areas: vagina, labia minora and labia majora. The most common type of anogenital injury was superficial tear/laceration (n=11); in three women abrasions were documented, and in one woman petechial hemorrhage. Among cases in which charges were filed, two of 18 had sustained more than one anogenital injury, compared with




Figure 1. Legal outcome among all police-reported cases of rape and attempted rape in the Norwegian county of Sør-Trøndelag from January 1997 to June 2003.

five in the 54 non-charged cases. Restricting the analysis to those reporting anal/vaginal penetrative assault or adjusting for time interval from assault to medical examination did not change this pattern.

Swabs were collected from 90 women. In the 30 cases where trace evidence was analyzed, swabs had been collected from the anogenital area in 28 cases and from both anogenital and extragenital locations (skin or mouth) in eight women, and oral samples were analyzed from two women. Trace evidence analysis was associated with charge filing ( $\chi^2=12.2$ , p=0.0001). In 26 of these cases the interval from assault to collection was  $\leq$ 24 hours ( $\chi^2$ =3.7, p=0.055; data not shown). Among the 72 SAC cases where an assailant was identified, the relationship between the assailant and the woman was known in 70. The trace evidence kits were analyzed in eight of 22 (36%) of the cases with casual acquaintance/stranger assailant, vs. 18 of 39 (46%) of the cases with partner/acquaintance assailant ( $\chi^2=0.55$ , p=0.46). We found no differences in women's age or in self-reported penetration regarding trace evidence analysis.

Spermatozoa were identified in 14 swabs collected from the anogenital area and in one collected from the woman's umbilicus, and in one case spermatozoa were identified both in

swabs collected from an anogenital site and from the umbilical area. Identification of spermatozoa was proportionally more common in cases where charges were filed; however, the difference was not statistically significant. Given a DNA profile matching the suspect, charges were filed in four cases, while in one case evidence of crime was considered insufficient.

#### **Discussion**

Most cases of rape did not lead to charge filing. Physical injuries were documented in a high proportion of women, but this was not associated with charges being filed. Police-requested analysis of swabs collected from the woman's body was associated with charge filing.

The strength of the study is the comprehensive data set based on both police files and medical records. Another strength is the long follow up, allowing for a final legal conclusion, as the legal process may take several years. Even though this study includes numerous cases collected over a long period, results regarding rare events may be hampered by type 2 statistical error, i.e. the inability to demonstrate significant associations where real differences exist. This is especially so

**Table 2.** Personal characteristics and medico-legal findings among 101 women who reported rape and attempted rape to the police and had undergone medical examination, and by charge filing<sup>a</sup>, in Sør-Trøndelag, Norway between January 1997 and June 2003.

Characteristics	Total N=101		ges filed =72
	n (%)	Yes	No
		n=18	n=54
		n (%)	n (%)
Interval between assault and medical example	mination		
≤24 hours	70 (69)	12 (67)	40 (74)
24–72 hours	18 (18)	0	11 (20)
>72 hours	11(11)	5 (28)	2(4)
Missing	2(2)	1(6)	1(2)
Alcohol intake at event			
No intake	9 (9)	1(6)	5 (9)
<5 units	24 (24)	5 (28)	13 (24)
≥5 units	44 (44)	8 (44)	24 (44)
Missing	24 (24)	4(22)	12 (22)
Psychosocial factors			
No	52 (52)	9 (50)	28 (52)
Physical/mental disability	12 (12)	4(22)	7 (13)
Prior or current psychiatric disorder	26 (26)	1(6)	14 (26)
Prior assault history	10(10)	3 (17)	5 (9)
Missing	1(1)	1(6)	0
Emotional state at examination			
Distressed (e.g. crying, shaking)	63 (62)	11 (61)	33 (61)
Calm, rational	16 (16)	4(22)	9 (17)
Missing	22 (22)	3 (17)	12 (22)
Extragenital injuries			
None	41 (41)	5 (28)	24 (44)
Minor	39 (39)	8 (44)	18 (33)
Moderate	5 (5)	2(11)	2(4)
Serious	5 (5)	2(11)	3 (6)
Missing	11 (11)	1(6)	7 (13)
Four or more extragenital injuries			
Yes	15 (15)	3 (17)	7 (13)
No	67 (66)	13 (72)	36 (67)
Missing	19 (19)	2(11)	11 (20)
Anogenital injuries			
Yes	14 (14)	2(11)	9 (17)
No	78 (77)	13 (72)	40 (74)
Missing	9 (9)	3 (17)	5 (9)
More than one anogenital injury			
Yes	8 (8)	2(11)	5 (9)
No	83 (82)	13 (72)	43 (80)
Missing	10 (10)	3 (17)	6 (11)
Trace evidence analyzed			
Yesb	30 (30)	12 (67)	14 (26)
No	59 (58)	3 (17)	34 (63)
Missingc	12 (12)	3 (17)	6 (11)
Spermatozoa detected			
Yes	16 (16)	7 (39)	7 (13)
No	13 (13)	5 (28)	6 (11)
Missing	72 (71)	6 (33)	41 (76)
DNA typing <sup>b</sup>			
Matching suspect	5 (5)	4 (22)	1(2)
Unidentified male	4 (4)	0	3 (6)
Other	9 (9)	3 (17)	5 (9)
No typing/missing	83 (82)	11 (61)	45 (83)

<sup>&</sup>lt;sup>a</sup> Excluded cases with unknown assailant (n=22) and unfounded cases (n=7).

for rare events, such as signs of attempted strangulation and multiple anogenital injuries. The design of the study does not allow us to look into other aspects of police and court work, which obviously may influence legal outcome in rape cases. Further discussion on limitations can be found elsewhere (9).

We have conducted an analysis of all police-reported cases, and in about half of the cases the victim had been medically examined at the SAC. Considerations on which complainants are sent for medical examination in police-reported rape cases have been described recently (9). Prosecution was more common in cases examined at the SAC, but not significantly so, suggesting that other investigative endeavors also might be rewarding.

Few studies worldwide have addressed the impact of medico-legal findings on legal outcome. In a review paper by Du Mont and White, 13 studies were identified, with the size of series varying from 72 to 888 (6), and three more studies have been published (3,12,13). The reviewed studies are mostly from the USA (six studies) and Canada (four studies). The three studies from the Nordic countries are older, representing a time when police reporting of rape was much less common (8,14,15). In the Norwegian study (8), which covered the period between 1989 and 1992, the conviction rate was much higher (48% compared with 12% in the present study). This is an indication that the pattern of police-reported rape changes, as more women nowadays file a formal complaint. The increase most likely reflects women's willingness to report and not the incidence of rape occurring in the population. The lower conviction rate in our present study may thus reflect an increase in police-reported cases that are more challenging to the legal system.

In most of the studies reviewed (6), no significant association was found between extragenital injuries and legal outcome in terms of charges being filed. Even fewer studies demonstrated any association between anogenital injuries and legal outcome. In the recent Danish study covering the five year period 1999-2004, extragenital injuries were documented in 78% of 216 women and anogenital injuries in 19%. No association with conviction was found (3). In one of the reviewed studies from San Diego, CA, USA (16), colposcopy was routinely used to identify anogenital injuries and a much higher proportion of such injuries was reported (any injury among 67% and multiple anogenital injuries in 36%) compared with that in our study (14% and 8%, respectively). Documentation of multiple anogenital injuries was significantly associated with charge filing in the San Diego study. Hence, an increased attention to techniques to identify minor injuries might increase the willingness of police to file charges. Documentation of multiple injuries is shown to be associated with non-consensual compared with consensual sexual activity (17,18).

Some authors argue that rape usually does not lead to genital injuries and that focus on increased use of technical

<sup>&</sup>lt;sup>b</sup> Swabs collected from the woman's body.

<sup>&</sup>lt;sup>c</sup> Included cases where no trace evidence was collected (*n*=11).

procedures such as colposcopy is therefore futile (19). Others strongly support techniques which will increase chances to identify all injuries (20). An interesting finding in the recent study from South Africa (12) is that documentation of anogenital injuries was not associated with charge filing and arrest of a suspect, but increased the likelihood for conviction in cases taken to court. Thus, information from the acute examination might be needed at various stages in the legal system. Omission of immediate meticulous injury documentation with optimal techniques such as colposcopy is a lost opportunity. Most anogenital injuries heal quickly without scarring and are unlikely to be visible at a later stage.

In our study only a third of the trace evidence kits collected upon examination of the women were sent for analysis, in contrast to a little more than half of the kits in other Nordic studies (3,21). In accordance with a Canadian study (11), we found that non-use of trace evidence preserved in the various swabs collected during the acute phase negatively influenced the progress of the case in the legal system. In the recent study from South Africa (12), 69% of collected trace evidence was sent for analysis, indicating a higher level of ambition, at least early in the police investigation, compared with what seems to be the case in our study. The decision by police not to use all available information before deciding not to proceed might be seen as a lack of quality and disregard of the woman's rights, as the collection of trace evidence from her body is not performed for healthcare reasons and may even hamper the healing process.

We do not have information on time aspects of the decision by police on whether to analyze the trace evidence kits or whether they chose to analyze more often in cases with a potential for prosecution, irrespective of forensic analysis. Another Norwegian study has shown that financial factors might also play a role (21).

In situations where the assailant admits sexual contact with the woman, the decision not to request analysis of biological samples may be plausible. However, in our study, when the assailant was a stranger, an even smaller proportion of the trace evidence kits collected from the women's body was analyzed compared with when the assailant was known. Even so, the observed association between the analysis of trace evidence and charge filing might be influenced by other and unknown confounders.

#### Conclusions

One or more physical injury was documented in half of the women in this series. The police decided to analyze only one-third of the trace evidence kits collected from the women's anogenital area. The analysis of swabs was associated with charge filing, regardless of test results. Increasing the utilization of this kind of medical evidence, especially in cases of

stranger rape, may ensure women's rights and increase available information to the legal system.

#### **Acknowledgements**

The Sør-Trøndelag Police Department supplied the police files. Kurt Saake at the Department of Public Health and General Practice, NTNU, registered the data electronically. Senior Public Prosecutor in Sør-Trøndelag Bjørn Kristian Soknes is thanked for information about police investigative routines and prosecution in sexual assault cases.

#### **Funding**

Cecilie Hagemann has received financial support from the organization Helse & Rehabilitering through the NGO Norske Kvinners Sanitetsforening.

#### References

- Crime and the justice. Table 4 Offences reported to the police, by type of offence. 1993–2009. Statistics Norway, 2010. Available online at: http://www.ssb.no/english/subjects/ 03/05/a'krim'tab'en/tab/tab-2010–04-15–04-en.html (accessed 27 May 2010).
- Case closed. Rape and human rights in the Nordic countries. Amnesty International 2008. Report. Available online at: http://www.amnesty.no/sites/default/files/1/Case% 20closed%202008.pdf (accessed August 7, 2011).
- Ingemann-Hansen O, Brink O, Sabroe S, Sørensen V, Charles AV. Legal aspects of sexual violence– does forensic evidence make a difference? Forensic Sci Int. 2008;180:98–104.
- Grevholm E, Nilsson L, Carlstedt M. National study of rapes reported to the police. Stockholm: National Council for Crime Prevention (BRÅ) 2005. Report no.: 2005:7.
- Fra ord til handling. Bekjempelse av voldtekt krever handling [Prevention of rape requires action]. Oslo, Norway: Justis- og politidepartementet, 2008:4.
- Du Mont J, White D. The uses and impacts of medico-legal evidence in sexual assault cases: a global review. World Health Organization, Department of Gender; Women and Health, World Health Organization DoGWaH; 2007. Report no.: 978 92 4 159604 6.
- Overgrepsmottak: Veileder for helsetjenesten [Sexual assault centers. Guidelines for health care personnel]. Oslo, Norway: Sosial- og helsedirektoratet, 2007.
- Schei B, Muus KM, Moen MH. Medisinske og rettslige aspekter av voldtekt. Henvendelser til voldtektsteamet ved Regionsykehuset i Trondheim i perioden 1989–92. [Medical and legal aspects of rape. Referrals to a team for care of rape victims at the regional hospital in Trondheim during the period 1989–1992]. Tidsskr Nor Laegeforen. 1995;115:30–3.
- 9. Stene LE, Ormstad K, Schei B. Implementation of medical examination and forensic analyses in the investigation of

Appendix I

### REGISTRERINGSSKJEMA

### Politijournal Ingen journal hos Voldtektsmottaket

	P-Var. 1:	Registreringsnummer:		
	Rettslige data			
)	P-Var. 2:	Anmeldelsesdato:	dag	mnd år
	P-Var. 3:	Dato for rettskraftig avgjørelse (første endelige dom):	dag	mnd år
	P-Var. 4:	Dato for påtalemessig avgjørelse		mnd år
	P-Var. 5:	Rettskraftig avgjørelse:	0 1 2 3 4 5 6 7	Ikke straffbart forhold Henlagt p.g.a. foreldelse Påtale trukket Henlagt, manglende opplysninger om gjerningsperson Henlagt etter bevisets stilling. Henlagt, gjerningsperson ikke strafferettslig ansvarlig Forelegg Tiltale
			9	Annet:  Ikke opplyst

11.07.2005

P-Var. 6:	Dersom tiltale:		0 1 2 3 4 5 9	Beti Delv delv Ann Frifi Ann	is beting en straft nnelse	aff nget straff, get straff. f:	
P-Var. 7:	Straffeutmåling:						
P-Var. 8:	Hvilke(n) straffekode(r) er br	ukt?					
□ 0 □ 1 □ 2 □ 3 □ 4 □ 5 □ 6	1401: Voldtekt (§192, 1. ledd 1413: Forsøk på voldtekt 1414: Skaffe utuktig omgang 1416: Utuktig omgang med b 1419: Utuktig omgang med m 1420: Voldtekt (§192, 2.ledd) Annet:	ved trusler/u evisstløs (§1 nisbruk av sti	92) illing.	J			
□ 9	Ikke opplyst						
P-Var. 9:	Ble dommen anket?		0 1 2 3	Ja, a	v påtale v påtalte v begge		
P-Var. 10:	Utfall av eventuell anke:						
Mistenkte							
Dersom flere overgrepet.	overgripere, føres opplysninger	ne på I, II og	III ette	r grad	av delta	kelse i	
P-Var. 11:	Antall overgripere:						
P-Var. 12:	Kjønn	I 			0 1 9	Mann Kvinne Ikke opplyst	

11.07.2005

P-Var. 13:	Alder:		] ]	Overg	griper 1 griper 2 griper 3	
P-Var. 14:	Opprinnelse	I   			0 1	Norsk Utenlandsk:
					9	Ikke opplyst
P-Var. 15:	Tidligere mistenkt for vold/seksualforbrytelse?		0	Nei Ja		
P-Var. 16:	Tidligere dømt for		9		pplyst	
	vold/seksualforbrytelse?		0 1 9	Nei Ja Ikke o	pplyst	
P-Var. 17:	Inntatt alkohol før handlingen?		0 1 9	Nei Ja Ikke o	pplyst	
P-Var. 18:	Andre rusmidler:		0 1 9	Nei Ja: Ikke o		
P-Var. 19:	Har mistenkte vært til avhør?		0 1 9	Nei Ja Ikke o	pplyst	
P-Var. 20:	Er det oppgitt en psykiatrisk diagnomistenkte?	se eller	rettsps	ykiatrisl	k konkl	usjon hos
	materiale.		0 1 2	Beviss	tløs på	handlingstiden
			3			n lingshemmet i
			4	Alvorl	ig psyk	isk lidelse
			5		evissth	kotisk) ets-
			6	Lettere	psykis ngshem	
			7		lfullt u	unet tviklede
			8 9	Varig	svekked	le sjelsevner
			9		or gjenta are hand	akelse av dlinger

	Saker uten jo	ournal hos Voldtektsmottaket				
	P-Var. 21:	Innrømmer mistenkte seksuell kontakt med fornærmede?		0 1 9	Nei Ja Ikke opplyst	
	P-Var. 22:	Innrømmer mistenkte utuktig omgang/voldtekt?		0 1	Nei Ja	
		a		9	Ikke opplyst	
	P-Var. 23:	Erkjenner mistenkte straffeskyld?		0 1 9	Nei Ja Ikke opplyst	
$\bigcirc$	P-Var. 24:	Ble det foretatt en registrering av m	nistenkt	tes DNA	A-profil?	
				0 1 9	Nei Ja Ikke opplyst	
	Fornærme	de				
					Nei	
	P-Var. 25:	Er fornærmede avhørt?		0 1 9	Ja Ikke opplyst	
	P-Var. 25:	Hvis ja, skjedde <u>første</u> avhør		1	Ja	
0				1	Ja	
		Hvis ja, skjedde <u>første</u> avhør før eller etter medisinsk	se hos	1 9 0 1 2	Ja Ikke opplyst  Før Etter Medisinsk undersøkelse ikke utført Ikke opplyst	
	P-Var. 26;	Hvis ja, skjedde <u>første</u> avhør før eller etter medisinsk undersøkelse?	se hos	1 9 0 1 2	Ja Ikke opplyst  Før Etter Medisinsk undersøkelse ikke utført Ikke opplyst	

Handling	en				
P-Var. 28:	Dato:	Første overgrep:	dag	mnd å	r
		Siste overgrep:	dag	mnd å	r
P-Var. 29:	Klokkeslett:	Start:		]	
		Slutt:		]	
P-Var. 30:	Frekvens			0 1	Ett overgrep Gjentatte overgrep:
Etterforsk	ningen				
P-Var. 31:	Har politiet fo	retatt åstedsbefaring?		0	Nei
			Ħ	0 1 9	Ja Ikke opplyst
P-Var. 32:	Er det foretatt	sporsikring av biologi	isk ma	teriale h	
				0	Nei
				1	Ja, hos voldtektsmottaket
				1 2 3	Ja, av andre
				3	Ja, kun blod og/eller urin
				_	(usikkert opphav)
				9	Ikke opplyst
P-Var. 33:	Er det foretatt	sporsikring av biologi	sk mat	teriale h	os <u>mistenkte</u> ?
				0	Nei
			Ħ	1	Ja, kun blod-/urinprøver
			H	2	Ja, annet:
				2	Ja, annet
				9	Ikke opplyst
P-Var. 34:	Er det gjort bes	slag av <u>fornærmedes</u> k	lær?		
				0	Nei
				1	Ja
				9	Ikke opplyst

P	P-Var. 35:	Er det gjort beslag av mistenktes k	lær?		
				0	Nei
				1 9	Ja Ikke opplyst
P	P-Var. 36:	Er det dokumentert fysiske skader	hos for	nærmed	<u>le</u> ?
				0 1 9	Nei Ja
				9	Ikke opplyst
p	-Var. 37:	Er det dokumentert fysiske skader	hoe mie	tankta?	
•	- var. 57.	Li det dekumentert Tysiske skader			
				0 1 9	Nei Ja
				9	Ikke opplyst
P	-Var. 38:	Hvis ja, etter hvor mange timer skj	edde be	vissikri	ng dersom <72 t m.h.t.:
					Åsted Biologisk materiale,
					fornærmede
					Biologisk materiale, mistenkte
					Fornærmedes klær Mistenktes klær
					Fysiske skader, fornærmede Fysiske skader, mistenkte
					•
P	-Var. 39:	Dersom bevissikring skjedde etter angis tid i døgn:	72 t elle	r eksak	t timeantall ikke foreligger,
					Åsted
					Biologisk materiale, fornærmede
					Biologisk materiale,
					Fornærmedes klær
					Mistenktes klær Fysiske skader, fornærmede Fysiske skader, mistenkte
					Livrai alsa alsa dan mai atami ata

O Nei   Ja:   (antall)	P-Var. 40:	Er det innkalt vitner til avhør utenor	n medi	sinsk sa	akkyndi	g og fornærmede:	
P-Var. 41: Er medisinsk undersøkelse foretatt?				1	Ja:		
P-Var. 42: Hvis ja, er erklæring blitt innhentet?  P-Var. 43: Hvis ja, er erklæringen nevnt i eventuelle domspremisser?  P-Var. 44: Er skisser/fotografi vedlagt saken?  P-Var. 44: Er skisser/fotografi vedlagt saken?  P-Var. 45: Hvor ble medisinsk undersøkelse utført?  P-Var. 45: Hvor ble medisinsk undersøkelse utført?  P-Var. 46: Er medisinsk sakkyndig innkalt som vitne?  P-Var. 46: Er medisinsk sakkyndig innkalt som vitne?	Medisinsk	e undersøkelser av fornærmed	e				
P-Var. 43: Hvis ja, er erklæringen nevnt i eventuelle domspremisser?	P-Var. 41:	Er medisinsk undersøkelse foretatt?			1	Ja	
domspremisser?	P-Var. 42:	Hvis ja, er erklæring blitt innhentet?			1	Ja	
1	P-Var. 43:		uelle		1	Ja <sup>1</sup>	
P-Var. 46: Er medisinsk sakkyndig innkalt som vitne?    1	P-Var. 44:	Er skisser/fotografi vedlagt saken?			1 2 3 4	Ja, av åsted Ja, av skader på fornærmede Ja, av klær Ja, annet:	
O Nei  1 Ja, psykiater/ psykolog  2 Ja, lege fra Voldtektsmottaket  3 Ja, annen lege	P-Var. 45:	Hvor ble medisinsk undersøkelse utf	ørt?		1 2 3	Voldtektsmottaket Legevakt/fastlege Annet:	
	P-Var. 46:	Er medisinsk sakkyndig innkalt som	vitne?		1 2 3	Ja, psykiater/ psykolog Ja, lege fra Voldtektsmottaket Ja, annen lege	

Aktuelle tekst avskrives som vedlegg til registreringsskjema.

### Rettsmedisinske undersøkelser, klær og sporsikring

P-Var. 47:	Er det foretatt teknisk beslag?		0 1 9	Nei Ja: [ (antall) Ikke opplyst
P-Var. 48:	Har politiet selv undersøkt klær?		0 1 9	Nei Ja Ikke opplyst
P-Var. 49:	Er det sendt prøver til Rettsmedisinsk Insti	tutt?		
			0 1 9	Nei Ja Ikke opplyst
P-Var. 50:	Antall prøver mottatt av Rettsmedisinsk Ins	stitutt:		
P-Var. 51:	Antall prøver analysert av Rettsmedisinsk I	Institutt	: 🔲 🗆	
P-Var. 52:	Er sporsikringspakken analysert?		0 1	Nei Ja, sporsikrings- pakken omtalt i analyserapporten
			2	Ja, analyse av aktuelle prøver uten at sporsikrings- pakken er nevnt
P-Var. 53:	Er det påvist spermier på fornærmedes krop	pp?		
			0 1 2	Nei Ja, på genitalia Ja, utenfor genitalia

All relevant tekst angående prøver sendt til Rettsmedisinsk Institutt, eventuelle resultater og vektlegging av disse i saksavgjørelsen vedlegges som fritekst.

Saker uten journal hos Voldtektsmottaket Rettstoksikologi P-Var. 54: Er det gjort rettstoksikologiske analyser av blod/urin fra fornærmede? 0 Nei 1 Ja, prøver sendt fra Voldtektsmottaket 2 Ja, prøver sendt fra annen lege 3 Ja, usikkert hvem som utførte prøvetakingen 9 Ikke opplyst P-Var. 55: Hvis ja, hvilke stoffer ble eventuelt påvist hos fornærmede? Ingen Etanol 1 2 Benzodiazepiner Annet:\_ P-Var. 56: Er det gjort rettstoksikologiske analyser av blod/urin fra mistenkte? Nei Ja P-Var. 57: Hvis ja, hvilke stoffer ble eventuelt påvist hos mistenkte? 0 Ingen Etanol 1 2 Benzodiazepiner

11.07.2005 9

Annet:\_

## Variabler fra Voldtektsmottakets registreringsskjema:

### Opplysninger om fornærmede (S.O.)


P-Var. 58:	Født	dag	mnd å	
P-Var. 59:	Kjønn	П	0	Mann
1 (41.55.	20,000		1	Kvinne
P-Var. 60:	Bostedsadresse:		0	Trondheim by
			1	Sør-Trøndelag,
			2	utenom byen Utenfor fylket
		H	2	Utenfor landet
			9	Ikke opplyst
		_		
P-Var. 61:	Er S.O. i arbeid utenfor hjemmet?		0	Nei
		$\square$	1	Ja
			9	Ikke opplyst
P-Var. 62:	Hvis nei		0	Husmor
			1	Skoleelev
			2	Student
			3	Stønad
		$\square$	4	Arbeidsledig
		片	5 9	Annet:
		Ш	9	Ikke opplyst
P-Var. 63:	Hvis ja, hvilken type arbeid?			
P-Var. 64:	Hvilken utdannelse har S.O.?		0	Mindre enn 9 år
		П	1	9 – 12 år
			3	Høyskole
			4	Universitet
			9	Ikke opplyst
P-Var. 65:	Sivilstand nå:	П	0	Ikke flyttet hjemmefra
			1	Aleneboende
			3	Samboende
			4	Gift
			5	Separert
	•		6	Skilt
			9	Ikke opplyst
P-Var. 66:	Sivilstand tidligere:		0	Samboende
			1	Gift
			2	Separert
			3	Annet
			9	Ikke opplyst

Overgripe	r(e)					
P-Var. 67:	Relasjon til S.O., familie				0 1 2 3 4 5 6 7 8 9	Far/stefar Mor/stemor Søsken Bestefar/-mor Onkel/tante/ søskenbarn Annen slekt Ektemann/samboer Tidligere ektemann Kjæreste Ikke opplyst
P-Var. 68:	Relasjon UTENOM familie	e/par I	п	Ш	0	Venn/bekjent
					1	Ukjent fra før/ tilfeldig
					2 3	Fremmed(e) Autoritetsperson:
					4 9	Annet:Ikke opplyst
Hendelsen						
P-Var. 69:	Hvor skjedde det?			0 1 2 3	Hos o	me hos forurettede vergriper t privat sted tlig lokale:
				4	Ute:_	
				5 9		åt, buss opplyst
P-Var. 70:	Hvor alvorlig var den fysisk (etter den alvorligste)?	ce volde	n     	0 1 2		el om vold el om hevn:
				3 4 5 6	Kvele Mode: Grove	rat, slått etc. re vold
				7 8 9	Våper Annet Ikke o	

	P-Var. 71:	Seksuell handling etter alvorligste:		0	Ingen
	1- vai. /1.	Seaster Handring etter arvorngste.	H		
				1	Usikker/uopplyst
				2	Beføling/tukling
				3	Beføling – også
					kjønnsorganer
				4	Forsøk på inntrengning
			H		
			$\sqcup$	5	Vaginal inntrengning
				6	Anal inntrengning
			П	7	Oral inntrengning
			$\sqcap$	8	Tvunget til å suge/onanere
			_	·	overgriper
				•	
				9	Annet:
	A namnosti	ske opplysninger og funn			
	Anamicsci	ske opprysmiger og tumi			
)	P-Var. 72:	Tidligere celcuelle overgren		0	A ldei
Here.	1-Val. 12.	Tidligere seksuelle overgrep:	H	0	Aldri
			$\Box$	1	Seks. ovr., barndom
			Ш	2	Seks. ovr., partner
				3	Tidligere overgrep, annet:
			_		
				4	Fys. overgrep, barndom
			Ħ	5	Fys. overgrep, partner
			H	6	
			$\vdash$		Voldtekt, ukjent overgriper
			$\sqcup$	7	Voldtekt, kjent overgriper
				9	Ikke opplyst
	P-Var. 73:	Expiden alcodor no legomen stanton en			
	r-val. /5:	Fysiske skader på kroppen utenom g	gemitam	a:	
				0	Ingen
			Ħ		
			H	1	Lette: blåflekker, skrubbsår
			Щ	2	Moderate: sår, kutt
			$\square$	3	Alvorlige: brudd, mistanke
					om indre skader
			П	4	Merker etter kveletak
			Ħ	9	Ikke opplyst
			ш	,	ikke oppryst
	P-Var. 74:	Gynekologiske funn:		0	Ingen forandringer
		- ^	Ħ		
			H	1	Rubor, hevelse
				2	Rifter, sår
				3	Større skade
				4	Annen skade:
			П	5	Annet, sykdom:
			Ħ	6	•
			H		Gyn. u.s. ikke utført
				9	Ikke opplyst

	Saker uten j	ournal hos Voldtektsmottaket		
	P-Var. 75:	Tidligere psykiatrisk anamnese?	0 1 2 3 9	Nei Ja, uspesifisert Tidligere innlagt psyk Tidligere psyk. beh. Ikke opplyst
	P-Var. 76:	Handikapp/funksjonshemmet:	0 1 2 3 4 5	Nei Psykisk, uspes Fysisk, uspes Misbruk: Mentalt tilbakestående Andre fysiske (sanser, bevegelse)
)				
	Alkohol/ru	us ®		
	P-Var. 77:	Alkohol (forurettede):	0 1 2	Intet alkoholinntak Mindre inntak (under 5 øl eller drinker)
				Større inntak (over 4 øl e.l/ synlig beruset)
			3	Større inntak med amnesiperiode
			4	Mener å være påført stoff i drink eller mat
			5	Uaktuelt, gammel sak eller
			9	residiverende overgrep Ikke opplyst
	P-Var. 78:	Narkotika/medikament (forurettede	0 1 2	Nei Ja Usikkert
	P-Var. 79:	Tid på døgnet for overgrepet:	0 1 2 9	7-20 20-24 0-7 Ikke opplyst

Appendix II



If System Error, Print Screen and send image to Berit.Bjelkasen@ntnu.no | Last updated: 03.06.2014

## □ NTNU Norges teknisk-naturvitenskapelige universitet Det medisinske fakultet > Institutt for kreftforskning og molekylær medisin

#### Voldtektsregistrering Participant No: 14 Inclusion date: 26/07/2011

Annen deltager / Another participant

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Unde	ersøkelsen-Anmeldelse
Initial Page	Om un	dersøkelsen – henvisning
Change password	1. 🕷	Dato for førstegangsundersøkelse(dd/mm/åååå)
Information		
	2. 🐞	Tid på dagen for undersøkelsen Vanlig arbeidstid?
Statistics		O Nei
Study Progress		O Ja
Study Documents	3. *	Uopplyst
,	3. *	Tid som er gått etter hendelsen  Under 24 timer
Vis svarhistorikk / View log		Under 24 timer Under en uke
Identification		Under en måned
Study parts		O Under ½ år
Undersøkelsen-Anmeldelse		O Under 1 år
Pasienten-overgriper-		Over 1 år
nendelsen		O Under 72 timer
Anamnese-funn-behandling- prøver		O Uopplyst
Sårbarhetsfaktorer-rus- oppfølging-retts	4.	Antall timer fra avlutning av overgrep til undersøkelsen, dersom under 72 timer
Skader 🌒		
	5. 🕷	Hvem var til stede ved undersøkelsen?
		O Bare lege(r)
		O Bare sykepleier
		O Begge
		O Uopplyst
	6.	Hvor var pas. henvist fra?
		☐ Tok kontakt direkte ☐ Politi
		☐ Lege ☐ Sosialkontor
		□ Krisesenterr
		□ Helsesøster
		□ Annet
		Uopplyst
	7.	Hvis henvist fra annet, hva?
	8.	I følge med hvem?
		☐ Ingen ledsager
		☐ Venn/venninne
		Foreldre
		Partner
		☐ Helsearbeider ☐ Søsken
		□ Annet
		Uppplyst
	9.	Hvis annet, spesifiser
	Anmelo	delse og rettslig utfall
	10. 🕷	Har pas. anmeldt saken (evt. opplysn. om senere anmeldelse)?
		O Anmeldt før u.s.
		O Anmeldt etter u.s. *
		O Anmeldt senere **
		O Ikke anmeldt
		O Annet
		Uopplyst *Rett etter us. **Senere enn i den akutte situasjonen
	*Rett etter us. **Senere enn i den akutte situasjonen Save	
11. Hvis annet, spesifiser		
	•	
	12. 🕷	Sakens gang
		☐ Ikke anmeldt

	☐ Saken henlagt, ukjent mistenkt
	☐ Saken henlagt av andre årsaker (bevisets stilling)
	□ Etterforskn.pågår
	☐ Tiltalt, gj.mann frifunnet
	☐ Tiltalt, gj.mann dømt (ang. mndr. under)
	□ Voldsofferersatning idømt
	Annet
	□ Uopplyst
13.	Hvis tiltalte dømt, antall mnd.
14.	Hvis annet, spesifiser
15. 🕸	Hvor er forholdet anmeldt?
	☐ Ikke anmeldt
	☐ Trondheim politikammer
	☐ Sør-Trøndelag politidistrikt
	☐ Nord-Trøndelag politidistrikt
	☐ Annet i Norge
	☐ Annet land i Norden
	☐ Utenfor Norden
	☐ Uopplyst
16.	Politiets anmeldelsesnummer
17.	Dato anmeldt
18. 💥	Dato for ankomst (dd:mm:åååå)
10 19	
19. 🕷	Klokkeslett for ankomst (tt:mm)
20. *	Klokkeslett for førstegangsundersøkelse (tt:mm)
20. 2	Niokesiett for førstegangsundersøkeise (tt.filliff)
	Save
	Save
	Andre opplysninger / Additional Information or Corrections
	<b>○</b>
	Lagre svar / Save and view log Tilbakestill skjema / Reset
	Via graphistorikk / Vian Ioa
	<u>Vis svarhistorikk / View log</u> Print page

If System Error, Print Screen and send image to Berit.Bjelkasen@ntnu.no | Last updated: 03.06.2014

# NTNU Norges teknisk-naturvitenskapelige universitet Det medisinske fakultet > Institutt for kreftforskning og molekylær medisin

#### Voldtektsregistrering Participant No: 14 Inclusion date: 26/07/2011

Annen deltager / Another participant

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Pasie	nten-overgriper-hendelsen	
Initial Page	Opnlysi	ninger om kvinnen/mannen (pasienten)	
Change password	1. ∰	Fødselsår	
Information	2. 🕸	Kjønn	
Statistics		O Mann	
Study Progress		O Kvinne	
		O Uopplyst	
Study Documents	3. 🕸	Bostedsadresse	
Vis svarhistorikk / View log		O Trondheim by	
_		O Sør-Trøndelag utenom byen	
Identification		O Utenfor fylket	
Study parts		O Utenfor landet	
Undersøkelsen-Anmeldelse		O Uopplyst	
Pasienten-overgriper- hendelsen	4. 亲	Er pas. i arbeid utenfor hjemmet?	
		O Nei	
Anamnese-funn-behandling- prøver		O Ja	
Sårbarhetsfaktorer-rus- oppfølging-retts		O Uopplyst	
Skader	5.	Hvis nei	
		☐ Husmor	
		Skoleelev	
		☐ Student	
		Stønad	
		☐ Arbeidsledig	
		☐ Annet, spesifiser under	
		☐ Uopplyst	
	6.	Annet, spesifiser	
	7.	Hvis ja, type arbeid	
	8. 🕷	Hvilken utdannelse har pas.	
		○ Mindre enn 9 år	
		O 9 – 12 år	
		Høyskole	
		Universitet	
		O Uopplyst	
	9. 🐞	Sivilstand nå	
		ikke flyttet hjemmefra	
		O Aleneboende	
		O Samboende	
		O Gift	
		Separert	
		O Skilt	
		O Annet	
		O Uopplyst	
	10.	Hvis annet, angi	
		Save	
	11. 郷	Sivilstand tidligere	
		Samboende	
		O Gift	
		Separert	
		Annet	
		O Uopplyst	
	12. 🕷	Antall barn	
	13. 🕷	Antall svangerskap	
	14 =	Parisitat	
	14. 🕸	Etnisitet	
		○ Norsk	

	O Annet	
	○ Ikke norsk, vestlig	
	○ Ikke norsk, ikke vestlig	
	O Uopplyst	
15.	Annet, spesifiser:	
Overgri		
16.	Hvis flere overgripere, antall:	
Onniver	linger føres på overgriper I & II & III etter hvem som er viktigst	
17. ※	Kjønn overgriper I	
	O Mann	
	O Kvinne	
	O Uopplyst	
18.	Kjønn overgriper II	
	O Uopplyst	
	O Mann	
	O Kvinne	
19.	Kjønn overgriper III	
	Uopplyst	
	O Mann	
20 3	O Kvinne	
20. 🕷	Alder overgriper I	
	(ca., antall år)	
	Save	
21.	Alder overgriper II	
22.	Alder overgriper III	
***		
23. 💥	Etnisitet overgriper I	
	O Norsk O Annet	
	Ikke norsk, vestlig	
	Ikke norsk, vestlig     Ikke norsk, ikke vestlig	
	O Uopplyst	
24.	Annen etnisitet, spesifiser	
25.	Etnisitet overgriper II	
	O Norsk	
	Annet	
	O Ikke norsk, vestlig	
	Ikke norsk, ikke vestlig	
26.	O Uopplyst Annen etnisitet, spesifiser	
20.	Americanstee, spesinser	
27.	Etnisitet overgriper III	
	O Norsk	
	O Annet	
	O Ikke norsk, vestlig	
	Ikke norsk, ikke vestlig	
	O Uopplyst	
28.	Annen etnisitet, spesifiser	
29.	Relasjon til pas. familie/partner overgriper I	
23.	O Far/stefar	
	O Mor/stemor	
	○ Søsken*	
	O Bestefar/-mor	
	Onkel/tante/søskenbarn	
	O Annen slekt**	
	O Ektemann/samboer	
	O Tidligere ektemann	
	O Kjæreste	
	Uoppl. familie/partner	
30.	* Bror, stebror, søster, stesøster, ** Sønn, datter Relasjon til pas. familie/partner overgriper II	

	○ Kjæreste
	○ Far/stefar
	Mor/stemor
	O Søsken
	O Bestefar/-mor
	Onkel/tante/søskenbarn
	O Annen slekt
	O Ektemann/samboer
	O Tidligere ektemann
	O Uoppl. familie/partner
	Save
31.	Relasjon til pas. familie/partner overgriper III
	O Kjæreste
	O Far/stefar
	Mor/stemor
	O Søsken
	O Bestefar/-mor
	Onkel/tante/søskenbarn Annen slekt
	Ektemann/samboer
	Tidligere ektemann
	Uoppl. familie/partner
32.	Relasjon UTENOM familie/partner overgriper I
	○ Venn/bekjent*
	Ukjent fra før/tilfeldig**
	○ Fremmede***
	O Autoritetsperson, spesifiser under****
	O Internett-kontakt
	Annet, spesifiser under
	O Uopplyst
	* Arbeidskamerat, skole/studie-kamerat, ** Møtt innenfor de siste 24 timer, *** Aldri sett før, **** Lærer, sjef, behandler, pleier, offentlig person (politi mm), taxisjåfør mm
33.	Relasjon UTENOM familie/partner overgriper II
	O Venn/bekjent
	O Ukjent fra før/tilfeldig
	O Fremmede
	Autoritetsperson, spesifiser under
	O Internett-kontakt
	Annet, spesifiser under
34.	O Uopplyst Relasjon UTENOM familie/partner overgriper III
34.	Venn/bekjent
	Ukjent fra før/tilfeldig
	O Fremmede
	Autoritetsperson, spesifiser under
	O Internett-kontakt
	O Annet, spesifiser under
	O Uopplyst
35.	Spesifiser autoritetsperson eller annet for alle overgriperne
	^
	Max 255 characters. remaining.
36. 🕷	Tid for overgrepet
	O KI 7-20
	○ KI 20-24 ○ KI 0-7
	○ Uopplyst
37.	Tid på døgnet for overgrepet, start-tidspkt. Dato (dd.mm.åååå)
57.	The paragraph of the pa
38.	Tid på døgnet for overgrepet, start-tidspkt. Klokkeslett (tt:mm)
39.	Tid på døgnet for overgrepet, stopp-tidspkt. Dato (dd.mm.åååå)
40.	Tid på døgnet for overgrepet, stopp-tidspkt. Klokkeslett (tt:mm)
	Save
41.	Varighet av overgrepet (Ca antall minutter)

Hendels	sen .
42. 🕸	Hvor skjedde det?
	Hjemme hos pasienten
	O Hjemme hos overgriper
	Annet privat sted
	Offentlig lokale, Spesifiser
	Utendørs, Spesifiser
	Transportmiddel, Spesifiser
	Pasienten husker ikke
42	O Uopplyst
43.	Spesifiser åsted
	^
	V
	Max 255 characters. remaining.
44. 🕷	Hvor alvorlig var den fysiske volden?
	☐ Ingen
	☐ Trussel om vold
	☐ Trussel om hevn, spesifiser
	☐ Mildere*
	☐ Halsgrep
	☐ Moderat**
	☐ Grovere vold
	☐ Bruk av våpen
	Pasienten husker ikke
	Pasienten hindret i å komme seg unna
	☐ Tvungen abduksjon av beina
	☐ Annet, Spesifiser
	□ Uopplyst
	* Holdt fast, ** Slag, spark
45.	Spesifiser hevn og/eller annet:
46. 🕷	Seksuell handling (Rangeres etter den alvorligste.)
	☐ Ingen
	☐ Usikker/uopplyst
	☐ Beføling kropp*
	☐ Beføling kjønnsorgan**
	☐ Forsøk inntrengning***
	□ Vaginal inntrengning****
	☐ Anal inntrengning****
	□ Oral inntrengning****
	☐ Tvunget til å suge/onanere overgriper
	☐ Fremmedlegeme
	□ Annet
	□ Pasienten husker ikke
	* Inkl. bryst, ** Inkl. finger i skjeden, ***Vaginalt, analt, oralt, **** Av penis, femmedlegeme, ikke fingre
47.	Spesifiser evt annet og/eller fremmedlegeme
	^
	<b>▽</b>
	Max 255 characters. remaining.
48.	Sædavgang
	□ Nei
	□ Usikkert
	□ Vaginalt
	□ Oralt
	□ Analt
	☐ Annet sted på kroppen
	□ På klær/sengetøy
	☐ Andre steder
	☐ Uopplyst
49. *	Kondom benyttet?
+7. 零	
	○ Nei ○ Ja
	O Pasienten vet det ikke
	O Annet
F0	O Uopplyst
50.	Annet:

Max 255 characters.	remaining			
Save				
Andre opplysnin	ger / Additional	Information or Co	rrections	
			<b>\$</b>	

If System Error, Print Screen and send image to Berit.Bjelkasen@ntnu.no | Last updated: 03.06.2014

# □ NTNU Norges teknisk-naturvitenskapelige universitet Det medisinske fakultet > Institutt for kreftforskning og molekylær medisin

### Voldtektsregistrering

Cecilie Hagemann St. Olavs Hospital (400)

Participant No: 14 Inclusion date: 26/07/2011 Annen deltager / Another participant

Log out →	Anamnese-funn-behandling-prøver	
Initial Page	Seksuell anamnese / graviditet	
Change password	1. M Graviditet i forb med overgrep	
Information	Aldri vært gravid	
Statistics	Gravid før, ikke nå	
	☐ Gravid ved overgrepet, hvis ja, noter antall uker under ☐ Gravid som følge av SO	
Study Progress	☐ Gravi-test neg (0-prøve)	
Study Documents	Gravitest pos (0-prøve)	
Vis svarhistorikk / View log	☐ Ikke tatt gravitest (0-prøve)	
Identification	☐ Uopplyst	
	2. Antall uker	
Study parts	Hvis gravid som følge av overgrep	
Undersøkelsen-Anmeldelse  Pasienten-overgriper-	☐ Svangerskapsavbrudd	
Pasienten-overgriper- hendelsen	□ Fostervannsprøve	
Anamnese-funn-behandling- prøver	☐ Fødsel	
Sårbarhetsfaktorer-rus- oppfølging-retts	☐ Annet	
Skader	☐ Uopplyst	
	4. Hvis annet, angi her:	
	5. Seksuell debut/virgo	
	Debut ved aktuelle SO	
	Debutert før aktuelle hendelse, angi evt alder under	
	O Nei	
	O Annet	
	O Uopplyst	
	6. Angi evt alder v debut	
	7.   Siste frivillige samleie	
	O Debut ved aktuelle SO	
	○ For < 72 timer siden	
	○ 3-7 døgn siden	
	O 7-14 døgn siden	
	○ > 14 døgn siden	
	O Uopplyst	
	8. Tidl fysiske /seksuelle overgrep (SO)	
	☐ Aldri	
	□ S0 i barndommen*	
	<ul> <li>         □ SO v/partner         □ Annet, angi under     </li> </ul>	
	☐ Fys. overgrep barndom	
	☐ Fysiske overgrep, annet	
	☐ Fys. overgr. partner	
	SO ukjent overgr.	
	☐ SO ( ikke partner)	
	☐ SO 12-16 år	
	☐ SO > 16 år	
	☐ SO annet	
	* Barndommen vil si < 12 år	
	9. Angi evt annet SO/ fysiske overgrep	
	10. # Prevensjon, nå	
	☐ Ingen	
	□ Kondom	
	□ P-piller/p-plaster/ring	
	□ Spiral	
	P-sprøyte/ p-stav	
	Sterilisert/ hysterectomert	

	☐ Annet
	☐ Uopplyst
	Save
11.	Angi evt. annet
(Se elle	ed undersøkelsen rs tilleggsvariabler til slutt (Var 60 - 65) ang rus-påvirkning, og mer detaljer om kroppslige (Var 78 – 81) og anogenitale
(Var 68	– 77) skadefunn. Hvis anogenitale skadefunn, fyll ut tabellen på side 20)
12. 🕸	Psykiske reaksjoner ved undersøkelsestidspunktet (alvorligste)
	Ingen ved undersøkelsen  Moderate psykiske reaksjoner*
	Alvorlige psykiske reaksjoner**
	Vanskelig å vurdere
	Annet, angi under
	O Uopplyst
	* Gråt, innesluttethet, lett angst, sinne eller verbal aggresjon, ** Alvorlig angstm tilbaketrukkenhet, bevissthetsinnsnevring, desorientering, fortvilelse/hāpløshet, hyperaktivitet, ubehersket eller overdreven sorgreaksjon
13.	Angi evt annet
14. 🕷	Fysiske skader på kroppen utenom genitalia
	☐ Ingen
	Lette, blåflekker, skrubbsår etc
	Moderate: sår, kutt* etc.
	Alvorlige: brudd, mistanke om indre skader
	Merker etter halsgrep
	□ Skjæresår
	☐ Uopplyst ☐ Kroppslig us ikke gjort
	* Her menes ikke skjæresår
15.	Fysiske skader på kroppen utenom genitalia (alvorligste skader)
	O Ingen skade
	Mild skade: Rødhet, hevelse, blåmerker, overflatisk hudavskrap, overflatiske rifter,
	sugemerker (uansett lokalisasjon)
	<ul> <li>Moderate skade: Hevelse eller blålig misfarging i hoderegionen (inkl. "blåveis" rundt øyet og hevelse over nesen) som man kan forvente gir betydelig hoderpine i etterkant), stikkmerker, bitemerker, lacerasjoner som krever suturering eller plastring.</li> </ul>
	<ul> <li>Alvorlig skade: brudd, mistanke om indre skader, merker etter halsgrep, knivrisp (selv om det ikke trengs å sys)</li> </ul>
	O Uopplyst
	Croppslig us ikke gjort
16.	Beskriv fysiske skader med ord
	^
	Y
	Max 255 characters. remaining.
17.	Fysiske skader forts:
	<u> </u>
18.	Max 255 characters. remaining.
10.	Gynekologiske funn  ☐ Ingen forandringer
	☐ Lokal rødme, hevelse ☐ Rifter, overflatesår
	□ Større skade
	☐ Annen skade
	☐ Annen sykdom
	Uopplyst
19.	Beskriv gynekologiske funn med ord
	^
	<b>▽</b>
	Max 255 characters. remaining.
20.	Gynekologiske funn forts.
	^
	Max 255 characters. remaining.
	Save
Behand	-
21.	Forordninger ved undersøkelsen
	☐ Ingen

	Nødprevensjon	
	☐ Antibiotika mot PID*	
	□ Beroligende	
	Sovemedisin	
	☐ Smertestillende	
	☐ Xylokain salve	
	☐ Kvalmestillende	
	Har allerede tatt nødprev.	
	Tetanusvaksine	
	☐ Hepatitt B- vaksine	
	☐ HIV postexpo. profyl.	
	Annet, spesifiser under	
	☐ Uopplyst	
	* Pelvic inflammatory disease, som regel Azitromax gitt	
22.	Angi evt. annet	
23. 💥	Sykmelding	
23. 38		
	○ Ingen, ikke i arbeid	
	Ingen, trenger ikke	
	O Ja, angi uker under	
	O Uopplyst	
24.	Angi evt antall uker	
25.	Henvist til videre oppfølging	
	☐ Gyn pol	
	☐ Fastlege	
	□ Sosialkontor	
	Barneklinikken	
	Psykolog/psykiater	
	BUP	
	PP-tjeneste	
	☐ Ikke henvist	
	☐ Studenthelsetjenesten	
	☐ Annet overgrepsmottak	
	- runet overgrepshottak	
	☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt)	
	$\ \square$ Innlagt somatisk sykehus (i forlengelse av 1. kontakt)	
	☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt) ☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)	
	<ul> <li>☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt)</li> <li>☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)</li> <li>☐ Annet, spesifiser under</li> </ul>	
	☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt) ☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) ☐ Annet, spesifiser under ☐ Uopplyst	
26.	<ul> <li>☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt)</li> <li>☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)</li> <li>☐ Annet, spesifiser under</li> </ul>	
26.	☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt) ☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) ☐ Annet, spesifiser under ☐ Uopplyst	
	☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt) ☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) ☐ Annet, spesifiser under ☐ Uopplyst Angi evt. annet	
Kliniske	☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt) ☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) ☐ Annet, spesifiser under ☐ Uopplyst Angi evt. annet ☐ prøver tatt / prøvesvar	
	Innlagt somatisk sykehus (i forlengelse av 1. kontakt) Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) Annet, spesifiser under Uopplyst Angi evt. annet prøver tatt / prøvesvar Bakteriologi Klamydia (prøve tatt)	
Kliniske	☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt) ☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) ☐ Annet, spesifiser under ☐ Uopplyst Angi evt. annet ☐ prøver tatt / prøvesvar	
Kliniske	Innlagt somatisk sykehus (i forlengelse av 1. kontakt) Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) Annet, spesifiser under Uopplyst Angi evt. annet prøver tatt / prøvesvar Bakteriologi Klamydia (prøve tatt)	
Kliniske	Innlagt somatisk sykehus (i forlengelse av 1. kontakt) Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) Annet, spesifiser under Uopplyst Angi evt. annet prøver tatt / prøvesvar Bakteriologi Klamydia (prøve tatt) Skjede	
Kliniske	Innlagt somatisk sykehus (i forlengelse av 1. kontakt) Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) Annet, spesifiser under Uopplyst Angi evt. annet  prøver tatt / prøvesvar Bakteriologi Klamydia (prøve tatt) Skjede Livmorhalskanal Endetarmsåpning	
Kliniske	Innlagt somatisk sykehus (i forlengelse av 1. kontakt) Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) Annet, spesifiser under Uopplyst Angi evt. annet Prøver tatt / prøvesvar Bakteriologi Klamydia (prøve tatt) Skjede Uivmorhalskanal Endetarmsåpning Munn	
Kliniske	Innlagt somatisk sykehus (i forlengelse av 1. kontakt) Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) Annet, spesifiser under Uopplyst  Angi evt. annet  prøver tatt / prøvesvar  Bakteriologi Klamydia (prøve tatt) Skjede Livmorhalskanal Endetarmsåpning Munn Urin/urethra	
Kliniske	Innlagt somatisk sykehus (i forlengelse av 1. kontakt) Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) Annet, spesifiser under Uopplyst Angi evt. annet Prøver tatt / prøvesvar Bakteriologi Klamydia (prøve tatt) Skjede Uivmorhalskanal Endetarmsåpning Munn	
Kliniske	Innlagt somatisk sykehus (i forlengelse av 1. kontakt) Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) Annet, spesifiser under Uopplyst  Angi evt. annet  prøver tatt / prøvesvar  Bakteriologi Klamydia (prøve tatt) Skjede Livmorhalskanal Endetarmsåpning Munn Urin/urethra	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst  Angi evt. annet   Sprøver tatt / prøvesvar  Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst	
Kliniske	☐ Innlagt somatisk sykehus (i forlengelse av 1. kontakt) ☐ Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt) ☐ Annet, spesifiser under ☐ Uopplyst  Angi evt. annet ☐ Sprøver tatt / prøvesvar  Bakteriologi Klamydia (prøve tatt) ☐ Skjede ☐ Livmorhalskanal ☐ Endetarmsåpning ☐ Munn ☐ Urin/urethra ☐ Annet	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet   Uopplyst	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst  Angi evt. annet   Sprøver tatt / prøvesvar  Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet   Uopplyst	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Parwer tatt / prøvesvar     Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Deprover tatt / prøvesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet   Uopplyst   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Parwer tatt / prøvesvar     Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Deprover tatt / prøvesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet   Uopplyst   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Seprever tatt / prøvesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal    Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet   Uopplyst   Annet   Endetarmsåpning   Munn   Annet	
Kliniske 27. 28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Sprøver tatt / prøvesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser    Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Endetarmsåpning   Munn   Annet   Livmorhalskanal	
Kliniske 27.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Seprever tatt / prøvesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal    Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet   Uopplyst   Annet   Endetarmsåpning   Munn   Annet	
Kliniske 27. 28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Sprøver tatt / prøvesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser    Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Endetarmsåpning   Munn   Annet   Livmorhalskanal	
Kliniske 27. 28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Uopplyst   Annet, spesifiser	
28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst    Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/arethra   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Uopplyst   Annet, spesifiser	
Kliniske 27. 28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst    Annet, spesifiser   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst    Annet, spesifiser   Skjede   Livmorhalskanal   Endetarmsåpning   Annet, spesifiser   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet, spesifiser   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet, spesifiser   Skjede   Uopplyst   Annet, spesifiser	
28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst    Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/arethra   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Uopplyst   Annet, spesifiser	
28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst    Annet, spesifiser   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst    Annet, spesifiser   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Uopplyst    Annet, spesifiser   Endetarmsåpning   Munn   Annet   Uopplyst    Annet, spesifiser   Endetarmsåpning   Munn   Annet   Uopplyst   Annet, spesifiser   Endetarmsåpning   Munn   Endetarmsåpning   Munn   Endetarmsåpning   Munn   Endetarmsåpning   Munn   Endetarmsåpning   Munn   Endetarmsåpning   Endetarmsåpning   Munn   Endetarmsåpning	
28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Ange evt. annet   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Prøver tatt / prøvesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Uopplyst   Annet, spesifiser   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Annet   Uopplyst   Annet, spesifiser   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Annet   Uopplyst   Annen bakteriologisk prøve tatt   Ingen annen prøve tatt   Ungen annen prøve tatt   Ungen annen prøve tatt	
28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Angi evt. annet   Prover tatt / provesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Livmorhalskanal   Endetarmsåpning   Munn   Urinderspesifiser   Munnetspesifiser   Munnet	
28. 29.	Innlagt somatisk sykehus (i forlengelse av 1. kontakt)   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Ange evt. annet   Innlagt psykiatrisk sykehus (i forlengelse av 1. kontakt)   Annet, spesifiser under   Uopplyst   Prøver tatt / prøvesvar   Bakteriologi Klamydia (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Urin/urethra   Annet   Uopplyst   Annet, spesifiser   Bakteriologi Gc (prøve tatt)   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Uopplyst   Annet, spesifiser   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Annet   Uopplyst   Annet, spesifiser   Skjede   Livmorhalskanal   Endetarmsåpning   Munn   Annet   Annet   Uopplyst   Annen bakteriologisk prøve tatt   Ingen annen prøve tatt   Ungen annen prøve tatt   Ungen annen prøve tatt	

32.	Annet, spesifiser	
33.	Sædcelleprøve (børste*) (prøve tatt)	
	☐ Ikke tatt	
	☐ Skjede	
	Livmorhalskanal	
	Annet	
	☐ Uopplyst	
	* Børsteprøve brukt vanligvis fra 2008, før dette bruk av "rødt strå"	
34.	Annet, spesifiser	
35.	Toksikologi (prøve tatt)	
55.	☐ Ikke tatt	
	□ Blod	
	□ Urin	
	Annet	
	□ Uopplyst	
36.	Annet, spesifiser	
37.	Gravitest (prøve tatt)	
	☐ Ikke tatt	
	Blod	
	□ Urin	
	Annet	
20	☐ Uopplyst	
38.	Annet, spesifiser	
39.	Serologi (blodprøve) (prøve tatt)	
	☐ Ikke tatt	
	□ Hiv	
	☐ Hepatitt B	
	☐ Hepatitt C	
	☐ Syfilis	
	☐ Herpes simplex	
	Annet	
	Uppplyst	
40.	Annet, spesifiser:	
	Save	
41. 🕸	Mikroskopi mhp sæd (prøvesvar)	
71. 86	☐ Ingen sædceller påvist	
	☐ Ikke aktuelt	
	☐ Sædceller påvist	
	☐ Prøve tatt fra cervix	
	☐ Prøve tatt fra skjede	
	☐ Uopplyst	
42.	Positivt svar PCR/Dyrkning (0-prøve)	
	☐ Ikke tatt	
	Ingen infeksjon	
	Gardnerella	
	Herpes simplex	
	☐ Anogenitale vorter ☐ Klam. fra livmorhalskanal/skjede	
	□ Klam. urin	
	□ Klam. anus	
	☐ Klam. munn	
	☐ Gc-prøve fra livmorhalskanal/skjede	
	☐ Gc urethra	
	☐ Gc anus	
	☐ Gc munn	
	Urindyrking (urinveisinfeksjon)	
	Candida	
	☐ Trichonomas	
	☐ Annet, spesifiser under	
43.	Uopplyst Spesifiser annet	

44.	Positivt svar PCR/Dyrkning (senere prøve)	
	☐ Ikke tatt	
	☐ Ingen infeksjon	
	Gardnerella	
	☐ Herpes simplex	
	☐ Anogenitale vorter	
	☐ Klam. livmorhalskanal/ skjede	
	☐ Klam. urin	
	☐ Klam. anus	
	☐ Klam. munn	
	☐ Gc livmorhalskanal/ skjede	
	☐ Gc urethra	
	☐ Gc anus	
	☐ Gc munn	
	☐ Urindyrking (urinveisinfeksjon)	
	☐ Candida	
	☐ Trichonomas ☐ Annet, spesifiser under	
	☐ Uopplyst	
	Kryss ved positivt svar	
45.	Spesifiser annet	
46.	Positive prøvesvar (0-prøve)	
	☐ 0-prøve ikke tatt	
	☐ Ingen positive prøvesvar	
	☐ Hepatitt B	
	Hepatitt C	
	HIV	
	Herpes simplex antist	
	Syfilis	
	☐ Annet, spesifiser	
47.	Uopplyst Spesifiser annet	
47.	Spesifiser affried	
48.	Positive prøvesvar (senere prøve)	
	☐ Ingen senere prøve tatt	
	☐ Ingen positive prøvesvar	
	☐ Hepatitt B	
	hepatitt Bs antistoff lavt titer (<100 IU/l)	
	☐ Hepatitt Bs antistoff høyt titer (immun) (>100 IU/I)	
	☐ Hepatitt C	
	□ HIV	
	Syfilis	
	Herpes simplex antist	
	Annet, spesifiser	
	Uopplyst	
49.	Spesifiser annet	
Sporprø	over -	
50.	Sporprøver tatt	
	☐ Ingen sporprøver tatt	
	☐ Prøve tatt fra ytre kjønnsorgan	
	☐ Prøve tatt fra ytre skjede	
	☐ Prøve tatt fra indre skjede	
	☐ Prøve tatt fra livmorhalskanalen	
	☐ Prøve tatt fra ytre endetarm	
	☐ Prøve tatt fra indre endetarm	
	☐ Prøve tatt fra munn	
	Prøve tatt fra neglekanter	
	☐ Klær tatt i beslag på mottaket	
	Annet, spesifiser under	
	Uopplyst	
	Save	
51.	Spesifiser annet	
52.	Sporprøver hentet av politiet	
JZ.	Sporprøver hentet av politiet  Nei	
	o no	

\_

	O Uopplyst
53.	Etter hvor lang tid etter undersøkelsen ble prøvene hentet av politiet
	antall dager
54.	Dato for politiets henting av prøver
55.	Har pasienten badet/dusjet eller skiftet klær før undersøkelsen?
	☐ Ikke dusjet eller skiftet klær
	☐ Dusjet/badet
	☐ Skiftet klær
	Annet
	Uopplyst
56.	Angi evt annet:
57.	Annet:
	^
	<b>▽</b>
	Max 255 characters. remaining.
	Andre opplysninger / Additional Information or Corrections
	^
	Lagre svar / Save and view log Tilbakestill skjema / Reset
	Vis svarhistorikk / View log Print page

If System Error, Print Screen and send image to Berit.Bjelkasen@ntnu.no | Last updated: 03.06.2014

□ NTNU Norges teknisk-naturvitenskapelige universitet

Det medisinske fakultet > Institutt for kreftforskning og molekylær medisin

#### Voldtektsregistrering

Cecilie Hagemann St. Olavs Hospital (400)

Participant No: 14 Inclusion date: 26/07/2011

Annen deltager / Another participant

Log out →	Sårbarhetsfaktorer-rus-oppfølging-retts
Initial Page	Sårbarhetsfaktorer
Change password	Tidligere psykiatrisk anamnese
I6	□ Nei
Information	☐ Ja, uspes.
Statistics	☐ Tidligere innlagt psyk
Study Progress	☐ Tidligere psyk. beh.
-	☐ Tidligere rusmisbruker*
Study Documents	☐ Uopplyst
Vis svarhistorikk / View log	* Tidligere, dvs tørrlagt
Identification	2. Handikapp / funksjonshemmet
	☐ Nei
Study parts	☐ Psykisk, uspes
Undersøkelsen-Anmeldelse	Fysisk, uspes
Pasienten-overgriper- hendelsen	☐ Rusmisbruker* ☐ Sikkert mentalt tilbakestående
Anamnese-funn-behandling-	☐ Sikkert mentalt ulbakestaende ☐ Andre fysiske (sanser, bevegelse)
prøver Sårbarhetsfaktorer-rus-	* Nåværende, hvilke(t) rusmiddel
opprøiging-retts	3. Angi rusmiddel
Skader	
	Alkohol/rus-inntak ved overgrepet
	4. * Alkohol (forurettede) Selvrapportert inntak (frivillig)
	☐ Intet alkoholinntak
	☐ Mindre inntak (< 5 alkoholenheter*)
	Større inntak (5 alkoholenheter eller mer/evt. synlig beruset).
	☐ Større inntak med amnesiperiode ("Black outs" eller dyp søvn)
	☐ Uaktuelt – gammel sak eller residiverende overgrep
	Uopplyst
	* 1 alkoholenhet = 33 cl øl, 1 glass vin eller 1 drink  5. Tid på døgnet for alkoholinntak, start-tidspkt. Dato (dd.mm.åååå)
	(
	6. Tid på døgnet for alkoholinntak, start-tidspkt. Klokkeslett (tt:mm)
	7. Tid på døgnet for alkoholinntak, stopp-tidspkt. Dato (dd.mm.åååå)
	8. Tid på døgnet for alkoholinntak, stopp-tidspkt. Klokkeslett (tt:mm)
	9. Påført rus
	Nei, ingen mistanke om dette
	Ja, mener å være påført rusmiddel/legemiddel
	Uopplyst
	10. Mistanke om spes stoff? mengde?
	Save
	11. Tid på døgnet for mistenkt inntak påført rusmiddel. Dato (dd.mm.åååå)
	12. Tid på døgnet for mistenkt inntak påført rusmiddel. Klokkeslett (tt:mm)
	13. Annet rusmiddel/legemiddel (forurettede)*
	O Nei
	O Ja
	O Uopplyst
	* Selvrapportert inntak (frivillig)
	14. Hvilke(t) stoff(er) 1, mengde:
	15. Stoff/ medikament1: Tid på døgnet for inntak stoff/medik, start-tidspkt. Dato (dd.mm.åååå)
	16 Stoff/ modily month. Tid of depart for instaly stoff/modily stort hidself (Maldeslath (Manager))
	16. Stoff/ medikament1: Tid på døgnet for inntak stoff/medik, start-tidspkt. Klokkeslett (tt:mm)
	17. Stoff/ medikament1: Tid på døgnet for inntak stoff/medik, stopp-tidspkt. Dato (dd.mm.åååå)

18.	Stoff/ medikament1: Tid på døgnet for inntak stoff/medik, stopp-tidspkt. Klokkeslett (tt:mm)
19.	Hvilke(t) stoff(er) 2, mengde:
20.	Stoff/ medikament2: Tid på døgnet for inntak stoff/medik, start-tidspkt. Dato (dd.mm.åååå)
	Save
21.	Stoff/ medikament2: Tid på døgnet for inntak stoff/medik, start-tidspkt. Klokkeslett (tt:mm)
22.	Stoff/ medikament2: Tid på døgnet for inntak stoff/medik, stopp-tidspkt. Dato (dd.mm.åååå)
23.	Stoff/ medikament2: Tid på døgnet for inntak stoff/medik, stopp-tidspkt. Klokkeslett (tt:mm)
24.	Hvilke(t) stoff(er) 3, mengde:
25.	Stoff/ medikament3: Tid på døgnet for inntak stoff/medik, start-tidspkt. Dato (dd.mm.ååååå)
26.	Stoff/ medikament3: Tid på døgnet for inntak stoff/medik, start-tidspkt. Klokkeslett (tt:mm)
27.	Stoff/ medikament3: Tid på døgnet for inntak stoff/medik, stopp-tidspkt. Dato (dd.mm.åååå)
28.	Stoff/ medikament3: Tid på døgnet for inntak stoff/medik, stopp-tidspkt. Klokkeslett (tt:mm)
29.	Evt. flere opplysninger om stoff/medikament inntak
	<u> </u>
00 101	Max 255 characters. remaining.
30. 🕷	Alkohol (overgriper)
	O Nei
	O Ja
	OUopplyst
	Save
31.	Annet rusmiddel/legemiddel (overgriper)
	O Nei
	O Ja, kjent misbruker
	O Ja, ruset ved overgrepet
	O Uopplyst
	ing ved lege ved voldtektsmottaket / gyn pol
32. 🕷	Oppfølgning intervall til første kontroll
	O Møter ikke
	O < 3 uker
	O 3 uker - 3 måneder O > 3 måneder
	Ingen kontroll avtalt     Uopplyst
33.	Kontroll hos lege ved voldtektsmottaket etterpå. Antall ganger
55.	0 0
	O 1
	2 eller flere
Oppføld	ing ved psykiatrisk sykepleier/rådgiver/psykolog BUK
34. 🕷	Ved ankomst: Informert om oppfølgingstilbud:
	O Nei
	O Ja
	O Uopplyst
35. 🕸	Hvis ja, ønsket kontakt/oppfølging
	□ Nei
	□ Ja
	☐ Hadde annen oppfølging
	□ Uopplyst
36.	Kontakt med rådgiver:
	O Nei
	○ Ja, rådgiver ringte
	Ja, pasienten tok selv kontakt
	O Ja, pårørende tok kontakt
	O Annet, spes. under
	O Uopplyst
37.	Antall dager etter akutthenvendelsen

38.	Hvis annet, spesifiser	
39.	Antall telefonkonsultasjoner med rådgiver	
40.	Antall samtaler med rådgiver	
41.	Save Pårørende , antall telefonkonsultasjoner m rådgiver	
41.	Parørence , antali telefonkonsultasjoner m raugiver	
42.	Pårørende, antall samtaler m rådgiver	
42	11312 28 2 2 2 2	
43.	Hvilke pårørende?	
	□ Far	
	Partner	
	☐ Annen familie, hvilke	
	☐ Andre, hvilke	
	☐ Uopplyst	
44.	Angi annen familie og andre	
45.	Hvordan sluttet kontakten?	
	☐ Etter gjensidig avtale	
	☐ Pasienten ønsket å slutte	
	☐ Pasienten uteble	
	Rådgiver besluttet å slutte	
	Annen hjelpeinstans overtok	
	Annet	
	Uopplyst	
46.	Angi annet	
Rettsve	esen	
47.	Rådgiver / psykiatrisk sykepleier og kontakt med rettsvesen	
	☐ Ingen kontakt m/politi/ rettsvesen	
	☐ Kontakt med bistandsadvokat	
	☐ Kontakt med aktor	
	☐ Kontakt med forsvarer	
	Skrevet erklæring til aktorat	
	☐ Skrevet erklæring til bistandsadvokat ☐ Rådgiver innkalt som vitne	
	Uppplyst	
48.	Psykiatrisk sykepleiers post- traumatisk stress score	
	☐ Ingen problemer	
	☐ Søvnproblemer	
	☐ Drømmer eller mareritt om det som er hendt	
	Depresjon, nedtrykt sinnstilstand	
	Skvettenhet ved plutselige lyder eller brå bevegelser	
	Tendenser til å isolere seg fra andre	
	☐ Irritasjon, blir lett ergelig ☐ Følelser som svinger lett opp og ned	
	□ Dårlig samvittighet, selvbebreidelser, skyldfølelse	
	☐ Frykt for situasjoner som minner om det som er hendt	
	☐ Anspenthet i kroppen	
	☐ Nedsatt evne til å huske	
	☐ Dårlig konsentrasjonsevne	
	Annet	
40	Uppplyst (1.4.2)	
49.	Scoringsverdi (0-12)	
50.	Etter hvor lang tid etter overgrepet ble post-traumatisk stress scoret (symptomer oppgitt)	
	antall dager	
	Save	
51.	Dato for posttraumatisk stress score	
52. 🗯	Legeerklæring sendt til politi:*	
	Nei	

	O Ja, men ikke innkalt som vitne	
	Ja, og lege innkalt som vitne	
	Ja, andre innkalt som vitne	
	O Uopplyst	
	* Rettsmedisinsk journal etter egen mal for voldtektssaker	
53.	Etter hvor lang tid ble legeerklæring innsendt til politiet (mnd)	
F.4	Construction for a Market Market	
54.	Signeringsdato for erklæring til politiet	
55.	Tilbakemelding fra Den Rettsmedisinske Kommisjon	
	O Nei	
	O Ja, og ingen kommentar	
	Ja, og mindre kommentarer, ikke nødvendig med tilleggserklæring	
	O Ja, og nødvendig med tilleggserklæring	
	O Annet	
	O Uopplyst	
56.	Tilbakemelding fra Den rettsmedisinske kommisjon datert	
57. 🖹	/rus-detaljer Rusprøve tatt	
37. m	☐ Ingen rus-prøver tatt	
	☐ Ja, rus-urinscreening	
	☐ Ja, blodprøve	
	☐ Ja, kun blod-alkohol tatt	
	☐ Ikke aktuelt	
	☐ Uopplyst	
	tid for prøvetaking rusprøver	
58.	Urin dato: (dd.mm.åååå)	
59.	Urin klokkeslett: (tt:mm)	
39.	Offit Klokkesiett. (tt.fillif)	
60.	Blod dato: (dd.mm.åååå)	
	Save	
61.	Blod klokkeslett: (tt:mm)	
62.	Ca tid fra starttidspunkt for hendelsen til prøvetaking urin, timer	
63.	Ca tid fra starttidspunkt for hendelsen til prøvetaking blod, timer	
64.	Rusprøver sendt hvor?	
	☐ Farmak.avd., St Olav*	
	☐ Folkehelseinst., Oslo	
	☐ Klinisk kjemisk avdeling, St Olavs	
	☐ Annet	
	□ Uopplyst	
	Akkreditert for rettsmed –bruk fra 2007	
65.	Symptomer angitt av pasienten	
	☐ Ingen ☐ Blackout	
	☐ Trøtt, sedert, sløv	
	Oppstemt, euforisk, ukritisk	
	□ Annet	
	☐ Uopplyst	
66.	Annet, spesifiser	
67.	Kliniske tegn på ruspåvirkning	
	Ingen tegn	
	Unormalt trøtt, sedert, sløv	
	Oppstemt, euforisk, ukritisk	
	Små pupiller*	
	☐ Utvidede pupiller** ☐ Uttalt alkoholpåvirkning	
	☐ Uttait aikonolpavirkning ☐ Lett alkoholpåvirkning	
	☐ Annet	
	☐ Uopplyst	
	* Opioider kan gi små pupiller, ** Kan være stressbetinget	
68.	Annet, spesifiser	

Andre opplysninger / Additional Information or Corrections	
Ô	
Lagre svar / Save and view log Tilbakestill skjema / Reset	
Vis svarhistorikk / View log	int page

If System Error, Print Screen and send image to Berit.Bjelkasen@ntnu.no | Last updated: 03.06.2014

# □ NTNU Norges teknisk-naturvitenskapelige universitet Det medisinske fakultet > Institutt for kreftforskning og molekylær medisin

### Voldtektsregistrering

Cecilie Hagemann St. Olavs Hospital (400)

Participant No: 14 Inclusion date: 26/07/2011 Annen deltager / Another participant

Log out →	Skad	ler
Initial Page	Anoge	nitale skader påvist
Change password	1.	Markert på skisse
Information		O Ja
Statistics		O Nei
	2.	Uopplyst
Study Progress	۷.	Foto/video  Ja
Study Documents		O Nei
Vis svarhistorikk / View log		O Uopplyst
Identification	3.	Kolposkopi
Study parts		O Ja
		O Nei
Undersøkelsen-Anmeldelse  Pasienten-overgriper-	4. 樂	O Uopplyst GU utført
Pasienten-overgriper- hendelsen	7. 40	O Ja, akutt
Anamnese-funn-behandling- prøver		Nei, ikke indikasjon
Sårbarhetsfaktorer-rus- oppfølging-retts		O Nei, pas ønsket det ikke
Skader		O Ja, men ikke akutt
		O Annet
	5.	O Uopplyst Annet, spesifiser
	٥.	Amer, spesified
	6. 🕷	Anoskopi utført
		O Ja, akutt
		Nei, ikke indikasjon
		Nei, pas ønsket det ikke Ja, men ikke akutt
		O Annet
		O Uopplyst
	7.	Annet, spesifiser
	_	
	8.	Hvis skade er påvist, angi lokalisasjon:  Labia majora
		☐ Labia minora
		Periurethralt
		☐ Perineum
		Bakre kommissur
		☐ Fossa navicularis
		☐ Hymen ☐ Vaginalvegg
		□ Portio
		☐ Anus
		Rectum
		☐ Annet ☐ Uopplyst
	9.	Annet, spesifiser
	10.	Type anogenital-skade:
		☐ Ingen skade
		Rifter, lacerasj, fissur
		☐ Hud/slimhinne-avskrap ☐ Blåflekk, ekkymose
		Petekkier
		Rødhet
		Hevelse
		☐ Ømhet/smerte*
		☐ Annet ☐ Uopplyst
		* Ingen synlig skade, men palpasjonsømhet

	Save
11.	Annet, spesifiser
12.	Om hymenskade
	Normal hymenalrest, uten tegn til ferske skader
	Fersk gjennomgående rift/kløft i hymen
	Rødblå misfarging/ ekkymose
	Slimhinneavskrap
	Hymen uten dype kløfter baktil
	☐ Petekkier ☐ Rødhet
	□ Hevelse
	☐ Annet
	☐ Uopplyst
13.	Annet, spesifiser
14.	Om anale skader
	☐ Ingen fersk skade påvist
	☐ Fersk rift / fissur
	☐ Ekkymose
	☐ Slimhinneavskrap
	☐ Venøs stase
	Perianalt arrvev*
	Hemorhoider
	Marisker
	Petekkier
	☐ Rødhet ☐ Hevelse
	□ preveise
	□ Uopplyst
	□ Annet
	* DD: Mb Crohn, ulykker, tidligere med. prosedyrer
15.	Annet, spesifiser
16.	Om roctale skader
	Om rectale skader
	$\square$ Ingen fersk skade påvist
	☐ Ingen fersk skade påvist ☐ Ekkymose
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi)
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi) ☐ Hemorhoider
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi)
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi) ☐ Hemorhoider ☐ Petekkier
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi) ☐ Hemorhoider ☐ Petekkier ☐ Rødhet
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi) ☐ Hemorhoider ☐ Petekkier ☐ Rødhet ☐ Hevelse
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi) ☐ Hemorhoider ☐ Petekkier ☐ Rødhet ☐ Hevelse ☐ Ømhet
17.	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi) ☐ Hemorhoider ☐ Petekkier ☐ Rødhet ☐ Hevelse ☐ Ømhet ☐ Annet
17.	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi) ☐ Hemorhoider ☐ Petekkier ☐ Rødhet ☐ Hevelse ☐ Ømhet ☐ Annet ☐ Uopplyst  Annet, spesifiser
	☐ Ingen fersk skade påvist ☐ Ekkymose ☐ Slimhinneavskrap ☐ Venøs stase ☐ Interne rifter (ved anoskopi) ☐ Hemorhoider ☐ Petekkier ☐ Rødhet ☐ Hevelse ☐ Ømhet ☐ Annet ☐ Uopplyst  Annet, spesifiser ☐ Type anogenital skade Fossa navicularis
17.	Ingen fersk skade påvist  Ekkymose Slimhinneavskrap Venøs stase Interne rifter (ved anoskopi) Hemorhoider Petekkler Rødhet Hevelse Ømhet Annet Uopplyst Annet, spesifiser  Type anogenital skade Fossa navicularis Normal, ingen skade
17.	Ingen fersk skade påvist  Ekkymose Slimhinneavskrap Venøs stase Interne rifter (ved anoskopi) Hemorhoider Petekkler Rødhet Hevelse Ømhet Annet Uopplyst  Annet, spesifiser  Type anogenital skade Fossa navicularis Rift / laserasjon/ fissur
17.	Ingen fersk skade påvist  Ekkymose Slimhinneavskrap Venøs stase Interne rifter (ved anoskopi) Hemorhoider Petekkier Rødhet Hevelse Ømhet Annet Uopplyst Annet, spesifiser  Type anogenital skade Fossa navicularis Normal, ingen skade Rift / laserasjon/ fissur Hud/slimhinne-avskrap
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Type anogenital skade Fossa navicularis   Normal, ingen skade   Rif / laserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Type anogenital skade Fossa navicularis   Normal, ingen skade   Rift / laserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)   Petekkier
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Type anogenital skade Fossa navicularis   Normal, ingen skade   Riff / laserasjon/ fissur   Hud/slimhinne-avskrap   Bilåflekk (ekky-mose)   Petekkier   Rødhet
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Type anogenital skade Fossa navicularis   Normal, ingen skade   Rift / laserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)   Petekkier
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Type anogenital skade Fossa navicularis   Normal, ingen skade   Rift / laserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)   Petekkler   Rødhet   Hevelse   Rødhet   Hevelse   Rødhet   Hevelse
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Type anogenital skade Fossa navicularis   Normal, ingen skade   Rift / laserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)   Petekkier   Rødhet   Hevelse   Ømhet   Mekker   Rødhet   Hevelse   Ømhet   Mekker   Mekker   Rødhet   Hevelse   Ømhet   Mekker   Mekker
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Type anogenital skade Fossa navicularis   Normal, ingen skade   Rift / laserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)   Petekkier   Rødhet   Rødhet   Hevelse   Ømhet   Annet   Hevelse   Ømhet   Annet   Annet   Rødhet   Hevelse   Ømhet   Annet   A
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Piglia fileskopen skade   Rif / Iaserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Mormal, ingen skade   Rif / Iaserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet   Uopplyst   Annet   Uopplyst   Annet   Uopplyst   Annet, spesifiser   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Rødhet   Hevelse   Mormal Roman (Roman (Roma
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Bifflekk (ekky-mose)   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Individual skade Fossa navicularis   Normal, ingen skade   Ritf, laserasjon/ fissur   Hud/slimhinne-avskrap   Bifflekk (ekky-mose)   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Annet   Uopplyst   Annet, spesifiser   Individual skade Bakre kommisur   Type anogenital skade
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   American Safake   Rift / laserasjon/ fissur   Hud/slimhinne-avskrap   Blåflekk (ekky-mose)   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Indicate the state of
17.	Ingen fersk skade påvist   Ekkymose   Slimhinneavskrap   Venøs stase   Interne rifter (ved anoskopi)   Hemorhoider   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Bifflekk (ekky-mose)   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Individual skade Fossa navicularis   Normal, ingen skade   Ritf, laserasjon/ fissur   Hud/slimhinne-avskrap   Bifflekk (ekky-mose)   Petekkier   Rødhet   Hevelse   Ømhet   Annet   Uopplyst   Annet, spesifiser   Annet   Uopplyst   Annet, spesifiser   Individual skade Bakre kommisur   Type anogenital skade

	☐ Blåflekk (ekky-mose)
	Petekkier
	Rødhet
	Hevelse
	□ Ømhet
	Annet
	Uopplyst
	Save
21.	Annet, spesifiser
22.	Type anogenital skade Perineum
	□ Normal, ingen skade
	Rift / laserasjon/ fissur
	Hud/slimhinne-avskrap
	☐ Blåflekk (ekky-mose)
	Petekkier
	Rødhet
	Hevelse
	□ Ømhet
	☐ Annet
	☐ Uopplyst
23.	Annet, spesifiser
24.	Type anogenital skade Peri-urethralt
	☐ Normal, ingen skade
	Rift / laserasjon/ fissur
	Hud/slimhinne-avskrap
	Blåflekk (ekky-mose)
	Petekkier
	Rødhet
	Hevelse
	☐ Ømhet
	☐ Annet
	Uopplyst
25.	Annet, spesifiser
26.	Type anogenital skade Labia minora
	☐ Normal, ingen skade
	☐ Rift / laserasjon/ fissur
	☐ Hud/slimhinne-avskrap
	☐ Blåflekk (ekky-mose)
	Petekkier
	Rødhet
	Hevelse
	□ Ømhet
	Annet
	Uopplyst
27.	Annet, spesifiser
28.	Type anogenital skade Labia majora
	☐ Normal, ingen skade
	☐ Rift / laserasjon/ fissur
	☐ Hud/slimhinne-avskrap
	☐ Blåflekk (ekky-mose)
	Petekkier
	Rødhet
	☐ Hevelse
	□ Ømhet
	Annet
	Uoppyst
29.	Annet, spesifiser
30.	Type anogenital skade Vaginalvegg
	$\square$ Normal, ingen skade
	☐ Rift / laserasjon/ fissur
	☐ Hud/slimhinne-avskrap
	☐ Blåflekk (ekky-mose)

	☐ Petekkier	
	Rødhet	
	☐ Hevelse	
	☐ Ømhet	
	Annet	
	☐ Uopplyst	
	Save	
31.	Annet, spesifiser	
32.	Type anogenital skade Portio	
	□ Normal, ingen skade	
	Rift / laserasjon/ fissur	
	☐ Hud/slimhinne-avskrap	
	☐ Blåflekk (ekky-mose)	
	Petekkier	
	☐ Rødhet ☐ Hevelse	
	□ Ømhet	
	Annet	
	□ Uopplyst	
33.	Annet, spesifiser	
Antall s	skader pr lokalisasjon	
34.	Hymen	
35.	Fossa navicularis	
26	Data da maria	
36.	Bakre kommisur	
37.	Perineum	
57.	remedii	
38.	Periurethralt	
39.	Labia minora	
40.	Labia majora	
	Save	
41.	Vaginalvegg	
42.	Portio	
12	Anus	
43.	Affus	
44.	Rectum	
45.	Total antall skader genitalt	
46.	Total antall skader perianalt	
47.	Total antall skader anogenitalt	
48.	Utfyllende kommentar	
	<u> </u>	
<b>V</b>	Max 255 characters. remaining.	
49.	lige (ekstragenitale) skader Skader markert på kroppsskisse	
	O Ja	
	○ Nei	
	O Uopplyst	
50.	Foto/video foreligger	
	O Ja	
	O Nei	
	Uopplyst	
	Save	
51. 🕸	Kroppslig undersøkelse utført	

	O Ja, akutt	
	Nei, ikke indikasjon	
	Nei, pas ønsket det ikke  Ja, men ikke akutt	
	Annet	
	O Uopplyst	
52.	Hvis skade er påvist, angi lokalisasjon:	
	☐ Hode/ansikt	
	☐ Hals/svelg	
	☐ Lepper/munnslimhinne/tenner	
	☐ Skuldre	
	□ Bryst/rygg	
	□ Buk	
	☐ Lille bekken (uterus/ blære/ urinrør)	
	□ Hofter	
	☐ Armer/hender	
	□ Ben/føtter	
	☐ Typisk "defence injury"	
	☐ Merker innside lår	
	Annet	
	□ Uopplyst	
53.	Annet, spesifiser	
54.	Hvis skade er påvist, type skade:	
	☐ Rifter, lacerasj, fissur	
	Hudavskrap	
	☐ Blåflekk /ekkymose	
	Petekkier	
	Rødhet	
	☐ Hevelse	
	☐ Ømhet/smerte*	
	☐ Brudd	
	☐ Tannskade	
	Forsturning	
	☐ Indre organ-skade**	
	Hjernerystelse	
	☐ Annen hodeskade	
	Petekkier etter kvelning	
	☐ Bitt-merke	
	Sugemerke	
	Skarpvoldsskade, risp/stikk/skjære/huggsår	
	Skuddsår	
	Arr etter selvskading	
	Merker etter fingre/grep	
	Annet	
	☐ Uopplyst	
55.	* Ingen synlige skader, men palpasjonsømhet, ** F.eks i buken  Spesielt om halsgrep	
	☐ Intet halsgrep	
	☐ Ingen følger	
	☐ Heshet	
	☐ Svelgebesvær	
	□ Pustebesvær	
	☐ Svartning for øynene	
	☐ Besvimelse, bevisstløshet	
	☐ Ufrivillig urin/fæces avgang	
	☐ Annet	
	☐ Uopplyst	
56.	"Injury extent score" Se under Study documents for definisjon	
	O 0	
	0 1	
	O 2	
	○ 3	
	kader kroppslig pr lokalisasjon	
57.	Hode/ansikt	
	United transfer	
FO		

59.	Lepper/munnslimhinne/tenner
60.	Bryst/rygg
	Save
61.	Buk
62.	Lille bekken/(uterus/ blære/ urinrør)
02.	Line bekken/(dierds/ bizere/ diffing)
63.	Armer/hender
64.	Ben/føtter
65.	Typisk "defence injury"
66.	Merker innside lår
00.	rier Rei Illisiue Idi
67.	Merker etter fingre/grep
68.	Antall Annet
69.	Totalt antall kroppslige skader
70.	Totalt antall skader (kroppslige og anogenitale)
70.	Total: antali skader (kroppsiige og anogenitale)
	Save
Unders	økers erfaring
71.	Undersøkers erfaring?
	O Første sak
	O 2-5 saker
	O Håndtert > 5 saker
	Håndtert > 30 saker
	Overlege ved voldtektsmottak
Kontak	O Uopplyst
72.	Aktuelle kontaktårsak
,	□ Voldtekt/forsøk < 14d
	□ Voldtekt/forsøk > 14d
	□ Incest
	☐ Vold i nære relasjoner
	☐ Falsk anmeldelse
	Annet
	Uopplyst
73.	Annet:
	^
	<u> </u>
	Max 255 characters. remaining.
	Andre opplysninger / Additional Information or Corrections
	^
	Lagre svar / Save and view log Tilbakestill skjema / Reset
	Vie graphistariide / View lee
	Vis svarhistorikk / View log Print page

Appendix III

Politiregistrering v	oldte	ekt				Cecilie Hagemann St. Olavs Hospital (400)
		ite: 06/06/2011	An	nen deltager / Another participant		,
Log out →	Ident	tifikasjon / Identi	fication			
Initial Page	1. 💥	Politiets anmeldels	sesnummer			
Change password		2		cechag ( 06/06/2011	)	
Information		Andre opplysninger /	Additional Informat	tion or Corrections		
Statistics						1
Study Progress						
Study Documents						
otady Documents						
Identification						
Study parts						
Rettslige data		Endre andre opplysnii	nger / Save changes	Tilbakestill / Reset		
Overgripere/mistenkte			ngen een en en en gee			
Overgripere/mistenkte 2						Print page
Fornærmede / handlingen						
Etterforskningen						
Medisinske undersøkelser av fornærmede						
Basert på lab-rapport fra Rettsmedisinsk						
Rettstoksikologi						
Variabler fra Overgrepsenhetens registre						
Hendelsen 🗎						
Sykehistorie og funn 🗎						

Participant No: 2001001 Inclusion date: 06/06/2011

Cecilie Hagemann St. Olavs Hospital (400)

Annen deltager / Another participant

C Frøya lensmannskontor © Røros lensmannskontor

Log out →	Retts	lige data		
Initial Page	1. *	Anmeldelsestidspunkt Dato (dd.mm.åååå)		
Change password				
Information	2. 💥	Hvem anmelder?		
information		C Politipatrulje		
Statistics		C Fornærmede selv		
Study Progress		C Familie		
		C Annen relasjon		
Study Documents		C Helsetjenesten		
Vis svarhistorikk / View log		Anmeldelsestidspunkt Dato (dd.mm.åååå)  Hvem anmelder?  C Politipatrulje C Fornærmede selv C Famille C Annen relasjon		
		Hvem anmelder? C Politipatrulje C Pormærmede selv C Familie C Annen relasjon C Helsetjenesten C Annen offentlig tjeneste C Annet C Uopplyst Hvis annet, hvem? Fornærmede ønsker ikke å anmelde? C Nei, vil likke anmelde C Ja, vil anmelde C Uopplyst Hvis annet, hva Hvis annet, hva  Hvis annet, hva  Anmeldelsessted (Politienhet) C Sentrum politistasjon C Kizebu lensmannskontor Melhus lensmannskontor Melhus lensmannskontor C Melvik lensmannskontor C Melvik lensmannskontor C Melvik lensmannskontor C Hemne og Snillfjord lensmannskontor C Hemne og Snillfjord lensmannskontor C Holtåle lensmannskontor C Røros lensmannskontor		
Identification		C Politipatrulje C Fornærmede selv C Familie C Annen relasjon C Helsetjenesten C Annen offentlig tjeneste C Annet C Uopplyst Hvis annet, hvem?  Fornærmede ønsker ikke å anmelde? C Ja, vil anmelde C Ja, vil anmelde C Uopplyst C Annet Hvis annet, hva  # Anmeldelsessted (Politienhet) C Sentrum politistasjon C Heimdal politistasjon C Heimdal politistasjon C Klæbu lensmannskontor C Malvik lensmannskontor C Malvik lensmannskontor C Meldus lensmannskontor C Hitra lensmannskontor C Hemne og Snillfjord lensmannskontor C Hitra lensmannskontor C Frøya lensmannskontor C Røros lensmannskontor C Røros lensmannskontor C Hottålen lensmannskontor C Hottålen lensmannskontor C Røros lensmannskontor C Røros lensmannskontor C Hottålen lensmannskontor C Hottålen lensmannskontor C Hottålen lensmannskontor C Hottålen lensmannskontor C Røros lensmannskontor C Hottålen lensmannskontor		
Study parts	3.	Hvis annet, hvem?		
Rettslige data 🗎	4. 💥	Fornarmodo greker ikke § annolde?		
Overgripere/mistenkte	4.36			
Overgripere/mistenkte 2  Fornærmede / handlingen				
Etterforskningen				
Medisinske undersøkelser av				
fornærmede  Basert på lab-rapport fra	_			
Rettsmedisinsk	5.	HVIS annet, nva		
Rettstoksikologi	6. 🕸	Anmaldalsessted (Politianhet)		
Variabler fra  Overgrepsenhetens registre	0. 45			
Hendelsen 🖟				
Sykehistorie og funn 🛡				
		_		
		C Røros lensmannskontor		
		C Holtålen lensmannskontor		
		Midtre Gauldal lensmannskontor		
		© Rennebu lensmannskontor		
		C Oppdal lensmannskontor		
		C Rissa lensmannskontor		
		© Ørland og Bjugn lensmannskontor		
		C Åfjord lensmannskontor		
		C Selbu og Tydal lensmannskontor		
		O Annet		
		O Uopplyst		
	7.	Hvis annet, hva		
	o Mi			
	8. 🕷			
		Skaun lensmannskontor		
		Orkdal og Agdenes lensmannskontor Meldal lensmannskontor		
		Hemne og Snillfjord lensmannskontor		
		Hitra lensmannskontor		

	C Holtålen lensmannskontor
	Midtre Gauldal lensmannskontor
	C Rennebu lensmannskontor
	C Oppdal lensmannskontor
	C Rissa lensmannskontor
	© Ørland og Bjugn lensmannskontor
	Áfjord lensmannskontor     Selbu og Tydal lensmannskontor
	C Annet
	C Uopplyst
9.	Hvis annet, hva
10.	Dato for påtalemessig avgjørelse (dd.mm.åååå)
	Save
11.	Dato for rettskraftig avgjørelse (første endelige dom): (dd.mm.åååå)
12.	 Rettskraftig avgjørelse:
12.	☐ Ikke straffbart forhold (10/50)
	Henlagt p.g.a. foreidelse (15/67)
	Påtale trukket
	Henlagt, manglende opplysninger om gjerningsperson (14)
	☐ Henlagt pga mangel på bevis/ bevisets stilling (17/58)
	Henlagt, gjerningsperson ikke strafferettslig ansvarlig (65)
	Forelegg (40)
	☐ Tiltale/domstolsbehandling (42)
	Annet
	☐ Henlagt pga ressursmangel (25/78)
	Henlagt, åpenbar grunnløs (26/104)
	□ Jevnbyrdighet i alder og utvikling (60)
	□ Konfliktråd (37/44)
	Siktelse (tilståelsesdom) (41)
	Påtaleunnlatelse (43)
	□ Ennå ikke rettskraftig avgjort
	☐ Ukjent avgjørelse/ikke opplyst
13.	Hvis annet, angi
14.	Avgjørelseskode:
15.	Initialt henlagt pga uidentifisert gjerningsperson:
13.	Nei
	C Ja
	C Ikke opplyst
16.	Dersom tiltale:
10.	☐ Ubetinget fengsel
	□ Betinget fengsel
	□ Dels ubetinget, dels betinget fengsel
	Annen straff *
	□ Frifinnelse
	□ Erstatning
	□ Annet
	☐ Ikke opplyst
	* F.eks. Bot, inndragning, samfunnstjeneste, rettighetstap (besøksforbud, sikring, voldsalarm)
17.	Dersom annen straff, erstatning eller annen tiltale, angi:
	May 255 shows than
10	Max 255 characters. remaining.

	Max 255 characters. remaining.	
19.	Hvilke(n) straffekode(r) er brukt (STRASAK-koder)?	
	© 1401: Voldtekt (§l92, 1. og 2.ledd)	
	C 1413: Forsøk på voldtekt (§192, jfr §49)	
	© 1420: Voldtekt (§192, 3.ledd) (grovere)	
	© 1423 Grov uaktsom voldtekt (§192, 4. ledd)	
	O Annet	
	C Ikke opplyst	
20.	Dersom annen straffekode, angi:	
	Save	
21		
21.	Ble dommen anket?	
	O Nei	
	O Ja, av påtalemyndighetene	
	O Ja, av påtalte	
	O Ja, av begge parter	
	O Uopplyst	
	C Ikke aktuelt	
22.	Utfall av eventuell anke:	
22.	Ottali av eventueli anke.	
	Max 255 characters. remaining.	
	remaining.	
	Andre opplysninger / Additional Information or Corrections	
	Lagre svar / Save and view log Tilbakestill skjema / Reset	
	Vis svarhistorikk / View log	Print page

Participant No: 2001001 Inclusion date: 06/06/2011

Cecilie Hagemann St. Olavs Hospital (400)

1 Inclusion date: 06/06/2011 Annen deltager / Another participant

Log out →	Overgripere/mistenkte	
Initial Page	Dersom flere overgripere, føres opplysningene på I, II og III etter grad av deltakelse i overgrepet.	
Change password	Antall overgripere	
Information		
	Opplysninger føres på overgriper I & II & III etter hvem som er viktigst	
Statistics	2.   Kjønn overgriper I	
Study Progress	C Mann C Kvinne	
Study Documents	C Uopplyst	
ottaty Doutmonto	3. Kjønn overgriper II	
Vis svarhistorikk / View log	O Uopplyst	
Identification	O Mann	
Study parts	© Kvinne	
	4. Kjønn overgriper III	
Rettslige data		
Overgripere/mistenkte  Overgripere/mistenkte 2	C Uopplyst C Mann	
Fornærmede / handlingen		
Etterforskningen	C Kvinne	
Medisinske undersøkelser av	5. ** Alder overgriper I	
fornærmede  Basert på lab-rapport fra	(co. patall 8v)	
Rettsmedisinsk	(ca., antall år) 6. Alder overgriper II	
Rettstoksikologi	- Add overgriper in	
Variabler fra Overgrepsenhetens registre	7. Alder overgriper III	
Hendelsen	, and overgripe in	
Sykehistorie og funn 🗎	8. * Etnisitet overgriper I	
	O Norsk	
	O Annet	
	O Ikke norsk, vestlig	
	Ikke norsk, ikke vestlig	
	O Uopplyst	
	9. Annen etnisitet, spesifiser	
	Author extractly specified	
	10. Etnisitet overgriper II	
	O Norsk	
	C Annet	
	O Ikke norsk, vestlig	
	O Ikke norsk, ikke vestlig	
	O Uopplyst	
	Save	
	11. Annen etnisitet, spesifiser	
	12. Etnisitet overgriper III	
	O Norsk	
	C Annet	
	O Ikke norsk, vestlig	
	O Ikke norsk, ikke vestlig	
	© Uopplyst	
	13. Annen etnisitet, spesifiser	
	14. Bosted overgriper I	
	C Trondheim by	
	Sør-Trøndelag utenom byen	
	O Utenfor fylket	
	C Utenfor landet	
	© Uopplyst	
	C Ikke aktuelt	
	15. Bosted overgriper II	
	13. Dosted Overgriper 11	

	C Trondheim by	
	C Sør-Trøndelag utenom byen	
	O Utenfor fylket	
	O Utenfor landet	
	C Uopplyst	
	O Ikke aktuelt	
16.	Bosted overgriper III	
	C Trondheim by	
	Sør-Trøndelag utenom byen	
	Utenfor fylket	
	C Utenfor landet	
	O Uopplyst	
	C Ikke aktuelt	
17. *	Er mistenkte I i arbeid utenfor hjemmet?	
	○ Nei	
	O Ja	
	C Uopplyst	
	C Ikke aktuelt	
18. 🕷	Er mistenkte II i arbeid utenfor hjemmet?	
	○ Nei	
	O Ja	
	O Uopplyst	
	○ Ikke aktuelt	
19. *		
19. 🛪	Er mistenkte III i arbeid utenfor hjemmet?	
	O Nei	
	Оја	
	O Uopplyst	
	C Ikke aktuelt	
20.	Hvis nei mistenkt I	
	C Hjemmeværende	
	Skoleelev	
	C Student	
	C På stønad	
	O Arbeidsledig	
	C Annet	
	○ Ikke aktuelt	
	Save	
21.	Hvis annet mistenkt I, angi	
21.	TWIS differ fillscenke 1, angl	
22	Lhuis noi mistanta TI	
22.	Hvis nei mistenkt II	
	O Hjemmeværende	
	C Skoleelev	
	C Student	
	C På stønad	
	C Arbeidsledig	
	O Annet	
	C Ikke aktuelt	
22		
23.	Hvis annet mistenkt II, angi	
24.	Hvis nei mistenkt III	
	C Hjemmeværende	
	○ Skoleelev	
	C Student	
	C På stønad	
	O Arbeidsledig	
	- Albeidsledig	
	G. Annah	
	O Annet	
	C Ikke aktuelt	
25.		
	C Ikke aktuelt  Hvis annet mistenkt III, angi	
25.	C Ikke aktuelt	
	C Ikke aktuelt  Hvis annet mistenkt III, angi	
	C Ikke aktuelt  Hvis annet mistenkt III, angi  Hvilken utdannelse har mistenkte I?  C Mindre enn 9 år	
	C Ikke aktuelt  Hvis annet mistenkt III, angi  Hvilken utdannelse har mistenkte I?  C Mindre enn 9 år  C 9-12 år	
	C Ikke aktuelt  Hvis annet mistenkt III, angi  Hvilken utdannelse har mistenkte I?  C Mindre enn 9 år  C 9-12 år  C Høyskole	
	C Ikke aktuelt  Hvis annet mistenkt III, angi  Hvilken utdannelse har mistenkte I?  C Mindre enn 9 år  C 9-12 år	

	O Ikke aktuelt	
27.	Hvilken utdannelse har mistenkte II?	
	O Mindre enn 9 år	
	O 9-12 år	
	O Høyskole	
	O Universitet	
	O Uopplyst	
	C Ikke aktuelt	
28.	Hvilken utdannelse har mistenkte III?	
	O Mindre enn 9 år	
	O 9-12 år	
	O Høyskole	
	O Universitet	
	O Uopplyst	
	Ikke aktuelt	
	Andre opplysninger / Additional Information or Corrections	
	Lagre svar / Save and view log Tilbakestill skjema / Reset	
	<u>Vis svarhistorikk / View log</u>	Print page

Participant No: 2001001 Inclusion date: 06/06/2011

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Overgripere/mistenkte 2	
Initial Page		
	1. Tidligere mistenkt for forbrytelse, mistenkt I?	
Change password	O Nei	
Information	O Ja, for vold	
Statistics	O Ja, for seksualforbrytelse	
	O Ja, for narkotika	
Study Progress	O Ja, for skadeverk	
Study Documents	C Ja, for vinning C Ja, for annen krim	
	O Uopplyst	
Vis svarhistorikk / View log	C Ikke aktuelt	
Identification	Hvis annen krim, mistenkt I, angi	
Study parts	The same of the sa	
Rettslige data	3. Tidligere mistenkt for forbrytelse, mistenkt II?	
Overgripere/mistenkte	O Nei	
Overgripere/mistenkte 2 D	O Ja, for vold	
Fornærmede / handlingen	O Ja, for seksualforbrytelse	
Etterforskningen  Medisinske undersøkelser av	O Ja, for narkotika	
tornærmede	C Ja, for skadeverk	
Basert på lab-rapport fra Rettsmedisinsk	C Ja, for vinning	
Rettstoksikologi	O Ja, for annen krim	
Variabler fra Overgrepsenhetens registre	O Uopplyst	
Hendelsen	○ Ikke aktuelt	
Sykehistorie og funn 🛡	4. Hvis annen krim, mistenkt II, angi	
	5. Tidligere mistenkt for forbrytelse, mistenkt III?	
	, ,	
	O Nei	
	O Ja, for vold	
	C Ja, for seksualforbrytelse C Ja, for narkotika	
	O Ja, for skadeverk	
	O Ja, for vinning	
	O Ja, for annen krim	
	O Uopplyst	
	O Ikke aktuelt	
	6. Hvis annen krim, mistenkt III, angi	
	7. Tidligere dømt for forbrytelse, mistenkt I?	
	C Nei	
	C Ja, for vold	
	C Ja, for seksualforbrytelse	
	C Ja, for narkotika	
	O Ja, for skadeverk	
	O Ja, for vinning	
	O Ja, for annen krim	
	O Uopplyst	
	C Ikke aktuelt	
	8. Hvis dømt for annen krim, mistenkt I, angi	
	9. Tidligere dømt for forbrytelse, mistenkt II?	
	O Nei	
	O Ja, for vold	
	O Ja, for seksualforbrytelse	
	O Ja, for narkotika	
	O Ja, for skadeverk	
	O Ja, for vinning	
	O Ja, for annen krim	
	O Uopplyst	
	C Ikke aktuelt	

10.	Hvis dømt for annen krim, mistenkt II, angi	
	Save	
11.	Tidligere dømt for forbrytelse, mistenkt III?	
	O Nei	
	O Ja, for vold	
	O Ja, for seksualforbrytelse	
	O Ja, for narkotika	
	O Ja, for skadeverk	
	O Ja, for vinning	
	C Ja, for annen krim	
	O Uopplyst	
	C Ikke aktuelt	
12.	Hvis dømt for annen krim, mistenkt III, angi	
13.	Inntatt alkohol før handlingen, mistenkt I?	
13.	Nei	
	O Ja	
	© Uopplyst	
	O Ikke aktuelt	
14.	Inntatt alkohol før handlingen, mistenkt II?	
	O Nei	
	O Ja	
	O Uopplyst	
	C Ikke aktuelt	
15.	Inntatt alkohol før handlingen, mistenkt III?	
	C Nei	
	O Ja	
	C Uopplyst	
	○ Ikke aktuelt	
16.	Andre rusmidler, mistenkt I?	
	C Nei	
	O Ja, hva	
	O Uopplyst	
17.	C Ikke aktuelt  Hvis ja, hva (mistenkt I)?	
17.	This ja, the (filsterict ):	
18.	Andre rusmidler, mistenkt II?	
	O Nei	
	O Ja, hva	
	C Uopplyst	
	○ Ikke aktuelt	
19.	Hvis ja, hva (mistenkt II)?	
20.	Andre warridler michaeld III2	
20.	Andre rusmidler, mistenkt III?	
	C Nei C Ja, hva	
	O Uopplyst	
	O Ikke aktuelt	
	Save	
21.	Hvis ja, hva (mistenkt III)?	
22. 💥	Har mistenkte vært til avhør (mistenkte I)?	
	C Nei	
	Оја	
	C Uopplyst	
	O Ikke aktuelt	
23. 🕷	Har mistenkte vært til avhør (mistenkte II)?	
	O Nei	
	О Ја	
	O Uopplyst	
	C Ikke aktuelt	
24. 🕸	Har mistenkte vært til avhør (mistenkte III)?	

	C Nei
	C Ja C Uopplyst
	C Ikke aktuelt
25.	Tid for avhør av mistenkte (dato, dd.mm.åååå)
23.	Tid for avrillar av miscerice (dato, dd.min.adad)
26.	Er mistenkte I varetektsfengslet?
	□ Nei
	□ Uopplyst
	□ Annet
	☐ Ikke aktuelt
27.	Hvis annet
28.	Er mistenkte II varetektsfengslet?
	□ Nei
	□ Ja
	□ Uopplyst
	☐ Annet
	$\square$ Ikke aktuelt
29.	Hvis annet
30.	Er mistenkte III varetektsfengslet?
	□ Nei
	□ Ja
	Uopplyst
	☐ Annet
	☐ Ikke aktuelt
	Save
31.	Hvis annet
32.	Er det oppgitt en psykiatrisk diagnose hos mistenkte før overgrepet? (Mistenkte I)
	□ Nei
	☐ Ja, psykisk utviklingshemming
	☐ Ja, psykose
	☐ Ja, personlighetsforstyrrelse
	Alkohol/rusmisbruk
	Rar", "snodig", "spesiell" *
	Annet
	☐ Ikke aktuelt
33.	* For eksempel snakker med seg selv, unngår øyekontakt med fornærmede  Annet, angi:
55.	Amet, angi.
34.	Er det oppgitt en psykiatrisk diagnose hos mistenkte før overgrepet? (Mistenkte II)
	□ Nei
	☐ Ja, psykisk utviklingshemming
	□ Ja, psykose
	☐ Ja, personlighetsforstyrrelse
	☐ Alkohol/rusmisbruk
	"Rar", "snodiq", "spesiell" *
	□ Annet
	$\square$ Ikke aktuelt
	* For eksempel snakker med seg selv, unngår øyekontakt med fornærmede
35.	Annet, angi:
36.	Er det oppgitt en psykiatrisk diagnose hos mistenkte før overgrepet? (Mistenkte III)
	□ Nei
	☐ Ja, psykisk utviklingshemming
	☐ Ja, psykose
	☐ Ja, personlighetsforstyrrelse
	Alkohol/rusmisbruk
	Rar", "snodig", "spesiell" *
	Annet
	Tikke aktuelt

37.	Annet, angi:	
38.	Er det oppgitt en rettspsykiatrisk konklusjon hos mistenkte I?	
	□ Nei	
	$\square$ Ja, men psykiatrisk lidelse ikke funnet	
	Psykotisk på handlingstiden	
	☐ Bevisstløs på handlingstiden	
	$\square$ Psykisk utviklingshemmet i høy grad	
	Alvorlig psykisk lidelse (men ikke psykotisk)	
	☐ Sterk bevissthetsforstyrrelse	
	☐ Lettere psykisk utviklingshemmet	
	☐ Mangelfullt utviklede sjelsevner	
	$\square$ Varig svekkede sjelsevner	
	$\square$ Fare for gjentakelse av straffbare handlinger	
	☐ Ikke aktuelt	
39.	Er det oppgitt en rettspsykiatrisk konklusjon hos mistenkte II?	
	□ Nei	
	☐ Ja, men psykiatrisk lidelse ikke funnet	
	□ Psykotisk på handlingstiden	
	Bevisstløs på handlingstiden	
	Psykisk utviklingshemmet i høy grad	
	Alvorlig psykisk lidelse (men ikke psykotisk)	
	Sterk bevissthetsforstyrrelse	
	Lettere psykisk utviklingshemmet	
	Mangelfullt utviklede sjelsevner	
	□ Varig svekkede sjelsevner	
	Fare for gjentakelse av straffbare handlinger	
	☐ Tikke aktuelt	
40.	Er det oppgitt en rettspsykiatrisk konklusjon hos mistenkte III?	
40.	Nej	
	☐ Ja, men psykiatrisk lidelse ikke funnet	
	Psykotisk på handlingstiden	
	Bevisstløs på handlingstiden	
	Psykisk utviklingshemmet i høy grad	
	Alvorlig psykisk lidelse (men ikke psykotisk)	
	Sterk bevissthetsforstyrrelse	
	Lettere psykisk utviklingshemmet	
	Mangelfullt utviklede sjelsevner	
	☐ Varig svekkede sjelsevner	
	Fare for gjentakelse av straffbare handlinger	
	☐ Ikke aktuelt	
	Save	
41.	Dato for rettspsykiatrisk konklusjon: (dd.mm.åååå)	
42.	Nekter mistenkte initialt seksuell kontakt med fornærmede (Mistenkte I)?	
	O Nei	
	О Ја	
	O Uopplyst	
	O Ikke aktuelt	
43.	Nekter mistenkte initialt seksuell kontakt med fornærmede (Mistenkte II)?	
	O Nei	
	O Ja	
	O Uopplyst	
	C Ikke aktuelt	
44.	Nekter mistenkte initialt seksuell kontakt med fornærmede (Mistenkte III)?	
	C Nei	
	O Ja	
	C Uopplyst	
	C Ikke aktuelt	

	O Nei
	O Ja
	C Uopplyst
	C Ikke aktuelt
46.	Innrømmer mistenkte (evt. etter hvert) seksuell kontakt med fornærmede(Mistenkte II)?
	O Nei
	O Ja
	© Uopplyst
	○ Ikke aktuelt
47.	Innrømmer mistenkte (evt. etter hvert) seksuell kontakt med fornærmede(Mistenkte III)?
	O Nei
	O Ja
	O Uopplyst
	Ouppiyst  Ikke aktuelt
40	
48.	Innrømmer mistenkte voldtekt/voldtektsforsøk/grov uaktsom voldtekt(Mistenkte I)?
	O Nei
	O Ja
	C Uopplyst
	○ Ikke aktuelt
	C Annet
49.	Hvis annet, hva (Mistenkte I)
50.	Innrømmer mistenkte voldtekt/voldtektsforsøk/grov uaktsom voldtekt(Mistenkte II)?
	O Nei
	O Ja
	© Uopplyst
	○ Ikke aktuelt
	O Annet
	Save
51.	Hvis annet, hva (Mistenkte II)
52.	Innrømmer mistenkte voldtekt/voldtektsforsøk/grov uaktsom voldtekt(Mistenkte III)?
	O Nei
	O Ja
	O Uopplyst
	Ikke aktuelt
	O Annet
53.	Hvis annet, hva (Mistenkte III)
55.	TVIS diffice, TVI (FISCERICE III)
54.	Erkjenner mistenkte straffeskyld (Mistenkte I)?
	O Nei
	O Ja
	O Uopplyst
	C Ikke aktuelt
55.	Erkjenner mistenkte straffeskyld (Mistenkte II)?
	O Nei
	O Ja
	C Uopplyst
	C Ikke aktuelt
56.	Erkjenner mistenkte straffeskyld (Mistenkte III)?
	O Nei
	O Ja
	O Uopplyst
	○ Ikke aktuelt
57.	Ble det foretatt en registrering av mistenktes DNA-profil(Mistenkte I)?
	O Nei
	O Ja
	O Uopplyst
F0	C Ikke aktuelt
58.	Ble det foretatt en registrering av mistenktes DNA-profil (Mistenkte II)?
	O Nei
	O Ja
	C Uopplyst
	C Ikke aktuelt
59.	Ble det foretatt en registrering av mistenktes DNA-profil (Mistenkte III)?

O Nei		
O Ja		
-		
оорр./усс		
Ikke aktuelt		
Andre onniveninger / Addition	onal Information or Corrections	
Andre opplysninger / Addition	onal Information or Corrections	
Lagre svar / Save and view log	Tilbakestill skjema / Reset	
Lagre svar / Save and view log	Tilbakestill skjema / Reset	
Lagre svar / Save and view log	Tilbakestill skjema / Reset	

Participant No: 2001001 Inclusion date: 06/06/2011

Annen deltager / Another participant

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Fornærmede / handlingen
Initial Page	Er fornærmede avhørt?
Change password	© Nei
lufa matia n	O Ja
Information	C Uopplyst
Statistics	C Fornærmede ønsker ikke å bli avhørt
Study Progress	O Annet
Study Documents	2. Hvis annet, angi
Vis svarhistorikk / View log	Tid for avhør av fornærmede (dato, dd.mm.åååå)
Identification	4. Hvis ja, skjedde første avhør før eller etter medisinsk undersøkelse?
Study parts	Før
	© Etter
Rettslige data  Overgripere/mistenkte	Medisinsk undersøkelse ikke utført
Overgripere/mistenkte 2	O Uopplyst
Fornærmede / handlingen	Er det oppgitt en psykiatrisk diagnose hos fornærmede før overgrepet?
Etterforskningen 🗎	□ Nei
Medisinske undersøkelser av fornærmede	☐ Ja, psykisk utviklingshemming
Basert på lab-rapport fra	☐ Ja, psykose
Rettsmedisinsk Rettstoksikologi	☐ Ja, personlighetsforstyrrelse
Variabler fra	☐ Alkohol/rusmisbruk
Overgrepsenhetens registre	☐ Annet
Hendelsen  Sykehistorie og funn	6. Hvis annet, angi hva
,	
	7. Er det oppgitt en psykiatrisk diagnose hos fornærmede etter overgrepet?
	□ Nei
	☐ Ja, post traumatisk stress symptomer
	☐ Ja, psykose
	☐ Ja, suicidalitet
	☐ Alkohol/rusmisbruk
	☐ Angst og/eller depresjon
	□ Annet
	8. Hvis annet, angi hva
	9. Første overgrep: (dd.mm.åååå)
	10. Siste overgrep: (dd.mm.åååå)
	Save
	11. Hvis ett overgrep: Tid på døgnet for overgrepet, start-tidspkt. Dato (dd.mm.åååå)
	12. Hvis ett overgrep: Tid på døgnet for overgrepet, start-tidspkt. Tidspunkt: (tt:mm)
	13. Tid på døgnet for overgrepet, slutt-tidspkt. Dato (dd.mm.åååå)
	14. Tid på døgnet for overgrepet, slutt-tidspkt. Klokkeslett: (tt:mm)
	15. Frekvens
	© Ett overgrep
	© Gientatte overgrep
	C Annet
	© Uopplyst
	Andre opplysninger / Additional Information or Corrections

Lagre svar / S	Save and view log	Tilbakestill skjema / Reset	
Vis svarhistor	ikk / View log		Print page

Participant No: 2001001 Inclusion date: 06/06/2011

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Etterforskningen	
Initial Page	Er det identifisert et åsted?	
Change password	C Nei	
Information	O Ja	
	C Uopplyst	
Statistics	2. Har det vært noen politipatrulje på åstedet?	
Study Progress	O Nei	
Study Documents	○ Ja ○ Uopplyst	
	Har politiet foretatt åstedsundersøkelse?	
Vis svarhistorikk / View log	C Nei	
Identification	O Ja	
Study parts	C Uopplyst	
Rettslige data  Overgripere/mistenkte	4. Tid for åstedsundersøkelse, dato (dd.mm.ååååå)	
Overgripere/mistenkte 2	5. Tid for åstedsundersøkelse, klokkeslett (tt:mm)	
Fornærmede / handlingen	in the decease of the many	
Etterforskningen  Medisinske undersøkelser av	6. Er det foretatt teknisk beslag*?	
fornærmede Basert på lab-rapport fra	□ Nei	
Rettsmedisinsk	☐ Ja, antall oppgis under	
Rettstoksikologi  Variabler fra	□ Film, video □ PC	
Overgrepsenhetens registre	□ PC □ Beslag fra åsted	
Hendelsen  Sykehistorie og funn	□ våpen	
	□ Annet	
	* Se beslagsrapport. Herunder menes ikke rettsmedisinsk beslag.	
	7. Oppgi evt antall beslag	
	8. Hvis andre beslag, angi her	
	9. Er det foretatt sporsikring av biologisk materiale hos fornærmede?  C Nei  C Nei	
	Nei  Solution Ja, hos Overgrepsenheten, St Olavs Hospital	
	O Ja, av andre	
	O Uopplyst	
	10. Hvis andre, angi	
	Save  11. Tid for sporsikring fornærmede, dato (dd.mm.åååå)	
	in the spotshing formatticacy data (administrator)	
	12. Tid for sporsikring fornærmede, klokkeslett (tt:mm)	
	13. Er det foretatt sporsikring av biologisk materiale hos mistenkte I?	
	Nei	
	O Ja, av politiet	
	O Ja, av andre	
	C Annet	
	O Uopplyst	
	C Ikke aktuelt  14. Hvis andre eller annet, angi	
	2.1 This share eller united, ungi	
	15. Tid for sporsikring mistenkt I, dato (dd.mm.åååå)	
	The second state of the late of the second s	
	16. Tid for sporsikring mistenkt I, klokkeslett (tt:mm)	
	17. Er det foretatt sporsikring av biologisk materiale hos mistenkte II?	

	C Nei	
	O Ja, av politiet	
	O Ja, av andre	
	O Annet	
	O Uopplyst	
	O Ikke aktuelt	
18.	Hvis andre eller annet, angi	
19.	Tid for sporsikring mistenkt II, dato (dd.mm.åååå)	
20		
20.	Tid for sporsikring mistenkt II, klokkeslett (tt:mm)	
	Save	
21.	Er det foretatt sporsikring av biologisk materiale hos mistenkte III?	
	O Nei	
	O Ja, av politiet	
	C Ja, av andre C Annet	
	O Uopplyst	
	O Ikke aktuelt	
22.	Hvis andre eller annet, angi	
23.	Tid for sporsikring mistenkt III, dato (dd.mm.åååå)	
2.4		
24.	Tid for sporsikring mistenkt III, klokkeslett (tt:mm)	
25.	Er det gjort beslag av fornærmedes klær?	
	O Nei	
	O Ja	
2.5	O Uopplyst	
26.	Tid for beslag av fornærmedes klær, dato (dd.mm.åååå)	
27.	Tid for beslag av fornærmedes klær, klokkeslett (tt:mm)	
20	Endet wind hadron and wind to (7) March	
28.	Er det gjort beslag av mistenktes(I) klær?  O Nei	
	O Ja	
	O Uopplyst	
	O Ikke aktuelt	
29.	Tid for beslag av mistenktes(I) klær, dato (dd.mm.åååå)	
30.	Tid for beslag av mistenktes(I) klær, klokkeslett (tt:mm)	
	Save	
31.	Er det gjort beslag av mistenktes(II) klær?	
51.	O Nei	
	O Ja	
	O Uopplyst	
	○ Ikke aktuelt	
32.	Tid for beslag av mistenktes(II) klær, dato (dd.mm.åååå)	
33.	Tid for beslag av mistenktes(II) klær, klokkeslett (tt:mm)	
33.	Tid for besidg av Histeriktes(11) klær, klokkesiett (tt.Hilli)	
34.	Er det gjort beslag av mistenktes(III) klær?	
	O Nei	
	O Ja	
	O Uopplyst	
	C Ikke aktuelt	
35.	Tid for beslag av mistenktes(III) klær, dato (dd.mm.åååå)	
26	Tid for beslag av mistenktes(III) klær, klokkeslett (tt:mm)	
36.	TIG TOT Desiag av Tillstelliktes(111) klær, klokkeslett (tt:mm)	
37.	Er det dokumentert fysiske skader hos fornærmede?	
	O Nei	
	C Ja, på Overgrepsenheten, St Olavs Hospital	
	O Ja, av politiet	

	C Ja, annet
	C Uopplyst
38.	Hvis annet, hva
39.	Tid for dokumentasjon av skader, fornærmede, dato (dd.mm.åååå)
40.	Tid for dokumentasjon av skader, fornærmede, klokkeslett (tt:mm)
41.	Save Er det dokumentert fysiske skader hos mistenkte I?
71.	© Nei
	C Ja, av politiet
	C Ja, annet
	C Uopplyst
42.	C Ikke aktuelt Hvis annet, hva
42.	Tivis affilee, fiva
43.	Tid for dokumentasjon av skader, mistenkt I, dato (dd.mm.åååå)
44.	I Tid for dokumentasjon av skader, mistenkt I, klokkeslett (tt:mm)
45.	Fundat delumentat finisha ekadar has mistaalite III
45.	Er det dokumentert fysiske skader hos mistenkte II?  O Nei
	C Ja, av politiet
	© Ja, annet
	O Uopplyst
4.5	C Ikke aktuelt
46.	Hvis annet, hva
47.	Tid for dokumentasjon av skader, mistenkt II, dato (dd.mm.åååå)
48.	Tid for dokumentasjon av skader, mistenkt II, klokkeslett (tt:mm)
49.	Er det dokumentert fysiske skader hos mistenkte III?  Nei
	C Ja, av politiet
	O Ja, annet
	© Uopplyst
50.	C Ikke aktuelt Hvis annet, hva
30.	Tivis affilee, fiva
	Save
51.	Tid for dokumentasjon av skader, mistenkt III, dato (dd.mm.åååå)
52.	Tid for dokumentasjon av skader, mistenkt III, klokkeslett (tt:mm)
53.	Er det vitner avhørt (utenom medisinsk sakkyndig og fornærmede):
	C Nei
	C Ja, antall
	Vitner innkalt, men ikke møtt
	C Annet C Uopplyst
54.	Angi eventuelt antall
	likis seset hus
55.	Hvis annet, hva
	Andre opplysninger / Additional Information or Corrections
	Andre opplyshinger / Additional Information of Corrections
	Lagre svar / Save and view log Tilbakestill skjema / Reset

Participant No: 2001001 Inclusion date: 06/06/2011

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Medisinske undersøkelser av fornærmede		
Initial Page	Er medisinsk undersøkelse foretatt?		
Change password	O Nei		
Information	Оја		
Statistics	C Uopplyst  2. Tid for medisinsk undersøkelse fornærmede, dato (dd.mm.åååå)		
Study Progress	2. Ita for medishisk undersystelse fornæmlede, dato (dd.iiiii.aada)		
	3. Tid for medisinsk undersøkelse fornærmede, klokkeslett (tt:mm)		
Study Documents			
Vis svarhistorikk / View log	Hvis ja, er erklæring blitt innhentet?     Nei		
Identification	C Ja		
Study parts	O Uopplyst		
Rettslige data	5. Mandat fra politiet datert (dd.mm.åååå)		
Overgripere/mistenkte			
Overgripere/mistenkte 2	6. Hvis ja, er erklæringen nevnt i eventuelle domspremisser?		
Fornærmede / handlingen   Etterforskningen	O Nei		
Medisinske undersøkelser av	O Ja, se nedenfor		
fornærmede  Basert på lab-rapport fra	C Uopplyst		
Rettsmedisinsk	C Ikke aktuelt		
Rettstoksikologi	Aktuell tekst om legeerklæringen i dommen		
Variabler fra Overgrepsenhetens registre			
Hendelsen 🕪			
Sykehistorie og funn 🛡			
	Max 255 characters. remaining.		
	8. Er skisser/fotografi vedlagt saken?		
	□ Nei		
	$\square$ Ja, av åsted		
	Ja, av skader på fornærmede		
	☐ Ja, av klær		
	☐ Ja, annet		
	Uopplyst		
	☐ Ikke aktuelt		
	9. Hvis annet, hva		
	10. Hvor ble medisinsk undersøkelse utført?		
	○ Ikke utført		
	Overgrepsenheten, St Olavs Hospital		
	C Legevakt, fastlege		
	O Annet		
	C Uopplyst		
	Save		
	11. Hvis annet, hva		
	12. En era dicinale calde en discinale de conservicion 2		
	12. Er medisinsk sakkyndig innkalt som vitne?		
	□ Nei □ Ja, psykiater/psykolog		
	☐ Ja, psykiater/psykolog ☐ Ja, lege fra Overgrepsenheten, St Olavs Hospital		
	☐ Ja, lege fra Overgrepsenheten, St Olavs Hospital ☐ Ja, annen lege		
	□ Ja, annen lege □ Uopplyst		
	Uopplyst  13. Hvis annen lege, angi		
	13. Tivis aimen rege, angr		
	14. Er det foretatt rettsmedisinsk beslag?		

	□ Nei
	□ Ja
	☐ Sporprøver fra fornærmede
	□ Annet
	□ Uopplyst
15.	Hvis ja, angi antall
16.	Hvis andre beslag, angi
17.	Har politiet selv undersøkt klær?
	O Nei
	Оја
	O Uopplyst
	○ Ikke aktuelt
18.	Er det sendt prøver til Rettsmedisinsk Institutt?
	O Nei
	Оја
	O Uopplyst
	○ Ikke aktuelt
19.	Dato for politiets innsending av prøver til Rettsmedisinsk institutt: (dd.mm.åååå) (Evt. dato mottatt RMI)
20.	Antall prøver mottatt av Rettsmedisinsk Institutt:
	Save
21.	Antall prøver analysert av Rettsmedisinsk institutt:
22.	Er sporsikringspakken analysert?
	O Nei
	O Ja, sporsikringspakken omtalt i analyserapporten
	O Ja, analyse av aktuelle prøver uten at sporsikringspakken er nevnt
	© Uopplyst
	○ Ikke aktuelt
23.	Analyserapporten fra Rettsmedisinsk institutt datert: (dd.mm.åååå)
24.	Er det påvist spermier på fornærmedes kropp?
	O Nei
	O Ja, på genitalia
	O Ja, utenfor genitalia
	O Uopplyst
	O Ikke aktuelt
All rel	evant tekst angående prøver sendt til Rettsmedisinsk Institutt, eventuelle resultater og vektlegging av disse i
saksa	vgjørelsen vedlegges som fritekst.
	Andre opplysninger / Additional Information or Corrections
	Lagre svar / Save and view log Tilbakestill skjema / Reset
	Vis svarhistorikk / View log

Participant No: 2001001 Inclusion date: 06/06/2011

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Basert på lab-rapport fra Rettsmedisinsk
Initial Page	1. * Vattpinner tatt til sporsikring fra fornærmede
Change password	□ Nei
Information	☐ Ja, fra anogenitalt område
information	☐ Ja, fra kropp utenom genitalia
Statistics	2. Antall vattpinner totalt
Study Progress	
Study Documents	<ol> <li>Sædvæske (sure fosfataser/PSA) påvist på vattpinnene tatt fra fornærmede?</li> </ol>
otady bocaments	□ Nei
Vis svarhistorikk / View log	☐ Ja, fra anogenitalt område
Identification	☐ Ja, fra kropp utenom genitalia
Study parts	☐ Ikke testet
Rettslige data	☐ Usikkert resultat ☐ Annet
Overgripere/mistenkte	□ Uopplyst
Overgripere/mistenkte 2	4. Hvis annet, angi
Fornærmede / handlingen   Etterforskningen	This affect, any
Medisinske undersøkelser av	5. Sædceller påvist på vattpinnene tatt fra fornærmede?
fornærmede Basert på lab-rapport fra	□ Nei
Rettsmedisinsk	☐ Ja, fra anogenitalt område
Rettstoksikologi  Variabler fra	$\square$ Ja, fra kropp utenom genitalia
Overgrepsenhetens registre	☐ Ikke testet
Hendelsen	☐ Usikkert resultat
Sykehistorie og funn	Annet
	Uopplyst
	6. Sædvæske (sure fosfataser/PSA) påvist på klær fra fornærmede?
	□ Nei
	☐ Ja, på truse
	☐ Ja, på andre klær
	☐ Ikke testet
	☐ Usikkert resultat ☐ Annet
	□ Uopplyst
	7. Hvis annet, angi
	7. This affect, digit
	8. Sædceller påvist klær fra fornærmede?
	□ Nei
	□ Ja, på truse
	☐ Ja, på andre klær
	☐ Ikke testet
	☐ Usikkert resultat
	Annet
	□ Uopplyst
	9. Hvis annet, angi
	10. Vattpinner tatt til sporsikring fra mistenkte/siktede (I)?
	□ Nei
	☐ Ja, fra anogenitalt område
	☐ Ja, fra kropp utenom genitalia
	☐ Kun referanseprøve tatt
	☐ Ikke aktuelt
	Save
	11. Antall vattpinner totalt (mistenkte I)
	12. Vattpinner tatt til sporsikring fra mistenkte/siktede (II)?

	□ Nei
	☐ Ja, fra anogenitalt område
	☐ Ja, fra kropp utenom genitalia
	☐ Kun referanseprøve tatt
	☐ Ikke aktuelt
13.	Antall vattpinner totalt (mistenkte II)
14.	Vattpinner tatt til sporsikring fra mistenkte/siktede (III)?
	□ Nei
	☐ Ja, fra anogenitalt område
	☐ Ja, fra kropp utenom genitalia
	☐ Kun referanseprøve tatt
	☐ Ikke aktuelt
15.	Antall vattpinner totalt, (mistenkte III)
13.	Antan vartpinner total, (mistericle m)
16.	DNA-typing foretatt?
	□ Nei
	☐ Ja, av vattpinner tatt fra fornærmede, anogenitalt område
	☐ Ja, av vattpinner tatt fra fornærmede, utenfor anogenitalt område
	☐ Ja, av vattpinner tatt fra mistenkte, anogenitalt område
	☐ Ja, av vattpinner tatt fra mistenkte, utenom anogenitalt område
	☐ Ja, av truse tatt fra fornærmede
	☐ Ja, av andre klær tatt fra fornærmede
	☐ Ja, av klær tatt fra mistenkte
	☐ Ja, av kker dat in instellate
	☐ Ja, fostervannsprøve/ abortmateriale
	□ Ja, lostervalinsprøve/ abortiliateriale □ Annet
	Uopplyst
17.	Hvis annet, angi
18.	DNA-match funnet?
10.	□ Nei
	☐ Ja, vattpinner tatt fra fornærmede matcher mistenkte
	Nei, vattpinner tatt fra fornærmede, annet mannlig DNA
	☐ Ja, vattpinner tatt fra mistenkte, fornærmedes DNA
	☐ Ja, fra truse tatt fra fornærmede, matcher mistenkte
	□ Nei, fra truse tatt fra fornærmede, annet mannlig DNA
	☐ Ja, fra andre klær tatt fra fornærmede, matcher mistenkte
	☐ Nei, fra andre klær tatt fra fornærmede, annet mannlig DNA
	☐ Ja, av klær tatt fra mistenkte, matcher fornærmedes DNA
	☐ Ja, av laken, sneip, blod eller annet fra åsted, matcher fornærmedes og mistenktes DNA
	☐ Ja, fostervannsprøve/abortmateriale matcher mistenktes DNA
	☐ Nei, fostervannsprøve/ abortmateriale mismatcher mistenktes DNA
	Annet
	Uopplyst
	☐ Ikke aktuelt
	Andre opplysninger / Additional Information or Corrections
	Lagre svar / Save and view log Tilbakestill skjema / Reset
	Via graphistoriide / Vian Ian
	Vis svarhistorikk / View log Print page

Participant No: 2001001 Inclusion date: 06/06/2011

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Rettstoksikologi	
Initial Page	Er det tatt blod og/eller urinprøve av fornærmede?	
Change password	Nei	
Information	Ja, hos Overgrepsenheten, St Olavs Hospital	
	O Ja, av andre	
Statistics	O Uopplyst	
Study Progress	2. Tid for blod/urinprøve fornærmede, dato (dd.mm.åååå)	
Study Documents	3. Tid for blod/urinprøve fornærmede, klokkeslett (tt:mm)	
Vis svarhistorikk / View log	4. Rusprøver av fornærmede sendt hvor?	
Identification	Farmak.avd. St.Olavs Hospital	
Study parts	C Folkehelseinst. i Oslo	
Rettslige data	O Annet	
Overgripere/mistenkte	O Uopplyst	
Overgripere/mistenkte 2	C Ikke aktuelt	
Fornærmede / handlingen   Etterforskningen	5. Hvis annet, angi	
Medisinske undersøkelser av	Hvis ja, hvilke stoffer ble eventuelt påvist hos fornærmede?	
fornærmede Basert på lab-rapport fra	Ingen	
Rettsmedisinsk	□ Ingen □ Etanol	
Rettstoksikologi  Variabler fra	□ Benzodiazepiner	
Overgrepsenhetens registre	□ Annet	
Hendelsen	Uopplyst	
Sykehistorie og funn 🗎	☐ Ikke aktuelt	
	7. Hvis annet, angi	
	8. Er det tatt blod og/eller urinprøve av mistenkte I?	
	O Nei	
	O ja	
	O Uopplyst	
	C Ikke aktuelt	
	9. Hvis ja, hvem tok prøven?	
	10. Er det tatt blod og/eller urinprøve av mistenkte II?	
	O Nei	
	O Ja	
	O Uopplyst	
	C Ikke aktuelt	
	Save  11. Hvis ja, hvem tok prøven?	
	11. Hvis ja, hvem tok prøven?	
	12. Er det tatt blod og/eller urinprøve av mistenkte III?	
	O Nei	
	O Ja	
	O Uopplyst	
	C Ikke aktuelt	
	13. Hvis ja, hvem tok prøven?	
	14. Tid for blod/urinprøve mistenkte I dato (dd.mm.åååå)	
	15. Tid for blod/urinprøve mistenkte I klokkeslett (tt:mm)	
	16. Tid for blod/urinprøve mistenkte II dato (dd.mm.åååå)	
	17. Tid for blod/urinprøve mistenkte II klokkeslett (tt:mm)	
	18. Tid for blod/urinprøve mistenkte III dato (dd.mm.åååå)	

19.	Tid for blod/urinprøve mistenkte III klokkeslett (tt:mm)	
20.	Rusprøver av mistenkte I sendt hvor?	
20.	Farmak.avd. St.Olavs Hospital	
	Folkehelseinst. i Oslo	
	O Annet	
	O Uopplyst	
	O Ikke aktuelt	
	Save	
21.	Hvis annet, angi	
22.	Rusprøver av mistenkte II sendt hvor?	
	C Farmak.avd. St.Olavs Hospital C Folkehelseinst. i Oslo	
	Annet	
	C Uopplyst	
	O Ikke aktuelt	
23.	Hvis annet, angi	
24.	Rusprøver av mistenkte III sendt hvor?	
	○ Farmak.avd. St.Olavs Hospital	
	© Folkehelseinst. i Oslo	
	C Annet	
	Uopplyst     Ikke aktuelt	
25.	C Ikke aktuelt  Hvis annet, angi	
25.	nvis affriet, angi	
26.	Hvis ja, hvilke stoffer ble eventuelt påvist hos mistenkte I?	
	□ Ingen	
	□ Etanol	
	Benzodiazepiner	
	Annet	
	Uopplyst	
	$\square$ Ikke aktuelt	
27.	Hvis ja, hvilke stoffer ble eventuelt påvist hos mistenkte II?	
	□ Ingen	
	□ Etanol	
	Benzodiazepiner	
	Annet	
	☐ Ikke aktuelt	
28.	Hvis ja, hvilke stoffer ble eventuelt påvist hos mistenkte III?	
	☐ Ingen	
	Etanol	
	☐ Benzodiazepiner	
	☐ Annet	
	Uopplyst	
	□ Ikke aktuelt	
	Andre opplysninger / Additional Information or Corrections	
	Lagre svar / Save and view log Tilbakestill skjema / Reset	
	Vis svarhistorikk / View log	age

Participant No: 2001001 Inclusion date: 06/06/2011 Annen deltager / Another participant

C Uopplyst
Save
Hvis annet, angi

Antall barn

Etnisitet

Antall svangerskap

12.

13.

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Variabler fra Overgrepsenhetens registre		
Initial Page	Opplysn	inger om fornærmede	
Change password	1.	Alder	
Information			
Information	2.	Kjønn	
Statistics		© Mann	
Study Progress		© Kvinne	
Study Progress		© Uopplyst	
Study Documents	3.	Bostedsadresse	
		C Trondheim by	
Vis svarhistorikk / View log		C Sør-Trøndelag utenom byen	
Identification		C Utenfor fylket	
Study parts		C Utenfor landet	
		C Uopplyst	
Rettslige data  Overgripere/mistenkte	4.	Er fornærmede i arbeid utenfor hjemmet?	
Overgripere/mistenkte 2		© Nei	
Fornærmede / handlingen			
Etterforskningen			
Medisinske undersøkelser av		C Uopplyst	
fornærmede  Basert på lab-rapport fra	5.	Hvis nei	
Rettsmedisinsk		© Husmor	
Rettstoksikologi 🗎		○ Skoleelev	
Variabler fra Overgrepsenhetens registre		C Student	
Hendelsen		C På stønad	
Sykehistorie og funn 🛡		C Arbeidsledig	
		C Annet	
		C Uopplyst	
	6.	Hvis annet, hva	
	7.	Hvis ja, hvilken type arbeid?	
	8.	Hvilken utdannelse har fornærmede?	
		O Mindre enn 9 år	
		O 9 - 12 år	
		O Høyskole	
		O Universitet	
		O Uopplyst	
	9.	Sivilstand nå	
		C Ikke flyttet hjemmefra	
		C Aleneboende	
		C Samboende	
		C Gift	
		C Separert	
		O Skilt	
		C Uopplyst	
	10.	Sivilstand tidligere	
	20.	C Samboende	
		© Gift	
		C Separert C Annet	
		Annet	

	C Norsk
	Took .
	, milet
	O Tikke-norsk, vestlig
15.	Ikke-norsk, ikke-vestlig  Hvis annet, angi
13.	Tivis ailliet, aligi
Overgrip	per(e)
	ninger føres på I & II & III etter hvem som er viktigst, hvis flere
16.	Relasjon til fornærmedes familie, mistenkt I
	□ Far/stefar
	Mor/stemor
	Søsken *
	Bestefar/-mor
	Onkel/tante/søskenbarn
	Annen slekt **
	Ektemann/samboer
	Tidligere ektemann
	Kjæreste
	Uoppl. familie/partner
17.	* Bror, stebror, søster, stesøster ** Sønn, datter Relasjon til fornærmedes familie, mistenkt II
17.	Far/stefar
	□ Far/sterar □ Mor/stemor
	Søsken *
	Bestefar/-mor
	Onkel/tante/søskenbarn
	□ Annen slekt **
	☐ Ektemann/samboer
	☐ Tidligere ektemann
	□ Kjæreste
	Uoppl. familie/partner
	* Bror, stebror, søster, stesøster ** Sønn, datter
18.	Relasjon til fornærmedes familie, mistenkt III
	□ Far/stefar
	☐ Mor/stemor
	□ Søsken *
	□ Bestefar/-mor
	□ Onkel/tante/søskenbarn
	☐ Annen slekt **
	Ektemann/samboer
	☐ Tidligere ektemann
	☐ Kjæreste
	Upppl. familie/partner
19.	* Bror, stebror, søster, stesøster ** Sønn, datter Relasjon UTENOM familie/par, mistenkte I
19.	Venn/bekjent *
	Ukjent fra før/tilfeldig **
	Fremmede ***
	☐ Autoritetsperson ****
	Annet
	□ Internett-kontakt
	□ Kundeforhold *****
	Uppplyst
	* Arbeidskamerat, skole/studie-kamerat ** Møtt innenfor de siste 24 timer *** Aldri sett før **** Lærer,
	sjef, behandler, pleier, offentlig tjenestemann (politi mm), taxisjåfør med mer. ***** Ved salg av seksuelle tjenester
20.	Hvis autoritetsperson eller annet, angi
	Save
21.	Relasjon UTENOM familie/par, mistenkte II
	□ Venn/bekjent *
	Ukjent fra før/tilfeldig **
	Fremmede ***
	Autoritetsperson ****
	□ Annet

	☐ Internett-kontakt	
	☐ Kundeforhold *****	
	Uppplyst	
	* Arbeidskamerat, skole/studie-kamerat ** Møtt innenfor de siste 24 timer *** Aldri se sjef, behandler, pleier, offentlig tjenestemann (politi mm), taxisjåfør med mer. ***** V tjenester	
22.	Hvis autoritetsperson eller annet, angi	
23.	Relasjon UTENOM familie/par, mistenkte III	
	☐ Venn/bekjent *	
	☐ Ukjent fra før/tilfeldig **	
	☐ Fremmede ***	
	Autoritetsperson ****	
	☐ Annet	
	☐ Internett-kontakt	
	☐ Kundeforhold *****	
	☐ Uopplyst	
	* Arbeidskamerat, skole/studie-kamerat ** Møtt innenfor de siste 24 timer *** Aldri se sjef, behandler, pleier, offentlig tjenestemann (politi mm), taxisjåfør med mer. ***** V tjenester	
24.	Hvis autoritetsperson eller annet, angi	
	Andre opplysninger / Additional Information or Corrections	
	Lagre svar / Save and view log Tilbakestill skjema / Reset	
	Vis svarhistorikk / View log	Print page

# □ NTNU Norges teknisk-naturvitenskapelige universitet Det medisinske fakultet > Institutt for kreftforskning og molekylær medisin

#### Politiregistrering voldtekt

Cecilie Hagemann St. Olavs Hospital (400)

Participant No: 2001001 Inclusion date: 06/06/2011

Log out →	Hendelsen					
Initial Page	A shed for initial trade to for shed and					
Change password	Åsted for initial kontakt (møteplass)?  Hjemme hos fornærmede					
Information	☐ Hjemme hos overgriper					
	☐ Annet privat sted					
Statistics	☐ Offentlig lokale					
Study Progress	Utendørs					
Study Documents	Transportmiddel					
	Uopplyst					
Vis svarhistorikk / View log	Fornærmede husker ikke     Spesifiser evt.					
Identification	2. Spesifiser evt.					
Study parts	3. Åsted for overgrepet?					
Rettslige data	☐ Hjemme hos fornærmede					
Overgripere/mistenkte  Overgripere/mistenkte 2	☐ Hjemme hos overgriper					
Fornærmede / handlingen 🖤	Annet privat sted					
Etterforskningen  Medisinske undersøkelser av	Offentlig lokale					
tornærmede	Utendørs					
Basert på lab-rapport fra Rettsmedisinsk	☐ Transportmiddel					
Rettstoksikologi	□ Uopplyst □ Fornærmede husker ikke					
Variabler fra Overgrepsenhetens registre	4. Spesifiser evt.					
Hendelsen 🎚	Spesified et al.					
Sykehistorie og funn	5. Beskriv den fysiske volden?					
	□ Ingen					
	☐ Trussel om vold					
	☐ Trussel om hevn					
	☐ Mildere *					
	Drag i håret					
	Biting					
	☐ Klyping med hender					
	☐ Halsgrep/kvelning med rep etc.					
	☐ Kneblet/holdt for munnen					
	☐ Fastbinding ☐ Moderat **					
	□ Moderat *** □ Klyping med verktøy, pisking etc.					
	☐ Brenning(for eksempel m/sigarett)					
	Skjæring (for eksempel m/kniv)					
	Grovere vold					
	☐ Bruk av våpen					
	☐ Annet					
	□ Uopplyst					
	☐ Fornærmede husker ikke					
	Fornærmede hindret i å komme seg unna ***					
	☐ Tvungen abduksjon av beina					
	* Holdt fast ** Slag, spark *** Holdt av andre, døra låst, bundet osv.  6. Hvis annet, oppgi					
	o. Hvis affriet, oppgi					
	Max 255 characters. remaining.					
	Max 255 characters. remaining.  7. Annet, forts.					

	Max 255 characters. remaining.
8.	Hva slags reaksjoner fra fornærmede?
	☐ Ingen, fulgte instrukser/krav
	□ Verbal motstand *
	Fysisk motstand
	☐ Handlingslammet
	□ Annet
	Uopplyst
9.	* F.eks skriker, forhandler med overgriper  Hvis annet, oppgi
э.	Tivis affilet, oppgi
10.	Seksuell handling
20.	
	•
	☐ Beføling kropp *
	☐ Klemming
	☐ Kyssing/slikking kropp
	Beføling kjønnsorgan **
	Forsøk inntrengning ***
	$\square$ Vaginal inntrengning av penis
	☐ Vaginal inntrengning av fingre
	☐ Vaginal inntrengning av fremmedlegeme
	☐ Slikking av offerets kjønnsorgan (cunnilingus)
	☐ Anal inntrengning av penis
	☐ Anal inntrengning av fingre
	☐ Anal inntrengning av fremmedlegeme
	☐ Slikking av offerets anus (anilingus)
	□ Oral inntrengning av penis (fellatio)
	□ Oral inntrengning av fingre
	□ Oral inntrengning av fremmedlegeme
	☐ Tvunget til å suge overgriper
	☐ Tvunget til å onanere overgriper
	☐ Gnir penis mot fornærmede
	Samleieliknende bevegelser
	Annet
	□ Annet □ Fornærmede husker ikke
	Usikker/Uopplyst
	Usikker/Uopplyst  * Inkl. bryst ** Ikke inntrenging *** Vaginalt, analt, oralt
	* Inkl. bryst ** Ikke inntrenging *** Vaginalt, analt, oralt  Save
11.	Hvis fremmedlegeme, hva?
11.	ivis irenimediegenie, riva:
12.	Hvis annet, angi
	This armed, dright
13.	Sædavgang
	□ Nei
	Usikker
	□ Vaginalt
	□ vaginait □ Oralt
	L. Urair
	□ Analt
	□ Analt □ Annet sted på kroppen
	☐ Analt ☐ Annet sted på kroppen ☐ På klær/sengetøy
	☐ Analt ☐ Annet sted på kroppen ☐ På klær/sengetøy ☐ Andre steder
	☐ Analt ☐ Annet sted på kroppen ☐ På klær/sengetøy
14.	☐ Analt ☐ Annet sted på kroppen ☐ På klær/sengetøy ☐ Andre steder

	O Nei	
	C Ja C Fornærmede vet ikke	
	O Annet	
	C Uopplyst	
	uell historie/ graviditet	
16.	Hvis gravid som følge av overgrep	
	O Svangerskapsavbrudd	
	© Fostervannsprøve	
	© Fødsel	
	C Annet	
	© Uopplyst	
17.	Hvis annet, oppgi	
18.	Seksuell debut/virgo?	
	O Debut ved aktuelle SO	
	O Debutert før aktuelle hendelse	
	C Nei	
	C Annet	
	O Uopplyst	
19.	Hvis annet, oppgi	
20.	Siste frivillige samleie	
	O Debut ved aktuelle SO	
	For < 72 timer siden	
	O 3-7 døgn siden	
	C 7-14 døgn siden	
	C > 14 døgn siden	
	© Uopplyst	
	Save	
	Andre opplysninger / Additional Information or Corrections	
	Lagre svar / Save and view log Tilbakestill skjema / Reset	
	Vis svarhistorikk / View log	Print page
		_ Int page

Participant No: 2001001 Inclusion date: 06/06/2011

Cecilie Hagemann St. Olavs Hospital (400)

Log out →	Sykehistorie og funn			
Initial Page	Tidl fysiske /seksuelle overgrep (SO)			
Change password	□ Aldri			
Information	□ SO i barndommen*			
Statistics	□ SO v/partner			
	☐ Annet			
Study Progress	□ Fys. overgr. barndom □ Fys. overgr. annet			
Study Documents	Fys. overgr. partner			
Vis svarhistorikk / View log	SO ukjent overgr.			
Identification	$\square$ SO ( ikke partner)			
Study parts	□ Uopplyst			
	□ SO 12-16 år			
Rettslige data  Overgripere/mistenkte	□ SO > 16 år			
Overgripere/mistenkte 2	□ SO annet			
Fornærmede / handlingen 🖤	*Barndommen vil si < 12 år			
Etterforskningen	2. Hvis annet, angi			
Medisinske undersøkelser av fornærmede	3. Prevensjon, nå			
Basert på lab-rapport fra				
Rettsmedisinsk Rettstoksikologi	□ Ingen			
Variabler fra	□ Kondom			
Overgrepsenhetens registre	P-piller/p-plaster/ring			
Hendelsen  Sykehistorie og funn	□ Spiral □			
oynomotorio og rami z	P-sprøyte/ p-stav			
	Sterilisert/ hysterektomert			
	Annet			
	Uopplyst			
	4. Hvis annet, angi			
	5. Psykiske reaksjoner ved undersøkelsestidspunktet (alvorligste)			
	Ingen ved undersøkelsen			
	Moderate psykiske reaksjoner *			
	Alvorlige psykiske reaksjoner **			
	Vanskelig å vurdere			
	O Annet			
	C Uopplyst			
	* Gråt, innesluttethet, lett angst, sinne eller verbal aggresjon ** Alvorlig angst, tilbaketrukkenhet, bevissthetsinnsnevring, desorientering, fortvilelse/håpløshet, hyperaktivitet, ubehersket eller overdreven			
	sorgreaksjon 6. Hvis annet, angi			
	7. * Fysiske skader på kroppen utenom genitalia (alvorligste skader)			
	☐ Ingen			
	Lette, blåflekker, skrubbsår			
	Moderate: sår, kutt *			
	☐ Alvorlige: brudd, mistanke om indre skader			
	☐ Merker etter halsgrep ☐ Skjæresår			
	□ Skjæresar □ Uopplyst			
	□ Kroppslig us ikke gjort * Her menes ikke skjæresår			
	8. Beskriv fysiske skader nærmere:			

		1	
	Max 255 characters. remaining.		
9.	Gynekologiske funn		
	☐ Ingen forandringer		
	☐ Lokal rødme, hevelse		
	Rifter, overflatesår		
	Større skade		
	Annen skade		
	☐ Annet, sykdom		
	Gynekologisk undersøkelse ikke utført		
	□ Uopplyst		
10.	Beskriv gynekologisk funn nærmere:		
	3, 4 4 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	1	
	Max 255 characters. remaining.		
	Save		
11.	Tidligere psykiatrisk sykehistorie		
11.			
	Nei		
	□ Ja, uspes		
	☐ Tidligere innlagt psyk		
	☐ Tidligere psyk. beh.		
	☐ Tidligere alkohol/rusmisbruker *		
	Ukjent		
	* Tidligere, dvs tørrlagt		
12.	Handikapp / funksjonshemmet		
	□ Nei		
	Psykisk, uspes		
	☐ Fysisk, uspes		
	☐ Alkohol/rusmisbruker *		
	☐ Psykisk utviklingshemmet		
	Andre fysiske (sanser, motorikk)		
	* Nåværende, hvilke(t) rusmiddel		
12			
13.	Angi evt. rusmiddel		
Alkohol	leuc .		
14.	Alkohol (forurettede)		
14.			
	_ Intet alkoholinntak		
	☐ Mindre inntak (< 5 alkoholenheter *)		
	$\square$ Større inntak (5 alkoholenheter eller mer/evt. synlig beruset).		
	☐ Større inntak med amnesiperiode ("Black outs" eller dyp søvn)		
	☐ Uaktuelt – gammel sak eller residiverende overgrep		
	Ingen opplysninger		
15	* 1 alkoholenhet = 33 cl øl, 1 glass vin eller 1 drink		
15.	Påført rus		
	Nei, ingen mistanke om dette		
	O Ja, mener å være påført rusmiddel/legemiddel		
16.	Mistanke om spes. stoff? mengde?		

	Max 255 characters. remaining.
17.	Annet rusmiddel/legemiddel (fornærmede) *
	O Nei
	O Ja
	O Usikkert
	*Selvrapportert inntak (frivillig)
18.	Hvilke(t) stoff(er), mengde:
	Max 255 characters. remaining.
	Andre opplysninger / Additional Information or Corrections
	Lagre svar / Save and view log Tilbakestill skjema / Reset
	Vis svarhistorikk / View log Print page

Appendix IV



Trondheim, januar 2011

#### Informasjon om forskningsprosjekt

Vi henvender oss til deg på grunn av at du er registrert som tidligere pasient ved St Olavs Hospital i perioden 2003 – 2010.

Vi vil med dette informere deg om at vi planlegger å foreta en studie ved St Olavs Hospital fra den samme tidsperioden. Studien vil ta utgangspunkt i skriftlige sykehusjournaler, prøvesvar, samt eventuelle ultralyd- og røntgenundersøkelser som måtte foreligge. Alle opplysningene og prøvene vil bli behandlet uten navn og fødselsnummer eller andre direkte gjenkjennende opplysninger. Det vil ikke være mulig å identifisere deg i resultatene av studien når disse publiseres.

Studien vil ikke medføre noen ekstra samtale, undersøkelse eller behandling for deg.

Studien er godkjent av den regionale komiteen for medisinsk og helsefaglig forskningsetikk.

Det er frivillig å delta i studien. Dersom du *ikke* ønsker at dine journalopplysninger skal brukes eller har spørsmål til studien, kan du kontakte prosjektleder Cecilie Hagemann på telefon 72 57 38 25 eller 73 59 75 37. Alternative telefonnummer er gynekologisk poliklinikk 72 57 47 19 eller 72 57 47 09.

Vennlig hilsen

Cecilie Hagemann Prosjektleder og overlege ved Kvinneklinikken St Olavs Hospital HF 7006 Trondheim